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Myeloid leukemias have been studied for decades, and considerable progress has been 
made in the elucidation of critical pathogenetic factors including transcription factor 
networks and signaling pathways and in the diagnosis and treatment of these 
leukemias. However, while the prognosis of a fraction of patients (particularly those 
with chronic myeloid leukemia in chronic phase) has improved dramatically with the 
advent of novel rationally designed therapies, the prognosis of many other patients 
(i.e. with most subtypes of acute myeloid leukemia) has not improved to the same 
degree. Futhermore, molecular targeted therapies are expensive and are not readily 
available in all parts of the world. 
The intention of this book is to provide a global scope on these issues. Following an 
open call, authors were invited to propose topics and send in an abstract of the chapter 
they wanted to contribute. After selection of appropriate abstracts, full chapters were 
provided and reviewed. Revised chapters were again reviewed and final chapters 
selected for publication. 
The topics of the present book focus on clinical aspects of myeloid leukemias and 
cover the following: 
 Diagnosis and treatment of chronic myeloid leukemia (CML), including standard 
and high dose imatinib as well  as second generation inhibitors 
 Response Monitoring in CML with a special focus on current molecular 
monitoring 
 Rare adverse events during TKI therapy (drug-induced pneumonitis) 
 Novel therapeutic approaches towards a potential cure of CML 
 Diagnosis and treatment of acute myeloid leukemia (AML), in line with the WHO 
2008 classification  
 Gene Expression Profiling in AML 
 Potential ethnic differences in the clinical characteristics of AML 
 Acute promyelocytic Leukemia lacking the classic translocation (15;17) 
 Treatment of Elderly Patients with AML 
 Prognosis and Survival in AML 
 Complications of Treatment in AML, including Bacillus cereus sepsis 
X Preface 
 
Each chapter is a sole-standing publication that reflects each author´s interpretation of 
the data. However, the unifying theme is myeloid leukemia.  Thus, the book displays a 
multi-facetted picture of our current understanding of the clinical implications for 
diagnosing and treating patients with myeloid leukemias. In addition, the open access 
structure of the book will guarantee wide-spread access even in cases where resources 
required for subscription to more expensive scientific journals or books are limited. 
We encourage the readers to send their comments.  This is an exciting new way of 
discussing science and to support the effort of increasing the alertness and education 
of patients and physicians all around the globe.  
 
Prof. Dr. Steffen Koschmieder 
Department of Medicine (Oncology, Hematology, and Stem Cell Transplantation) 
 at the University of Aachen,  
Germany 
Dr. Utz Krug 
Department of Medicine (Hematology, Oncology, Hemostaseology,  
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Treatment of Chronic Myeloid Leukaemia: 
Current Practice and Future Prospects 
Daniela M. Zisterer 
School of Biochemistry & Immunology, Trinity College Dublin 
Ireland 
1. Introduction 
Chronic myeloid leukaemia (CML) is a cancer of the hematopoietic system that arises from 
the Philadelphia chromosome (Ph1). This results from the reciprocal translocation of 
chromosomes 9 and 22 which generates a Bcr-Abl fusion gene encoding a 210kDa protein 
with constitutive tyrosine kinase activity (Ben-Neriah et al., 1986; Kuzrock et al., 1988). This 
constitutively active tyrosine kinase drives proliferation and survival through multiple 
downstream pathways (Reviewed in Cowan-Jacob et al., 2004; Ren et al., 2005). The disease 
is characterised by three stages; the chronic phase marked by an accumulation of mature 
granulocytes and myeloid precursors in the bone marrow and peripheral blood; the 
accelerated phase characterised by a rise in myeloid precursors and a blast crisis stage which 
is characterised by a marked accumulation of differentiation-arrested blast cells of either 
myeloid or lymphoid lineage (Calabretta & Perotti, 2004; Savage et al., 1997). The generation 
and clinical use of the Bcr-Abl tyrosine kinase inhibitor (TKI) imatinib mesylate (IM) has 
revolutionised the treatment of CML patients (Druker et al., 1996; Druker et al., 2006) and 
has become the standard line of therapy for CML patients. Following treatment with 
imatinib, over 90% of patients obtain a complete haematologic response and more than 80% 
achieve a complete cytogenetic response. However, there are limitations associated with IM 
therapy. The drug is highly effective in the chronic phase of the disease but the response of 
patients in blast crisis is limited (Hehlman & Saussele, 2008). Furthermore, in approximately 
40% of patients, resistance develops i.e. resistance in 100 patient years (Gorre et al., 2001). 
Great progress has been made over the last ten years in elucidating the molecular 
mechanisms of IM-resistance in vitro but correlating any of these individual resistance 
mechanisms in a clinical sample does not always indicate that it alone drives clinical 
progression as additional modes of resistance may be at work. The mechanisms by which 
patients become resistant to IM therapy include Bcr-Abl dependent mechanisms such as an 
increase in the levels of Bcr-Abl mRNA expression and corresponding upregulation of 
protein levels and amplification of the Bcr-Abl gene (Mahon et al. 2000). Bcr-Abl 
independent mechanisms include activation of signalling pathways downstream of Bcr-Abl 
including the phosphatidylinositol 3-kinase (PI3K)/Akt cell survival pathway or activation 
of signalling pathways separate to that of the Bcr-Abl gene and an efflux of IM via multidrug 
resistant proteins such as p-glycoprotein (Capdeville et al., 2002). The most  
well-characterised cooperating pathway involves the Src Family Kinases (SFKs) which have 
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been demonstrated to play a role in altering responsiveness to TKIs as well as promoting 
disease progression (Danhauser-Riedl et al., 1996; Wilson et al., 2002). 
However, the major factor influencing IM resistance is due to mutations at critical points in 
the kinase domain of the Bcr-Abl gene which interferes with the ability of IM to interact with 
the enzyme. To date over 60 amino acid substitutions in the kinase domain have been found. 
Of these T315I is one of the most common Bcr-Abl mutations identified in patients and 
importantly this is also associated with the highest degree of IM-resistance, preventing the 
formation of the critical hydrogen bond and changing the conformation of the Bcr-Abl 
protein in such a way to render the protein completely resistant to imatinib. The frequency 
of the T315I mutation in IM-resistant patients is reported to range between 2% and 20% with 
variability related to detection methods along with patient cohort characteristics and 
treatment (Nicolini et al., 2009). Recent data suggests that the survival rate of patients 
harbouring a T315I mutation is dependent on disease phase at the time of mutation 
detection, with chronic phase patients responding to some investigational compounds 
(Nicolini et al., 2009). For example, Legros et al, (2007) reported T315I transcript 
disappearance in an IM-resistant CML patient treated with homoharringtonine and Giles et 
al, (2007) reported that 3 patients harbouring the T315I mutation achieved clinical responses 
with the aurora kinase inhibitor MK-0457. A greater understanding of the molecular basis of 
IM-resistance has provided the molecular rationale for the development of second and now 
third generation therapies for patients with CML. Such therapies will play a key role in the 
control of CML over the next decade. 
2. Second generation tyrosine kinase inhibitors 
Shortly after the introduction of IM in the clinic, reports of primary and secondary resistance 
cases began to emerge which led to the search for agents that might overcome this problem. 
The first second-generation TKI that was clinically evaluated was dasatinib (BMS-354825) 
and it was approved by the FDA for treatment of all phases of IM-resistant CML in June 
2006. Dasatinib is able to bind to both Bcr-Abl and Src family kinases and it was originally 
identified in a screen of compounds that demonstrated potent Src/Abl kinase inhibition 
with antiproliferative activity in CML cell lines and xenograft models systems (Lombardo et 
al., 2004). Nilotinib (AMN107) was subsequently developed by rational drug design based 
on the crystal structure of an Abl/imatinib complex, allowing researchers to optimise the 
potency and selectivity of the compound (Weisberg et al., 2005). 
Dasatinib and nilotinib were initially evaluated in patients with IM-resistant or intolerant 
CML. In phase II clinical trials with a 24 month follow up, both dasatinib and nilotinib were 
shown to have efficacy in patients in the chronic phase of CML (see Table 1). In the nilotinib 
trial, intolerance to imatinib was defined as having intolerance with no major cytogenetic 
response whereas in the dasatinib trial, imatinib-intolerant patients included patients who 
had a major cytogenetic response. These results were very promising and led to further 
Phase 3 trials where these second-generation TKIs were compared directly with imatinib as 
front-line therapies. It would be of interest in the future to determine the optimal time point 
for switching to second line treatment.  
Saglio et al., (2010), recently reported results from the Evaluating Nilotinib Efficacy and 
Safety in Clinical Trials-Newly Diagnosed Patients (ENESTnd) trial. In this phase 3, 
randomized, multicenter study, 846 patients with chronic phase CML received either 
nilotinib (at a dose of either 300 mg or 400 mg twice daily) or imatinib (at a dose of 400 mg 
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once daily). At 12 months, the rates of major molecular response for nilotinib (44% for the 
300-mg dose and 43% for the 400-mg dose) were nearly twice that for imatinib (22%). The 
rates of complete cytogenetic response by 12 months were significantly higher for nilotinib 
(80% for the 300-mg dose and 78% for the 400-mg dose) than for imatinib (65%). Patients 
receiving nilotinib also had a significant improvement in the time to progression to the 
accelerated phase or blast crisis, as compared with those receiving imatinib. Based on these 
results the US FDA has granted accelerated approval of nilotinib for the treatment of 
patients with newly diagnosed CML in chronic phase. 
 
Response Dasatinib Nilotinib 
No. of patients 387 321 
Percent imatinib-resistant 74 70 
Percent imatinib-intolerant 26 30 
Percent CHR 91 95 
Percent McyR 62 59 
Percent CCyR 53 44 
Table 1. Summary of results of phase 2 studies of dasatinib and nilotinib in patients with 
chronic phase CML demonstrating either IM-resistance or intolerance. CHR. Complete 
hematologic response; McyR, major cytogenetic response; CCyR, complete cytogenetic 
response. 
Similarly, Kantarjian et al., (2010a) has reported the results of a trial comparing dasatinib 
versus imatinib in treatment naïve CML patients (DASISION trial). 519 patients with newly 
diagnosed chronic phase CML were randomly assigned to receive dasatinib at a dose of 100 
mg once daily (259 patients) or imatinib at a dose of 400 mg once daily (260 patients). After a 
follow-up of 12 months, the rate of complete cytogenetic response was higher with dasatinib 
than with imatinib (77% vs. 66%). The rate of major molecular response was higher with 
dasatinib than with imatinib (46% vs. 28%), and responses were achieved in a shorter time 
with dasatinib. Progression to the accelerated or blastic phase of CML occurred in 5 patients 
who were receiving dasatinib (1.9%) and in 9 patients who were receiving imatinib (3.5%) 
while the safety profiles of the two treatments were similar. These results also led to 
accelerated FDA approval in October 2010 for this second generation TKI for initial therapy 
of CML. Taken together, the results of these recent trials suggest that the best treatment for 
resistance may be preventing the emergence of resistance in the first place by using these 
alternative frontline therapies. In addition to second generation TKIs, modified imatinib-
based regimes (e.g. increasing the dose of imatinib to 800mg/day) are also currently under 
evaluation. It would also be of interest to determine whether administration of two or more 
TKIs together or consecutively would improve disease control as compared to single-agent 
therapy but such a course of study would present many difficulties in terms of clinical trial 
design.  
3. Combination approaches and investigational compounds  
The currently available TKIs do not demonstrate efficacy against the T315I mutation 
suggesting the need for additional strategies such as combination approaches with 
alternative classes of agents. Prior to the introduction of imatinib, interferon (IFN) alpha-
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suggesting the need for additional strategies such as combination approaches with 
alternative classes of agents. Prior to the introduction of imatinib, interferon (IFN) alpha-
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based regimens were the gold standard for treatment of early chronic phase CML patients. 
The combination of IFN-alpha with imatinib was recently investigated in two large clinical 
trials, the French SPIRIT trial and the German CML Study IV. In the SPIRIT trial 636 patients 
were randomised 1:1:1:1 to receive either imatinib 400mg/day, 600mg/day, 400mg/day 
plus cytarabine or 400mg/day plus INF-alpha. After 18 months MMR rates were 41% versus 
52% versus 53% versus 62% respectively (Preudhomme et al., 2010). In the German study 
CML IV, patients were given imaitinib 400mg/day versus 800mg/day versus 400mg/day 
plus IFN-alpha. Response rates were higher in the imatinib (800mg/day) cohort (CCyR 65%, 
MMR 54%) when compared to the imatinib (400mg/day) cohort with or without IFN-alpha 
(CCyR 52% and 51%; MMR 30% and 35%, respectively) suggesting in this case that high 
dose imatinib increases the rate of MMR at 12 months (Hehlmann et al., 2011). Furthermore, 
they demonstrated that achievement of MMR by month 12 is directly associated with 
improved survival (Hehlmann et al., 2011). 
A number of investigational compounds, many of which are active against T315I mutants 
have also been identified and many are currently undergoing clinical trials and are 
summarised in Table 2. These can be subdivided into four classes; third generation TKIs, 
aurora kinase inhibitors, switch pocket inhibitors and apoptosis modulators.  
3.1 Third generation TKIs 
Despite the very promising results with dasatinib and nilotinib there is still room for 
improvement. Due to the fact that the currently available TKIs have no activity against T315I 
mutants, many investigational compounds are currently being clinically evaluated in this 
cohort of patients. Ponatinib (AP24534) is an orally bioavailable multi-targeted compound 
with activity against many kinases including native Bcr-Abl, the T315I mutant and other 
mutants (O’Hare et al., 2009). Ponatinib does not need to make a hydrogen bond with T315 
therefore it can accommodate the side chain of the isoleucine residue in the T315I mutation 
(O’Hare et al., 2009). In kinase-based assays, ponatinib potently inhibited the activity of 
wild-type Bcr-Abl and the T315I mutant in the nanomolar range. Ponatinib also exhibited 
nanomolar activity against other kinases such as SRC, FGFR1, FLT3, KIT and VEGFR. A 
phase I trial of ponatinib has recently been completed and a phase II trial is currently 
underway. If ponatinib can be demonstrated to be a pan-Bcr-Abl inhibitor in the clinic and it 
is proven to be safe and effective it may be a future frontline therapeutic for CML. 
Bosutinib, is a third generation TKI that is currently being developed by Pfizer. It inhibits 
Bcr-Abl with higher potency than imatinib but it also demonstrates activity against a 
number of other kinases including SFKs, c-Kit and PDGF receptors (Remsing-Rixet et al., 
2009). Bosutinib is currently undergoing frontline testing against imatinib with promising 
results. This third generation TKI may shortly win FDA approval for initial therapy of CML 
(Bixby & Talpaz, 2011).  
INNO-406 is an orally bioavailable dual Abl/Lyn kinase inhibitor which is up to 50 times 
more potent than imatinib against Bcr-Abl. Results of a Phase I trial with this TKI have 
recently been reported (Kantarjian et al., 2010b). INNO-406 was administered to 56 patients 
with imatinib resistance (n = 40) or intolerance (n = 16). Other previous treatments included 
nilotinib (n = 20 patients), dasatinib (n = 26 patients), and dasatinib/nilotinib (n = 9 
patients). Of 31 patients with CML in chronic phase who received INNO-406, the major 
cytogenetic response rate was 19%. No responses were observed in patients who had CML 
in accelerated phase or in blastic phase. The maximium tolerated dose was identified at 
240mg twice daily and further phase II studies are planned.  
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XL228 is an intravenously available multi-targeted TKI that has significant in vitro activity 
against the T315I mutant. It is currently been investigated in a small clinical trial of 27 
patients where 20 of the patients harbour the highly resistant T315I (10 patients), F317L (7 
patients) and V299L (3 patients) mutations. Preliminary clinical activity has been reported in 
a poster session at the 50th Annual American Society of Haematology in December 2008 
(Abstract 3232) and looks promising. XL228 is being currently tested in two Phase I clinical 
trials, one for the treatment of CML or Ph+ acute lymphoblastic leukaemia (ALL), and the 
second for the treatment of advanced malignancies including lymphoma.  
3.2 Aurora kinase inhibitors 
Aurora kinases A and B are a group of serine/threonine kinases also known as mitotic 
kinases, that regulate the transition from G2 through cytokinesis. Aurora kinases are 
overexpressed in several types of solid tumours and some haematological malignancies 
including acute myeloid leukaemia (AML) (Ye et al., 2009). Inhibition of these kinases in 
leukaemia cells has been shown to result in aberrant mitosis which in turn can lead to 
mitotic catastrophe. Aurora kinase inhibitors are being developed as potential targeted 
therapies for cancer patients. There is much similarity between the ATP binding sites of 
aurora kinases and other kinases including Bcr-Abl.  
Danusertib is an intravenously administered multi-targeted kinase inhibitor which 
demonstrates significant activity against various aurora kinases (Gontarewicz & 
Brummendorf, 2010). It has also demonstrated in vitro efficacy against native Bcr-Abl and 
the T315I mutant. A phase I clinical trial is currently underway with advanced phase CML 
patients resistant or intolerant to imatinib and/or a second generation TKI. 
AT9283 is an Aurora kinase A and B inhibitor which is administered intravenously. It 
exhibits efficacy in the nanomolar range against Abl and the T315I mutant along with a 
range of other kinases including JAK 2 and 3 and FGF4 (Howard et al., 2009). Phase I trials 
are currently underway in the United States. 
One potential problem associated with aurora kinase inhibitors is that they all require 
prolonged intravenous administration and response have frequently been associated with 
the periods at which the drug is administered. 
3.3 Switch pocket inhibitors 
Recently a series of non-ATP competitive multi-kinase inhibitors have been developed. 
Switch pocket inhibitors bind to amino acid residues that kinases use to undergo the 
conformational change from the inactive(closed) to the active(open) state and therefore they 
keep the kinase in the inactive conformation (Chan et al., 2011; Eide et al., 2011). An 
important structural feature of the Abl kinase is the presence of a series of hydrophobic 
residues that are stacked in a layer and help to stabilise the active conformation. Indeed the 
T315I mutant further stabilises the active conformation possibly leading to increased activity 
of the enzyme. DCC-2036 is one of the lead switch pocket inhibitors. It is an orally 
bioavailable compound that has demonstrated activity against both native Abl and the 
T315I mutant and a number of other kinases such as VEGFR2 (Chan et al., 2011; Eide et al., 
2011). The compound is currently been evaluated in a phase 1 clinical trial for use in 
imatinib-resistant CML including patients with T315I mutation. 
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3.4 Apoptosis modulators 
Certain compounds that function independently of kinase inhibition activity are also being 
developed. Omacetaxine is one such compound. Omacetaxine is a semisynthetic 
formulation of the alkaloid homoharringtone which can be administered subcutaneously. 
Homoharringtone has been shown to exhibit anti-tumoural effects by disrupting protein 
synthesis and downregulating the anti-apoptotic protein myeloid cell leukaemia-1 (MCL-1) 
(Tang et al., 2006). This leads to disruption of the mitochondrial membrane with release of 
cytochrome c, caspase activation resulting in apoptotic cell death (Tang et al., 2006). 
Omacetaxine is currently been evaluated in two multicentre Phase III clinical trials for 
patients with CML who have failed two or more TKIs or for patients with the T315I 
mutation. It may become the first drug to be approved for third-line therapy in CML. 
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Table 2. Investigational compounds in chronic myeloid leukaemia 
Heat shock protein 90 (Hsp90) is a chaperone protein that assists client proteins in folding 
and prevents protein misfolding and degradation by the proteasome. The Hsp90 antagonist, 
17-allyamino-17-demethoxygeldanamycin (17-AAG), has been shown to cause release of 
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cytochrome c, caspase activation and apoptosis in native Bcr-Abl cells and those expressing 
the T315I mutant (Gorre et al., 2002). Clinical trials with the more soluble analogue of 17-
AAG, 17-DMAG (KOS-1022) are currently ongoing. 
Our group have recently reported the effects of representative members of the novel pro-
apoptotic microtubule depolymerising pyrrolo-1,5-benzoxazepines or PBOX compounds on 
chemotherapy-refractory CML cells using a series of Bcr-Abl mutant cell lines, clinical ex 
vivo patient samples and an in vivo mouse model (Bright et al., 2010). The PBOX compounds 
potently reduced cell viability in cells expressing the E225K and H396P mutants as well as 
the highly resistant T315I mutant. The PBOX compounds also induced apoptosis in primary 
CML samples including those resistant to imatinib. In addition we have shown that the 
PBOXs enhance the apoptotic efficacy of imatinib in CML cell lines (Bright et al., 2009; 
Greene et al., 2007). Furthermore we have demonstrated the in vivo efficacy of a 
representative pro-apoptotic PBOX compound, PBOX-6, in a CML mouse model of the 
T315I Bcr-Abl mutant. Results from this study highlight the potential of these novel series of 
PBOX compounds as potential therapy against CML. 
4. Stem cell transplantation 
Prior to the advent of imatinib and other TKIs, allogeneic hematopoietic stem cell 
transplantation (HSCT) was the main therapeutic option for CML patients and indeed is the 
only known curative treatment for CML to date. After the initial results with imatinib were 
published, allogeneic transplantation began to decline as a frontline treatment for CML. 
However to date there is no prospective study that compares imatinib and HSCT as 
frontline treatments. A retrospective review of over 1000 patients who received an 
allogeneic transplant in the pre-imatinib era reported an overall survival rate of 47% after 8 
years and a relapse rate of 33% after 5 years (Gratwohl et al., 1993). More recently, Saussele 
et al., reported the results of an analysis of a subgroup of the randomized German CML 
study IV. These patients received a transplant after imatinib failure and demonstrated a 91% 
survival after 3 years (Saussele et al., 2010). Imatinib does not appear to impair engraftment 
and the incidence of graft versus host disease and survival was the same as for patients in 
the same stage of the disease who were not treated with imatinib. Since TKIs have no 
harmful effect on the transplant outcome they can be used until a suitable donor is found 
and the transplant procedure is performed. On the recommendation of the European 
LeukemiaNet, allogeneic transplant is now considered for those patients who have failed 
treatment with a second-generation TKI, patients in the advanced or blastic phase of CML at 
the time of diagnosis (as these patients are not responsive to TKIs) or those with the T315I 
mutation (see Table 3). Transplantation may also be an option for those patients that 
develop mutations while undergoing second line therapy (Baccarani et al., 2009). Finally 
transplantation may possibly be an option for pediatric or young patients with a suitable 
donor as the long term effects of TKIs such as drug toxicity (Kerkala et al., 2006) and 
immune dysfunction (Dietz et al., 2004) have not been clearly identified to date. Finally the 
capacity to combine novel TKIs with allogeneic transplantation in high-risk patients will 
potentially improve survival but further studies are required. Unfortunately only a low 
percentage of patients receive a transplant for a variety of reasons such as age and lack of 
appropriate donors. In the German CML study IV, of the 1,242 CML patients involved, 84 
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patients underwent allogeneic HSCT, with a relatively young age of patients reported 
(median age of 36 years) (Saussele et al., 2010).  
 
Chronic phase, frontline therapy Imatinib (400mg daily) 
Chronic phase, second-line therapy 
IM-intolerance 
IM-failure 
Nilotinib (400mg twice daily) or Dasatinib 
(100mg daily) 
Nilotinib (400mg twice daily) or Dasatinib 
(100mg daily) or HSCT in low 
transplantation risk and high risk disease 
(e.g. T315I mutation) 
Chronic Phase, third-line therapy 
In case of dasatinib or nilotinib failure 
HSCT 
Accelerated and blastic phase 
Frontline 
Second-line 
Imatinib followed by HSCT wherever 
possible 
Nilotinib or Dasatinib followed by HSCT 
wherever possible 
Table 3. Current recommendations for treatment of CML patients (modified from Baccarani 
et al., 2009) 
5. Chronic myeloid leukaemia stem cells 
There is also a mounting body of evidence suggesting that in many cancers, including CML, 
cancer stem cells (CSCs) evolve as a result of both genetic and epigenetic events that alter 
hematopoietic progenitor differentiation, survival and self-renewal. Hematopoietic stem 
cells (HSCs) are defined by their capacity for self-renewal and their ability to give rise to all 
mature haematopoietic cell lineages throughout an individual’s lifetime. There is 
accumulating evidence to suggest that CML cells emerge due to expression of Bcr-Abl in 
normal HSCs. Transplantation of multipotent murine HSCs expressing Bcr-Abl into 
recipient mice induces a CML-like myeloproliferative disorder (Pear et al., 1998) whereas 
CML is not induced in committed murine haematopoietic progenitor cells expressing Bcr-
Abl (Huntly et al., 2004). There is also accumulating evidence that the signalling pathways 
that control normal HSC fate also determine maintenance of stem cell function. Recently 
signalling pathways or molecules such as Wnt/-catenin, hedgehog (Hh), promyelocytic 
leukaemia (PML) and forkhead box class O of transcription factors (FOXO) have been 
shown to control stem cell fate in both normal hematopoiesis and in CML. 
5.1 Signalling pathways underlying maintenance of CML stem cells  
The wnt/-catenin signalling pathway is thought to play a role in maintenance of CML stem 
cells. There are numerous reports demonstrating that -catenin regulates normal mouse 
HSC renewal (Reya et al., 2003; Zhao et al., 2007). Furthermore, Zhao et al., 2007 performed 
a series of mouse genetic studies demonstrating that conditional deletion of -catenin 
reduced maintenance of CML stem cells in the chronic phase. Loss of -catenin also 
suppressed infiltration of CML cells into the lung and liver of mice injected with CML stem 
cells (Zhao et al., 2007).  
The hedgehog signalling pathway is also though to underlie stem cell fate in both normal 
hematopoiesis and CML. In the absence of Hh ligands, Patched (Ptch) a twelve-
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transmembrane receptor inhibits smo, a seven-transmembrane receptor. The binding of Hh 
ligands such as Indian hedgehog, Desert hedgehog or Sonic hedgehog to the Patched 
receptor in turn activates Smo and this receptor activates downstream signalling events 
mediated through activation of Gli transcriptional effectors. Two recent studies have 
demonstrated that expansion of Bcr-Abl leukaemic stem cells is dependent on the hedgehog 
pathway. Conditional Smo deletion caused CML stem cell suppression and impaired CML 
progression (Dierks et al., 2008; Zhao et al., 2009). Furthermore expression of constitutively 
active Smo increased the frequency of CML stem cells and accelerated CML development 
(Zhao et al., 2009) demonstrating an essential requirement for the Hh signalling pathway in 
maintenance of CML stem cells.  
The promyelocytic leukaemia (PML) protein is a tumour suppressor protein localising to 
PML nuclear bodies. It plays a role in a wide array of biological activities including 
apoptosis, senescence and the DNA damage response pathway. Ito et al., 2008 reported high 
expression of PML in normal HSCs and demonstrated that conditional deletion of Pml 
resulted in intensive cell cycling which in turn resulted in impaired self-renewal capacity. 
They also demonstrated the defective ability of Pml-/- CML stem cells to develop CML at the 
3rd serial transplantation.  
Forkhead box class O of transcription factors (FOXO) have been shown to control stem cell 
fate in both normal hematopoiesis and in CML. The FOXO family of transcription factors 
include FOXO1, FOXO3a, FOXO4 and FOXO6 and they are all downstream targets of the 
cell survival phosphatidylinositol-3-kinase-AKT signalling pathway. When a ligand such as 
a growth factor or insulin binds to its receptor and activates the PI3-K-AKT pathway, AKT 
phosporylates FOXOs preventing their translocation to the nucleus and causing their 
degradation. It is widely believed that Bcr-Abl activates AKT signalling and suppresses 
FOXOs which in turn enhances the proliferation or inhibits the apoptosis of CML cells. 
However, Naka et al., (2010) have recently shown that FOXO3a plays an essential role in the 
maintenance of CML stem cells through the use of a syngeneic transplantation system and a 
CML-like myeloproliferative disease mouse model. They demonstrated that cells with a 
nuclear localisation of FOXO3a and decreased AKT phosphorylation are enriched in CML 
stem cell population, despite expression of Bcr-Abl. They also found that the ability of CML 
stem cells to promote malignancy at the 3rd transplantation is significantly decreased by 
Foxo3a deficiency in vivo. In addition, they have shown that TGF-beta is a critical regulator 
of AKT activation in CML stem cells and control the localisation of FOXO3a. This suggests 
the potential of TGF-beta-FOXO signalling inhibitors in eradicating CML stem cells.  
The transcription factor JunB has been shown to protect against myeloid malignancies 
including CML by limiting hematopoietic stem cell proliferation and differentiation. 
Inactivation of JunB deregulates the cell-cycle machinery and increases the proliferation of 
HSCs without impairing their self-renewal or regenerative potential in vivo (Santaguida et 
al., 2009). Such data increases our understanding of how defects in signalling pathways that 
control the proliferation of stem cells leads to an increase in their transformation ability. 
5.2 Mechanisms of tyrosine kinase inhibitor resistance of CML stem cells 
Many studies have shown that TKIs such as imatinib, dasatinib and nilotinib potently 
inhibit TKI in differentiated CML stem cells but are not as effective in quiescent CML stem 
cells. For example, the presence of detectable primitive leukaemic progenitor cells in CML 
patients with an established complete cytogenetic response after 5 years on imatinib 
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patients underwent allogeneic HSCT, with a relatively young age of patients reported 
(median age of 36 years) (Saussele et al., 2010).  
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IM-failure 
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In case of dasatinib or nilotinib failure 
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Frontline 
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There is also a mounting body of evidence suggesting that in many cancers, including CML, 
cancer stem cells (CSCs) evolve as a result of both genetic and epigenetic events that alter 
hematopoietic progenitor differentiation, survival and self-renewal. Hematopoietic stem 
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transmembrane receptor inhibits smo, a seven-transmembrane receptor. The binding of Hh 
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pathway. Conditional Smo deletion caused CML stem cell suppression and impaired CML 
progression (Dierks et al., 2008; Zhao et al., 2009). Furthermore expression of constitutively 
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They also demonstrated the defective ability of Pml-/- CML stem cells to develop CML at the 
3rd serial transplantation.  
Forkhead box class O of transcription factors (FOXO) have been shown to control stem cell 
fate in both normal hematopoiesis and in CML. The FOXO family of transcription factors 
include FOXO1, FOXO3a, FOXO4 and FOXO6 and they are all downstream targets of the 
cell survival phosphatidylinositol-3-kinase-AKT signalling pathway. When a ligand such as 
a growth factor or insulin binds to its receptor and activates the PI3-K-AKT pathway, AKT 
phosporylates FOXOs preventing their translocation to the nucleus and causing their 
degradation. It is widely believed that Bcr-Abl activates AKT signalling and suppresses 
FOXOs which in turn enhances the proliferation or inhibits the apoptosis of CML cells. 
However, Naka et al., (2010) have recently shown that FOXO3a plays an essential role in the 
maintenance of CML stem cells through the use of a syngeneic transplantation system and a 
CML-like myeloproliferative disease mouse model. They demonstrated that cells with a 
nuclear localisation of FOXO3a and decreased AKT phosphorylation are enriched in CML 
stem cell population, despite expression of Bcr-Abl. They also found that the ability of CML 
stem cells to promote malignancy at the 3rd transplantation is significantly decreased by 
Foxo3a deficiency in vivo. In addition, they have shown that TGF-beta is a critical regulator 
of AKT activation in CML stem cells and control the localisation of FOXO3a. This suggests 
the potential of TGF-beta-FOXO signalling inhibitors in eradicating CML stem cells.  
The transcription factor JunB has been shown to protect against myeloid malignancies 
including CML by limiting hematopoietic stem cell proliferation and differentiation. 
Inactivation of JunB deregulates the cell-cycle machinery and increases the proliferation of 
HSCs without impairing their self-renewal or regenerative potential in vivo (Santaguida et 
al., 2009). Such data increases our understanding of how defects in signalling pathways that 
control the proliferation of stem cells leads to an increase in their transformation ability. 
5.2 Mechanisms of tyrosine kinase inhibitor resistance of CML stem cells 
Many studies have shown that TKIs such as imatinib, dasatinib and nilotinib potently 
inhibit TKI in differentiated CML stem cells but are not as effective in quiescent CML stem 
cells. For example, the presence of detectable primitive leukaemic progenitor cells in CML 
patients with an established complete cytogenetic response after 5 years on imatinib 
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treatment has been demonstrated (Bhatia et al., 2003). Furthermore, patients with an 
apparent molecular remission of CML following cessation of imatinib treatment quickly 
relapse (Cortes et al., 2004). It has been suggested therefore that these quiescent stem cells 
may be a reservoir for relapse (Holyoake, 1999; Wang et al., 1998). Drugs that are capable of 
eradicating the CML stem cells would provide much improved treatment for CML patients. 
To date, a number of potential mechanisms mediating TKI-resistance of CML stem cells 
have been postulated.  
Firstly FOXO has been suggested to contribute to resistance to TKI therapy. Komatsu et al., 
(2003), has previously reported that FOXO3a is a downstream effector of imatinib induced 
cell cycle arrest in Bcr-Abl expressing cells and that FOXO inactivation sensitises cells to 
imatinib treatment suggesting that FOXO contributes to resistance to TKI treatment. To 
study this further in CML stem cells, Naka et al., (2010) investigated the roles of Foxo3a in 
response to TKI therapy using a CML mouse model. They showed that Foxo3a deficiency 
sensitised CML stem cells to TKI treatment and suggested that Foxo3a plays diverse roles in 
CML stem cell and non-stem cells. In their model, FOXO activation protects CML stem cells 
against TKI treatment while in non-CML stem cells it induces apoptosis or cell cycle arrest. 
In this same paper, they provided both in vitro and in vivo data which demonstrates a role 
for the TGF-beta/FOXO signalling pathway in maintaining imatinib-resistant CML stem 
cells. Treatment of CML stem cells with a TGF-beta inhibitor, Ly364947, impaired their 
colony forming ability in vitro and a combination of TGF-beta inhibition, Foxo3a deficiency 
and imatinib treatment resulted in efficient depletion of CML in vivo. Thus inhibition of 
TGF-beta signalling may result in eradication of the reservoir of CML stem cells. 
There have also been recent reports demonstrating that Bcr-Abl stimulates the proteasome 
mediated degradation of certain FOXO family members in an animal model and in samples 
taken from CML patients (Jagani et al., 2009). Treatment with the proteasome inhibitor, 
bortezomib, resulted in an inhibition of Bcr-Abl mediated downregulation of FOXO and a 
regression of leukaemia suggesting that bortezomib is a candidate therapeutic in the 
treatment of Bcr-Abl-induced leukaemia. Furthermore, recent data demonstrate that 
bortezomib has significant activity against CML stem cells and synergises with imatinib in a 
CML murine model (Heaney et al., 2010; Hu et al., 2009). Bortezomib has also been shown to 
inhibit proteosomal degradation of protein phosphatase 2A (PP2A). This in turn reactivates 
PP2A which is an important negative regulator of Bcr-Abl (Hu et al., 2009). However, due to 
the known toxicities of bortezomib, including myelosuppression, the likely initial clinical 
application of bortezomib in CML would be in resistant and advanced disease. 
Other work has demonstrated that Hh signalling contributes to TKI resistance. Dierks et al., 
(2008) demonstrated that inhibition of the Hh signalling pathway with cyclopamine, which 
maintains Smo in its inactive form, impairs development of CML by CML stem cells. In 
addition, a combination of cyclopamine with nilotinib delayed the recurrence of the disease 
compared to treatment with nilotinib alone (Dierks et al., 2008).  
Another key molecule that may control TKI resistance of CML stem cells is reported to be 
the arachidonate 5-lipoxygenase (Alox5) gene which encodes a lipoxygenase 5-LO (Chen et 
al., 2009). Gene expression profiling demonstrated that Alox5 expression is up-regulated by 
Bcr-Abl. In the absence of Alox5, Bcr-Abl failed to induce CML in mice. This Alox5 
deficiency caused impairment of the function of CML stem cells but not normal 
hematopoietic stem cells by affecting their differentiation and cell division. This in turn 
caused a depletion of CML stem cells and a failure of CML development. Treatment of CML 
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mice with a 5-LO inhibitor, zileuton, also impaired the function of CML stem cells and 
prolonged survival of CML affected mice. These results demonstrate that a specific target 
gene can be found in CML stem cells and its inhibition can inhibit the function of these stem 
cells. It is of interest to note that upregulation of Alox5 was not inhibited by treatment with 
TKIs which may go some way to explaining why imatinib does not affect CML stem cells. 
PML as described above is also an important target of CML stem cell therapy. Ito et al., 
(2008) demonstrated the critical role of this tumour suppressor in CML stem cell 
maintenance, and presented a new therapeutic approach for targeting quiescent CML stem 
cells by pharmacological inhibition of PML. Treatment of mice with arsenic trioxide, which 
downregulates PML expression, completely eradicated CML stem cells when used in 
combination with the chemotherapeutic drug Ara-C. This suggests that targeting PML for 
degradation could be an attractive therapeutic approach for targeting CML stem cells. 
Autophagy is a genetically controlled process whereby organelles and long lived proteins 
are sequestered and engulfed into vacuoles called autophagosomes. These autophagosomes 
then fuse with lysosomes to produce autolysosomes which are targeted for either 
destruction or recycling (Kroemer & Levine, 2008). In certain situations autophagy serves as 
an alternative to apoptosis and is thus called type II cell death whereas in other cellular 
contexts, such as starvation induced by growth factor withdrawal/metabolic stress, it serves 
as a cell survival mechanism allowing tumour cells to become metabolically dormant. It has 
recently been reported that imatinib not only induces apoptotic cell death in CML cells but 
also induces autophagy following the induction of ER stress (Bellodi et al., 2009). In 
addition, inhibition of autophagic cell death using pharmacological inhibitors of 
autophagosome-lysosome fusion (chloroquine and bafilomycin) enhanced imatinib-induced 
cell death in CML cell lines and primary CML cells including those expressing partially IM-
resistant Bcr-Abl mutants. Furthermore and of even greater importance, CML stem cells 
were shown to be extremely sensitive to the combination treatment. Knockdown of the 
autophagy genes Atg5 and Atg7 in CML cells also enhanced TKI-induced cell death. These 
workers therefore postulated that TKI-induced autophagy may antagonise TKI-induced cell 
death through apoptosis and inhibition of autophagy may eliminate this survival 
mechanism by restoring sensitivity of CML stem cells to TKI therapy (Bellodi et al., 2009). 
This approach would avoid the necessity of targeting CML stem cells through Bcr-Abl-
indpendent approaches. In addition normal stem cells would not be targeted as these 
autophagic inhibitors had little or no effect on normal progenitors. The results of the Bellodi 
study have recently led to a randomised phase II clinical trial of IM versus 
IM/hydrochloroquine in CML patients which is being initiated at a number of centres in the 
U.K. This is known as the CHOICES (chloroquine and imatinib combination to eliminate 
stem cells) trial. 
Histone deacetylase inhibitors (HDACIs) are drugs that target histone deacetylase 
complexes which modulate chromatin acetylation resulting in changes in gene expression. 
These inhibitors have a wide variety of effects as they also inhibit deacetylation of 
chaperone proteins such as Hsp90, transcription factors and a variety of other signalling 
mediators. It has previously been shown that treatment of CML cells with HDACIs such as 
LBH589 resulted in a downregulation of Bcr-Abl and an induction of apoptosis (Fiskus et al., 
2006). In addition synergistic effects were observed with HDACIs in combination with a 
variety of TKIs (dasatinib, nilotinib and imatinib). The HDACIs are thought to target Hsp90 
which results in decreased chaperone activity of Hsp90 leading to increased proteosomal 
degradation of Bcr-Abl. A recent report has demonstrated that the HDACI LBH589 when 
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treatment has been demonstrated (Bhatia et al., 2003). Furthermore, patients with an 
apparent molecular remission of CML following cessation of imatinib treatment quickly 
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(2003), has previously reported that FOXO3a is a downstream effector of imatinib induced 
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sensitised CML stem cells to TKI treatment and suggested that Foxo3a plays diverse roles in 
CML stem cell and non-stem cells. In their model, FOXO activation protects CML stem cells 
against TKI treatment while in non-CML stem cells it induces apoptosis or cell cycle arrest. 
In this same paper, they provided both in vitro and in vivo data which demonstrates a role 
for the TGF-beta/FOXO signalling pathway in maintaining imatinib-resistant CML stem 
cells. Treatment of CML stem cells with a TGF-beta inhibitor, Ly364947, impaired their 
colony forming ability in vitro and a combination of TGF-beta inhibition, Foxo3a deficiency 
and imatinib treatment resulted in efficient depletion of CML in vivo. Thus inhibition of 
TGF-beta signalling may result in eradication of the reservoir of CML stem cells. 
There have also been recent reports demonstrating that Bcr-Abl stimulates the proteasome 
mediated degradation of certain FOXO family members in an animal model and in samples 
taken from CML patients (Jagani et al., 2009). Treatment with the proteasome inhibitor, 
bortezomib, resulted in an inhibition of Bcr-Abl mediated downregulation of FOXO and a 
regression of leukaemia suggesting that bortezomib is a candidate therapeutic in the 
treatment of Bcr-Abl-induced leukaemia. Furthermore, recent data demonstrate that 
bortezomib has significant activity against CML stem cells and synergises with imatinib in a 
CML murine model (Heaney et al., 2010; Hu et al., 2009). Bortezomib has also been shown to 
inhibit proteosomal degradation of protein phosphatase 2A (PP2A). This in turn reactivates 
PP2A which is an important negative regulator of Bcr-Abl (Hu et al., 2009). However, due to 
the known toxicities of bortezomib, including myelosuppression, the likely initial clinical 
application of bortezomib in CML would be in resistant and advanced disease. 
Other work has demonstrated that Hh signalling contributes to TKI resistance. Dierks et al., 
(2008) demonstrated that inhibition of the Hh signalling pathway with cyclopamine, which 
maintains Smo in its inactive form, impairs development of CML by CML stem cells. In 
addition, a combination of cyclopamine with nilotinib delayed the recurrence of the disease 
compared to treatment with nilotinib alone (Dierks et al., 2008).  
Another key molecule that may control TKI resistance of CML stem cells is reported to be 
the arachidonate 5-lipoxygenase (Alox5) gene which encodes a lipoxygenase 5-LO (Chen et 
al., 2009). Gene expression profiling demonstrated that Alox5 expression is up-regulated by 
Bcr-Abl. In the absence of Alox5, Bcr-Abl failed to induce CML in mice. This Alox5 
deficiency caused impairment of the function of CML stem cells but not normal 
hematopoietic stem cells by affecting their differentiation and cell division. This in turn 
caused a depletion of CML stem cells and a failure of CML development. Treatment of CML 
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mice with a 5-LO inhibitor, zileuton, also impaired the function of CML stem cells and 
prolonged survival of CML affected mice. These results demonstrate that a specific target 
gene can be found in CML stem cells and its inhibition can inhibit the function of these stem 
cells. It is of interest to note that upregulation of Alox5 was not inhibited by treatment with 
TKIs which may go some way to explaining why imatinib does not affect CML stem cells. 
PML as described above is also an important target of CML stem cell therapy. Ito et al., 
(2008) demonstrated the critical role of this tumour suppressor in CML stem cell 
maintenance, and presented a new therapeutic approach for targeting quiescent CML stem 
cells by pharmacological inhibition of PML. Treatment of mice with arsenic trioxide, which 
downregulates PML expression, completely eradicated CML stem cells when used in 
combination with the chemotherapeutic drug Ara-C. This suggests that targeting PML for 
degradation could be an attractive therapeutic approach for targeting CML stem cells. 
Autophagy is a genetically controlled process whereby organelles and long lived proteins 
are sequestered and engulfed into vacuoles called autophagosomes. These autophagosomes 
then fuse with lysosomes to produce autolysosomes which are targeted for either 
destruction or recycling (Kroemer & Levine, 2008). In certain situations autophagy serves as 
an alternative to apoptosis and is thus called type II cell death whereas in other cellular 
contexts, such as starvation induced by growth factor withdrawal/metabolic stress, it serves 
as a cell survival mechanism allowing tumour cells to become metabolically dormant. It has 
recently been reported that imatinib not only induces apoptotic cell death in CML cells but 
also induces autophagy following the induction of ER stress (Bellodi et al., 2009). In 
addition, inhibition of autophagic cell death using pharmacological inhibitors of 
autophagosome-lysosome fusion (chloroquine and bafilomycin) enhanced imatinib-induced 
cell death in CML cell lines and primary CML cells including those expressing partially IM-
resistant Bcr-Abl mutants. Furthermore and of even greater importance, CML stem cells 
were shown to be extremely sensitive to the combination treatment. Knockdown of the 
autophagy genes Atg5 and Atg7 in CML cells also enhanced TKI-induced cell death. These 
workers therefore postulated that TKI-induced autophagy may antagonise TKI-induced cell 
death through apoptosis and inhibition of autophagy may eliminate this survival 
mechanism by restoring sensitivity of CML stem cells to TKI therapy (Bellodi et al., 2009). 
This approach would avoid the necessity of targeting CML stem cells through Bcr-Abl-
indpendent approaches. In addition normal stem cells would not be targeted as these 
autophagic inhibitors had little or no effect on normal progenitors. The results of the Bellodi 
study have recently led to a randomised phase II clinical trial of IM versus 
IM/hydrochloroquine in CML patients which is being initiated at a number of centres in the 
U.K. This is known as the CHOICES (chloroquine and imatinib combination to eliminate 
stem cells) trial. 
Histone deacetylase inhibitors (HDACIs) are drugs that target histone deacetylase 
complexes which modulate chromatin acetylation resulting in changes in gene expression. 
These inhibitors have a wide variety of effects as they also inhibit deacetylation of 
chaperone proteins such as Hsp90, transcription factors and a variety of other signalling 
mediators. It has previously been shown that treatment of CML cells with HDACIs such as 
LBH589 resulted in a downregulation of Bcr-Abl and an induction of apoptosis (Fiskus et al., 
2006). In addition synergistic effects were observed with HDACIs in combination with a 
variety of TKIs (dasatinib, nilotinib and imatinib). The HDACIs are thought to target Hsp90 
which results in decreased chaperone activity of Hsp90 leading to increased proteosomal 
degradation of Bcr-Abl. A recent report has demonstrated that the HDACI LBH589 when 
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used in combination with imatinib induced apoptosis of quiescent CML stem cells with a 
subsequent lack of engraftment in immunodeficient mice (Zhang et al., 2010). Thus a further 
possibility for eradication of CML stem cells may lie in combining TKIs with HDACIs. 
Table 4 below summarises the key signalling pathways/molecules that are thought to play a 
role in mediating resistance to TKI therapy and drugs that target these pathways/molecules 
that may have potential either alone or in combination for CML therapy.  
 
Drug Drug target in CML 
stem cells 






Ly364947 and imatinib  
improved survival of CML 
mice 
Komatso et al., 
2003 
Cyclopamine Smo in the hedgehog  
signalling pathway 
Cyclopamine and nilotinib 
 improved survival of 
CML mice 
Dierks et al., 
2008 
Zileuton 5-lipoxygenase Zileuton and imatinib 
 prolonged survival of 
CML mice 
Chen et al., 
2009 
Arsenic trioxide PML Arsenic trioxide and AraC  
prolonged survival of 
CML mice 
Ito et al., 2008 
Chloroquine  
 
Autophagy  Chloroquine sensitised 
primary 
 CML stem cells to 
imatinib-induced  
cell death 
Bellodi et al., 
2009 
LBH589 HDACs LBH589 and imatinib co-
treatment  
induced apoptosis of CML 
stem 
 cells and prevented  
subsequent engraftment in 
immunodeficient mice 
Zhang et al., 
2010 
Table 4. Signalling pathway/key molecules underlying TKI-resistance in CML stem cells as 
potential drug targets 
6. Immunotherapy for the treatment of CML 
Clinical interest in immunotherapy still remains as allogeneic stem cell transplantation, 
which relys on a graft versus leukaemia effect, provides the only long-term eradication of 
CML. The differences in minor histocompatibility antigens between recipient and donor 
along with effector cells specifically targeted at leukaemic antigens contributes to the cure 
of the disease (Rezvani & Barret., 2008). Additional evidence that CML is a disease 
susceptible to immunotherapy is provided by reports demonstrating the benefit of 
allogeneic donor lymphocyte infusions following transplantation (Drobyski & Keever, 
1993; Kolb et al., 1995).  
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As mentioned above, CML is a clonal disorder of pluripotent haematopoietic stem cells 
which is characterised by the Bcr-Abl fusion protein. This results from the reciprocal 
translocation of chromosomes 9 and 22 which generates a Bcr-Abl fusion gene (Ben-Neriah 
et al., 1986). The t(9;22) mRNA is translated to a chimeric Bcr-Abl protein of molecular 
weight 210kDa often referred to as the p210 protein. However different breakpoint areas in 
the bcr gene have been identified resulting in slight variations in fusion transcripts. The 
most commonly expressed transcripts are the b3a2 and b2a2 transcripts (Deininger & 
Goldman, 2000). This generates a neo-antigen which is tumour specific because it contains a 
new sequence of amino acids in the junctional region of p210 that are not present in normal 
hematopoietic stem cells. This in turn provides a unique target for immunotherapeutic 
intervention using a vaccine-based approach.  
6.1 Antigen-specific targets in CML-Bcr-Abl junctional peptides 
The junctional regions of p210 contain not only a unique sequence of amino acids but 
additionally a new amino acid is formed due to codon split during translocation. Thus a 
lysine in b3a2 and a glutamic acid in b2a2 is generated (Shtivelman et al., 2006). There have 
been many reports of immunogenicity of the fusion region derived peptides of p210 with 
respect to the major histocompatibility complex (MHC) class I and II. For example, the 
p210/b3a2-derived fusion protein amino acid sequences have been shown to bind to various 
class I HLA antigen molecules including A0201, A3, A11 and B8 (Berke et al., 2000) 
supporting the potential of these peptides as target for class I HLA-restricted T-cell 
cytotoxicity. However, presentation of other Bcr-Abl junctional peptides has not been 
established in other HLA types which somewhat limits the clinical potential of class I 
peptides to subpopulations with specific HLA alleles. Strategies have been implemented to 
improve the binding of HLA class I molecules by amino acid substitutions at key binding 
residues of Bcr-Abl peptides to try and overcome their somewhat poor immunogenicity 
(Pinilla-Ibarz et al., 2005). Interest has also developed in class II Bcr-Abl specific peptides 
although less is known regarding the interaction of Bcr-Abl peptides with HLA class II 
molecules (Mannering et al., 1997; Yasukawaet al., 1998). In addition several clinical trials 
have been initiated using peptide based vaccines to treat CML, often with concomitant 
treatment of interferon-alpha or imatinib (Bocchia et al., 2005; Cathcart et al., 2004; Pinilla-
Ibarz et al., 2000; Rojas et al., 2007). Results of these trials are reviewed by Pinilla-Ibarz et al., 
(2009).  
6.2 Selectively expressed and over-expressed antigens in CML 
Another potential target for immunotherapy are antigens that are selectively expressed or 
over-expressed. Wilms’ tumour antigen 1 (WT1) is a transcription factor that is over-
expressed in many human leukaemias including CML and also in solid malignancies and 
several class I restricted epitopes have been identified to date (Ariyaratana & Loeb, 2007). 
The expression of WT1 in CML has been shown to correlate with disease progression. Many 
peptides have been designed and cytotoxic T-lymphocytes generated in the presence of 
some of these peptides were able to specifically target WT1-expressing leukemic cells while 
sparing normal progenitors (Oka et al., 2000).  
The efficacy of WT1-based vaccines has been the study of a number of trials with patients 
with AML, breast cancer, lung cancer, myelodysplastic syndrome and mesothelioma with 
promising results (Chaise et al., 2008; Li Z et al., 2005; Oka et al., 2004).  
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used in combination with imatinib induced apoptosis of quiescent CML stem cells with a 
subsequent lack of engraftment in immunodeficient mice (Zhang et al., 2010). Thus a further 
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 CML stem cells to 
imatinib-induced  
cell death 
Bellodi et al., 
2009 
LBH589 HDACs LBH589 and imatinib co-
treatment  
induced apoptosis of CML 
stem 
 cells and prevented  
subsequent engraftment in 
immunodeficient mice 
Zhang et al., 
2010 
Table 4. Signalling pathway/key molecules underlying TKI-resistance in CML stem cells as 
potential drug targets 
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susceptible to immunotherapy is provided by reports demonstrating the benefit of 
allogeneic donor lymphocyte infusions following transplantation (Drobyski & Keever, 
1993; Kolb et al., 1995).  
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As mentioned above, CML is a clonal disorder of pluripotent haematopoietic stem cells 
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et al., 1986). The t(9;22) mRNA is translated to a chimeric Bcr-Abl protein of molecular 
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the bcr gene have been identified resulting in slight variations in fusion transcripts. The 
most commonly expressed transcripts are the b3a2 and b2a2 transcripts (Deininger & 
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new sequence of amino acids in the junctional region of p210 that are not present in normal 
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intervention using a vaccine-based approach.  
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lysine in b3a2 and a glutamic acid in b2a2 is generated (Shtivelman et al., 2006). There have 
been many reports of immunogenicity of the fusion region derived peptides of p210 with 
respect to the major histocompatibility complex (MHC) class I and II. For example, the 
p210/b3a2-derived fusion protein amino acid sequences have been shown to bind to various 
class I HLA antigen molecules including A0201, A3, A11 and B8 (Berke et al., 2000) 
supporting the potential of these peptides as target for class I HLA-restricted T-cell 
cytotoxicity. However, presentation of other Bcr-Abl junctional peptides has not been 
established in other HLA types which somewhat limits the clinical potential of class I 
peptides to subpopulations with specific HLA alleles. Strategies have been implemented to 
improve the binding of HLA class I molecules by amino acid substitutions at key binding 
residues of Bcr-Abl peptides to try and overcome their somewhat poor immunogenicity 
(Pinilla-Ibarz et al., 2005). Interest has also developed in class II Bcr-Abl specific peptides 
although less is known regarding the interaction of Bcr-Abl peptides with HLA class II 
molecules (Mannering et al., 1997; Yasukawaet al., 1998). In addition several clinical trials 
have been initiated using peptide based vaccines to treat CML, often with concomitant 
treatment of interferon-alpha or imatinib (Bocchia et al., 2005; Cathcart et al., 2004; Pinilla-
Ibarz et al., 2000; Rojas et al., 2007). Results of these trials are reviewed by Pinilla-Ibarz et al., 
(2009).  
6.2 Selectively expressed and over-expressed antigens in CML 
Another potential target for immunotherapy are antigens that are selectively expressed or 
over-expressed. Wilms’ tumour antigen 1 (WT1) is a transcription factor that is over-
expressed in many human leukaemias including CML and also in solid malignancies and 
several class I restricted epitopes have been identified to date (Ariyaratana & Loeb, 2007). 
The expression of WT1 in CML has been shown to correlate with disease progression. Many 
peptides have been designed and cytotoxic T-lymphocytes generated in the presence of 
some of these peptides were able to specifically target WT1-expressing leukemic cells while 
sparing normal progenitors (Oka et al., 2000).  
The efficacy of WT1-based vaccines has been the study of a number of trials with patients 
with AML, breast cancer, lung cancer, myelodysplastic syndrome and mesothelioma with 
promising results (Chaise et al., 2008; Li Z et al., 2005; Oka et al., 2004).  
 
Myeloid Leukemia – Clinical Diagnosis and Treatment 
 
14
Another promising target in immunotherapy is PR3, a serine protease which is stored in 
neutrophils and is over-expressed in 75% of CML patients. CD8+ T cells specific for PR3 
have been identified in patients in remission following HSCT and correlated with 
cytogenetic remission (Moldrem et al., 2006). 
Several other antigens have been reported as being over-expressed in CML including 
preferentially expressed antigen of melanoma (PRAME) (Rezvani et al., 2009) and human 
telomerase reverse transcriptase (hTERT) (Gannage et al., 2005) and these may also be useful 
for immunotherapy in leukaemia.  
It is also important to note the differential and sequential expression of several tumour 
antigens in different phases of CML suggesting the importance of combining several 
antigens in the design of future vaccines. The safety and immunogenicity of a combined 
vaccine of two antigenic peptides, PR1 and WT1, has recently been described and supports 
further studies of immunisation strategies in CML patients (Rezvani et al., 2008).  
6.3 Immunomodulatory effects of TKIs 
It has been hypothesised that imatinib reduces the efficacy of graft versus leukemia effect or 
other T-cell-based immunotherapies. This is based on several studies reporting impaired T-
cell specific proliferation and responses as well as the inhibition of antigen-specific memory 
T cells (Boissel et al., 2006; Mumprecht et al., 2006). Conversely, imatinib has also been 
demonstrated to initiate an increase in IFN-gamma-producing T cells following 3 months of 
treatment and it may restore the function of Th1 helper T cells (Aswald et al., 2002).  
In vivo antitumour T-cell immunity has been observed in several clinical trials using both 
Bcr-Abl peptide vaccines and other cellular vaccines (Maslak et al., 2008 & Smith et al., 
2006). The use of imatinib in conjunction with donor lymphocyte infusion for relapsed CML 
patients following HSCT has also been shown to be efficacious suggesting that the clinical 
effect of imatinib may actually be beneficial (Olavarria et al., 2007; Savani et al., 2005). 
Second generation TKIs have also been shown to have immunomodulatory effects. For 
example, nilotinib has been shown to inhibit the expansion of CD8+ T lymphocytes specific 
for viral or leukemia antigens much more potently that the same inhibitory effect elicited by 
imatinib. These effects are thought to mediated through inhibition of phosphorylation of the 
Src family kinase Lck (Blake et al., 2008). Furthermore, dasatinib was found to inhibit T-cell 
receptor mediated signal transduction, cytokine production and in vivo T cell responses 
(Blake et al., 2008; Fei et al., 2008). Again the effect is thought to be mediated by the 
inhibition of Lck.  
7. New application of old therapies 
Interferon was the most efficacious drug in the treatment of patients in the chronic phase of 
the disease prior to the advent of TKIs. There is now evidence that interferon-alpha may 
interfere with stem cell retention in the microenvironment and that it activates dormant 
haematopoietic stem cells (Essers et al., 2009). In response to treatment of mice with 
interferon-alpha, HSCs efficiently exited the dormant G(o) and entered an active cell cycle. 
In addition, HSCs pretreated with interferon-alpha were eliminated by 5-fluorouracil 
treatment, which raises the possibility for new applications of type I interferons to target 
CML stem cells. Two large randomized studies show improved outcome when pegylated 
IFN-alpha is combined with imatinib (Hughes et al., 2010). It could be suggested that IFN-
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alpha stimulates the quiescent stem cells to proliferate thereby increasing sensitivity to 
imatinib. Although imatinib and other TKIs are very efficient, they are rarely curative. IFN-
alpha could be included in combination treatment protocols aimed at curing patients and 
thus could still be an important drug in CML treatment. 
8. Concluding remarks 
The understanding of the biology underlying CML has rapidly advanced in the last fifty 
years. From initially identifying a cytogenetic abnormality, we have gone on to translating 
this finding into treatment strategies for this disease. Imatinib has revolutionised the 
treatment of CML and for patients who fail this treatment, nilotinib and dasatinib may 
reduce the rate of progression of the disease. Indeed some of these second generation 
tyrosine kinase inhibitors may represent a better first-line treatment option for some patients 
with possible benefits including an improvement in side-effects and tolerability profiles, the 
ability to suppress a wider range of mutant clones and reaching a response milestone sooner 
thus avoiding or reducing the risk of relapse. Furthermore third generation drugs are in 
development that show activity against the T315I mutant, which has emerged as a common 
Bcr-Abl mutation based resistance mechanism. However, despite the enormous therapeutic 
benefits of TKIs these drugs do not eradicate leukaemia-initiating stem cells allowing the 
persistence of a reservoir of Bcr-Abl positive stem cells that are potentially responsible for 
disease progression. There is therefore a requirement to elucidate why CML stem cells are 
insensitive to TKIs and to define differences in quiescent versus proliferating CML stem 
cells. Thus current research should lead to development of novel therapeutic strategies that 
may eradicate the stem cell population and finally lead to a cure for CML. It is likely though 
that any new therapeutics for CML will be administered either following or in combination 
with a tyrosine kinase inhibitor. 
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1. Introduction  
1.1 Historical notes 
The last decade has witnessed profound changes in the treatment of chronic myeloid 
leukemia (CML). Previously, therapeutic options were restricted to the use of conventional 
chemotherapeutic agents such as hydroxyurea (Goldman, & Marin, 2003) and busulfan 
(Brodsky, 1993). These were essentially cosmetic treatments, offering only palliative care, and 
not substantially altering the natural history of the disease. Later in the 90s interferon alpha 
(IFNα), was introduced in the therapeutic armamentarium for CML patients (Goldman, 
2003). When used at high doses, this agent proved to be superior to conventional 
chemotherapy in terms of hematological and cytogenetic response rates. In particular, 9- or 
10-year overall survival (OS) rates in the range of 27% to 53% (Bonifazi, 2001) have been 
reported. However, residual leukemia was still detectable at the molecular level in the vast 
majority of patients (Baccarani, 2003). Overall, these observations indicated that none of 
these treatment options were curative for CML and allogeneic bone marrow transplantation 
remained the only disease-eradicating therapy, albeit at the price of substantial treatment-
related mortality, especially for the higher EBMT risk score patients (Gratwohl,  1998 ; 
Baccarani, 2006; Passweg , 2004).  
1.2 The modern era of CML treatment: the TKi revolution 
In 1960 Nowell and Hungerford, working in Philadelphia, noticed the consistent presence of 
a small abnormal chromosome in the leukemic cells of CML patients (Nowell & Hungerford, 
1960). Strikingly, this abnormality was present in nearly all cases and in all leukemic cells of 
a single patient, indicating that it could represent a disease marker and, possibly, a 
tumorigenic alteration. The abnormal chromosome was named “Philadelphia”. Since then, 
the development of more sophisticated and reliable diagnostic technologies has led to 
precise characterization of the Philadelphia chromosome (Ph) as the result of the reciprocal 
translocation t(9;22), as well as the corresponding molecular defect, consisting in the 
formation of a chimeric oncogene, BCR-ABL, from the juxtaposition of the broken ends of 
chromosomes 9 (ABL) and 22 (BCR) (Rowley, 1973) (Fig.1). Molecular biology studies 
suggested that the product of BCR-ABL was an oncoprotein, provided with constitutive 
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formation of a chimeric oncogene, BCR-ABL, from the juxtaposition of the broken ends of 
chromosomes 9 (ABL) and 22 (BCR) (Rowley, 1973) (Fig.1). Molecular biology studies 
suggested that the product of BCR-ABL was an oncoprotein, provided with constitutive 
 
Myeloid Leukemia – Clinical Diagnosis and Treatment 
 
26
phosphorylating activity (Gale & Canaani 1984; Sefton, 1981; Witte, 1980). This was shown to 
promote escape from apoptosis, uncontrollable proliferation, diminished adherence to the 
marrow stroma, and significant genetic instability (Lugo, 1990; Melo,V 2004) (Fig.2). Most 
importantly, when expressing BCR-ABL in animal models, the investigators demonstrated 
that BCR-ABL, as the sole oncogenic event, was able to induce leukemia (Lugo, 1990; Melo, 
2004). 
In the late 80s the tyrosine kinase inhibitor (TKi) program started and one leading 
compound of the 2-phenylaminopyrimidine class capable of inhibiting the ABL kinase was 
identified: STI571, or imatinib (Zimmermann, 1996; Druke, 1996; Buchdunge, 1996; Druker & 
Lydon 2000; Carrol, 1997). Since then, the drug has rapidly undergone preclinical and clinical 
development until FDA approval only 3 years after the initiation of the phase I study 
(Druker, 2001a; Druker, 2001b; Kantarjian, 2002; Sawyers, 2002). In June 2000 the landmark 
International Randomized Study of Interferon and STI571 (IRIS) was initiated. More than 
1000 previously untreated CML patients in chronic phase (CP) were randomly allocated to 
either IFN+cytosine arabinoside (ARA-C) or imatinib. The remarkable superiority of the 
latter in terms of complete hematologic, major and complete cytogenetic responses, as well 
as rates of progression to advanced disease phases, namely accelerated phase (AP) or blastic 
phase (BP), led to early closure of the study and most of IFN+ARA-C patients being crossed 
over to imatinib (Druker, 2006; O'Brien, 2003). 
 
 
Fig. 1. Schematic diagram of the translocation that results in Philadephia chromosome. The 
ABL gene resides on the long arm of chromosome 9, the BCR gene resides on the long arm of 
chromosome 22. As a result of the (9;22) translocation, a BCR-ABL gene is formed on the 
derivative chromosome 22 (Philadelphia chromosome) 
 





Fig. 2. Schematic signalling pathways activated by BCR-ABL that contribute to growth and 
survival   
Overall, the introduction of TKis in clinical practice has brought dramatic improvement in 
the rates and quality of hematologic and cytogenetic responses and has led to a paradigm 
shift in the treatment approach of CML patients. These drugs have also defined our current 
view of desirable cancer therapy as a targeted tumor cell killing using agents that directly 
interfere with oncogenetic mechanisms. Finally, CML is a significant example of the 
usefulness of molecular. These techniques may also be used to predict early treatment 
failure and to direct therapeutic choices accordingly. This chapter covers various aspects of 
CML patient molecular monitoring, including the use of well-established diagnostic 
techniques, past and ongoing standardization practices, and the role of molecular 
diagnostics in clinical practice.Some as-yet open issues and unanswered questions in the 
field will also be pointed out. 
2. Assessment and monitoring of CML: Molecular tools 
As most patients treated with TKis achieve a complete cytogenetic remission (CCyR), highly 
sensitive molecular diagnostic techniques have been implemented in parallel with the 
clinical development of these drugs. This has allowed to fully appreciate the potency of 
these compounds and, more importantly, to evaluate leukemic cell clearance and quantify 
residual disease at a much deeper level. These techniques encompass fluorescent in-situ 
hybridization (FISH), reverse transcriptase (RT)-polymerase chain reaction (PCR) and real-
time quantitative (RQ)-PCR, and will be briefly discussed. 
2.1 FISH 
This technique can be used to ascertain the presence of the BCR-ABL fusion gene in a given 
cell sample. FISH allows analysis of both dividing (metaphase) and non-dividing 
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Fig. 1. Schematic diagram of the translocation that results in Philadephia chromosome. The 
ABL gene resides on the long arm of chromosome 9, the BCR gene resides on the long arm of 
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Fig. 2. Schematic signalling pathways activated by BCR-ABL that contribute to growth and 
survival   
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interfere with oncogenetic mechanisms. Finally, CML is a significant example of the 
usefulness of molecular. These techniques may also be used to predict early treatment 
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field will also be pointed out. 
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these compounds and, more importantly, to evaluate leukemic cell clearance and quantify 
residual disease at a much deeper level. These techniques encompass fluorescent in-situ 
hybridization (FISH), reverse transcriptase (RT)-polymerase chain reaction (PCR) and real-
time quantitative (RQ)-PCR, and will be briefly discussed. 
2.1 FISH 
This technique can be used to ascertain the presence of the BCR-ABL fusion gene in a given 
cell sample. FISH allows analysis of both dividing (metaphase) and non-dividing 
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(interphase) cells (Faderl, 1999), and can be performed on either peripheral blood or bone 
marrow samples. A minimum of 200 cells should be analyzed in order for the test to be 
informative (Kantarjian, 2008). Its sensitivity is high and the upper limit of false positivity is 
1% to 5% (Dewald, 1998). The hypermetaphase FISH allows analysis of up 500 cells in 
metaphase per sample and produces no false positive results but cannot be performed on 
peripheral blood samples (Seong, 1995). The dual-color FISH (D-FISH) uses double-color 
probes that allow detection of a fusion signal. In CML, modern D-FISH strategies use a 
“green” probe to identify BCR and a “red” one to highlight ABL. A yellow signal indicates 
the presence of a BCR-ABL fusion sequence (Tefferi, 2005). This technique allows to detect 
not only the presence, but also the copy number of the fusion gene on the Ph, as well as the 
number of any additional BCR-ABL-bearing chromosomes, such as the ones resulting from 
variant translocations, cryptic translocations or insertions (Dewald,  1998). D-FISH has very 
low false-positive rates (≤0.8%) (Wolff, 2007). It should be remembered that D-FISH does not 
substitute for conventional cytogenetics because it will not detect additional cytogenetic 
abnormalities, unless specifically requested. 
CML patients show 85 to 99% of BCR-ABL-positive nuclei in bone marrow before treatment, 
which decrease to less than 1% when therapy is successful (Tefferi, 2005). FISH has been 
evaluated as an alternative to routine marrow cytogenetics for monitoring purposes (Testoni, 
2006). However, up to 18% of patients in CCyR by standard cytogenetics has 1% to more 
than 5% FISH-positive cells (Kantarjian, 2008a). The GIMEMA (Gruppo Italiano Malattie 
Ematologiche Adulto) CML working party has reported that as much as 83% of patients 
having a CCyR by conventional testing, also had <1% of BCR-ABL positive nuclei at 
interphase FISH. Conversely, among patients who had <1% positive nuclei by interphase 
FISH, 98% had a CCyR using conventional cytogentic analysis. Moreover, major molecular 
response rates were significantly higher in patients with <1% positivity by interphase FISH 
compared with patients with positivity rates of 1% to 5% (Testoni, 2009). This data show that 
interphase FISH is more sensitive than conventional karyotyping, and can be used as a 
monitoring tool in patients who are in CCyR as per classical cytogenetics (Quintás-Cardama, 
2011).  
2.2 RT-PCR 
The ABL gene encodes a 145kd non-receptor tyrosine kinase. The breakpoint in ABL occurs 
usually at 5’ (toward centromere) of exon 2 of ABL. The ABL exons 2 (a2), are translocated 
and joined to the major breakpoint cluster region (M-bcr) of the BCR gene on chromosome 
22 between exons 12 and 16 (b1 to b5). The breakpoint locations within BCR fall either 5’ 
between exons b2 and b3 or 3’ between b3 and b4. A BCR-ABL fusion gene with a b2a2 
(40%) or b3a2 (55%) junction is created and transcribed into a 8.5 kb mRNA that encodes for 
a 210 kd fusion protein termed BCR-ABL (Faderl, 1999; Sawyers 1999,Quintás-Cardama & 
Cortes 2006). A second breakpoint involves a minor cluster region on chromosome 22, which 
is located upstream at the e1a2 junction, and gives rise to an mRNA translated into 190kDa 
protein (Okamoto, 1997)(Fig.3). In 5% of cases, alternative splicing produces an e1a2 fusion 
transcript. This encodes a p230 oncoprotein, which appears to be provided with less 
pronounced oncogenic potential.  
PCR is used to detect and measure the amount of specific DNA sequences. For practical 
reasons it is easier to amplify a BCR-ABL mRNA that includes b2a2, b3a2 or e1a2 fusion 
sequences (Hughes, 1990a; Hughes, 1990b). In reverse transcriptase (RT)-PCR disease-specific 
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mRNA is first converted to complementary DNA and subsequently subjected to standard 
PCR (Sawyers,1990;Kawasaki, 1988). The resulting amplified product is then assessed by gel 
electrophoresis. Assay specificity and sensitivity in RT-PCR can be enhanced by the use of 
nested primers (nested RT-PCR) (Biernaux, 1995). Nested RT-PCR, is a two-step process. A 
first pair of PCR primers amplifies the target sequence in a standard RT-PCR. A second pair 
of primers (nested primers) then bind within the primary amplified PCR product to produce 
a second PCR product that is shorter in length. This technique is capable of detecting 1 
leukemic cell in 106 to 107 (Roth, 1992,  Lion, 1999; Lee M 1992,Dhingra K 1992) normal cells. 
Since CML patients in hematologic and cytogenetic remission may still show residual 
leukemic cells at RT-PCR, this technique has extensively been used to assess and monitor 
minimal residual disease in these cases (Cross, 1993a). However, because of the lack of 
quantitative information, positive detection of BCR-ABL transcript provides uncertain 
information and does not allow tracing disease level trends over time. Indeed, some PCR-
positive patients could maintain their minimal disease state and eventually become PCR-
negative while on therapy (Hochhaus, 2000,Hughes, 1991). 
 
 
Fig. 3. Breakpoints within the BCR and ABL genes and corriponding proteins 
2.3 RQ-PCR 
Quantification of specific sequences of DNA has been made possible by the use of RQ-PCR 
(or Q-PCR) (Mensink, 1998). Compared to RT-PCR , RQ-PCR enables accurate quantification 
of gene expression during the exponential phase of the PCR amplification process. This is 
achieved by concomitantly measuring one ubiquitously expressed housekeeping gene, such 
as ABL1, BCR, β2-microglobulin, β-glucuronidase or glucose-6-phosphate dehydrogenase. (Hughes, 
2006)  (Guo, 2002) (Beillard, 2003). Real-time PCR is based on the measurement of 
fluorescence emission during the PCR reaction. The detected fluorescence is proportional to 
the amount of target in the sample. Currently, three different RQ-PCR techniques are 
available: RQ-PCR using SYBR Green I Die, RQ-PCR using hydrolysis probes, RQ-PCR 
using hybridization probes (Gabert, 2003). The Europe Against Cancer (EAC) program 
standardized the RQ-PCR for the detection of residual disease in leukemia. This protocol 
uses the ABI 7700 platform with TaqMan probes that permit analysis of a large number of 
samples in a single run (96-well plate format). The TaqMan technology uses a single internal 
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mRNA is first converted to complementary DNA and subsequently subjected to standard 
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oligonucleotide probe bearing a 5’ reporter fluorophore and 3’ quencher fluorophore. As 
long as the two fluorochromes are in each other’s close vicinity (probe is intact), the 
fluorescence emitted by the reporter fluorochrome will be “adsorbed” by the quencher 
fluorochrome. During the amplification of the target sequence, the probe is hydrolyzed by 
the nuclease activity of the Taq polymerase, resulting in separation of the reporter and 
quencher fluorochromes and consequently in an increase in fluorescence. During each 
consecutive PCR cycle, this fluorescence will further increase because of the progressive and 
exponential accumulation of free reporter fluorochromes. In the TaqMan technology, the 
number of PCR cycles necessary to detect a signal above the threshold is called the cycle 
threshold (Ct) and is directly proportional to the amount of target present at the beginning 
of the reaction. Using standards or calibrators with a known number of molecules, one can 
establish a standard curve and determine the precise amount of target present in the test 
sample (Gabert ,2003; Mocellin,  2003; Beillard, 2003; van der Velden, 2003 ; White, 2010 ;Cross, 
1993b). A sensitivity of 1 leukemic cell in up to 105 normal elements is achievable with RQ-
PCR. False negatives (lack or sub-optimal integrity of mRNA and/or cDNA) must be 
considered and controlled (Béné & Kaeda, 2009). Although less sensitive than nested RT-PCR, 
RQ-PCR has gained an important role in CML molecular monitoring, especially to identify 
earlier patients not optimally responding to or at high risk of relapse on TKi therapy (Lange, 
2004; Serrano, 2000; Martinelli, 2000). 
3. The international scale 
Molecular diagnostics have been tested as a means of assessing patient prognosis beyond 
the predictive power of cytogenetic tools. However, there has been considerable variability 
in the results of such analyses depending on the particular testing laboratory. 
Harmonization of critical pre-analytical and procedural steps in the PCR technique has 
proven feasible and was the first significant step towards full reproducibility and 
comparability of the quantitative results provided by different laboratories using different 
RQ-PCR platforms around the world (Müller, 2009). 
One turning point in the process of harmonization has been represented by a consensus 
meeting held in Bethesda, MD, USA in 2005. An internationally recognized panel of experts 
aimed at providing recommendations to standardize the measurement of BCR-ABL RNA 
levels in any given laboratory worldwide by means of a reference scale, now known as the 
International Scale (IS) (White, 2010). The IS relies upon two specific concepts: the 
standardized baseline, or IS 100%, which is, by definition, the median pre-treatment level of 
BCR-ABL RNA in early chronic phase CML (as defined in IRIS imatinib trial), and major 
molecular response (MMR), or IS 0.1%, or a 3-log (1,000-fold) drop from the baseline value 
(Hughes, 2003; Branford, 2006). A level of IS 1-2% roughly corresponds to the threshold for 
karyotypic CCyR. Following this line, a “complete molecular remission” was defined as 
undetectable BCR-ABL transcripts, that is, below the sensitivity of the assay. A comparison 
between cytogenetic and molecular response milestones is depicted in Fig 4. The panel 
recommended a desirable test sensitivity of at least IS 0.01% (= 4-log reduction from 
baseline) (Quintás-Cardama, 2011). It is to be noted that original material from the IRIS study 
was limited and therefore is no longer available as primary reference. However, traceability 
to the IRIS scale is provided by the extensive quality control data generated by the Adelaide 
laboratory over a period of several years (Branford, 2008). 
 





Fig. 4. Relationship between response, the number of leukemic cells and the level of BCR-
ABL transcript. Reproduced and adapted with permission; Baccarani et al., Blood 2006: Sep 
15;108(6):1809-20. 
3.1 Generation of the IS 
The standardized baseline value was determined by an exchange of reference standards 
with values established in reference labs. Reference and quality control samples would have 
to be widely available for any peripheral laboratory to standardize its internal protocol. The 
easiest way to achieve such standardization is by a laboratory-specific conversion factor 
(CF), established using the Adelaide laboratory process as the initial reference (Branford, 
2008). In order for a certain laboratory to establish its own CF, typically 20-30 samples are 
exchanged with the reference laboratory that span at least 3 logs of detectable transcript 
levels, not exceeding IS 10%, to avoid distortions resulting from different control genes at 
higher disease levels. These samples are then analyzed by both laboratories over a certain 
period of time (to avoid intralab biases) and then compared. The results are plotted on a log 
scale for comparison. Lastly, they are validated through a second material exchange 
(Branford, 2008).  
Currently, there is an ongoing collaborative effort to harmonize 57 different laboratories 
across Europe in the context of the European Treatment and Outcome Study (EUTOS) for 
CML project. The European reference laboratory is in Mannheim, Germany, by direct 
 
Myeloid Leukemia – Clinical Diagnosis and Treatment 
 
30
oligonucleotide probe bearing a 5’ reporter fluorophore and 3’ quencher fluorophore. As 
long as the two fluorochromes are in each other’s close vicinity (probe is intact), the 
fluorescence emitted by the reporter fluorochrome will be “adsorbed” by the quencher 
fluorochrome. During the amplification of the target sequence, the probe is hydrolyzed by 
the nuclease activity of the Taq polymerase, resulting in separation of the reporter and 
quencher fluorochromes and consequently in an increase in fluorescence. During each 
consecutive PCR cycle, this fluorescence will further increase because of the progressive and 
exponential accumulation of free reporter fluorochromes. In the TaqMan technology, the 
number of PCR cycles necessary to detect a signal above the threshold is called the cycle 
threshold (Ct) and is directly proportional to the amount of target present at the beginning 
of the reaction. Using standards or calibrators with a known number of molecules, one can 
establish a standard curve and determine the precise amount of target present in the test 
sample (Gabert ,2003; Mocellin,  2003; Beillard, 2003; van der Velden, 2003 ; White, 2010 ;Cross, 
1993b). A sensitivity of 1 leukemic cell in up to 105 normal elements is achievable with RQ-
PCR. False negatives (lack or sub-optimal integrity of mRNA and/or cDNA) must be 
considered and controlled (Béné & Kaeda, 2009). Although less sensitive than nested RT-PCR, 
RQ-PCR has gained an important role in CML molecular monitoring, especially to identify 
earlier patients not optimally responding to or at high risk of relapse on TKi therapy (Lange, 
2004; Serrano, 2000; Martinelli, 2000). 
3. The international scale 
Molecular diagnostics have been tested as a means of assessing patient prognosis beyond 
the predictive power of cytogenetic tools. However, there has been considerable variability 
in the results of such analyses depending on the particular testing laboratory. 
Harmonization of critical pre-analytical and procedural steps in the PCR technique has 
proven feasible and was the first significant step towards full reproducibility and 
comparability of the quantitative results provided by different laboratories using different 
RQ-PCR platforms around the world (Müller, 2009). 
One turning point in the process of harmonization has been represented by a consensus 
meeting held in Bethesda, MD, USA in 2005. An internationally recognized panel of experts 
aimed at providing recommendations to standardize the measurement of BCR-ABL RNA 
levels in any given laboratory worldwide by means of a reference scale, now known as the 
International Scale (IS) (White, 2010). The IS relies upon two specific concepts: the 
standardized baseline, or IS 100%, which is, by definition, the median pre-treatment level of 
BCR-ABL RNA in early chronic phase CML (as defined in IRIS imatinib trial), and major 
molecular response (MMR), or IS 0.1%, or a 3-log (1,000-fold) drop from the baseline value 
(Hughes, 2003; Branford, 2006). A level of IS 1-2% roughly corresponds to the threshold for 
karyotypic CCyR. Following this line, a “complete molecular remission” was defined as 
undetectable BCR-ABL transcripts, that is, below the sensitivity of the assay. A comparison 
between cytogenetic and molecular response milestones is depicted in Fig 4. The panel 
recommended a desirable test sensitivity of at least IS 0.01% (= 4-log reduction from 
baseline) (Quintás-Cardama, 2011). It is to be noted that original material from the IRIS study 
was limited and therefore is no longer available as primary reference. However, traceability 
to the IRIS scale is provided by the extensive quality control data generated by the Adelaide 
laboratory over a period of several years (Branford, 2008). 
 





Fig. 4. Relationship between response, the number of leukemic cells and the level of BCR-
ABL transcript. Reproduced and adapted with permission; Baccarani et al., Blood 2006: Sep 
15;108(6):1809-20. 
3.1 Generation of the IS 
The standardized baseline value was determined by an exchange of reference standards 
with values established in reference labs. Reference and quality control samples would have 
to be widely available for any peripheral laboratory to standardize its internal protocol. The 
easiest way to achieve such standardization is by a laboratory-specific conversion factor 
(CF), established using the Adelaide laboratory process as the initial reference (Branford, 
2008). In order for a certain laboratory to establish its own CF, typically 20-30 samples are 
exchanged with the reference laboratory that span at least 3 logs of detectable transcript 
levels, not exceeding IS 10%, to avoid distortions resulting from different control genes at 
higher disease levels. These samples are then analyzed by both laboratories over a certain 
period of time (to avoid intralab biases) and then compared. The results are plotted on a log 
scale for comparison. Lastly, they are validated through a second material exchange 
(Branford, 2008).  
Currently, there is an ongoing collaborative effort to harmonize 57 different laboratories 
across Europe in the context of the European Treatment and Outcome Study (EUTOS) for 
CML project. The European reference laboratory is in Mannheim, Germany, by direct 
 
Myeloid Leukemia – Clinical Diagnosis and Treatment 
 
32
alignment with results obtained in Adelaide (Müller, 2009). In the first step, samples are 
prepared by the reference lab to specifically reflect 10, 1, 0.1, and 0.01% disease levels. These 
are then shipped to the local laboratory for analysis. The local laboratory in turn sends 
patient samples covering approximately the same transcript levels, using internal protocols, 
as well as duplicate results for the calculation of the CF. This is generated by comparing 
reference and local laboratory values by linear regression. For labs with linear results a 
preliminary CF is calculated, and then validated using the method published by Branford et 
al. (Branford, 2008). Patient samples from the peripheral laboratory are analyzed by the 
reference one. Preliminary CFs are then used to compare the patient sample results from the 
reference laboratory (each multiplied by the Mannheim CF which is 0.878) and local 
laboratories (each multiplied by their respective preliminary CF). Concordance is recorded, 
and calculation adjustments to take bias into account are made (Bland & Altman 1986, 1999, 
Müller, 2009). 
3.2 Beyond conversion factors: independent laboratory access to the IS 
Despite the above mentioned efforts to standardize local protocols for BCR-ABL mRNA 
quantitation, (Gabert, 2003) there is still substantial variation among the various laboratories 
worldwide in the way RQ-PCR is performed and results are reported. (Cross, 2009, Müller, 
2007). Such variability is evident even among laboratories that use the same commercially 
available kit. Reasons for this variability include the fact that there is no universally 
accepted control gene and the absence of independent reference materials. The use of CFs as 
a means of harmonization has undoubtedly allowed testing centers to continue use their 
internal protocols and express results according to local preferences in addition to the IS 
percentage values. Nevertheless, the establishment of CFs is a time-consuming, complex, 
and expensive procedure. Moreover, the timing with which a certain CF needs to be 
revalidated is not defined (Müller, 2009). For these reasons, a collaborative project has been 
undertaken among 11 reference laboratories worldwide with the aim of developing 
calibrated, accredited primary reference reagents for BCR-ABL RQ-PCR analysis. The 
experts chose freeze-dried K562 cells as a source of BCR-ABL and HL60 cells, known to be 
BCR-ABL-negative, as a source of control genes, including ABL, BCR and GUSB, as 
recommended by the Bethesda group. They then created a cell line mixture consisting of 
K562 cells and HL60 cells and corresponding to %BCR-ABL/ABL values of 10%, 1%, 0.1%, 
and 0.01%. Cell mixtures proved to be stable over time at temperatures below 37°C and 
homogeneous in terms of material distribution at each %BCR-ABL/control gene. This work 
has produced 3500 vials for each dilution level. Since this would be insufficient for the 
worldwide annual demand, a decision has been made to use these primary reagents as 
reference for calibration of secondary reagents that could be produced on a larger scale by 
laboratories, companies or other agencies and provided to single testing centers (White, 
2010). Although of no immediate use, the development of primary reference reagents will be 
of great importance in the future to facilitate the production of more readily available IS 
calibrated reagents worldwide. 
4. Prognostic role of molecular remission 
The attainment of a CCyR has uniformly been shown to improve event free survival (EFS) 
and OS in CML patients receiving imatinib regardless of the baseline Sokal risk score, and 
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thus has been established as a robust endpoint for CML patients treated with imatinib in CP. 
However, conflicting data exist regarding similar prognostic value of MMR in this patient 
population. There is some evidence that the achievement of an MMR at 12 or 18 months 
after imatinib initiation, or at any time after CCyR predicts superior long-term clinical 
outcomes, as well as a significantly decreased risk of disease progression to more advanced 
disease stages (AP/BP). (Baccarani, 2009b; Deininger, 2009, Hughes 2010) It is true that, 
although OS should be considered the final endpoint in such clinical trials, sustained 
survival of CML patients in CP on TKi therapy implies that very long term follow-up may 
be needed for statistically significant differences in outcome to become apparent. For this 
reason, EFS, progression free survival (PFS), and transformation-free survival (TFS) are 
often used as surrogate endpoints.   
4.1 The prognostic role of cytogenetic remission 
Data from studies on CML patients treated upfront with imatinib 400 mg daily indicate a 
CCyR rate of 45 to 59% at 6 months, 57 to 72% at 12 months and 76% at 18 months (O'Brien,2 
003; Druker, 2006; Kantarjian, 2003, 2010; Saglio, 2010; Cortes, 2010a). Patients attaining a 
CCyR were protected from disease transformation, compared with those who did not 
achieve such response degree (Deininger, 2009). Several subsequent landmark analyses 
confirmed a shorter survival free of progression to AP/BP for patients not achieving a CCyR 
both at 12 and 18 months of therapy (O'Brien, 2003). However an OS advantage was seen 
only in patients who achieved at least a partial response at 6 and 12 months versus patients 
who did not (Kantarjian, 2008b). Increasing upfront the dose of imatinib to 800 mg daily 
could not provide any survival advantage (Baccarani, 2009a). 
4.2 CCyR duration is improved in patients who achieve an MMR 
Information on the prognostic implications of molecular response in CML patients in CCyR 
on imatinib therapy was provided by the IRIS study. In that trial, 39% of patients in CCyR 
on the imatinib arm achieved a 3-log reduction in BCR-ABL values. Landmark analysis at 12 
months in patients on imatinib without disease progression revealed that PFS was 100%, 
95% and 85% for patients with CCyR and 3-log BCR-ABL reduction (proposed as the 
definition of MMR), CCyR but no such reduction, and no CCyR, respectively (Hughes, 2003, 
2006). A synopsis of relevant studies analyzing the relationship between CCyR duration and 
level of molecular response is shown in Table 1. 
Paschka et al. analyzed 323 samples from 48 Ph-positive IFNα-pretreated CML patients 
receiving imatinib. CCyR was obtained in 41 cases. At the time of best response, overall 
median BCR-ABL/ABL ratio in peripheral blood was 0.086%, but best responses of patients 
destined to relapsed were significantly higher than those of patients in continuous CCyR, 
either globally considered or in CP only (1.4% vs 0.071%, p .0017 and 2.1% vs 0.075%, p 
.0011, respectively). More importantly, whereas all 16 patients who achieved a BCR-
ABL/ABL ratio of <0.1%were still in continuous CCyR at the time of writing, 6 (46%) patients 
with ratios ≥0.1%did lose their cytogenetic response, and this was the only significantly 
different parameter between the two groups. One possible weakness of this study is the 
shortness of follow-up, of only 13 (0-35) months, especially in light of the extremely 
sustained response durations seen with TKi therapy (Paschka, 2003).  
In line with these results, Iacobucci et al. assessed 97 CML patients in late CP for the 
duration of cytogenetic response according to the level of molecular response. BCR-ABL 
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alignment with results obtained in Adelaide (Müller, 2009). In the first step, samples are 
prepared by the reference lab to specifically reflect 10, 1, 0.1, and 0.01% disease levels. These 
are then shipped to the local laboratory for analysis. The local laboratory in turn sends 
patient samples covering approximately the same transcript levels, using internal protocols, 
as well as duplicate results for the calculation of the CF. This is generated by comparing 
reference and local laboratory values by linear regression. For labs with linear results a 
preliminary CF is calculated, and then validated using the method published by Branford et 
al. (Branford, 2008). Patient samples from the peripheral laboratory are analyzed by the 
reference one. Preliminary CFs are then used to compare the patient sample results from the 
reference laboratory (each multiplied by the Mannheim CF which is 0.878) and local 
laboratories (each multiplied by their respective preliminary CF). Concordance is recorded, 
and calculation adjustments to take bias into account are made (Bland & Altman 1986, 1999, 
Müller, 2009). 
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homogeneous in terms of material distribution at each %BCR-ABL/control gene. This work 
has produced 3500 vials for each dilution level. Since this would be insufficient for the 
worldwide annual demand, a decision has been made to use these primary reagents as 
reference for calibration of secondary reagents that could be produced on a larger scale by 
laboratories, companies or other agencies and provided to single testing centers (White, 
2010). Although of no immediate use, the development of primary reference reagents will be 
of great importance in the future to facilitate the production of more readily available IS 
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thus has been established as a robust endpoint for CML patients treated with imatinib in CP. 
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reason, EFS, progression free survival (PFS), and transformation-free survival (TFS) are 
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on the imatinib arm achieved a 3-log reduction in BCR-ABL values. Landmark analysis at 12 
months in patients on imatinib without disease progression revealed that PFS was 100%, 
95% and 85% for patients with CCyR and 3-log BCR-ABL reduction (proposed as the 
definition of MMR), CCyR but no such reduction, and no CCyR, respectively (Hughes, 2003, 
2006). A synopsis of relevant studies analyzing the relationship between CCyR duration and 
level of molecular response is shown in Table 1. 
Paschka et al. analyzed 323 samples from 48 Ph-positive IFNα-pretreated CML patients 
receiving imatinib. CCyR was obtained in 41 cases. At the time of best response, overall 
median BCR-ABL/ABL ratio in peripheral blood was 0.086%, but best responses of patients 
destined to relapsed were significantly higher than those of patients in continuous CCyR, 
either globally considered or in CP only (1.4% vs 0.071%, p .0017 and 2.1% vs 0.075%, p 
.0011, respectively). More importantly, whereas all 16 patients who achieved a BCR-
ABL/ABL ratio of <0.1%were still in continuous CCyR at the time of writing, 6 (46%) patients 
with ratios ≥0.1%did lose their cytogenetic response, and this was the only significantly 
different parameter between the two groups. One possible weakness of this study is the 
shortness of follow-up, of only 13 (0-35) months, especially in light of the extremely 
sustained response durations seen with TKi therapy (Paschka, 2003).  
In line with these results, Iacobucci et al. assessed 97 CML patients in late CP for the 
duration of cytogenetic response according to the level of molecular response. BCR-ABL 
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transcript levels were significantly lower in patients maintaining their cytogenetic response, 
compared with those who subsequently relapsed. Moreover, with a median follow up time 
of 36 (12-54) months, CCyR duration was significantly longer in patients with MMR 
(defined as either an absolute BCR-ABL/β2 microglobulin % value ≤ 0.0005 or a 3-log 
reduction from pre-treatment median population or individual BCR-ABL value) both at the 
time of first CCyR and at 12 months from the start of imatinib treatment. Patients with loss 
of CCyR also showed a significantly reduced 4-year OS compared with stable CCyR patients 
(60% vs 95%, p .0004) (Iacobucci, 2006). 
 
Study No.
Length of follow-up 
in months 
(median) 
% losing CCyR 
   
Pts with MMR 
at 12 months (%) 
Pts without MMR 
at 12 months (%) 
Paschka 2003 29 13 0 46 
Cortes 2005 280 31 5 37 
Iacobucci 2006 97 36 8 30 
Marin 2008 224 46.1 2.6 23.9 
Marin 2008* 224 46.1 0 24.6 
Press 2007 90 49 16 57 
Table 1. Selected studies of the impact of molecular response on the duration of CCyR; 
*analysis at 18 months 
Prognostic relevance of MMR with imatinib as first line has also been investigated (Cortes, 
2005). Two hundred eighty previously untreated CML patients in CCyR on imatinib therapy 
with at least 1 PCR test done for follow-up were observed for a median of 31 (3-52) months 
at the M.D. Anderson Cancer Center (MDACC). MMR and complete molecular response 
(CMR) rates were 62% and 34%, respectively. CCyR was lost by 9 (5%) and 25 (37%) patients 
who did or did not achieve MMR defined as a 0.05% value, respectively (p .0001). The 
percentage of patients losing their CCyR was not significantly different between MMR and 
CMR patients (Cortes, 2005). Press et al. reached similar conclusions. They evaluated 90 CML 
patients, using a 3-log drop in BCR-ABL values from baseline as a definition of MMR. With 
a median follow-up of 49 months after the initiation of imatinib, 20 (22%) patients relapsed. 
Once again, the median BCR-ABL level as detected by RQ-PCR was significantly lower in 
patients with future stable cytogenetic response compared with those who subsequently 
relapsed at every time point from 12 to 36 months. Relapse rate was 16% in patients who 
attained MMR and 57% in patients who never did. Accordingly, relapse-free survival was 
significantly shorter in patients who did not achieve an MMR (median 46 months) versus 
patients that did (median not reached at the time of writing; p.0008), and the hazard ratio for 
relapse was 4.1 (95% confidence interval, 1.7-10; p.002) (Press, 2007). The Hammersmith 
group also has published their data from a series of 224 consecutive CML patients, with 
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particular attention to patients failing or sub optimally responding to first-line imatinib 
according to the 2006 version of the recommendations of the European LeukemiaNet (ELN). 
When analyzing the effect of molecular response on the probability of losing a CCyR, they 
found that patients in CCyR who had failed to achieve MMR at 12 or 18 months had a 
higher CCyR loss rate than patients who did achieve MMR, (23.6% versus 2.6%, p .04 and 
24.6% versus 0%, p<.006, respectively (Fig.5) (Marin, 2008). It is to be noted that these 
recommendations have been updated in 2009, but long-term considerations on these 





Fig. 5. Twelve- and 18-months landmark analyses for loss of CCyR according to the level of 
molecular response. Vertical lines represent censored patients. Reprinted with permission; 
Marin et al., Blood 2008;112(12):4437-44.  
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Once again, the median BCR-ABL level as detected by RQ-PCR was significantly lower in 
patients with future stable cytogenetic response compared with those who subsequently 
relapsed at every time point from 12 to 36 months. Relapse rate was 16% in patients who 
attained MMR and 57% in patients who never did. Accordingly, relapse-free survival was 
significantly shorter in patients who did not achieve an MMR (median 46 months) versus 
patients that did (median not reached at the time of writing; p.0008), and the hazard ratio for 
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group also has published their data from a series of 224 consecutive CML patients, with 
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particular attention to patients failing or sub optimally responding to first-line imatinib 
according to the 2006 version of the recommendations of the European LeukemiaNet (ELN). 
When analyzing the effect of molecular response on the probability of losing a CCyR, they 
found that patients in CCyR who had failed to achieve MMR at 12 or 18 months had a 
higher CCyR loss rate than patients who did achieve MMR, (23.6% versus 2.6%, p .04 and 
24.6% versus 0%, p<.006, respectively (Fig.5) (Marin, 2008). It is to be noted that these 
recommendations have been updated in 2009, but long-term considerations on these 
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molecular response. Vertical lines represent censored patients. Reprinted with permission; 
Marin et al., Blood 2008;112(12):4437-44.  
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4.3 Impact of molecular remission on long-term patient outcome 
In CML patients treated upfront with standard 400 mg imatinib daily, cumulative rates of 
MMR ranged from 12 to 40% at 12 months, and from 50 to 52% at 18 months in published 
studies. As previously mentioned, initial report from the IRIS trial on 370 patients (337 
receiving imatinib as first-line) showed a 12-month MMR rate of 39% across all Sokal risk 
groups, with PFS 100% for patients achieving both CCyR and MMR at a median follow-up 
of 25 months (O'Brien,2003; Hughes, 2010). Seven-year follow-up analysis of the same trial 
highlighted some important points: first, rates of molecular responses tend to increase with 
continuous imatinib therapy over time. At 84 months, MMR rates were 87-92% and BCR-
ABL/ABL ratio was 0.003-0.004% according to the IS (Hughes, 2010). Second, the virtually all 
MMR patients were also in CCyR at several timepoints. Third, and most importantly, at 12 
and 18 months, but not at 6 months, there was a statistically significant advantage in EFS 
and TFS for MMR versus non-MMR patients (EFS rate: 91 vs 79.4% and 94.9 vs 75.3%, 
respectively, at 12 months; TFS: 99 vs 89.9% and 99.1 vs 90.1%, respectively, at 18 months). 
However, when comparing MMR patients to those with BCR-ABL ratios of >0.1 to ≤1%, an 
advantage of EFS for the former was evident only at the 18 month time point (Fig.6), and 
TFS was only marginally significant. Moreover, in each comparison, OS did not differ 





Fig. 6. EFS at the 18-month landmark by molecular response. EFS definition does not 
include loss of CCyR. Reprinted with permission; Hughes et al., Blood 2010, Nov 
11;116(19):3758-65. 
Similar conclusions were reached by several other single center analyses. For example, when 
looking at molecular responses in their published series, the Hammersmith group found 
that, either considering the whole patient population or only patients in CCyR after 12 
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months of imatinib therapy, the achievement of MMR at 12 or 18 months did not translate 
into a 5-year PFS or OS advantage (Marin, 2008). Similarly, in the MDACC series of 269 
patients treated with imatinib upfront with more than 1 molecular evaluation available, 
molecular response at various timepoints did predict from survival (mainly PFS), but this 
was not independent from the degree of cytogenetic response, PFS only somewhat differing 
in MMR-CCyR patients (Kantarjian, 2008b). Taken together, these data led the ELN to 
express specific recommendations: that failure to achieve an MMR after 12 months of 
imatinib therapy be considered a “warning sign” (patients may require more frequent 
monitoring); that failure to achieve an MMR after 18 months of imatinib therapy be a 
criterion for defining “suboptimal” response (consider possible change in therapy). 
However, failure to achieve a MMR at any timepoint is never considered a treatment failure 
in the last version of the ELN guidelines (Baccarani, 2009).  
It is important to consider that landmark analyses are used to study patients achieving a 
certain level of response by a specific time point, different from treatment start and, by 
definition, they consider only patients who are on treatment and evaluable at that time. By 
doing so, a “better performing” population is always selected for the analysis. On the other 
hand, the definitions of cumulative CCyR, MMR, and CMR also include patients that meet 
such milestones only once over a long course of therapy with multiple serial evaluations. 
This way of reporting data may also provide a better than real picture of treatment efficacy, 
a bias avoided by landmark analyses. 
4.4 The role of early MMR 
Early identification of cancer patients failing on a certain therapy has become increasingly 
important in order to make potentially beneficial therapeutic adjustments before the end of 
treatment, and improve prognosis of patients otherwise destined to fare poorly. One such 
brilliant example is Hodgkin disease, in which a positive post-II cycle positron emission 
tomography (PET) can identify patients with dismal outcome and allow PET-oriented 
differential therapeutic strategies. In CML, several studies suggested that the degree of 
molecular response at early time points may predict later achievement of an MMR and, 
possibly, improved rates of PFS and EFS. Overall survival advantage for these patients, 
however, is little, if any, within the available follow up. Merx et al. demonstrated that a 
reduction of the BCR-ABL/ABL ratio to at least 20% of baseline after 2 months of treatment 
confers a significantly higher probability of major cytogenetic response (MCyR) later at 6 
months (Merx, 2002). In a separate analysis, although on a smaller number of patients, a 
BCR-ABL/ABL ratio reduction of 50% at 4 weeks, or a reduction of 90% at 3 months 
significantly predicted for the attainment of a MCyR at the 6 month time point. Also, with a 
median follow up of 16.5 months, there was suggestion that these achievements could 
predict better PFS. Branford et al. performed early and serial molecular follow up studies on 
55 evaluable CML patients treated with imatinib either upfront or after failure of 
IFNα+ARA-C. The authors found a median 1.6-log reduction after 3 months of first-line TKi 
therapy, not significantly different from second-line imatinib. They used the 2-log reduction 
cutpoint (grossly equivalent to a CCyR in the study) at 3 months to distinguish rapid from 
slow responders and observed that the former had a higher likelihood of achieving an MMR 
by 24 months (100% vs 54.2% p .001) (Branford, 2003a). Further confirmation of these 
findings came from an analysis conducted at the MDACC, showing that at time points 
progressively farther (ie, 3, 6, 12 months) from imatinib start, the probability of attaining a 
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months of imatinib therapy, the achievement of MMR at 12 or 18 months did not translate 
into a 5-year PFS or OS advantage (Marin, 2008). Similarly, in the MDACC series of 269 
patients treated with imatinib upfront with more than 1 molecular evaluation available, 
molecular response at various timepoints did predict from survival (mainly PFS), but this 
was not independent from the degree of cytogenetic response, PFS only somewhat differing 
in MMR-CCyR patients (Kantarjian, 2008b). Taken together, these data led the ELN to 
express specific recommendations: that failure to achieve an MMR after 12 months of 
imatinib therapy be considered a “warning sign” (patients may require more frequent 
monitoring); that failure to achieve an MMR after 18 months of imatinib therapy be a 
criterion for defining “suboptimal” response (consider possible change in therapy). 
However, failure to achieve a MMR at any timepoint is never considered a treatment failure 
in the last version of the ELN guidelines (Baccarani, 2009).  
It is important to consider that landmark analyses are used to study patients achieving a 
certain level of response by a specific time point, different from treatment start and, by 
definition, they consider only patients who are on treatment and evaluable at that time. By 
doing so, a “better performing” population is always selected for the analysis. On the other 
hand, the definitions of cumulative CCyR, MMR, and CMR also include patients that meet 
such milestones only once over a long course of therapy with multiple serial evaluations. 
This way of reporting data may also provide a better than real picture of treatment efficacy, 
a bias avoided by landmark analyses. 
4.4 The role of early MMR 
Early identification of cancer patients failing on a certain therapy has become increasingly 
important in order to make potentially beneficial therapeutic adjustments before the end of 
treatment, and improve prognosis of patients otherwise destined to fare poorly. One such 
brilliant example is Hodgkin disease, in which a positive post-II cycle positron emission 
tomography (PET) can identify patients with dismal outcome and allow PET-oriented 
differential therapeutic strategies. In CML, several studies suggested that the degree of 
molecular response at early time points may predict later achievement of an MMR and, 
possibly, improved rates of PFS and EFS. Overall survival advantage for these patients, 
however, is little, if any, within the available follow up. Merx et al. demonstrated that a 
reduction of the BCR-ABL/ABL ratio to at least 20% of baseline after 2 months of treatment 
confers a significantly higher probability of major cytogenetic response (MCyR) later at 6 
months (Merx, 2002). In a separate analysis, although on a smaller number of patients, a 
BCR-ABL/ABL ratio reduction of 50% at 4 weeks, or a reduction of 90% at 3 months 
significantly predicted for the attainment of a MCyR at the 6 month time point. Also, with a 
median follow up of 16.5 months, there was suggestion that these achievements could 
predict better PFS. Branford et al. performed early and serial molecular follow up studies on 
55 evaluable CML patients treated with imatinib either upfront or after failure of 
IFNα+ARA-C. The authors found a median 1.6-log reduction after 3 months of first-line TKi 
therapy, not significantly different from second-line imatinib. They used the 2-log reduction 
cutpoint (grossly equivalent to a CCyR in the study) at 3 months to distinguish rapid from 
slow responders and observed that the former had a higher likelihood of achieving an MMR 
by 24 months (100% vs 54.2% p .001) (Branford, 2003a). Further confirmation of these 
findings came from an analysis conducted at the MDACC, showing that at time points 
progressively farther (ie, 3, 6, 12 months) from imatinib start, the probability of attaining a 
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CCyR for patients not yet at that point decreases, while in parallel the event rate increases. 
The probability of achieving a CCyR and a MMR by the degree of BCR-ABL/ABL ratio 
reduction showed that a reduction to at least 10% conferred a significantly higher likelihood 
of achieving such goal either at 3, 6 or 12 months. Moreover, when considering the 3 month 
cut point, 3 prognostic categories were distinguishable, ie, patients with a ratio of 1% or less, 
over 1% to 10%, and greater than 10%, with distinct probabilities of achieving CCyR and 
MMR (Quintás-Cardama, 2009) 
5. Early switch to second generation TKis 
As newer and more potent therapeutic options are being made available for CML 
patients, the need for early prediction of treatment failure is becoming more and more 
urgent, and the issue of early therapeutic switch in view of a non-satisfactory response 
has recently emerged as a crucial one. In fact, the above mentioned data suggest that 
treatment should not be continued indefinitely in patients not adequately responding to 
first-line imatinib as their likelihood of later response becomes progressively narrower, 
and especially early failure should prompt a change in the strategy. This concept is 
further reinforced by an analysis of the significance of suboptimal response to imatinib at 
different time points after the start of therapy. Such analysis was conducted in 281 CML 
patients mostly in early CP. Outcome of suboptimal responders in term of EFS tended to 
be more similar to that of failing patients at 6 months, whereas it was closer to the 
optimally responders thereafter (12 and 18 months). Likewise, the likelihood of achieving 
a MMR varied over time and tended to behave similarly to that of cytogenetic response 
(Fig. 7) (Alvarado, 2009). 
Options for patients failing on imatinib include switch to a second generation TKi, namely 
nilotinib or dasatinib, and, for those who are candidates, allogeneic bone marrow 
transplantation. There is data to suggest that waiting until clinical or hematological CML 
relapse may be too late for a switch. Patients who failed INFα therapy could obtain high 
response rates and survival times if they were treated with imatinib at the time of 
cytogenetic, rather than hematologic relapse (Kantarjian, 2002, 2004). In a subsequent 
analysis from MDACC, the 3-year survival rates were 72%, 30%, and 7% for patients who 
remained in CP, progressed to AP, or to BP after imatinib failure, respectively. Moreover, 
3-year survival rates were 92% and 57% for patients treated with second generation TKis 
at cytogenetic and hematologic relapse, respectively, with hematologic relapse, but not 
(yet?) therapy, being an independent poor prognostic factor (Kantarjian, 2007). A 
subsequent cumulative analysis of three, relatively homogeneous, dasatinib trials showed 
that patients treated with this second generation TKi at the time of loss of MCyR fared 
significantly better than those who received the drug when they had lost both MCyR and 
complete hematologic remission (CHR), or lost CHR having never attained an MCyR. For 
the three groups, CCyR rates were 72%, 42%, and 26% and MMR rates were 60%, 29%, 
and 26%, respectively. Twenty four month EFS, TFS, and OS were 89%, 98%, and 98%; 
29%, 93%, and 93%; 64%, 79%, and 86% for the same three patient groups, respectively 
(Quintás-Cardama & Cortes, 2009). Whether adjusting treatment strategy in patients 
categorized as suboptimal responders at various time points could be beneficial in terms 
of survival has not been established as yet and very long-term follow-up studies may be 
needed to demonstrate a statistically significant survival advantage applying this 
strategy.  
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6. Role of molecular remission with second generation TKis 
As previously discussed, early molecular response on imatinib therapy predicts the 
probability of later achievement of an MMR, improved rates of PFS and EFS and lower the 
risk of disease transformation. Likewise, attainment of a precocious MMR may be a positive 
prognostic indicator for patients treated with the second-generation TKIs. Indeed, these 
agents have proven to work quicker than imatinib and to induce higher cytogenetic and 
molecular remission rates. This has provided the clinical rationale for successfully testing 
these agents as frontline treatment options for CML patients in chronic phase. Dasatinib 
(formerly BMS-354825) is 325-fold more potent than imatinib at inhibiting the unmutated 
form of BCR-ABL in vitro (O'Hare, 2005). This drug is chemically unrelated to imatinib and 
binds to BCR-ABL protein at a different but overlapping site (Tokarski, 2006). Nilotinib 
(formerly AMN-107) is 20-fold more potent than imatinib in vitro. It was developed through 
a modification of the chemical structure of imatinib and therefore binds to a very similar 
binding site on the BCR-ABL. However, it fits much better into the tertiary structure of the 
oncoprotein, and this enhances its biological activity (O'Hare, 2005; Weisberg, 2005). These 
two drugs were evaluated in single-arm phase I and II studies, first in patients with 
resistance or intolerance to imatinib (Quintás-Cardama, 2009a), and subsequently in the 
frontline setting. The trials showed that first-line treatment with dasatinib or nilotinib 
resulted in higher rates of CCyR and MMR earlier compared to what historically observed 
with imatinib (Cortes, 2010, 2010c). Results from two important phase III trials have been 
recently published comparing either dasatinib or nilotinib with standard dose imatinib as 
first-line treatment for patients with newly diagnosed CML in chronic phase. 
In the ENESTnd trial (Evaluating Nilotinib Efficacy and Safety in clinical Trials of Newly 
Diagnosed Ph CML patients), nilotinib was employed at two different dosages, ie 300 mg or 
400 mg twice daily. The primary endpoint of the study, MMR rate at 12 months, was largely 
met for both nilotinib dosages with MMR rates of 44%, 43% and 22% for nilotinib 300 mg 
twice daily, nilotinib 400 mg twice daily and imatinib, respectively (p<.001). CCyR rates by 
the same time point also significantly favored both nilotinib arms (80% for nilotinib 300 mg 
twice daily, 78% for nilotinib 400 mg twice daily, 65% for imatinib; both p<.001), and a 
similar trend for CCyR was evident at 6 months. Median time to MMR was 8.6 months with 
nilotinib 300 mg, 11.0 months with nilotinib 400 mg, and not reached with imatinib. Rates of 
BCR-ABL transcript reduction to or below the sensitivity limit of the PCR assay (set at ratio 
0.0032%, CMR) were 13%, 12%, and 4%, respectively (Saglio, 2010). A 24 month follow up of 
the study showed MMR and CMR rates of 71% and 26% vs 67% and 21%, vs 44% and 10%, 
respectively, for nilotinib 400 mg BID vs nilotinib 300mg BID vs imatinib. Estimated 
freedom from progression to AP/BC and PFS at 24 months were also significantly superior 
for both nilotinib arms (99.3 (p .0059) and 98.1(p .0196)) versus imatinib (95.2), although 
estimated OS rate advantage at 24 month did not reach statistical significance (Larson, 2011 ). 
In the DASISION trial (Dasatinib vs Imatinib Study in Treatment-Naive CML Patients), 
dasatinib 100 mg once daily was tested against imatinib 400 mg daily. Both CCyR and MMR 
rates at 12 months were significantly higher with dasatinib (CCyR: 83% vs 72%, p. 0011; 
MMR: 46% vs 28%, p. 0001). Rate of confirmed (c) CCyR by 12 months (the primary 
endpoint of the study) was also significantly increased (77% vs 66%, respectively; p. 0067). 
Importantly, CCyR rates at 3 and 6 months for dasatinib and imatinib were 54% vs 31% and 
73% vs 59%, respectively. Median time to MMR for patients who achieved this goal was 6.3 
months for dasatinib and 9.2 months for imatinib(Kantarjian, 2010). Recent update of this 
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study showed that 18-mo response rates for dasatinib versus imatinib were: cCCyR 78% vs 
70%, p .0366; CCyR 84% vs 78%, p.0932; and MMR 56% vs 37%, p<.0001. CMR rates for 
dasatinib and imatinib were 13% and 7%, respectively. Six (2.3%) vs 9 (3.5%) patients, 
respectively, transformed to AP or BP on study (Kantarjian, 2011a). 
The results of the trials described above clearly indicate that second generation TKis are able 
to achieve higher cytogenetic response rates and a substantially deeper leukemia clearance 
as demonstrated by the higher MMR rates and roughly doubled CMR rates in comparison 
with imatinib. Moreover, patients treated with nilotinib or dasatinib can achieve these 
important therapeutic milestones relatively early in the course of treatment, and, if the 
prognostic relevance of molecular remission will be confirmed, be possibly protected 
against the risk of loss of response and/or disease transformation later on. 
7. Treatment failure prediction 
Loss of molecular response at any time during therapy, as measured by confirmed rising 
BCR-ABL RNA levels, is considered a reliable criterion for prognosticating early treatment 
failure, and might influence an early treatment strategy change (Press, 2010). However, at 
this time, there is no uniform definition of what should be considered a “significant” rise in 
BCR-ABL transcript level (Kantarjian, 2009; Press, 2007). In their study, Press et al. found half-
log BCR-ABL increase (after adjusting for a 0.5-log interassay variability) as a threshold to 
predict for subsequent relapse as well as for shortened relapse-free survival. This retained 
its prognostic value even with imatinib dose escalation as a therapeutic response. Moreover, 
such an increase remained predictive of shortened relapse-free survival when considering 
only MMR patients (Press, 2007). 
A major cause of TKi treatment failure is the appearance of CML clones bearing BCR-ABL 
mutations that confer variable degree of insensitivity to the drug. For this reason, once rising 
BCR-ABL transcript levels are documented, screening for ABL kinase domain mutations is 
reasonable and recommended. A large number of different point mutations have been 
described over the last few years, affecting different spots in various domains of the BCR-
ABL oncoprotein. Mutations can be categorized into four groups, based upon the 
crystallographic structure of ABL: a) those which directly impair imatinib binding to the 
catalytic domain of oncogenic protein; b) those within the ATP binding site; c) those within 
the activation loop, which prevent the kinase from inactivating, required for imatinib 
binding; d) those within the catalytic domain (Baccarani, 2008). Mutations in the P-loop 
(G250E; Q252H, Y253F; E255K) may impart a particularly poor prognosis (Soverini, 2005, 
2011, Quintás-Cardama, 2006). Several technologies are available for the identification of 
BCR-ABL mutations. These include direct sequencing, subcloning and sequencing, 
denaturing high-performance liquid chromatography (D-HPLC), pyrosequencing, double-
gradient denaturing electrophoresis, allele-specific oligonucleotide PCR. Direct sequencing 
is the most widely applied. Briefly, the total RNA from whole blood leukocytes is reverse 
transcribed with random primers and the cDNA product is amplified with BCR/ABL –
specific primer set. The PCR product is then sequenced with ABL-specific primers. Standard 
dideoxy chain-termination DNA sequencing is performed and then analyzed using a 
specific software (Jones, 2008). The assay detects mutations in the ABL kinase domain 
between amino-acids 50 and 510. Direct sequencing has a detection limit of a mutation 
frequency of 20% (Branford, 2002; Hochhaus, 2002; Roche-Lestienne, 2002). Newly identified 
mutations should be confirmed by amplifying the normal ABL alleles to exclude 
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polymorphisms (Hughes, 2006). Various groups use higher sensitivity D-HPLC to routinely 
screen for kinase domain mutations, and then characterize them by sequence analysis 
(Soverini, 2004; Deininger, 2004). Strategies to circumvent mutation-induced imatinib 
resistance include imatinib dose escalation (Branford, 2003b) and switch to a second 
generation TKi. These drugs have proven particularly effective in this regard, since most 
BCR-ABL-mutated patient can still achieve a quick and high-quality cytogenetic and 
molecular response when crossed over nilotinib (Kantarjian, 2011b) or dasatinib (Quintás-
Cardama, 2009) after imatinib failure. The T315I mutation confers resistance to most TKis 
including nilotinib, dasatinib, and bosutinib (Shah, 2004).  
8. Complete Molecular Remission 
A proportion of patients in MMR on imatinib therapy, eventually achieve CMR, defined as 
undetectable BCR-ABL mRNA transcripts by real-time QPCR and/or NESTED/RT-PCR in 2 
consecutive high-quality samples (with sensitivity >104) (Baccarani, 2009b). CMR rates 
ranged from 4 to 41% in published studies. Such wide variability may be due to 
heterogeneity in treatment duration and dose, as well as in detection techniques employed. 
In the study by Press et al. 28 MMR patients on imatinib therapy eventually achieved CMR 
(3% and 18% of the entire cohort of patients at 12 and 24 months, respectively). Relapses 
occurred in 4% of CMR patients compared with 23% in MMR patients who failed to achieve 
CMR, with a median relapse-free survival of 44 versus not reached at the time of writing (p 
.0052). The achievement of a CMR, thus appears to define an excellent long-term prognosis 
and may be regarded as an optimal therapeutic goal (Press, 2007 ). Furthermore, with the 
use of second-generation TKIs (nilotinib and dasatinib) as frontline therapy for CML CP 
patients, even increased numbers of patients will ultimately achieve this level of response 
(Saglio, 2010 ; Cortes, 2009 Shah, 2004; Quintás-Cardama & Cortes 2008). 
There is ongoing effort to better define CMR from a quantitative standpoint in order to use 
and validate it as a surrogate survival endpoint. Indeed, the definition of PCR negativity is 
poorly standardized among laboratories and certainly the phrase “below the sensitivity of 
the assay” cannot be used as a reference standard because such sensitivity is laboratory-
specific by nature. Moreover, evidence that achievement of a CMR has an impact on long-
term EFS, PFS, or OS is limited, and more follow up is needed to draw any conclusion in this 
regard. In conclusion, the concept of CMR is still an evolving one, and the consistency of its 
prognostic value remains to be proved. 
9. Cure for CML? 
The absence of detectable BCR-ABL transcripts in a CML patient does not appear to indicate 
disease eradication. Ross et al. analyzed by DNA PCR 18 CML patients in sustained CMR 
after imatinib, who stopped therapy as part of a clinical trial (Ross, 2010). DNA PCR has the 
advantage of being a genomic test (RQ-PCR detects BCR-ABL mRNA in up to 30% of normal 
individuals), of being patient-specific, and of eliminating the risk of cross-contamination 
between samples. It has a sensitivity of around 1/106 (Biernaux, 1995). Seventeen of 18 
studied patients in CMR had a positive DNA PCR result at least once. Ten patients did 
relapse and these had an exponential increase in the levels of BCR-ABL DNA. However, the 
test had positive and negative predictive values of 62 and 75%, respectively, and thus 
limited value as a predictor of relapse (Ross, 2010). 
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Several studies have explored the possibility of discontinuing imatinib therapy in patients 
with long lasting CMR, but high relapse rates have been observed in these study 
populations. In the Australian CML8 study, of 18 early or late CP-CML patients, 5 did 
relapse after stopping imatinib, all within 5 months. CMR was regained in every instance 
upon resuming treatment (Ross, 2008). Recently, a prospective multicenter Stop Imatinib 
(STIM) study has been published by Mahon et al (Mahon, 2010), in which 100 CP or AP CML 
patients treated with imatinib for at least 3 years, in sustained CMR for at least 2 years, were 
asked to stop therapy and were molecularly monitored monthly for the first year and 
bimonthly for the second. Combination of imatinib with other agents such as IFNα or ARA-
C was permitted. Sixty nine of them had at least 12 months of follow-up. At a median follow 
up of 14 months, 42 of these patients relapsed molecularly after treatment discontinuation, 
mostly within 6 months, for a molecular relapse-free survival of 41% at 1 year, and 38% at 2 
years (Fig. 8). Only two patients had a fluctuation of their BCR-ABL levels and remained in 
CMR. Sex, Sokal score and imatinib treatment duration, but not previous IFNα therapy, 
were independent prognostic factors for the risk of molecular relapse. Taken together, these 
data indicate that relapse after imatinib cessation occurs relatively early in a substantial 
proportion of CML patients in sustained CMR, and argue against the discontinuation of 
imatinib therapy in responding CML patients outside the context of a clinical trial. Better 
characterization of patients with sustained molecular responses after stopping imatinib is 
needed, especially in comparison with those who subsequently relapse having the same 
baseline level of BCR-ABL transcript. The issue has not yet been addressed with the upfront 
use of second generation TKis and no comment can be made in this regard. 
 
 
Fig. 8. Kaplan-Meier estimates of complete molecular remission after discontinuation of 
imatinib in patients with chronic myeloid leukemia for the 69 patients at least 12 months of 
follow-up after discontinuation of imatinib. The estimated molecular relapse-free survival 
was 41% (29-52) at 12 months and 38% (27-50) at 24 months. Reprinted with permission. 
Mahon et al. Lancet Oncol, 2010. Nov;11(11):1029-35. 
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Several studies have explored the possibility of discontinuing imatinib therapy in patients 
with long lasting CMR, but high relapse rates have been observed in these study 
populations. In the Australian CML8 study, of 18 early or late CP-CML patients, 5 did 
relapse after stopping imatinib, all within 5 months. CMR was regained in every instance 
upon resuming treatment (Ross, 2008). Recently, a prospective multicenter Stop Imatinib 
(STIM) study has been published by Mahon et al (Mahon, 2010), in which 100 CP or AP CML 
patients treated with imatinib for at least 3 years, in sustained CMR for at least 2 years, were 
asked to stop therapy and were molecularly monitored monthly for the first year and 
bimonthly for the second. Combination of imatinib with other agents such as IFNα or ARA-
C was permitted. Sixty nine of them had at least 12 months of follow-up. At a median follow 
up of 14 months, 42 of these patients relapsed molecularly after treatment discontinuation, 
mostly within 6 months, for a molecular relapse-free survival of 41% at 1 year, and 38% at 2 
years (Fig. 8). Only two patients had a fluctuation of their BCR-ABL levels and remained in 
CMR. Sex, Sokal score and imatinib treatment duration, but not previous IFNα therapy, 
were independent prognostic factors for the risk of molecular relapse. Taken together, these 
data indicate that relapse after imatinib cessation occurs relatively early in a substantial 
proportion of CML patients in sustained CMR, and argue against the discontinuation of 
imatinib therapy in responding CML patients outside the context of a clinical trial. Better 
characterization of patients with sustained molecular responses after stopping imatinib is 
needed, especially in comparison with those who subsequently relapse having the same 
baseline level of BCR-ABL transcript. The issue has not yet been addressed with the upfront 
use of second generation TKis and no comment can be made in this regard. 
 
 
Fig. 8. Kaplan-Meier estimates of complete molecular remission after discontinuation of 
imatinib in patients with chronic myeloid leukemia for the 69 patients at least 12 months of 
follow-up after discontinuation of imatinib. The estimated molecular relapse-free survival 
was 41% (29-52) at 12 months and 38% (27-50) at 24 months. Reprinted with permission. 
Mahon et al. Lancet Oncol, 2010. Nov;11(11):1029-35. 
 




Molecular monitoring of CML patients in CP receiving TKis as first-line treatment or after 
IFNα failure has emerged in recent years as a reliable, non-invasive diagnostic tool for 
assessing disease burden and treatment efficacy, and has replaced serial cytogenetic studies 
for these purposes. TKi therapy has dramatically increased the rates of high-quality 
response (ie, CCyR, MMR or CMR) compared to historical treatment options. Molecular 
studies, ie, RT- or RQ-PCR, allow appreciating this potency well under the threshold of 
classical cytogenetics. PCR protocols vary among different testing laboratories worldwide 
and may not provide fully comparable results and, ultimately, homogeneous measurement 
of treatment outcomes. The International Scale has represented a milestone in the 
achievement of harmonization of molecular monitoring and comparability of the test 
results. The first World Health Organization International Genetic Reference Panel for 
quantitation of BCR-ABL mRNA has been a major step forward in the standardization 
program allowing laboratory independent access to the IS. 
The achievement of a MMR has consistently been shown to predict for sustained CCyR in 
TKi treated CML patients, and is a marker of long-term EFS and PFS versus CCyR patients 
that do not reach this milestone. Whether this will translate into benefit remains to be seen 
and longer patient follow-up will be needed. In addition, early attainment of a significant 
BCR-ABL transcript level drop or a formal MMR may signify long-term protection from 
disease transformation into the AP/BP, and, possibly, survival benefit. Second generation 
TKis, namely dasatinib and nilotinib have recently been approved for first-line use in CML 
patients in chronic phase. These agents allow an even higher fraction of patients to enter 
MMR within 6 months of therapy, providing an additional strong rationale for their upfront 
employment. 
Confirmed rising BCR-ABL RNA levels, usually precedes cytogenetic and, eventually, 
clinical CML relapse, thus early predicting treatment failure, and prompting precocious 
strategy change. However, there is no consensus on when rise in BCR-ABL transcript level 
should be considered “significant”. BCR-ABL point mutation screening is recommended 
whenever a consistent transcript rise is documented and appropriate therapeutic action 
should be taken accordingly. 
Complete molecular remission may indicate the achievement of an even greater leukemic 
burden breakdown, but probably not yet disease eradication. Moreover, the definition of 
CMR has not been standardized yet, and its value as a positive prognosticator in CML 
patients treated with TKis in CP remains to be demonstrated. Finally, discontinuation of 
imatinib in patients with sustained CMR has been followed by disease relapse in more than 
50% of patients, and cannot be recommended at this time. 
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1. Introduction 
The therapy with imatinib became the standard of care for the initial treatment of chronic 
myeloid leukemia (CML) regardless of age, disease status or prognostic scores. Based on the 
most recent update of the International Randomized Interferon versus STI571 (IRIS) study 
comparing imatinib 400 mg once daily with interferon alpha plus low doses of Ara C the 
overall survival (OS) of CML patients at 8 years has improved dramatically to 85% 
(Deininger et al., 2009) and the estimated median survival is estimated to improve to more 
than 20 years. In consequence, this will increase the prevalence of CML patients in Europe 
dramatically from about 70.000 to 120.000 in 2011 to 160.000 and more than 300.000 in the 
year 2050, assuming a stable incidence of CML between 1 to 2 per 100.000 persons. 
Interestingly, despite this dramatic success in the therapy of CML with imatinib 400 mg 
once daily the maximum tolerated dose of imatinib has not been identified in the phase I 
study (Druker et al., 2001). Nevertheless, there is clear evidence of a dose response 
relationship from pre-clinical models as well as from the phase I study (Druker et al., 2001; 
Druker et al., 1996; Deininger et al., 1997; Cambacorti-Passerini et al., 1997). The main reason 
for choosing a dose of 400mg as starting dose for subsequent clinical trials was the fact that 
early and significant rates of hematologic and even more important, major and complete 
cytogenetic responses were achieved with the 400 mg dose that were not further increased 
with higher doses in these early times (Druker et al., 2001). In contrast, drug related adverse 
events (AEs), especially WHO grade 3 or 4 AEs that were not seen with imatinib doses up to 
300 mg slightly increased with higher doses ranging from 600 mg up to 1000 mg per day. In 
general, however, imatinib was well tolerated even at higher doses and demonstrated a 
clear benefit over interferon alpha plus low doses of Ara C in terms of both, efficacy and 
tolerability (Druker et al., 2001). 
2. Phase II studies on High Dose (HD) imatinib in Chronic Phase (CP) 
The rational for the use of higher imatinib doses frontline in CP CML patients is that despite 
the impressive results with 400 mg once daily a substantial number of patients experiences 
only suboptimal responses according to the criteria of the European Leukemia Net (ELN) 
(Baccaranai, JCO 2006, 2009) or a minority of patients even fails to reach a response. Early 
good responses are known to be associated with a favorable long-term outcome as shown 
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for choosing a dose of 400mg as starting dose for subsequent clinical trials was the fact that 
early and significant rates of hematologic and even more important, major and complete 
cytogenetic responses were achieved with the 400 mg dose that were not further increased 
with higher doses in these early times (Druker et al., 2001). In contrast, drug related adverse 
events (AEs), especially WHO grade 3 or 4 AEs that were not seen with imatinib doses up to 
300 mg slightly increased with higher doses ranging from 600 mg up to 1000 mg per day. In 
general, however, imatinib was well tolerated even at higher doses and demonstrated a 
clear benefit over interferon alpha plus low doses of Ara C in terms of both, efficacy and 
tolerability (Druker et al., 2001). 
2. Phase II studies on High Dose (HD) imatinib in Chronic Phase (CP) 
The rational for the use of higher imatinib doses frontline in CP CML patients is that despite 
the impressive results with 400 mg once daily a substantial number of patients experiences 
only suboptimal responses according to the criteria of the European Leukemia Net (ELN) 
(Baccaranai, JCO 2006, 2009) or a minority of patients even fails to reach a response. Early 
good responses are known to be associated with a favorable long-term outcome as shown 
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previously in patients from the IRIS study where none of the patients that achieved a 
complete cytogenetic response (CCyR) and a major molecular response (MMR) at 18 
months progressed during the follow up phase (Druker et al., 2006). The first non-
randomized study using high doses of imatinib front-line was performed at the M. D. 
Anderson Cancer Center with CML patients in chronic phase (CP) of their disease after 
failure to interferon alpha (IFN alpha) (Cortes et al, 2003). Cortes and colleagues treated 
36 CP CML patients after failure to interferon alpha with 400 mg of imatinib twice daily 
(total daily dose of imatinib: 800mg) and 90% of the evaluable patients achieved a major 
cytogenetic response (MCyR) and 89% a CCyR. Moreover, this treatment with HD 
imatinib was also associated with a high rate of molecular remissions. In 50% and 56%, 
however, the dose of imatinib had to be reduced to 600 mg or 400 mg after 3 months and 6 
months, respectively. The most common cause for dose reduction in this pre-treated 
patient population was myelosuppression including thrombocytopenia and neutropenia 
(Cortes et al, 2003). Nevertheless, 71% of the patients were at least capable to continue 
with an imatinib dose of ≥ 600 mg. In a subsequently performed phase II study in 114 
newly diagnosed CP CML patients, high imatinib doses of 800 mg per day were capable 
to induce a MCyR in 96% and a CCyR in 90% of the patients. The estimated 2 year 
survival rate was 94% (Kantarjian et al., 2004). In terms of toxicity the higher doses of 
imatinib were comparable to the standard imatinib dose of 400 mg in regard to non-
hematologic toxicities. Hematologic toxicities were again higher with the imatinib 800 mg 
dose compared to historical controls. In this trial on newly diagnosed CML patients in CP 
the dose of 800 mg of imatinib could be maintained in 64% of the evaluable patients at 6 
months and in 66% of the evaluable patients at 12 months (Kantarjian et al., 2004). The 
data from both studies suggested that higher doses of imatinib were capable to induce 
higher rates of cytogenetic (both MCyR and CCyR) and molecular responses with the 
price of more frequent myelosuppression. The Italian GIMEMA CML working party 
prospectively investigated efficacy and tolerability of high dose imatinib (800 mg per day) 
in a multi-institutional trial (Castagnetti et al., 2009) focusing on a particular subgroup of 
newly diagnosed CML patients in CP, namely on 78 patients with intermediate SOKAL 
risk score. (Sokal et al., 1984). They found high rates of CCyR (88%) at 12 months and at 24 
months (91%), respectively. Furthermore 56% and 73% of the patients having achieved a 
CCyR also achieved a major molecular remission (MMR) at 12 and 24 months. They 
reported on slightly more frequent non-hematologic toxicities like skin rash, myalgia, 
bone pain, gastrointestinal intolerance, fluid retention and asthenia compared to reported 
studies with standard dose imatinib. Moreover, they also found WHO grade 3 and 4 
hematologic toxicities in terms of leukopenia (18%), thrombocytopenia (17%) and anemia 
(9%). Between month 3 and 6 (second quarter of therapy) 44% of the patients received the 
full scheduled dose of 400 mg twice daily (Castagnetti et al., 2009). Another multicenter 
phase II study, the “Rationale and Insight for Gleevec High – Dose Therapy (RIGHT) trial 
was conducted in 115 newly diagnosed CML patients in CP (Cortes et al., 2009). This 
study has again suggested that imatinib 800 mg per day leads to a more rapid reduction 
in tumor burden with higher rates of MCyR, CCyR and major molecular responses 
(MMRIS) according to the international scale (IS) compared to historical controls for the 
price of a slightly increased toxicity including myelosuppression, rash, fatigue and 
musculoskeletal symptoms (Cortes et al., 2009). In this multicenter trial, 64% of the 
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patients attained 90% or more of the planned dose. The dose intensity was similar in 
patients younger than 65 years or in patients ≥ 65 years. The authors reported that the 
patients with ≥ 90% dose intensity had a significantly higher chance to obtain a MMRIS 
and a complete molecular remission (CMR) at 18 months: 79% of the patients who 
received ≥ 90% dose intensity achieved a MMRIS compared to only 42% of the patients 
who received < 90% dose intensity (p=0.015). Similarly, a CMR (defined as a ≥ 4.5 log 
reduction from a standardized baseline) was achieved at 18 months by 67% of the patients 
that received ≥ 90% dose intensity compared to 29% of patients that received < 90% dose 
intensity (p=0.029). 
A slightly different approach was chosen by the Australasian Leukemia and Lymphoma 
group (ALLG) that conducted a “Therapeutic Intensification in DE-novo Leukemia” 
(TIDEL) phase II study (Hughes et al., 2008). Compared to all other phase II studies they 
did not start with 800 mg imatinib per day but with a slightly lower dose of imatinib with 
600 mg per day in newly diagnosed CP CML patients and allowed an early dose 
intensification to 800 mg imatinib if specific response criteria were not met. All patients 
had an intense response monitoring of marrow cytogenetics and blood for RT-PCR of 
BCR-ABL mRNA levels every 3 months. The rationale for this design was the assumption 
that many patients would receive excellent responses with only 600 mg imatinib instead 
of 800 mg and that the 800 mg imatinib dose could be limited to those patients not 
achieving an optimal response with the 600 mg dose. The criteria for increasing the 
imatinib dose were as follows: failure to achieve a complete hematological response 
(CHR) at 3 months, a MCyR at 6 months, a CCyR at 9 months and a MMRIS (defined as 
less than 0.01% BCR-ABL by RQ-PCR on the international scale) at 12 months. Within the 
first year a dose escalation from 600 mg to 800 mg imatinib was indicated in 17 out of 103 
patients but only possible in 8 patients (47%) primarily due to ongoing toxicity or 
subsequent trial withdrawal. These patients failed to achieve or failed to maintain a 
MCyR at 6 months or a CCyR at 9 months. After the first year a dose escalation was 
indicated in 73 patients because these patients did not achieve MMRIS. Dose escalation 
was possible in 62% of the cases. Using this two-step design, the rates of CCyR were 88% 
at 12 months and 90% at 24 months, respectively. These CCyR-rates were significantly 
better than those obtained in the IRIS trial (CCyR was 69% at 12 months and 80% at 24 
months, respectively) where dose escalations were not allowed at early time points. 
Similarly were MMRIS rates superior with 47% at 12 months and 73% at 24 months in 
patients receiving a daily average dose of 600 mg imatinib compared to the IRIS trial (40% 
MMR at 12 months and 55% at 24 months).  
In summary, all these phase II studies suggest earlier and higher rates of cytogenetic and 
molecular remissions with higher imatinib doses for the price of slightly higher non-
hematologic toxicities and higher rates of hematologic toxicities. There was hope and 
enthusiasm – based on these studies - that earlier achievement of cytogenetic remissions, 
especially CCyR and molecular remissions would result in lower rates of treatment failures 
and subsequently translate in superior overall survival rates.  
3. Phase III studies on High Dose imatinib in Chronic Phase (CP) 
Based on the superior rates of cytogenetic and molecular responses that occur faster with 
doses > 400 mg imatinib, several phase III studies were initiated on this issue (Table 1).  
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patients attained 90% or more of the planned dose. The dose intensity was similar in 
patients younger than 65 years or in patients ≥ 65 years. The authors reported that the 
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Study Author Design Primary end point 
Comparison HD* vs 
SD** 
TOPS Cortes et al., 2010 newly diagnosed CP patients, 
n=476 
800 mg imatinib/day vs 400 mg 
imatinib/day 
MMRIS at 12 months: 
46% vs 40%  
p=0.2035 
ELN Baccarani et al., 
2009b 
newly diagnosed SOKAL high risk 
CP patients, n=216 
800 mg imatinib/day vs 400 
mg/day 
CCR at 12 months: 
64% vs 58% 
p=0.435 
ISTAHIT Petzer et al., 2010a non-TKI pre-treated patients in late 
CP, n=227; 800 mg imatinib/day 
for 6 months,  
400 mg imatinib thereafter as 
maintenance vs 400 mg 
imatinib/day 
MCyR at 12 months: 





Hehlmann et al., 
2011 
newly diagnosed CML patients, 
tolerability adapted 800 mg 
imatinib/day vs 400 imatinib 
mg/day 
MMRIS at 12 months: 
59% vs 44% 
p<0.001 
*HD: imatinib high dose (>400 mg/day) 
**SD: imatinib standard dose (≤400 mg/day) 
Table 1. Randomized phase III Studies comparing HD imatinib (600 mg - 800 mg per day) to 
SD imatinib (400 mg per day) 
3.1 The tyrosine kinase inhibitor optimization and selectivity study (TOPS) 
The tyrosine kinase inhibitor optimization and selectivity study (TOPS) evaluated the safety 
and efficacy of the initial treatment with imatinib 800 mg (400 mg twice daily) versus the 
regular 400 mg once daily dosing in newly diagnosed CML patients in CP (Cortes et al., 
2010). In this study all CP CML patients were included regardless of their Sokal risk status 
(Sokal et al., 1984). In spite of the fact that molecular (MMRIS) and cytogenetic responses 
(CCyR) occurred faster in patients assigned to the 800 mg dose these parameters were not 
significantly different at 12 months. This included the primary endpoint, the MMRIS rate at 
12 months which was only slightly, but not statistically significantly different with an 
MMRIS rate of 46% in the 800 mg and 40% in the 400 mg group (p=0.2035), respectively. 
Moreover, the progression free survival (PFS) and overall survival (OS) was also only 
slightly, but not statistically significantly improved with a PFS of 97.4% and an OS of 98.2% 
at 18 months in the imatinib 800 mg arm compared to a PFS of 95.0% and an OS of 98.7% at 
18 months in the 400 mg arm. Progression to AP or BC occurred in 1.9% in the 800 mg arm 
and in 3.2% in the 400 mg arm. Adverse events (AE) were generally reported to be mild or 
moderate in both arms. Rates of all-grade and WHO grade 3 or 4 AEs, however, were higher 
in the imatinib HD group (98.1% all grades and 63.6% WHO grade 3 or 4 AEs in the 800 mg 
group versus 93.6% all grades and 33.1% in the 400 mg group, respectively). Hematologic 
AEs including leukopenia, neutropenia, thrombocytopenia and anaemia were more 
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common in the 800 mg arm. Interestingly, biochemical abnormalities like 
hypophosphatemia, hypocalcaemia or transaminase elevations were not different between 
the 2 arms and were generally low except hypophosphatemia (12% in the 800 mg and 14.6% 
in the 400 mg imatinib arm, respectively). AEs in general led to a higher discontinuation rate 
of 9.4% in the imatinib HD group compared to 3.8% the 400 mg group. Half of the patients 
in the high dose arm required a dose reduction to < 600 mg at some point during the study. 
Nevertheless, the average daily doses of imatinib were 662 mg in the HD arm and 388 mg in 
the standard dose arm. At 12 months, 61% of the patients in the HD arm were still treated 
with their assigned dose and 78% of the patients in the HD arm were capable to take an 
imatinib dose of at least 600 mg per day.  
3.2 High dose imatinib for Sokal high risk patients? 
Potential candidates that were thought to benefit particularly from HD imatinib were 
patients with a high Sokal risk score (Sokal et al., 1984). A retrospective subgroup analysis of 
115 patients in the TOPS trial, however, reveals an almost identical overall CCyR rate by 12 
months for both groups (61.9% CCyR with 400mg/day and 63.0% with HD imatinib, p=1.0) 
and a slightly improved MMRIS rate at 12 months for the HD group (26.2% MMRIS with 
imatinib 400mg/day and 39.7% MMRIS with HD imatinib, p=0.16). The number of patients 
in the high Sokal risk group was, however, too small to draw definitive conclusions (n=68). 
A study on this particular patient population (i.e. patients with high Sokal risk score) was 
initiated by the ELN with a prospective trial that compared imatinib 400 mg and 800 mg 
daily in the front-line treatment of 216 Sokal high risk CML CP patients (Baccarani et al., 
2009a). This study, however, failed to demonstrate any benefit for HD imatinib over 
standard dose for the Sokal high risk population. The CCyR rate at 12 months (the primary 
endpoint of the study) was similar with 64% CCyR in the HD arm and 58% CCyR in the 
imatinib standard dose arm (p=0.435). CCyR rates, however, appeared to be related to the 
actual dose as 96% of the patients that were capable to take the intended dose of 800 mg 
imatinib in fact achieved a CCyR. In contrast, CCyR was lowest with 20% in patients 
assigned to the HD arm with an average daily dose of less than 400 mg imatinib per day. 
Furthermore, no significant differences could be detected in cytogenetic or molecular 
responses at any time and OS, PFS and event free survival (EFS) were also not different. The 
authors of this study therefore have suggested that HD imatinib (800 mg per day) cannot be 
recommended as front-line therapy in CML Sokal high risk patients (Baccarani et al., 2009a). 
In an additional study that compares a tolerability-adapted 800 mg imatinib dose per day 
with the standard 400 mg dose in newly diagnosed CML patients from the German CML 
study group in cooperation with the Swiss group for clinical research (SAKK) and which is 
described in detail below, the authors report that the rapidly occurring MMRIS that they 
noticed with the tolerability-adapted 800 mg imatinib dose were only observed in low- and 
intermediate-risk but not in high-risk patients according to the Sokal and the EuroScore 
(Hasford et al., 1998), another prognostic score that was initially developed to predict the 
survival of CML patients treated with interferons. For unknown reasons high-risk patients 
seem to be less responsive to any therapy including HD imatinib, although nowadays even 
Sokal high-risk CML patients benefit significantly from imatinib therapy compared to 
treatments from the pre-imatinib era and the survival has improved dramatically even in 
this high-risk cohort. 
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Study Author Design Primary end point 
Comparison HD* vs 
SD** 
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n=476 
800 mg imatinib/day vs 400 mg 
imatinib/day 
MMRIS at 12 months: 
46% vs 40%  
p=0.2035 
ELN Baccarani et al., 
2009b 
newly diagnosed SOKAL high risk 
CP patients, n=216 
800 mg imatinib/day vs 400 
mg/day 
CCR at 12 months: 
64% vs 58% 
p=0.435 
ISTAHIT Petzer et al., 2010a non-TKI pre-treated patients in late 
CP, n=227; 800 mg imatinib/day 
for 6 months,  
400 mg imatinib thereafter as 
maintenance vs 400 mg 
imatinib/day 
MCyR at 12 months: 





Hehlmann et al., 
2011 
newly diagnosed CML patients, 
tolerability adapted 800 mg 
imatinib/day vs 400 imatinib 
mg/day 
MMRIS at 12 months: 
59% vs 44% 
p<0.001 
*HD: imatinib high dose (>400 mg/day) 
**SD: imatinib standard dose (≤400 mg/day) 
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2010). In this study all CP CML patients were included regardless of their Sokal risk status 
(Sokal et al., 1984). In spite of the fact that molecular (MMRIS) and cytogenetic responses 
(CCyR) occurred faster in patients assigned to the 800 mg dose these parameters were not 
significantly different at 12 months. This included the primary endpoint, the MMRIS rate at 
12 months which was only slightly, but not statistically significantly different with an 
MMRIS rate of 46% in the 800 mg and 40% in the 400 mg group (p=0.2035), respectively. 
Moreover, the progression free survival (PFS) and overall survival (OS) was also only 
slightly, but not statistically significantly improved with a PFS of 97.4% and an OS of 98.2% 
at 18 months in the imatinib 800 mg arm compared to a PFS of 95.0% and an OS of 98.7% at 
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moderate in both arms. Rates of all-grade and WHO grade 3 or 4 AEs, however, were higher 
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in the 400 mg imatinib arm, respectively). AEs in general led to a higher discontinuation rate 
of 9.4% in the imatinib HD group compared to 3.8% the 400 mg group. Half of the patients 
in the high dose arm required a dose reduction to < 600 mg at some point during the study. 
Nevertheless, the average daily doses of imatinib were 662 mg in the HD arm and 388 mg in 
the standard dose arm. At 12 months, 61% of the patients in the HD arm were still treated 
with their assigned dose and 78% of the patients in the HD arm were capable to take an 
imatinib dose of at least 600 mg per day.  
3.2 High dose imatinib for Sokal high risk patients? 
Potential candidates that were thought to benefit particularly from HD imatinib were 
patients with a high Sokal risk score (Sokal et al., 1984). A retrospective subgroup analysis of 
115 patients in the TOPS trial, however, reveals an almost identical overall CCyR rate by 12 
months for both groups (61.9% CCyR with 400mg/day and 63.0% with HD imatinib, p=1.0) 
and a slightly improved MMRIS rate at 12 months for the HD group (26.2% MMRIS with 
imatinib 400mg/day and 39.7% MMRIS with HD imatinib, p=0.16). The number of patients 
in the high Sokal risk group was, however, too small to draw definitive conclusions (n=68). 
A study on this particular patient population (i.e. patients with high Sokal risk score) was 
initiated by the ELN with a prospective trial that compared imatinib 400 mg and 800 mg 
daily in the front-line treatment of 216 Sokal high risk CML CP patients (Baccarani et al., 
2009a). This study, however, failed to demonstrate any benefit for HD imatinib over 
standard dose for the Sokal high risk population. The CCyR rate at 12 months (the primary 
endpoint of the study) was similar with 64% CCyR in the HD arm and 58% CCyR in the 
imatinib standard dose arm (p=0.435). CCyR rates, however, appeared to be related to the 
actual dose as 96% of the patients that were capable to take the intended dose of 800 mg 
imatinib in fact achieved a CCyR. In contrast, CCyR was lowest with 20% in patients 
assigned to the HD arm with an average daily dose of less than 400 mg imatinib per day. 
Furthermore, no significant differences could be detected in cytogenetic or molecular 
responses at any time and OS, PFS and event free survival (EFS) were also not different. The 
authors of this study therefore have suggested that HD imatinib (800 mg per day) cannot be 
recommended as front-line therapy in CML Sokal high risk patients (Baccarani et al., 2009a). 
In an additional study that compares a tolerability-adapted 800 mg imatinib dose per day 
with the standard 400 mg dose in newly diagnosed CML patients from the German CML 
study group in cooperation with the Swiss group for clinical research (SAKK) and which is 
described in detail below, the authors report that the rapidly occurring MMRIS that they 
noticed with the tolerability-adapted 800 mg imatinib dose were only observed in low- and 
intermediate-risk but not in high-risk patients according to the Sokal and the EuroScore 
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survival of CML patients treated with interferons. For unknown reasons high-risk patients 
seem to be less responsive to any therapy including HD imatinib, although nowadays even 
Sokal high-risk CML patients benefit significantly from imatinib therapy compared to 
treatments from the pre-imatinib era and the survival has improved dramatically even in 
this high-risk cohort. 
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3.3 Imatinib standard dose versus high dose induction trial (“ISTAHIT” study) 
A different approach was tested by the Central European Leukemia Study Group 
(CELSG) in the international multicentre Imatinib STAndard dose versus High dose 
Induction Trial (“ISTAHIT”) ( Petzer et al., 2010a). Different from the other phase III trials 
that tested HD imatinib versus the standard dose they tested pre-treated CML patients in 
CP. These patients were - although pre-treated - tyrosine kinase inhibitor (TKI) naïve but 
pre-treated with drugs from the pre-imatinib era, such as hydroxyurea, interferons, 
busulfan or Ara-C. The medium number of pre-treatments before study entry was 2. 
Overall, this patient population was in later CP of their disease and subsequently at a 
higher risk for disease progression. In addition, HD imatinib (800 mg per day) was limited 
to the first 6 months of therapy and then reduced to 400 mg as “maintenance” therapy. 
The reasons for choosing this strategy were a “hit hard and early” concept in order to 
achieve rapid and deep cytogenetic and molecular responses on the one hand and 
concerns on reported hematotoxicity on the long term on the other hand, especially in 
regard to this pre-treated patient population in later chronic phase (Cortes et al, 2003). A 
report on a planned interim analysis (after half of the patients had been treated for 12 
months) demonstrated significant improvements in the rates of MCyR and CCyR at early 
time points such as 3 and 6 months as well as in MMRIS at 6 months in favour of HD 
imatinib compared to the standard dose (400 mg once daily) (Petzer et al., 2010a). As 
expected for this heavily pre-treated patient population, WHO grade 3 and 4 
hematotoxicity was significantly increased during the first 6 months in HD imatinib arm, 
whereas WHO grade 3 and 4 non-hematotoxic AEs were comparable. Notably, severe 
infections were not improved in spite of the higher rates of leukopenias and neutropenias. 
In a first report on the final analyses of this study the authors have reported that in spite 
of the fact that significantly higher and more rapid cytogenetic responses occurred not 
only at early time points but even at later time points when HD imatinib was already 
reduced to standard dose after 6 months (e.g. CCyR at 12 months was superior with 52.9% 
in the experimental HD arm compared to 31.8% in standard dose imatinib arm; p=0.006; 
MMRIS at 24 months was 42.5% compared to 26.5% in favour of the experimental HD arm; 
p=0.034 ) the strategy of using high doses of imatinib as induction therapy again did not 
improve OS and PFS (Petzer et al., 2010b). In general, in terms of the biologic effects (i.e. 
the achievement of cytogenetic and molecular responses) the data are similar to other 
imatinib HD trials, where imatinib was at least intended to be given throughout the entire 
study period.  
3.4 Tolerability-adapted 800 mg imatinib: Experience form the German CML-SG and 
the Swiss group for clinical research (SAKK) 
Another slightly different approach was chosen by the German CML study group in 
cooperation with the Swiss group for clinical research (SAKK) (Hehlmann et al). They 
tried to optimize the therapy for newly diagnosed CML patients in CP by comparing a 
tolerability-adapted 800 mg imatinib dose per day with the 400 mg dose in order to avoid 
higher grade toxicity. In the imatinib 800 mg/day arm the full 800 mg dose was given 
after a 6-week-run-in period with 400 mg imatinib per day to avoid excessive cytopenias. 
The median dose of imatinib in the tolerability-adapted 800 mg arm was 628 mg per day 
compared to 400 mg in the 400 mg per day arm. The highest median dose of imatinib was 
reached in the second 3-month period (month 3 to 6) with 737 mg per day. Thereafter, the 
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dosage decreased to around 600 mg/day due to adaptation of the dose to tolerability 
according to the protocol. Again, significantly higher rates of CCyR and MMRIS were 
achieved with the higher imatinib dosage compared to the 400 mg per day dose at earlier 
time points (e.g. at 6 and 12 months, respectively) but these differences again 
subsequently decreased at later time points (e.g. MMRIS at 36 months was 81.6% for the 
tolerability-adapted 800 mg imatinib dose and 79.3% for the imatinib standard dose arm 
with 400 mg per day). AEs were more frequent with 800mg imatinib per day, especially 
oedemas and gastrointestinal problems, but WHO grade 3 and 4 AEs were reported to be 
rare and not more frequent in the tolerability-adapted 800 mg imatinib dose arm. 
Although the rates of MMRIS by 12 months were superior in the tolerability-adapted 800 
mg imatinib dose arm and the achievement of MMRIS by 12 months was directly 
associated with an improved survival no differences were reported by the authors for OS 
(2-year survival was 96.0% in the tolerability-adapted 800 mg dose arm and 96.9% in the 
imatinib 400mg dose arm, respectively) and PFS when comparing the 2 different 
treatment arms. This also includes progressions and numbers and causes of death 
(Hehlmann et al). 
Taking all these phase III studies on early dose intensification of imatinib into consideration 
one has to state that so far none of these studies has demonstrated a substantial benefit over 
the standard dose of 400 mg/day, especially in terms of OS or PFS. This is somehow 
surprising as the majority of the studies showed a significantly higher rate of cytogenetic 
and molecular responses occurring at earlier time points. An improved early response was 
recently linked to a prolonged survival in CML-patients (Hughes et al.,2010; Iacobucci et al., 
2006). These data were, however, collected from CP CML patients that were all treated 
upfront with a daily imatinib dose of 400 mg. It very much looks as if, over time, the 
inhibitory effect of imatinib reaches a plateau that is accomplished earlier with higher doses 
of imatinib and later with the standard 400 mg dose and no clear evidence has been 
available so far that under these circumstances these earlier responses will translate into an 
improved survival. Maybe a longer follow-up will give us the appropriate answer. For the 
moment, based on the data available so far, an initial high dose imatinib treatment with 800 
mg per day cannot be recommended at the present time outside of clinical studies. A longer 
follow-up will show whether initial higher imatinib doses will possibly translate into 
improved long-term outcomes. 
4. Dose escalation after imatinib failure 
As outlined above, up front dose escalation with imatinib leads to improved and earlier 
cytogenetic and molecular responses in CML patients in CP but this has so far not led to an 
improved survival advantage. However, in the very beginning of the imatinib era the 
optimal dosing schedule has not been investigated extensively. This is reflected by the fact 
that the maximum tolerated dose has not been reached in the phase I trial (Druker et al., 
2001) that comprised 83 patients. Beyond a dose of 300 mg per day toxicity and efficacy was 
not different in a subset of patients which led to the use of 400 mg imatinib per day in the 
following phase II studies. Among these trials the option to increase the imatinib dose to 2 x 
400 mg per day after insufficient response to standard dose imatinib suggested that dose 
escalation might be a possible strategy in patients with imatinib resistance (Kantarjian et al., 
2002).  
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4.1 Primary and secondary resistance to imatinib 
Patients resistant to imatinib may experience primary (intrinsic) or secondary (acquired) 
resistance (Jabbour et al., 2009a). Primary resistance has been defined as the lack of a distinct 
level of response at various time points during treatment (landmark response). By the 
NCCN guidelines, primary resistance is defined as the failure to achieve CHR within 3 to 6 
months of treatment initiation, lack of any level of cytogenetic response at 6 months or the 
lack of a MCyR at month 12 or a CCyR at month 18 (National Comprehensive Cancer 
Network (NCCN). Clinical Practice Guidelines in Oncology. Chronic Myelogenous 
Leukemia. Version 2.2010. Jenkintown, Pa: NCCN; 2009. 
http://www.nccn.org/professionals/physician_gls/PDF/cml.pdf). 
According to recommendations from the ELN treatment failure is defined as lack of CHR at 
3 months, no CHR or lack of any cytogenetic response (CyR) at 6 months, less than partial 
CyR (PCyR) at 12 months or less than a CCyR at 18 months (Baccarani et al., 2009b).  
Secondary resistance is a disease progression and the loss of any therapeutic effect during 
the treatment with imatinib. This occurs in approximately 24% of patients, mostly within the 
first three years, as has been shown in the IRIS-trial (Druker et al., 2006).  
The reasons for resistance include point mutations of BCR-ABL, amplification of BCR-ABL, 
low Oct-1 activity resulting in low influx of imatinib, high MDR-1 activity resulting in high 
imatinib efflux, and additional clonal aberrations. According to the ELN-guidelines these 
patients might be candidates for dose escalation of imatinib. However, some point 
mutations like T315I, G250K, E255K, F486S and E255V cause absolute imatinib resistance 
and therefore are contraindications for a dose escalation strategy. With the exception of 
T315I the use of second generation TKIs like nilotinib or dasatinib is recommended in these 
cases. Patients with T315I are resistant to all currently available TKIs and should be treated 
within clinical trials and the option of stem cell transplantation should be evaluated. Other 
mutations like M315T, V299L etc., however, cause relative imatinib resistance, which makes 
dose escalation of imatinib feasible. A prerequisite for imatinib dose escalation is the 
absence of relevant side effects with the 400 mg dose once daily. Other reasons for relative 
imatinib resistance that potentially might be overcome by dose escalation are additional 
genetic abberations, a high efflux of the drug due to high MDR1-activity, low influx of the 
drug by low Oct-1 activity, and BCR-ABL amplification (figure 1). 
 
 
Fig. 1. Overview on causes leading to absolute or relative imatinib resistance in CML 
(adapted from Rudzki et al., 2011) 
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4.2 Clinical studies showing effect of dose escalation after imatinib failure 
There are several clinical trials supporting dose escalation in patients already receiving 
standard dose imatinib. First, a study performed by Kantarjian et al. included patients of 
the phase II studies 110 and 113 and represents a single center study at the MD Anderson 
Cancer Center. Dose escalation was allowed from 400 to 800 mg per day if standard dose 
imatinib was well tolerated. If the starting dose was 300 mg or if the dose had to be 
decreased from 400 mg to 300 mg due to initial side effects, the dose was escalated to 600 
mg per day. The indication for dose escalation was defined as not achieving a CHR 
(defined as haematological resistance) after 3 months, failure to achieve a MCyR at 12 
months (defined as cytogenetic resistance), if CHR was lost at any time (defined as 
hematologic relapse) or if Ph-positive cells increased by 30% at two occasions (defined as 
cytogenetic relapse). From 261 included patients, 47 were escalated to 800 mg per day and 
7 were escalated to 600 mg per day. Among 34 patients that were escalated due to 
cytogenetic resistance or relapse, 56% achieved a cytogenetic response again. CCyR, 
however, was only reached in 18%. Success rates were higher among patients treated for 
haematological resistance or relapse as from 20 dose escalated patients 65% regained a 
hematologic response. With this study the authors demonstrated that some effect could be 
achieved by dose escalation after primary imatinib failure. However, the depth of 
response achieved with this procedure might be insufficient as only a minority of patients 
reached CCyR. This, however, is the goal of treatment as CCyR or MMR (however, this 
study does not report on molecular response) is known to be of high relevance for the 
long-term outcome in CML patients (Kantarjian et al., 2003).  
Zonder et al. performed a dose escalation study in 12 CP CML and four CML patients in AP 
with signs of disease progression (Zonder et al., 2003) Again, some responses could be 
achieved but the majority of patients did not benefit from this treatment. Such a transient 
response has also been shown by Marin and colleagues (Marin et al., 2003). An Italian study 
(Breccia et al., 2010), however, was capable to demonstrate a prolonged response in patients 
with cytogenetic relapse, especially in patients with acquired cytogenetic resistance. 
According to the current ELN guidelines, patients with progressive disease or with 
cytogenetic resistance are currently considered as treatment failures and qualify for second 
generation TKIs or an allogeneic stem cell transplantation and not for dose escalation 
(Baccarani et al., 2009b). 
In patients with suboptimal molecular response the benefit also seems to be limited, 
whereas dose escalation in patients with suboptimal cytogenetic response is more 
promising (Rea et al., 2009). However, data obtained from these studies have to be 
interpreted with caution as the patient numbers are rather low. A larger study was again 
presented by the MD Anderson Cancer Center. Out of 626 patients, 84 patients were dose 
escalated due to treatment failure on standard dose imatinib (Jabbour et al., 2009b). In 72 
out of these patients the dose was increased from 400 mg to 800 mg per day and in 12 
patients from 300 mg to 600 mg per day. 40% achieved a CCyR with a minority of patients 
reaching deep and prognostic meaningful responses. Patients that already had a previous 
CCyR seemed to especially benefit from dose escalation. Other patients showed 
disappointing low and insufficient response rates with a significantly worse EFS. A point 
of criticism with this study is that only 25 out of the 84 patients were tested for BCR-ABL 
mutations and mutations that are associated with high imatinib resistance have not been 
detected. In contrast to the patient cohort of the MD Anderson Cancer Center, the patient 
population of the IRIS trial was not previously treated with IFN-alpha. Within the latter, a 
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dose escalation was performed in a two-step manner. The first step was an escalation to 
600 mg per day. If no sufficient response was noted two weeks later a further escalation to 
800 mg per day was allowed. 39 patients were treated by dose escalation, but only a small 
proportion of patients reached a CCyR (Kantarjian et al., 2009). PFS for these patients was 
84% and OS 89% three years after dose escalation. The criteria for resistance, however, 
were slightly different to the current ELN-guidelines (Baccarani et al. 2009b). 
Retrospectively, 48 patients would have fulfilled the criteria of imatinib resistance. 
Significantly different results, however, cannot be expected due to this fact. The Korean 
CML study group evaluated the efficacy of dose escalation in patients with suboptimal 
response or treatment failure according to the ELN-guidelines. In total they included 64 
CML patients in CP, AP or BC and reported a CCyR rate of 23,9% at 12 months and a clear 
correlation between early molecular response and time to treatment failure (Koh et al., 
2010).  
4.3 Dose escalation versus second-generation Tyrosine Kinase Inhibitor (TKI)  
or IFN-alpha 
The START trial compared the efficacy of imatinib dose escalation with the use of the 
second generation TKI dasatinib. Patients harbouring mutations associated with a high 
degree of imatinib resistance were excluded (Kantarjian et al., 2009). Patients previously 
treated with 400 to 600 mg imatinib per day were randomized to receive either 800 mg 
imatinib per day or dasatinib 70 mg twice a day. Treatment with dasatinib resulted in higher 
rates of CHR (93 vs 82%), MCyR (53 vs 33%), CCyR (44 vs 18%), MMR (29 vs 12%) and in a 
significantly prolonged PFS. A significant proportion of 70% of patients in this study, 
however, already were dose escalated to 500 or 600 mg of imatinib before the inclusion into 
the study, making the interpretation of these results difficult. If only patients are compared 
that were either dose escalated from 400 mg to 800 mg imatinib per day or received 
dasatinib, the results are less impressive in favour of dasatinib with almost identical rates in 
MCyR and CCyR. 
The Spanish PETHEMA and the Australasian CML study group also compared high dose 
imatinib to alternative treatments in patients not achieving an optimal response 
(Cervantes et al., 2010). If patients did not achieve a CHR at 3 months they were 
randomized to continuation of standard dose imatinib or to high dose imatinib (800 
mg/day). Patients not achieving a CCyR at 6 months were randomized to high dose 
imatinib or standard dose imatinib in combination with IFN-alpha and patients not 
achieving a MMRIS at 18 months were dose escalated as well. 210 patients were included. 
At month 6, 17 patients had the dose of imatinib increased, 16 out of them reached a 
CCyR at month 18. 9 patients were dose escalated at month 18 and 8 achieved an MMR a 
few months later (Cervantes et al., 2010).  
4.4 Early dose escalation 
A very interesting approach has been investigated by the Australasian CML study group 
with the TIDEL II study (Yeung et al., 2010). This is a single arm study that allowed dose 
escalation at a very early time point based on the levels of the imatinib plasma levels that 
had to be above 1000 ng/ml. BCR-ABL levels of >10% at 3 months, >1% at 6 months or less 
than a MMR (i.e. >0.1%) at 12 months were indications for a switch to nilotinib. The MMR 
achieved by this approach was 66% at 12 months which is far better than published for 
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nilotinib in the ENESTnd and dasatinib in the Daisision trial (43 and 46%, respectively). The 
early escalation of imatinib upon suboptimal response, therefore, seems an interesting 
approach for future studies. 
5. Accelerated phase and blast crisis 
High dose imatinib in accelerated phase (AP) and blast crisis (BC) has been studied in 
phase II studies only (table 2). Talpaz et al. firstly reported the results on 181 patients with 
CML-AP. Initially, patients were enrolled in the STI 571 0109 study and were treated with 
400 mg imatinib. In 119 patients the starting dose was increased to 600 mg per day after 
the final results of the phase I study confirmed the safety and efficacy of high dose 
imatinib. Analysis at 48 months revealed that 18% of patients remained on imatinib while 
82% discontinued imatinib. The primary reasons for that included progression or lack of 
efficacy. Best observed responses were CHR in 40%, PCyR in 7% and CCyR in 20% of 
patients. The median OS was 43 months for CML-AP patients treated with 600 mg 
imatinib per day. The major prognostic factor was response: 72% of the patients with a 
MCyR at month three were alive at 48 months compared to 42% of patients without 
MCyR at month three (Talpaz et al., 2002). In a long term follow up report the same 
authors stated that 23% of the patients remained on study follow up with 9% still taking 
the study drug (Silver et al., 2009). The circumstance that initially a part of the patients 
was treated with 400 mg imatinib enabled a retrospective analysis comparing these 
patients with the other part of the patients treated with 600 mg upfront. These analyses 
revealed that CML patients in AP that started with 600 mg imatinib had a favourable OS 
and PFS compared to patients starting with 400 mg imatinib once daily. These facts led to 
the recommendation to use 600 mg imatinib per day as starting dose for the treatment of 
advanced CML. These results were confirmed by a similar phase II study, which was 
performed by Palandri et al. They treated 111 patients in CML-AP with 600 mg imatinib 
per day. After a median long term follow up of 82 months they have reported that 96% of 
the patients converted to CML-CP and 71% of patients achieved a CHR. 30% of patients 
reached a MCyR and 21% a CCyR. These responses were maintained for at least 4 weeks. 
After the prolonged follow-up 14% of the patients received a second-generation tyrosine 
kinase inhibitor and 19% of the patients were still alive on imatinib therapy. The median 
OS was 37 months, and was significantly associated with CHR or CCyR (Palandri et al., 
2009).  
 
Author n CML-phase Dose imatinib [mg/d] median OS 
Talpaz et al., 2002 119 AP 600 43 months 
Palandri et al., 2009 111 AP 600 37 months 
Sawyers et al., 2002 229 BC 600 7 months 
Palandri et al., 2008 92 BC 600 7 months 
Table 2. Phase II studies investigating high dose imatinib in CML-AP and -BC 
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Efficacy of high dose imatinib in BC was investigated in the STI571 0102 study. 229 patients 
were enrolled in this phase II trial and treated with 400 mg or 600 mg imatinib per day 
(Sawyers et al., 2002). At 48 months, only 3% of patients still were on imatinib therapy while 
the remaining patients were off treatment due to progression or lack of efficacy. CHR was 
achieved in 9%, MCyR in 16%, and CCyR in 7% of patients. The estimated OS was 7 months 
for patients treated with 600 mg imatinib per day. Similar results were obtained in an Italian 
phase II study. Palandri et al. treated 92 patients in BC with 600 mg imatinib per day. The 
results are very similar to the STI571 0102 study by showing a median OS of 7 months and 
only a minority of patients reaching sufficient cytogenetic responses. These were maintained 
for at least 4 weeks and after a median follow-up of 66 months, 8% of the patients were alive 
(Palandri et al., 2008).  
6. Conclusion 
For the moment, sufficient data are not available to recommend an initial high dose imatinib 
therapy in CP CML patients in spite of well documented superior cytogenetic and molecular 
remissions that are obtained earlier by using higher imatinib doses. In contrast, a dose of 600 
mg per day is recommended for the treatment of advanced phases (i.e. AP and BC). A dose 
increase as a consequence of suboptimal response or failure according to ELN or NCCN 
criteria is a valid option if no imatinib resistant point mutation on the one hand and no 
significant side effects with the 400 mg imatinib dose on the other hand are present at that 
time. Alternative options at that time are also already commercially available second 
generation TKIs like dasatinib or nilotinib. These latter two TKIs are meanwhile also 
registered for the first line treatment of CP CML and may diminish the need of further 
investigations on the use of high imatinib doses in the future. 
7. Acknowledgement 
We thank Christiane Pfleger for typing and Birgit Petzer for proof-reading the manuscript. 
8. References 
Baccarani, M.; Saglio, G.; Goldman, J.; Hochhaus, A.; Simonsson, B.; Appelbaum, F.; 
Apperley, J.; Cervantes, F.; Cortes, J.; Deininger, M.; Gratwohl, A.; Guilhot, F.; 
Horowitz, M.; Hughes, T.; Kantarjian, H.; Larson, R.; Niederwieser, D.; Silver, 
R. & Hehlmann, R.; European LeukemiaNet. (2006) Evolving concepts in the 
management of chronic myeloid leukemia: recommendations from an expert 
panel on behalf of the European LeukemiaNet. Blood, Vol. 108 (6), pp. 1809-
1820.  
Baccarani, M.; Cortes, J.; Pane, F.; Niederwieser, D.; Saglio, G.; Apperley, J.; Cervantes, F.; 
Deininger, M.; Gratwohl, A.; Guilhot, F.; Hochhaus, A.; Horowitz, M.; Hughes, T.; 
Kantarjian, H.; Larson, R.; Radich, J.; Simonsson, B.; Silver, RT.; Goldman, J. & 
Hehlmann, R. European LeukemiaNet. (2009a). Chronic myeloid leukemia: an 
update of concepts and management recommendations of European LeukemiaNet. 
J Clin Oncol, Vol. 27 (35), pp. 6041-6051.  
 
Role of High Dose Imatinib in BCR/ABLpos/Phpos CML 
 
65 
Baccarani, M.; Rosti, G.; Gastagnetti, F.; Haznedaroglu, I.; Porkka, K.; Abruzzese, E.; 
Alimena, G.; Ehrencrona, H.; Hjorth-Hansen, H.; Kairisto, V.; Levato, L.; 
Martinelli, G.; Nagler, A.; Nielsen, J.L.; Ozbek, U.; Palandri, F.; Palmieri, F.; Pane, 
F.; Rege-Cambrin, G.; Russo, D.; Specchia, G.; Testoni, N.; Weiss-Bjerrum, O.; 
Saglio, G. & Simonsson B. (2009b). Comparison of imatinib 400 mg and 800 mg 
daily in the front-line treatment of high-risk, Philadelphia-positive chronic 
myeloid leukemia: a European LeukemiaNet study. Blood, Vol. 113, pp. 4497-
4504.  
Breccia, M.; Stagno, F.; Vigneri, P.; Latagliata, R.; Cannella, L.; Del Fabro, V.; Di Raimondo, 
F. & Alimena, G. (2010) Imatinib dose escalation in 74 failure or suboptimal 
response chronic myeloid leukaemia patients at 3-year follow-up. Am J Hematol, 
Vol. 85 (5), pp: 375-377.  
Castagnetti, F.; Palandri, F.; Amabile, M.; Testoni, N.; Luatti, S.; Soverini, S.; Iacobucci, I.; 
Breccia, M.; Rege Cambrin, G.; Stagno, F.; Specchia, G.; Galieni, P.; Iuliano, F.; 
Pane, F.; Saglio, G.; Alimena, G.; Martinelli, G.; Baccarani, M. & Rosti, G.; 
GIMEMA CML Working Party. (2009). Results of high-dose imatinib mesylate in 
intermediate Sokal risk chronic myeloid leukemia patients in early chronic phase: 
a phase 2 trial of the GIMEMA CML Working Party. Blood, Vol. 113 (15), pp. 3428-
3434.  
Cervantes, F.; López-Garrido, P.; Montero, M.I.; Jonte, F.; Martínez, J.; Hernández-Boluda, 
J.C.; Calbacho, M.; Sureda, A.; Pérez-Rus, G.; Nieto, J.B.; Pérez-López, C.; Román-
Gómez, J.; González, M.; Pereira, A. & Colomer, D. (2010). Early intervention 
during imatinib therapy in patients with newly diagnosed chronic-phase chronic 
myeloid leukemia: a study of the Spanish PETHEMA group. Haematologica, Vol. 95 
(8), pp. 1317-1324. 
Cortes, J.; Giles, F.; O'Brien, S.; Thomas, D.; Garcia-Manero, G.; Rios, M.B.; Faderl, S.; 
Verstovsek, S.; Ferrajoli, A.; Freireich, E.J.; Talpaz, M. & Kantarjian H. (2003). Result 
of high-dose imatinib mesylate in patients with Philadelphia chromosome—
positive chronic myeloid leukemia after failure of interferon-α. Blood, Vol. 102, pp. 
83-86.  
Cortes, J.E.; Kantarjian, H.M.; Goldberg, S.L.; Powell, B.L.; Giles, F.J.; Wetzler, M.; Akard, L.; 
Burke, J.M.; Kerr, R.; Saleh, M.; Salvado, A.; McDougall, K.; Albitar, M. & Radich, J. 
(2009). High-dose imatinib in newly diagnosed chronic-phase chronic myeloid 
leukemia: high rates of rapid cytogenetic and molecular responses. JCO, Vol. 27 
(28), pp. 4754-4759.  
Cortes, J.E.; Baccarani, M.; Guilhot, F.; Druker, B.J.; Branford, S.; Kim, D.; Pane, F.; 
Pasquini, R.; Goldberg, S.L.; Kalaycio, M.; Moiraghi, B.; Rowe, J.M.; Tothova, E.; 
De Souza, C.; Rudoltz, M.; Yu, R.; Krahnke, T.; Kantarjian, H.M.; Radich, J.P. & 
Hughes, T.P. (2010). Phase III, randomized, open-label study of daily imatinib 
mesylate 400 mg versus 800 mg in patients with newly diagnosed, previously 
untreated chronic myeloid leukemia in chronic phase using molecular end points: 
tyrosine kinase inhibitor optimization and selectivity study. JCO, Vol. 28 (3), pp. 
424-430. 
 
Myeloid Leukemia – Clinical Diagnosis and Treatment 
 
64
Efficacy of high dose imatinib in BC was investigated in the STI571 0102 study. 229 patients 
were enrolled in this phase II trial and treated with 400 mg or 600 mg imatinib per day 
(Sawyers et al., 2002). At 48 months, only 3% of patients still were on imatinib therapy while 
the remaining patients were off treatment due to progression or lack of efficacy. CHR was 
achieved in 9%, MCyR in 16%, and CCyR in 7% of patients. The estimated OS was 7 months 
for patients treated with 600 mg imatinib per day. Similar results were obtained in an Italian 
phase II study. Palandri et al. treated 92 patients in BC with 600 mg imatinib per day. The 
results are very similar to the STI571 0102 study by showing a median OS of 7 months and 
only a minority of patients reaching sufficient cytogenetic responses. These were maintained 
for at least 4 weeks and after a median follow-up of 66 months, 8% of the patients were alive 
(Palandri et al., 2008).  
6. Conclusion 
For the moment, sufficient data are not available to recommend an initial high dose imatinib 
therapy in CP CML patients in spite of well documented superior cytogenetic and molecular 
remissions that are obtained earlier by using higher imatinib doses. In contrast, a dose of 600 
mg per day is recommended for the treatment of advanced phases (i.e. AP and BC). A dose 
increase as a consequence of suboptimal response or failure according to ELN or NCCN 
criteria is a valid option if no imatinib resistant point mutation on the one hand and no 
significant side effects with the 400 mg imatinib dose on the other hand are present at that 
time. Alternative options at that time are also already commercially available second 
generation TKIs like dasatinib or nilotinib. These latter two TKIs are meanwhile also 
registered for the first line treatment of CP CML and may diminish the need of further 
investigations on the use of high imatinib doses in the future. 
7. Acknowledgement 
We thank Christiane Pfleger for typing and Birgit Petzer for proof-reading the manuscript. 
8. References 
Baccarani, M.; Saglio, G.; Goldman, J.; Hochhaus, A.; Simonsson, B.; Appelbaum, F.; 
Apperley, J.; Cervantes, F.; Cortes, J.; Deininger, M.; Gratwohl, A.; Guilhot, F.; 
Horowitz, M.; Hughes, T.; Kantarjian, H.; Larson, R.; Niederwieser, D.; Silver, 
R. & Hehlmann, R.; European LeukemiaNet. (2006) Evolving concepts in the 
management of chronic myeloid leukemia: recommendations from an expert 
panel on behalf of the European LeukemiaNet. Blood, Vol. 108 (6), pp. 1809-
1820.  
Baccarani, M.; Cortes, J.; Pane, F.; Niederwieser, D.; Saglio, G.; Apperley, J.; Cervantes, F.; 
Deininger, M.; Gratwohl, A.; Guilhot, F.; Hochhaus, A.; Horowitz, M.; Hughes, T.; 
Kantarjian, H.; Larson, R.; Radich, J.; Simonsson, B.; Silver, RT.; Goldman, J. & 
Hehlmann, R. European LeukemiaNet. (2009a). Chronic myeloid leukemia: an 
update of concepts and management recommendations of European LeukemiaNet. 
J Clin Oncol, Vol. 27 (35), pp. 6041-6051.  
 
Role of High Dose Imatinib in BCR/ABLpos/Phpos CML 
 
65 
Baccarani, M.; Rosti, G.; Gastagnetti, F.; Haznedaroglu, I.; Porkka, K.; Abruzzese, E.; 
Alimena, G.; Ehrencrona, H.; Hjorth-Hansen, H.; Kairisto, V.; Levato, L.; 
Martinelli, G.; Nagler, A.; Nielsen, J.L.; Ozbek, U.; Palandri, F.; Palmieri, F.; Pane, 
F.; Rege-Cambrin, G.; Russo, D.; Specchia, G.; Testoni, N.; Weiss-Bjerrum, O.; 
Saglio, G. & Simonsson B. (2009b). Comparison of imatinib 400 mg and 800 mg 
daily in the front-line treatment of high-risk, Philadelphia-positive chronic 
myeloid leukemia: a European LeukemiaNet study. Blood, Vol. 113, pp. 4497-
4504.  
Breccia, M.; Stagno, F.; Vigneri, P.; Latagliata, R.; Cannella, L.; Del Fabro, V.; Di Raimondo, 
F. & Alimena, G. (2010) Imatinib dose escalation in 74 failure or suboptimal 
response chronic myeloid leukaemia patients at 3-year follow-up. Am J Hematol, 
Vol. 85 (5), pp: 375-377.  
Castagnetti, F.; Palandri, F.; Amabile, M.; Testoni, N.; Luatti, S.; Soverini, S.; Iacobucci, I.; 
Breccia, M.; Rege Cambrin, G.; Stagno, F.; Specchia, G.; Galieni, P.; Iuliano, F.; 
Pane, F.; Saglio, G.; Alimena, G.; Martinelli, G.; Baccarani, M. & Rosti, G.; 
GIMEMA CML Working Party. (2009). Results of high-dose imatinib mesylate in 
intermediate Sokal risk chronic myeloid leukemia patients in early chronic phase: 
a phase 2 trial of the GIMEMA CML Working Party. Blood, Vol. 113 (15), pp. 3428-
3434.  
Cervantes, F.; López-Garrido, P.; Montero, M.I.; Jonte, F.; Martínez, J.; Hernández-Boluda, 
J.C.; Calbacho, M.; Sureda, A.; Pérez-Rus, G.; Nieto, J.B.; Pérez-López, C.; Román-
Gómez, J.; González, M.; Pereira, A. & Colomer, D. (2010). Early intervention 
during imatinib therapy in patients with newly diagnosed chronic-phase chronic 
myeloid leukemia: a study of the Spanish PETHEMA group. Haematologica, Vol. 95 
(8), pp. 1317-1324. 
Cortes, J.; Giles, F.; O'Brien, S.; Thomas, D.; Garcia-Manero, G.; Rios, M.B.; Faderl, S.; 
Verstovsek, S.; Ferrajoli, A.; Freireich, E.J.; Talpaz, M. & Kantarjian H. (2003). Result 
of high-dose imatinib mesylate in patients with Philadelphia chromosome—
positive chronic myeloid leukemia after failure of interferon-α. Blood, Vol. 102, pp. 
83-86.  
Cortes, J.E.; Kantarjian, H.M.; Goldberg, S.L.; Powell, B.L.; Giles, F.J.; Wetzler, M.; Akard, L.; 
Burke, J.M.; Kerr, R.; Saleh, M.; Salvado, A.; McDougall, K.; Albitar, M. & Radich, J. 
(2009). High-dose imatinib in newly diagnosed chronic-phase chronic myeloid 
leukemia: high rates of rapid cytogenetic and molecular responses. JCO, Vol. 27 
(28), pp. 4754-4759.  
Cortes, J.E.; Baccarani, M.; Guilhot, F.; Druker, B.J.; Branford, S.; Kim, D.; Pane, F.; 
Pasquini, R.; Goldberg, S.L.; Kalaycio, M.; Moiraghi, B.; Rowe, J.M.; Tothova, E.; 
De Souza, C.; Rudoltz, M.; Yu, R.; Krahnke, T.; Kantarjian, H.M.; Radich, J.P. & 
Hughes, T.P. (2010). Phase III, randomized, open-label study of daily imatinib 
mesylate 400 mg versus 800 mg in patients with newly diagnosed, previously 
untreated chronic myeloid leukemia in chronic phase using molecular end points: 
tyrosine kinase inhibitor optimization and selectivity study. JCO, Vol. 28 (3), pp. 
424-430. 
 
Myeloid Leukemia – Clinical Diagnosis and Treatment 
 
66
Deininger, M.W.; Goldman, M.J.; Lydon, N. & Melo, J.V. (1997). The tyrosine kinase 
inhibitor CGP57148B selectively inhibits the growth of BCR-ABL-positive cells. 
Blood, Vol. 90, pp. 3691-3698. 
Deininger, M.W.; O'Brien, S.G.; Guilhot, F.; MD3, John. J.M.; Hochhaus, A.; Hughes, T.; 
Radich, J.P.; Hatfield, A.K.; Mone, M.; Filian, J.; Reynolds J.; Gathmann, I.; Larson, 
R.A. & Druker, B.J. (2009). International Randomized Study of Interferon Vs STI571 
(IRIS) 8-Year Follow up: Sustained Survival and Low Risk for Progression or 
Events in Patients with Newly Diagnosed Chronic Myeloid Leukemia in Chronic 
Phase (CML-CP) Treated with Imatinib. Blood (ASH Annual Meeting Abstracts), 
Abstr. 1126.  
Druker, B.J.; Tamura, S.; Buchdunger, E.; Ohno, S.; Segal, G.M.; Fanning, S.; Zimmermann, J. 
& Lydon, N.B. (1996). Effects of a selective inhibitor of the Abl tyrosine kinase on 
growth of Bcr-Abl positive cells. Nat Med, Vol. 2, pp. 561-566. 
Druker, B.J.; Talpaz, M.; Resta, D.J.; Peng, B.; Buchdunger, E.; Ford, J.M.; Lydon, N.B.; 
Kantarjian, H.; Capdeville, R.; Ohno-Jones, S. & Sawyers, C.L. (2001). Efficacy and 
safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid 
leukemia. N Engl J Med, Vol. 344 (14), pp. 1031-1037. 
Druker, B.J.; Guilhot, F.; O'Brien, S.G.; Gathmann, I.; Kantarjian, H.; Gattermann, N.; 
Deininger, M.W.; Silver, R.T.; Goldman, J.M.; Stone, R.M.; Cervantes, F.; 
Hochhaus, A.; Powell, B.L.; Gabrilove, J.L.; Rousselot, P.; Reiffers, J.; Cornelissen, 
J.J.; Hughes, T.; Agis, H.; Fischer, T.; Verhoef, G.; Shepherd, J.; Saglio, G.; 
Gratwohl, A.; Nielsen. J.L.; Radich, J.P.; Simonsson, B.; Taylor, K.; Baccarani, M.; 
So, C.; Letvak, L. & Larson, R.A. (2006). IRIS Investigators. Five-year follow-up of 
patients receiving imatinib for chronic myeloid leukemia. N Engl J Med, Vol. 355 
(23), pp. 2408-2417. 
Gambacorti-Passerini, C.; Le Coutre, P.; Mologni, L.; Fanelli, M.; Bertazzoli, C.; Marchesi, 
E.; Di Nicola, M.; Biondi, A.; Corneo, G.M.; Belotti, D.; Pogliani, E. & Lydon N.B. 
(1997). Inhibition of the ABL Kinase Activity Blocks the Proliferation of 
BCR/ABL+ Leukemic Cells and Induces Apoptosis Blood Cells Mol Dis, Vol 23, 
pp. 380-394.  
Hasford, J.; Pfirrmann, M.; Hehlmann, R.; Allan, N.C.; Baccarani, M.; Kluin-Nelemans, J.C.; 
Alimena, G.; Steegmann J.L. & Ansari H. (1998). A New Prognostic Score for 
Survival of Patients With Chronic Myeloid Leukemia Treated With Interferon 
AlfaWriting Committee for the Collaborative CML Prognostic Factors Project 
Group. JNCI J Natl Cancer Inst , Vol. 90 (11), pp. 850-859.  
Hehlmann, R.; Lauseker, M.; Jung-Munkwitz, S.; Leitner, A.; Müller, M.C.; Pletsch, N.; 
Proetel, U.; Haferlach, C.; Schlegelberger, B.; Balleisen, L.; Hänel, M.; Pfirrmann, M.; 
Krause, S.W.; Nerl, C.; Pralle, H.; Gratwohl A.; Hossfeld, D.K.; Hasford J.; 
Hochhaus A. & Saußele S. (2011). Tolerability-Adapted Imatinib 800 mg/d versus 
400 mg/d versus 400 mg/d Plus Interferon-α in Newly Diagnosed Chronic 
Myeloid Leukemia. JCO, Vol. 29 (12), pp. 1634-1642. 
Hughes, T.P.; Branford S.; White, D.L.; Reynolds, J.; Koelmeyer, R.; Seymour, J.F.; Taylor, K.; 
Arthur, C.; Schwarer, A.; Morton, J.; Cooney, J.; Leahy, M.F.; Rowlings, P.; 
Catalano, J.; Hertzberg, M.; Filshie, R.; Mills, A.K.; Fay, K.; Durrant, S.; Januszewicz, 
 
Role of High Dose Imatinib in BCR/ABLpos/Phpos CML 
 
67 
H.; Joske, D.; Underhill, C.; Dunkley, S.; Lynch K. & Grigg, A.; On behalf of the 
Australasian Leukaemia and Lymphoma Group. (2008). Impact of early dose 
intensity on cytogenetic and molecular responses in chronicphase CMLpatients 
receiving 600 mg/day of imatinib as initial therapy. Blood, Vol. 112 (10), pp. 3965-
3973.  
Hughes, T.P.; Hochhaus, A.; Branford, S.; Müller, M.C.; Kaeda, J.S.; Foroni, L.; Druker, B.J.; 
Guilhot, F.; Larson, R.A.; O’Brien, S.G.; Rudoltz, M.S.; Mone, M.; Wehrle, E.; 
Modur, V.; Goldman, J.M. & Radich, J.P. (2010). Long-term prognostic significance 
of early molecular response to imatinib in newly diagnosed chronic myeloid 
leukemia: an analysis from the International Randomized Study of Interferon and 
STI571 (IRIS). Blood, Vol. 116 (19), pp. 3758-3765. 
Iacobucci, I.; Saglio, G.; Rosti, G.; Testoni, N.; Pane F.; Amabile, M.; Poerio, A.; Soverini, S.; 
Bassi, S.; Cilloni, D.; Bassan, R.; Breccia, M.; Lauria, F.; Izzo, B.; Merante, S.; 
Frassoni, F.; Paolini, S.; Montefusco, E.; Baccarani, M. & Martinelli, G.; for the 
GIMEMA Working Party on Chronic Myeloid Leukemia. (2006). Achieving a major 
molecular response at the time of a complete cytogenetic response (CCgR) predicts 
a better duration of CCgR in imatinib-treated chronic myeloid leukemia patients. 
Clin Cancer Res, Vol. 12, pp. 3037-3042.  
Jabbour, E.; Cortes, J. & Kantarjian, H. (2009a). Treatment selection after imatinib resistance 
in chronic myeloid leukemia. Target Oncol, Vol. 4(1), pp. 3-10.  
Jabbour, E.; Kantarjian, H.M.; Jones, D.; Shan, J.; O'Brien, S.; Reddy, N.; Wierda, W.G.; 
Faderl, S.; Garcia-Manero, G.; Verstovsek, S.; Rios, M.B. & Cortes J. (2009b). 
Imatinib mesylate dose escalation is associated with durable responses in patients 
with chronic myeloid leukemia after cytogenetic failure on standard-dose imatinib 
therapy. Blood, Vol. 113 (10), pp. 2154-2160. 
Kantarjian, H.M.; Smith, T.L.; O’Brien, S.; Beran, M.; Pierce, S. & Talpaz, M. (1995). 
Prolonged survival in chronic myelogenous leukemia after cytogenetic response to 
interferon-alpha therapy: the Leukemia Service. Ann Intern Med, Vol. 122, pp. 254-
261. 
Kantarjian, H.; Sawyers, C.; Hochhaus, A.; Guilhot, F.; Schiffer, C.; Gambacorti-Passerini, C.; 
Niederwieser, D.; Resta, D.; Capdeville, R.; Zoellner, U.; Talpaz, M. & Druker, B. 
(2002). Hematologic and cytogenetic responses to imatinib mesylate in chronic 
myelogenous leukemia. N Engl J Med, Vol. 346, pp. 645-652.  
Kantarjian, H.M.; Talpaz, M.; O'Brien, S.; Giles, F.; Garcia-Manero, G.; Faderl, S.; Thomas, D.; 
Shan, J.; Rios, M.B. & Cortes J. (2003). Dose escalation of imatinib mesylate can 
overcome resistance to standard-dose therapy in patients with chronic 
myelogenous leukemia. Blood, Vol. 101 (2), pp. 473-475.  
Kantarjian, H.; Talpaz, M.; O’Brien, S.; Garcia-Manero, G.; Verstovsek, S.; Giles F.; Rios 
M.B.; Shan, J.; Letvak, L.; Thomas, D.; Faderl, S.; Ferrajoli, A. & Cortes J. (2004). 
High-dose imatinib mesylate therapy in newly diagnosed Philadelphia 
chromosome-positive chronic phase chronic myeloid leukemia. Blood, Vol. 103 
(8), pp. 2873-2878. 
Kantarjian, H.M.; Larson, R.A.; Guilhot, F.; O'Brien, S.G.; Mone, M.; Rudoltz, M.; Krahnke, 
T.; Cortes, J. & Druker, B.J. (2009a) International Randomized Study of Interferon 
 
Myeloid Leukemia – Clinical Diagnosis and Treatment 
 
66
Deininger, M.W.; Goldman, M.J.; Lydon, N. & Melo, J.V. (1997). The tyrosine kinase 
inhibitor CGP57148B selectively inhibits the growth of BCR-ABL-positive cells. 
Blood, Vol. 90, pp. 3691-3698. 
Deininger, M.W.; O'Brien, S.G.; Guilhot, F.; MD3, John. J.M.; Hochhaus, A.; Hughes, T.; 
Radich, J.P.; Hatfield, A.K.; Mone, M.; Filian, J.; Reynolds J.; Gathmann, I.; Larson, 
R.A. & Druker, B.J. (2009). International Randomized Study of Interferon Vs STI571 
(IRIS) 8-Year Follow up: Sustained Survival and Low Risk for Progression or 
Events in Patients with Newly Diagnosed Chronic Myeloid Leukemia in Chronic 
Phase (CML-CP) Treated with Imatinib. Blood (ASH Annual Meeting Abstracts), 
Abstr. 1126.  
Druker, B.J.; Tamura, S.; Buchdunger, E.; Ohno, S.; Segal, G.M.; Fanning, S.; Zimmermann, J. 
& Lydon, N.B. (1996). Effects of a selective inhibitor of the Abl tyrosine kinase on 
growth of Bcr-Abl positive cells. Nat Med, Vol. 2, pp. 561-566. 
Druker, B.J.; Talpaz, M.; Resta, D.J.; Peng, B.; Buchdunger, E.; Ford, J.M.; Lydon, N.B.; 
Kantarjian, H.; Capdeville, R.; Ohno-Jones, S. & Sawyers, C.L. (2001). Efficacy and 
safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid 
leukemia. N Engl J Med, Vol. 344 (14), pp. 1031-1037. 
Druker, B.J.; Guilhot, F.; O'Brien, S.G.; Gathmann, I.; Kantarjian, H.; Gattermann, N.; 
Deininger, M.W.; Silver, R.T.; Goldman, J.M.; Stone, R.M.; Cervantes, F.; 
Hochhaus, A.; Powell, B.L.; Gabrilove, J.L.; Rousselot, P.; Reiffers, J.; Cornelissen, 
J.J.; Hughes, T.; Agis, H.; Fischer, T.; Verhoef, G.; Shepherd, J.; Saglio, G.; 
Gratwohl, A.; Nielsen. J.L.; Radich, J.P.; Simonsson, B.; Taylor, K.; Baccarani, M.; 
So, C.; Letvak, L. & Larson, R.A. (2006). IRIS Investigators. Five-year follow-up of 
patients receiving imatinib for chronic myeloid leukemia. N Engl J Med, Vol. 355 
(23), pp. 2408-2417. 
Gambacorti-Passerini, C.; Le Coutre, P.; Mologni, L.; Fanelli, M.; Bertazzoli, C.; Marchesi, 
E.; Di Nicola, M.; Biondi, A.; Corneo, G.M.; Belotti, D.; Pogliani, E. & Lydon N.B. 
(1997). Inhibition of the ABL Kinase Activity Blocks the Proliferation of 
BCR/ABL+ Leukemic Cells and Induces Apoptosis Blood Cells Mol Dis, Vol 23, 
pp. 380-394.  
Hasford, J.; Pfirrmann, M.; Hehlmann, R.; Allan, N.C.; Baccarani, M.; Kluin-Nelemans, J.C.; 
Alimena, G.; Steegmann J.L. & Ansari H. (1998). A New Prognostic Score for 
Survival of Patients With Chronic Myeloid Leukemia Treated With Interferon 
AlfaWriting Committee for the Collaborative CML Prognostic Factors Project 
Group. JNCI J Natl Cancer Inst , Vol. 90 (11), pp. 850-859.  
Hehlmann, R.; Lauseker, M.; Jung-Munkwitz, S.; Leitner, A.; Müller, M.C.; Pletsch, N.; 
Proetel, U.; Haferlach, C.; Schlegelberger, B.; Balleisen, L.; Hänel, M.; Pfirrmann, M.; 
Krause, S.W.; Nerl, C.; Pralle, H.; Gratwohl A.; Hossfeld, D.K.; Hasford J.; 
Hochhaus A. & Saußele S. (2011). Tolerability-Adapted Imatinib 800 mg/d versus 
400 mg/d versus 400 mg/d Plus Interferon-α in Newly Diagnosed Chronic 
Myeloid Leukemia. JCO, Vol. 29 (12), pp. 1634-1642. 
Hughes, T.P.; Branford S.; White, D.L.; Reynolds, J.; Koelmeyer, R.; Seymour, J.F.; Taylor, K.; 
Arthur, C.; Schwarer, A.; Morton, J.; Cooney, J.; Leahy, M.F.; Rowlings, P.; 
Catalano, J.; Hertzberg, M.; Filshie, R.; Mills, A.K.; Fay, K.; Durrant, S.; Januszewicz, 
 
Role of High Dose Imatinib in BCR/ABLpos/Phpos CML 
 
67 
H.; Joske, D.; Underhill, C.; Dunkley, S.; Lynch K. & Grigg, A.; On behalf of the 
Australasian Leukaemia and Lymphoma Group. (2008). Impact of early dose 
intensity on cytogenetic and molecular responses in chronicphase CMLpatients 
receiving 600 mg/day of imatinib as initial therapy. Blood, Vol. 112 (10), pp. 3965-
3973.  
Hughes, T.P.; Hochhaus, A.; Branford, S.; Müller, M.C.; Kaeda, J.S.; Foroni, L.; Druker, B.J.; 
Guilhot, F.; Larson, R.A.; O’Brien, S.G.; Rudoltz, M.S.; Mone, M.; Wehrle, E.; 
Modur, V.; Goldman, J.M. & Radich, J.P. (2010). Long-term prognostic significance 
of early molecular response to imatinib in newly diagnosed chronic myeloid 
leukemia: an analysis from the International Randomized Study of Interferon and 
STI571 (IRIS). Blood, Vol. 116 (19), pp. 3758-3765. 
Iacobucci, I.; Saglio, G.; Rosti, G.; Testoni, N.; Pane F.; Amabile, M.; Poerio, A.; Soverini, S.; 
Bassi, S.; Cilloni, D.; Bassan, R.; Breccia, M.; Lauria, F.; Izzo, B.; Merante, S.; 
Frassoni, F.; Paolini, S.; Montefusco, E.; Baccarani, M. & Martinelli, G.; for the 
GIMEMA Working Party on Chronic Myeloid Leukemia. (2006). Achieving a major 
molecular response at the time of a complete cytogenetic response (CCgR) predicts 
a better duration of CCgR in imatinib-treated chronic myeloid leukemia patients. 
Clin Cancer Res, Vol. 12, pp. 3037-3042.  
Jabbour, E.; Cortes, J. & Kantarjian, H. (2009a). Treatment selection after imatinib resistance 
in chronic myeloid leukemia. Target Oncol, Vol. 4(1), pp. 3-10.  
Jabbour, E.; Kantarjian, H.M.; Jones, D.; Shan, J.; O'Brien, S.; Reddy, N.; Wierda, W.G.; 
Faderl, S.; Garcia-Manero, G.; Verstovsek, S.; Rios, M.B. & Cortes J. (2009b). 
Imatinib mesylate dose escalation is associated with durable responses in patients 
with chronic myeloid leukemia after cytogenetic failure on standard-dose imatinib 
therapy. Blood, Vol. 113 (10), pp. 2154-2160. 
Kantarjian, H.M.; Smith, T.L.; O’Brien, S.; Beran, M.; Pierce, S. & Talpaz, M. (1995). 
Prolonged survival in chronic myelogenous leukemia after cytogenetic response to 
interferon-alpha therapy: the Leukemia Service. Ann Intern Med, Vol. 122, pp. 254-
261. 
Kantarjian, H.; Sawyers, C.; Hochhaus, A.; Guilhot, F.; Schiffer, C.; Gambacorti-Passerini, C.; 
Niederwieser, D.; Resta, D.; Capdeville, R.; Zoellner, U.; Talpaz, M. & Druker, B. 
(2002). Hematologic and cytogenetic responses to imatinib mesylate in chronic 
myelogenous leukemia. N Engl J Med, Vol. 346, pp. 645-652.  
Kantarjian, H.M.; Talpaz, M.; O'Brien, S.; Giles, F.; Garcia-Manero, G.; Faderl, S.; Thomas, D.; 
Shan, J.; Rios, M.B. & Cortes J. (2003). Dose escalation of imatinib mesylate can 
overcome resistance to standard-dose therapy in patients with chronic 
myelogenous leukemia. Blood, Vol. 101 (2), pp. 473-475.  
Kantarjian, H.; Talpaz, M.; O’Brien, S.; Garcia-Manero, G.; Verstovsek, S.; Giles F.; Rios 
M.B.; Shan, J.; Letvak, L.; Thomas, D.; Faderl, S.; Ferrajoli, A. & Cortes J. (2004). 
High-dose imatinib mesylate therapy in newly diagnosed Philadelphia 
chromosome-positive chronic phase chronic myeloid leukemia. Blood, Vol. 103 
(8), pp. 2873-2878. 
Kantarjian, H.M.; Larson, R.A.; Guilhot, F.; O'Brien, S.G.; Mone, M.; Rudoltz, M.; Krahnke, 
T.; Cortes, J. & Druker, B.J. (2009a) International Randomized Study of Interferon 
 
Myeloid Leukemia – Clinical Diagnosis and Treatment 
 
68
and STI571 (IRIS) Investigators. Efficacy of imatinib dose escalation in patients 
with chronic myeloid leukemia in chronic phase. Cancer, Vol. 115 (3), pp. 551-
560.  
Kantarjian, H.; Pasquini, R.; Lévy, V.; Jootar, S.; Holowiecki, J.; Hamerschlak, N.; Hughes, T.; 
Bleickardtm, E.; Dejardin, D.; Cortes, J. & Shah, N.P. (2009b). Dasatinib or high-
dose imatinib for chronic-phase chronic myeloid leukemia resistant to imatinib at a 
dose of 400 to 600 milligrams daily: two-year follow-up of a randomized phase 2 
study (START-R). Cancer, Vol. 115 (18), pp. 4136-4147.  
Koh, Y.; Kim, I.; Yoon, S.S.; Kim, B.K.; Kim, D.Y.; Lee J.H.; Lee, K.H.; Park, E.; Kim, H.J.; 
Sohn, S.K.; Joo, Y.D.; Kim, S.J.; Chung, J.; Shin, H.J.; Kim, S.H.; Kim, C.S.; Song, 
H.S.; Kim, M.K.; Hyun, M.S.; Ahn, J.S.; Jung, C.W. & Park, S. (2010). Korean 
Society of Hematology CML working party. Phase IV study evaluating efficacy of 
escalated dose of imatinib in chronic myeloid leukemia patients showing 
suboptimal response to standard dose imatinib. Ann Hematol, Vol. 89 (7), pp. 725-
731.  
Marin, D.; Goldman, J.M.; Olavarria, E. & Apperley, J.F. (2003). Transient benefit only 
from increasing the imatinib dose in CML patients who do not achieve 
complete cytogenetic remissions on conventional doses. Blood, Vol. 102 (7), pp. 
2702-2703. 
Palandri, F.; Castagnetti, F.; Testoni, N.; Luatti, S.; Marzocchi, G.; Bassi, S.; Breccia, M.; 
Alimena, G.; Pungolino, E.; Rege-Cambrin, G.; Varaldo, R.; Miglino, M.; Specchia, 
G.; Zuffa, E.; Ferrara, F.; Bocchia, M.; Saglio, G.; Pane, F.; Alberti, D.; Martinelli, G.; 
Baccarani, M. & Rosti, G; GIMEMA Working Party on Chronic Myeloid Leukemia. 
(2008). Chronic myeloid leukemia in blast crisis treated with imatinib 600 mg: 
outcome of the patients alive after a 6-year follow-up. Haematologica, Vol. 93 (12), 
pp. 1792-1796.  
Palandri, F.; Castagnetti, F.; Alimena, G.; Testoni, N.; Breccia, M.; Luatti, S.; Rege-Cambrin, 
G.; Stagno, F.; Specchia, G.; Martino, B.; Levato, L.; Merante, S.; Liberati, A.M.; 
Pane, F.; Saglio, G.; Alberti, D.; Martinelli, G.; Baccarani, M. & Rosti, G. (2009). The 
long-term durability of cytogenetic responses in patients with accelerated phase 
chronic myeloid leukemia treated with imatinib 600 mg: the GIMEMA CML 
Working Party experience after a 7-year follow-up. Haematologica, Vol. 94 (2), pp. 
205-212.  
Petzer, A.L.; Wolf, D.; Fong, D.; Lion, T.; Dyagil, I.; Masliak, Z.; Bogdanovic, A.; 
Griskevicius, L.; Lejniece, S.; Goranov, S.; Gercheva, L.; Stojanovic, A.; Peytchev, 
D.; Tzvetkov, N.; Griniute, R.; Oucheva, R.; Ulmer, H.; Kwakkelstein, M.; Rancati, 
F. & Gastl, G. (2010a). High-dose imatinib improves cytogenetic and molecular 
remissions in patients with pretreated philadelphia-positive, bcr-abl-positive 
chronic phase chronic myeloid leukemia: first results from the randomized 
CELSG phase III CML 11 „ISTAHIT“ study. Haematologica, Vol. 95 (6), pp. 908-
913.  
Petzer, A.L.; Fong, D.; Lion, T.; Dyagil, I.; Masliak, Z.; Bogdanovic, A.; Griskevicius, L.; 
Lejniece, S.; Goranov, S.; Gercheva, L.; Stojanovic, A.; Peytchev, D.; Tzvetkov, N.; 
Griniute, R.; Oucheva, R.; Grubinger, T.; Kwakkelstein, M.; Rancati, F.; Gastl, G. & 
 
Role of High Dose Imatinib in BCR/ABLpos/Phpos CML 
 
69 
Wolf, D. (2010b). High dose imatinib induction therapy (800 mg/day, 6 months) in 
pre-treated chronic phase cml patients improves cytogenetic and molecular 
responses but does not improve overall and progression free survival – a final 
results of the CELSG phase III cml 11 “ISTAHTI” trial. Blood (ASH Annual Meeting 
Abstracts), Abstr. 2271.  
Rea, D.; Etienne, G.; Corm, S.; Cony-Makhoul, P.; Gardembas, M.; Legros, L.; Dubruille, V.; 
Hayette, S.; Mahon, F.X.; Cayuela, J.M. & Nicolini, F.E. (2009). Imatinib dose 
escalation for chronic phase-chronic myelogenous leukaemia patients in primary 
suboptimal response to imatinib 400 mg daily standard therapy. Leukemia, Vol. 23 
(6), pp. 1193-1196.  
Rudzki, J. & Wolf, D. (2011). Dose escalation of imatinib in chronic-phase chronic 
myeloid leukemia patients: is it still reasonable? Expert Rev Hematol, Vol. 4 (2), 
pp. 153-159. 
Sawyers, C.L.; Hochhaus, A.; Feldman, E.; Goldman, J.M.; Miller, C.B.; Ottmann, O.G.; 
Schiffer, C.A.; Talpaz, M.; Guilhot, F.; Deininger, M.W.; Fischer, T.; O'Brien, S.G.; 
Stone, R.M.; Gambacorti-Passerini, C.B.; Russell, N.H.; Reiffers, J.J.; Shea, T.C.; 
Chapuis, B.; Coutre, S.; Tura, S.; Morra, E.; Larson, R.A.; Saven, A.; Peschel, C.; 
Gratwohl, A.; Mandelli, F.; Ben-Am, M.; Gathmann, I.; Capdeville, R.; Paquette, 
R.L. & Druker, B.J. (2002). Imatinib induces hematologic and cytogenetic responses 
in patients with chronic myelogenous leukemia in myeloid blast crisis: results of a 
phase II study. Blood, Vol. 99 (10), pp. 3530-3539.  
Silver, R.T.; Cortes, J.; Waltzman, R.; Mone, M. & Kantarjian H. (2009). Sustained durability 
of responses and improved progression-free and overall survival with imatinib 
treatment for accelerated phase and blast crisis chronic myeloid leukemia: long-
term follow-up of the STI571 0102 and 0109 trials. Haematologica, Vol. 94 (5), pp. 
743-744.  
Sokal, J.E.; Cox, E.B.; Baccarani, M.; Tura, S.; Gomez, G.A.; Robertson, J.E.; Tso, C.Y.; Braun, 
T.J.; Clarkson, B.D. & Cervantes, F. (1984). Prognostic discrimination in "good-risk" 
chronic granulocytic leukemia. Blood, Vol. 63, pp. 789-799.  
Talpaz, M.; Silver, R.T.; Druker, B.J.; Goldman, J.M.; Gambacorti-Passerini, C.; Guilhot, F.; 
Schiffer, C.A.; Fischer, T.; Deininger, M.W.; Lennard, A.L.; Hochhaus, A.; Ottmann, 
O.G.; Gratwohl, A.; Baccarani, M.; Stone, R.; Tura, S.; Mahon, F.X.; Fernandes-
Reese, S.; Gathmann, I.; Capdeville, R.; Kantarjian, H.M. & Sawyers, C.L. (2002). 
Imatinib induces durable hematologic and cytogenetic responses in patients with 
accelerated phase chronic myeloid leukemia: results of a phase 2 study. Blood, Vol. 
99 (6), pp. 1928-1937.  
Yeung, D.T.; Osborn, M.; White, D.L.; Branford, S.; Haswell, L.; Slader, C.; Issa, S.; Hiwas, 
D.K.; Hertzberg, M.S.; Schwarer, A.P.; Filshie, R.; Arthur, C.K.; Kwan, Y.L.; Forsyth, 
C.J.; Ross, D.M.; Mills, A.K.; Grigg, A. & Hughes T. (2010). Selective escalation of 
imatinib therapy and early switching to nilotinib in de novo chronic phae CML 
patients: interim results from the TIDEL-II Trial. Blood (ASH Annual Meeting 
Abstracts), Abstr. 209 
 
 
Myeloid Leukemia – Clinical Diagnosis and Treatment 
 
68
and STI571 (IRIS) Investigators. Efficacy of imatinib dose escalation in patients 
with chronic myeloid leukemia in chronic phase. Cancer, Vol. 115 (3), pp. 551-
560.  
Kantarjian, H.; Pasquini, R.; Lévy, V.; Jootar, S.; Holowiecki, J.; Hamerschlak, N.; Hughes, T.; 
Bleickardtm, E.; Dejardin, D.; Cortes, J. & Shah, N.P. (2009b). Dasatinib or high-
dose imatinib for chronic-phase chronic myeloid leukemia resistant to imatinib at a 
dose of 400 to 600 milligrams daily: two-year follow-up of a randomized phase 2 
study (START-R). Cancer, Vol. 115 (18), pp. 4136-4147.  
Koh, Y.; Kim, I.; Yoon, S.S.; Kim, B.K.; Kim, D.Y.; Lee J.H.; Lee, K.H.; Park, E.; Kim, H.J.; 
Sohn, S.K.; Joo, Y.D.; Kim, S.J.; Chung, J.; Shin, H.J.; Kim, S.H.; Kim, C.S.; Song, 
H.S.; Kim, M.K.; Hyun, M.S.; Ahn, J.S.; Jung, C.W. & Park, S. (2010). Korean 
Society of Hematology CML working party. Phase IV study evaluating efficacy of 
escalated dose of imatinib in chronic myeloid leukemia patients showing 
suboptimal response to standard dose imatinib. Ann Hematol, Vol. 89 (7), pp. 725-
731.  
Marin, D.; Goldman, J.M.; Olavarria, E. & Apperley, J.F. (2003). Transient benefit only 
from increasing the imatinib dose in CML patients who do not achieve 
complete cytogenetic remissions on conventional doses. Blood, Vol. 102 (7), pp. 
2702-2703. 
Palandri, F.; Castagnetti, F.; Testoni, N.; Luatti, S.; Marzocchi, G.; Bassi, S.; Breccia, M.; 
Alimena, G.; Pungolino, E.; Rege-Cambrin, G.; Varaldo, R.; Miglino, M.; Specchia, 
G.; Zuffa, E.; Ferrara, F.; Bocchia, M.; Saglio, G.; Pane, F.; Alberti, D.; Martinelli, G.; 
Baccarani, M. & Rosti, G; GIMEMA Working Party on Chronic Myeloid Leukemia. 
(2008). Chronic myeloid leukemia in blast crisis treated with imatinib 600 mg: 
outcome of the patients alive after a 6-year follow-up. Haematologica, Vol. 93 (12), 
pp. 1792-1796.  
Palandri, F.; Castagnetti, F.; Alimena, G.; Testoni, N.; Breccia, M.; Luatti, S.; Rege-Cambrin, 
G.; Stagno, F.; Specchia, G.; Martino, B.; Levato, L.; Merante, S.; Liberati, A.M.; 
Pane, F.; Saglio, G.; Alberti, D.; Martinelli, G.; Baccarani, M. & Rosti, G. (2009). The 
long-term durability of cytogenetic responses in patients with accelerated phase 
chronic myeloid leukemia treated with imatinib 600 mg: the GIMEMA CML 
Working Party experience after a 7-year follow-up. Haematologica, Vol. 94 (2), pp. 
205-212.  
Petzer, A.L.; Wolf, D.; Fong, D.; Lion, T.; Dyagil, I.; Masliak, Z.; Bogdanovic, A.; 
Griskevicius, L.; Lejniece, S.; Goranov, S.; Gercheva, L.; Stojanovic, A.; Peytchev, 
D.; Tzvetkov, N.; Griniute, R.; Oucheva, R.; Ulmer, H.; Kwakkelstein, M.; Rancati, 
F. & Gastl, G. (2010a). High-dose imatinib improves cytogenetic and molecular 
remissions in patients with pretreated philadelphia-positive, bcr-abl-positive 
chronic phase chronic myeloid leukemia: first results from the randomized 
CELSG phase III CML 11 „ISTAHIT“ study. Haematologica, Vol. 95 (6), pp. 908-
913.  
Petzer, A.L.; Fong, D.; Lion, T.; Dyagil, I.; Masliak, Z.; Bogdanovic, A.; Griskevicius, L.; 
Lejniece, S.; Goranov, S.; Gercheva, L.; Stojanovic, A.; Peytchev, D.; Tzvetkov, N.; 
Griniute, R.; Oucheva, R.; Grubinger, T.; Kwakkelstein, M.; Rancati, F.; Gastl, G. & 
 
Role of High Dose Imatinib in BCR/ABLpos/Phpos CML 
 
69 
Wolf, D. (2010b). High dose imatinib induction therapy (800 mg/day, 6 months) in 
pre-treated chronic phase cml patients improves cytogenetic and molecular 
responses but does not improve overall and progression free survival – a final 
results of the CELSG phase III cml 11 “ISTAHTI” trial. Blood (ASH Annual Meeting 
Abstracts), Abstr. 2271.  
Rea, D.; Etienne, G.; Corm, S.; Cony-Makhoul, P.; Gardembas, M.; Legros, L.; Dubruille, V.; 
Hayette, S.; Mahon, F.X.; Cayuela, J.M. & Nicolini, F.E. (2009). Imatinib dose 
escalation for chronic phase-chronic myelogenous leukaemia patients in primary 
suboptimal response to imatinib 400 mg daily standard therapy. Leukemia, Vol. 23 
(6), pp. 1193-1196.  
Rudzki, J. & Wolf, D. (2011). Dose escalation of imatinib in chronic-phase chronic 
myeloid leukemia patients: is it still reasonable? Expert Rev Hematol, Vol. 4 (2), 
pp. 153-159. 
Sawyers, C.L.; Hochhaus, A.; Feldman, E.; Goldman, J.M.; Miller, C.B.; Ottmann, O.G.; 
Schiffer, C.A.; Talpaz, M.; Guilhot, F.; Deininger, M.W.; Fischer, T.; O'Brien, S.G.; 
Stone, R.M.; Gambacorti-Passerini, C.B.; Russell, N.H.; Reiffers, J.J.; Shea, T.C.; 
Chapuis, B.; Coutre, S.; Tura, S.; Morra, E.; Larson, R.A.; Saven, A.; Peschel, C.; 
Gratwohl, A.; Mandelli, F.; Ben-Am, M.; Gathmann, I.; Capdeville, R.; Paquette, 
R.L. & Druker, B.J. (2002). Imatinib induces hematologic and cytogenetic responses 
in patients with chronic myelogenous leukemia in myeloid blast crisis: results of a 
phase II study. Blood, Vol. 99 (10), pp. 3530-3539.  
Silver, R.T.; Cortes, J.; Waltzman, R.; Mone, M. & Kantarjian H. (2009). Sustained durability 
of responses and improved progression-free and overall survival with imatinib 
treatment for accelerated phase and blast crisis chronic myeloid leukemia: long-
term follow-up of the STI571 0102 and 0109 trials. Haematologica, Vol. 94 (5), pp. 
743-744.  
Sokal, J.E.; Cox, E.B.; Baccarani, M.; Tura, S.; Gomez, G.A.; Robertson, J.E.; Tso, C.Y.; Braun, 
T.J.; Clarkson, B.D. & Cervantes, F. (1984). Prognostic discrimination in "good-risk" 
chronic granulocytic leukemia. Blood, Vol. 63, pp. 789-799.  
Talpaz, M.; Silver, R.T.; Druker, B.J.; Goldman, J.M.; Gambacorti-Passerini, C.; Guilhot, F.; 
Schiffer, C.A.; Fischer, T.; Deininger, M.W.; Lennard, A.L.; Hochhaus, A.; Ottmann, 
O.G.; Gratwohl, A.; Baccarani, M.; Stone, R.; Tura, S.; Mahon, F.X.; Fernandes-
Reese, S.; Gathmann, I.; Capdeville, R.; Kantarjian, H.M. & Sawyers, C.L. (2002). 
Imatinib induces durable hematologic and cytogenetic responses in patients with 
accelerated phase chronic myeloid leukemia: results of a phase 2 study. Blood, Vol. 
99 (6), pp. 1928-1937.  
Yeung, D.T.; Osborn, M.; White, D.L.; Branford, S.; Haswell, L.; Slader, C.; Issa, S.; Hiwas, 
D.K.; Hertzberg, M.S.; Schwarer, A.P.; Filshie, R.; Arthur, C.K.; Kwan, Y.L.; Forsyth, 
C.J.; Ross, D.M.; Mills, A.K.; Grigg, A. & Hughes T. (2010). Selective escalation of 
imatinib therapy and early switching to nilotinib in de novo chronic phae CML 
patients: interim results from the TIDEL-II Trial. Blood (ASH Annual Meeting 
Abstracts), Abstr. 209 
 
 
Myeloid Leukemia – Clinical Diagnosis and Treatment 
 
70
Zonder, J.A.; Pemberton, P.; Brandt, H.; Mohamed, A.N. & Schiffer, C.A. (2003). The effect of 
dose increase of imatinib mesylate in patients with chronic or accelerated phase 
chronic myelogenous leukemia with inadequate hematologic or cytogenetic 
response to initial treatment. Clin Cancer Res, Vol. 9 (6), pp. 2092-2097. 
4 
Therapeutic Drug Monitoring of Imatinib  
for Chronic Myeloid Leukemia Patients 
Naoto Takahashi and Masatomo Miura 
Akita University Graduate School of Medicine 
Japan 
1. Introduction 
Imatinib mesylate (Glivec®; Novartis, Basel, Switzerland), a protein kinase inhibitor of the 
BCR–ABL fusion protein, has demonstrated significant clinical efficacy in the treatment of 
Philadelphia (Ph) chromosome-positive chronic myeloid leukemia (CML). Imatinib 
mesylate (hereinafter shortly referred to as imatinib) produces durable responses and 
prolonged survival; therefore, it has become the standard of care for this disease (Goldman 
2007; O'Brien, et al. 2003a). Notwithstanding the positive effects of imatinib, nearly 20% of 
the patients who take imatinib fail to achieve a complete cytogenetic response (CCyR); 
others may develop intolerable side effects or drug resistance overtime. Factors that might 
be associated with suboptimal responses and failure to treatment include (i) biological 
factors, such as the baseline presence or later emergence of BCR–ABL mutations or other 
genetic variants (Gorre, et al. 2001; Radich, et al. 2006), or organic cation transporter-1 
(OCT1)-mediated drug influx (White, et al. 2010); (ii) clinical features, such as the disease 
status of the patients or the Sokal risk score at baseline (Crossman and O'Brien 2004); (iii) 
pharmacokinetic (PK) factors, such as PK-related interindividual variation affecting imatinib 
metabolism and drug–drug interactions (Cortes, et al. 2009; Peng, et al. 2004b); and (iv) the 
patient’s compliance with therapy (Marin, et al. 2010). 
In this chapter, we review the factors that affect imatinib pharmacokinetics, including the 
daily dose of imatinib, polymorphisms of imatinib-associated drug transporters, and the 
currently available methods for quantitative determination of imatinib. Moreover, we 
discuss the clinical significance of therapeutic drug monitoring (TDM) of imatinib. 
2. Relationship between daily dose of imatinib and clinical response 
The standard daily dose of imatinib—established by the International Randomized Study of 
Interferon and STI571 (IRIS)—is 400 mg for patients with chronic phase CML (Druker, et al. 
2006; Hochhaus, et al. 2009). However, several studies have suggested that the 
administration of doses higher than 400 mg improves the response in some patients. Indeed, 
a better response was observed in accelerated and blast phases of CML with a dose of 600 
mg/day (Talpaz, et al. 2002). In another study of 107 Japanese patients with chronic phase 
CML, patients given higher average daily doses of imatinib (more than 350 mg) not only 
achieved higher CCyR rate at 12 and 30 months but also had longer CCyR duration than 
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those given lower average daily doses (Nagai, et al. 2010). Collectively, these results suggest 
a clear dose-response relationship between daily dose of imatinib and treatment results. 
3. Clinical significance of trough imatinib plasma concentrations 
The imatinib plasma trough concentration (C0) appears to affect the clinical response of 
patients (Table 1) (Ishikawa, et al. 2010; Larson, et al. 2008; Picard, et al. 2007; Singh, et al. 
2009; Takahashi, et al. 2010b; Forrest, et al. 2009; Sakai, et al. 2009). Picard et al. reported that 
a steady-state imatinib C0 measured after at least 12 months of treatment with a standard 
imatinib dose correlated with both cytogenetic and molecular responses (Picard, et al. 2007). 
Takahashi et al. have reported that in multiple analyses, the major molecular response 
(MMR) is significantly associated with the age of patients and imatinib C0, whereas CCyR is 
associated only with daily dose (Takahashi, et al. 2010b). In addition, Picard et al. suggested 
that the threshold for the imatinib C0 should be set above 1002 ng/mL, as this level was 
significantly associated with an MMR based on a concentration-dependent receiver-
operating characteristic curve analysis with best sensitivity (77%) and specificity (71%) 
(Picard, et al. 2007). According to this threshold C0 of imatinib, clinical responses were 
evaluated in several reports (Table 2). Takahashi et al. and Marin et al. reported that patients 
with imatinib C0 less than 1000 ng/mL have a significantly lower success rate in achieving 
improved MMR (P = 0.012 and 0.02, respectively) but not CCyR (Marin, et al. 2010; 
Takahashi, et al. 2010b). Thus, the efficacy threshold C0 of imatinib should be set above 1000 
ng/mL for CML patients. 
 
Reference N Response 
Responders Nonresponders  
N Mean C0 (ng/mL)1 N
Mean C0 
(ng/mL)1 P value 
Larson et al. 351 CCyR 297 1,009 ± 544 54 812 ± 409 0.01 
Takahashi  
et al. 254
CCyR 218 1,057 ± 585 36 835 ± 524 0.033 
MMR 166 1,107 ± 594 88 873 ± 528 0.002 
Picard et al. 68 
CCyR 56 1,123 ± 617 12 694 ± 556 0.03 
MMR 34 1,452 ± 649 34 869 ± 427 0.001 
Singh et al. 40 Clinical response 20 2,340 ± 520 20 690 ± 150 0.002 
Ishikawa et al. 60 MMR 38 1,093 (median) 22 853 (median) 0.002 
Sakai et al. 33 Optimal 25 1,242 8 736 0.0087 
Forrest et al. 78 
CCyR 53 1,010 ± 469 24 1,175 ± 656 0.29 
MMR 51 1,067 ± 473 27 1,063 ± 643 0.74 
1All values, except those belonging to the studies by Ishikawa et al. and Sakai et al., are presented as the 
mean ± standard error. 
Abbreviations: C0, plasma trough concentration; CCyR, complete cytogenetic response; MMR, major 
molecular response 
Table 1. Correlation of imatinib pharmacokinetics with clinical response 
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Reference N Response C0 (ng/mL)N ≤1,000 N >1,000 P value 
Marin et al. 84 CCR 43 23.3% 41 44.4% 0.14 MMR 60.1% 83.2% 0.02 
Takahashi et al. 254 CCyR 146 83.6% 108 88.9% 0.276 MMR 58.9% 74.1% 0.012 
Picard et al. 68 MMR 32 25.0% 36 72.2% 0.03 
Ishikawa et al. 60 MMR 29 48.3% 31 77.4% 0.019 
Table 2. Clinical response and target plasma trough concentration (C0) 
4. Reported methods for the quantitative determination of imatinib 
Table 3 summarizes the available methods, including the internal standard used, for the 
quantitative determination of imatinib (Bakhtiar, et al. 2002; Chahbouni, et al. 2009; Davies, 
 
Reference Analyte(s) IS Method
Miura  
et al. (2011) 
Imatinib IS: Dasatinib HPLC–UV (265 nm) 
Roth  
et al. (2010) 
Imatinib IS: None HPLC–UV–Diode Array (265 
nm)
Davies  




IS: Clozapine HPLC–UV (260 nm) 
Chahbouni 




De Francia  




Rochat et al. 
(2008) 
Imatinib IS: D8-Imatinib LC–MS/MS
Oostendorp 





HPLC–UV (265 nm) 
Titier  
et al. (2005) 
Imatinib IS: D8-Imatinib LC–MS/MS
Widmer  
et al. (2004) 
Imatinib IS: Clozapine HPLC–UV–Diode Array (261 
nm)
Velpandian 
et al. (2004) 
Imatinib IS: None HPLC–UV (265 nm) 
Schleyer  
et al. (2004) 
Imatinib, N-
desmethylimatinib
IS: None HPLC–UV (260 nm) 
Parise  









Abbreviations: IS, internal standard; LC–MS, liquid chromatography with mass spectrometry; LC–
MS/MS, liquid chromatography with tandem mass spectrometry; HPLC–UV, high-performance liquid 
chromatography with ultraviolet detector 
Table 3. Analytical methods for the quantitation of imatinib in human plasma 
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patients (Table 1) (Ishikawa, et al. 2010; Larson, et al. 2008; Picard, et al. 2007; Singh, et al. 
2009; Takahashi, et al. 2010b; Forrest, et al. 2009; Sakai, et al. 2009). Picard et al. reported that 
a steady-state imatinib C0 measured after at least 12 months of treatment with a standard 
imatinib dose correlated with both cytogenetic and molecular responses (Picard, et al. 2007). 
Takahashi et al. have reported that in multiple analyses, the major molecular response 
(MMR) is significantly associated with the age of patients and imatinib C0, whereas CCyR is 
associated only with daily dose (Takahashi, et al. 2010b). In addition, Picard et al. suggested 
that the threshold for the imatinib C0 should be set above 1002 ng/mL, as this level was 
significantly associated with an MMR based on a concentration-dependent receiver-
operating characteristic curve analysis with best sensitivity (77%) and specificity (71%) 
(Picard, et al. 2007). According to this threshold C0 of imatinib, clinical responses were 
evaluated in several reports (Table 2). Takahashi et al. and Marin et al. reported that patients 
with imatinib C0 less than 1000 ng/mL have a significantly lower success rate in achieving 
improved MMR (P = 0.012 and 0.02, respectively) but not CCyR (Marin, et al. 2010; 
Takahashi, et al. 2010b). Thus, the efficacy threshold C0 of imatinib should be set above 1000 
ng/mL for CML patients. 
 
Reference N Response 
Responders Nonresponders  
N Mean C0 (ng/mL)1 N
Mean C0 
(ng/mL)1 P value 
Larson et al. 351 CCyR 297 1,009 ± 544 54 812 ± 409 0.01 
Takahashi  
et al. 254
CCyR 218 1,057 ± 585 36 835 ± 524 0.033 
MMR 166 1,107 ± 594 88 873 ± 528 0.002 
Picard et al. 68 
CCyR 56 1,123 ± 617 12 694 ± 556 0.03 
MMR 34 1,452 ± 649 34 869 ± 427 0.001 
Singh et al. 40 Clinical response 20 2,340 ± 520 20 690 ± 150 0.002 
Ishikawa et al. 60 MMR 38 1,093 (median) 22 853 (median) 0.002 
Sakai et al. 33 Optimal 25 1,242 8 736 0.0087 
Forrest et al. 78 
CCyR 53 1,010 ± 469 24 1,175 ± 656 0.29 
MMR 51 1,067 ± 473 27 1,063 ± 643 0.74 
1All values, except those belonging to the studies by Ishikawa et al. and Sakai et al., are presented as the 
mean ± standard error. 
Abbreviations: C0, plasma trough concentration; CCyR, complete cytogenetic response; MMR, major 
molecular response 
Table 1. Correlation of imatinib pharmacokinetics with clinical response 
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Reference N Response C0 (ng/mL)N ≤1,000 N >1,000 P value 
Marin et al. 84 CCR 43 23.3% 41 44.4% 0.14 MMR 60.1% 83.2% 0.02 
Takahashi et al. 254 CCyR 146 83.6% 108 88.9% 0.276 MMR 58.9% 74.1% 0.012 
Picard et al. 68 MMR 32 25.0% 36 72.2% 0.03 
Ishikawa et al. 60 MMR 29 48.3% 31 77.4% 0.019 
Table 2. Clinical response and target plasma trough concentration (C0) 
4. Reported methods for the quantitative determination of imatinib 
Table 3 summarizes the available methods, including the internal standard used, for the 
quantitative determination of imatinib (Bakhtiar, et al. 2002; Chahbouni, et al. 2009; Davies, 
 
Reference Analyte(s) IS Method
Miura  
et al. (2011) 
Imatinib IS: Dasatinib HPLC–UV (265 nm) 
Roth  
et al. (2010) 
Imatinib IS: None HPLC–UV–Diode Array (265 
nm)
Davies  




IS: Clozapine HPLC–UV (260 nm) 
Chahbouni 




De Francia  




Rochat et al. 
(2008) 
Imatinib IS: D8-Imatinib LC–MS/MS
Oostendorp 





HPLC–UV (265 nm) 
Titier  
et al. (2005) 
Imatinib IS: D8-Imatinib LC–MS/MS
Widmer  
et al. (2004) 
Imatinib IS: Clozapine HPLC–UV–Diode Array (261 
nm)
Velpandian 
et al. (2004) 
Imatinib IS: None HPLC–UV (265 nm) 
Schleyer  
et al. (2004) 
Imatinib, N-
desmethylimatinib
IS: None HPLC–UV (260 nm) 
Parise  









Abbreviations: IS, internal standard; LC–MS, liquid chromatography with mass spectrometry; LC–
MS/MS, liquid chromatography with tandem mass spectrometry; HPLC–UV, high-performance liquid 
chromatography with ultraviolet detector 
Table 3. Analytical methods for the quantitation of imatinib in human plasma 
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et al. 2010; De Francia, et al. 2009; Miura, et al. 2011; Oostendorp, et al. 2007; Parise, et al. 
2003; Rochat, et al. 2008; Roth, et al. 2010; Schleyer, et al. 2004; Titier, et al. 2005; Velpandian, 
et al. 2004; Widmer, et al. 2004). High-performance liquid chromatography (HPLC) with 
ultraviolet (UV) detection, liquid chromatography with mass spectrometry (LC–MS), and 
liquid chromatography with tandem mass spectrometry (LC–MS/MS) have been used in 
clinical studies to measure the plasma concentration of imatinib. HPLC–UV is less expensive 
than LC–MS or LC–MS/MS detection and requires equipment that is widely available in 
hospital laboratories. As such, a validated HPLC–UV assay provides the most practical 
platform to measure imatinib plasma concentration in actual clinical practice. 
5. Interpatient variability of trough imatinib plasma concentration 
Despite the linear relationship between imatinib C0 and its daily dose, substantial 
interpatient variability is observed (Takahashi, et al. 2010b). Even among patients taking the 
same 400 mg/day dose, the imatinib C0 ranges widely (140–3910 ng/mL) (Table 4) (Forrest, 
et al. 2009; Ishikawa, et al. 2010; Larson, et al. 2008; Marin, et al. 2010; Picard, et al. 2007; 
Takahashi, et al. 2010b). Factors that could underlie this interpatient variability include body 
size, age, gender, liver function, renal function, interaction with other medications given 
concomitantly, adherence to medication regimens, and polymorphisms of enzymes or 
transporters related to imatinib pharmacokinetics and/or pharmacodynamics. 
 
Reference  N C0 (ng/mL) Mean Minimum Maximum 
Larson et al.  351 979 153 3,910 
Picard et al.  68 1,058 181 2,947 
Marin et al.  84 900 400 1,600 
Forrest et al.  70 1,065 203 2,910 
Takahashi et al.  190 1,392 140 2,457 
Ishikawa et al.  46 1,005 (median) 450 1,875 
Table 4. Steady-state plasma trough concentration (C0) range at 400 mg of imatinib daily 
6. Pharmacokinetics of imatinib 
Imatinib is rapidly and completely absorbed because of an oral bioavailability of 98.3% 
(Peng, et al. 2004a). Moreover, it is extensively metabolized, with up to 80% of the 
administered dose recovered in feces as metabolites or unchanged drug (Gschwind, et al. 
2005). The mean plasma half-life of imatinib is 13.5–18.2 h (Gschwind, et al. 2005; le Coutre, 
et al. 2004; Peng, et al. 2004b; Wang, et al. 2009). The cytochrome P450 (CYP) system is 
involved in the oxidative metabolism of imatinib, the major reaction being catalyzed by 
CYP3A4/5 (O'Brien, et al. 2003b; Peng, et al. 2005; van Erp, et al. 2007). Indeed, the main 
metabolite of imatinib, the N-desmethyl derivative CGP74588, is primarily formed in the 
liver by cytochrome CYP3A4, whereas a number of other enzymes such as CYP1A2, 
CYP2D6, CYP2C9, and CYP2C19 are involved in the formation of minor metabolites 
(O'Brien, et al. 2003b; van Erp, et al. 2007). CGP74588 represents approximately 20% of the 
parent drug plasma level in patients, and it has similar biological activity but a longer 
terminal half-life (85–95 h) than imatinib, as measured after discontinuation of therapy 
 
Therapeutic Drug Monitoring of Imatinib for Chronic Myeloid Leukemia Patients 
 
75 
Transporter Polymorphism N Effects on PK Effects on clinical 
response 
Reference 
P-glycoprotein 3435 T 82 CL/F = - Gardner et al. 
(ABCB1) 3435 T 90 C0 =  MMR = Dulucq et al. 
 3435 T 34 CL/F ↓ - Yamakawa et al. 
 3435 T 67 C0 =  MMR =  Takahashi et al. 
 3435 T 22 CL/F ↑ - Gurney et al. 
 3435 T 229 - OS ↓ Kim et al. 
 3435 T 52 - Resistance ↑ Ni et al. 
 3435 T 46 - MMR, CMR ↓ Deenik et al. 
 3435 CC 65 - Failure ↑ Maffoli et al. 
  1236 T 90 C0 =  MMR ↑ Dulucq et al. 
 1236 T 34 CL/F = - Yamakawa et al. 
 1236 T 67 C0 =  MMR =  Takahashi et al. 
 1236 T 22 CL/F ↑ - Gurney et al. 
 1236 T 229 - CCyR, MMR = Kim et al. 
 1236 T 52 - Resistance ↑ Ni et al. 
 1236 T 46 - MMR, CMR ↓ Deenik et al. 
  2677 T/A 90 C0 =  MMR ↑ Dulucq et al. 
 2677 T/A 34 CL/F = - Yamakawa et al. 
 2677 T/A 67 C0 =  MMR =  Takahashi et al. 
 2677 T/A 22 CL/F ↑ - Gurney et al. 
 2677 T/A 229 - CCyR, MMR = Kim et al. 
 2677 A 52 - CCyR ↑ Ni et al. 
 2677 T 46 - CMR ↓ Deenik et al. 
  TTT haplotype 90 C0 ↑ MMR ↑ Dulucq et al. 
  TTT haplotype 22 CL/F ↑ - Gurney et al. 
BCRP 421 A 82 CL/F = - Gardner et al. 
(ABCG2) 421 A 34 CL/F = - Yamakawa et al. 
 421 A 67 C0 ↑ MMR =  Takahashi et al. 
 421 A 46 CL/F ↓ - Petain et al. 
  421 A 229 - MMR, CMR ↑ Kim et al. 
OCT1 480 G 229 - Loss of response Kim et al. 
(SLC22A1) 480 G 67 C0 =  MMR =  Takahashi et al. 
 1022 T 67 C0 =  MMR =  Takahashi et al. 
 1022 T 34 CL/F = - Yamakawa et al. 
  1222 G 67 C0 =  MMR ↑ Takahashi et al. 
Abbreviations: C0, plasma trough concentration; CCyR, complete cytogenetic response; CL/F, clearance; 
CMR, complete molecular response; MMR, major molecular response; PK, pharmacokinetics 
Table 5. Transporter polymorphism and effects on pharmacokinetics and the clinical 
response 
(Gschwind, et al. 2005; le Coutre, et al. 2004). Imatinib is a substrate for P-glycoprotein, 
which is encoded by the ABCB1 gene, and breast cancer-resistance protein (BCRP), which is 
encoded by the ABCG2 gene (Burger and Nooter 2004; Burger, et al. 2004; Dohse, et al. 2010; 
Ozvegy-Laczka, et al. 2004). P-Glycoprotein is a membrane efflux transporter normally 
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et al. 2010; De Francia, et al. 2009; Miura, et al. 2011; Oostendorp, et al. 2007; Parise, et al. 
2003; Rochat, et al. 2008; Roth, et al. 2010; Schleyer, et al. 2004; Titier, et al. 2005; Velpandian, 
et al. 2004; Widmer, et al. 2004). High-performance liquid chromatography (HPLC) with 
ultraviolet (UV) detection, liquid chromatography with mass spectrometry (LC–MS), and 
liquid chromatography with tandem mass spectrometry (LC–MS/MS) have been used in 
clinical studies to measure the plasma concentration of imatinib. HPLC–UV is less expensive 
than LC–MS or LC–MS/MS detection and requires equipment that is widely available in 
hospital laboratories. As such, a validated HPLC–UV assay provides the most practical 
platform to measure imatinib plasma concentration in actual clinical practice. 
5. Interpatient variability of trough imatinib plasma concentration 
Despite the linear relationship between imatinib C0 and its daily dose, substantial 
interpatient variability is observed (Takahashi, et al. 2010b). Even among patients taking the 
same 400 mg/day dose, the imatinib C0 ranges widely (140–3910 ng/mL) (Table 4) (Forrest, 
et al. 2009; Ishikawa, et al. 2010; Larson, et al. 2008; Marin, et al. 2010; Picard, et al. 2007; 
Takahashi, et al. 2010b). Factors that could underlie this interpatient variability include body 
size, age, gender, liver function, renal function, interaction with other medications given 
concomitantly, adherence to medication regimens, and polymorphisms of enzymes or 
transporters related to imatinib pharmacokinetics and/or pharmacodynamics. 
 
Reference  N C0 (ng/mL) Mean Minimum Maximum 
Larson et al.  351 979 153 3,910 
Picard et al.  68 1,058 181 2,947 
Marin et al.  84 900 400 1,600 
Forrest et al.  70 1,065 203 2,910 
Takahashi et al.  190 1,392 140 2,457 
Ishikawa et al.  46 1,005 (median) 450 1,875 
Table 4. Steady-state plasma trough concentration (C0) range at 400 mg of imatinib daily 
6. Pharmacokinetics of imatinib 
Imatinib is rapidly and completely absorbed because of an oral bioavailability of 98.3% 
(Peng, et al. 2004a). Moreover, it is extensively metabolized, with up to 80% of the 
administered dose recovered in feces as metabolites or unchanged drug (Gschwind, et al. 
2005). The mean plasma half-life of imatinib is 13.5–18.2 h (Gschwind, et al. 2005; le Coutre, 
et al. 2004; Peng, et al. 2004b; Wang, et al. 2009). The cytochrome P450 (CYP) system is 
involved in the oxidative metabolism of imatinib, the major reaction being catalyzed by 
CYP3A4/5 (O'Brien, et al. 2003b; Peng, et al. 2005; van Erp, et al. 2007). Indeed, the main 
metabolite of imatinib, the N-desmethyl derivative CGP74588, is primarily formed in the 
liver by cytochrome CYP3A4, whereas a number of other enzymes such as CYP1A2, 
CYP2D6, CYP2C9, and CYP2C19 are involved in the formation of minor metabolites 
(O'Brien, et al. 2003b; van Erp, et al. 2007). CGP74588 represents approximately 20% of the 
parent drug plasma level in patients, and it has similar biological activity but a longer 
terminal half-life (85–95 h) than imatinib, as measured after discontinuation of therapy 
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Transporter Polymorphism N Effects on PK Effects on clinical 
response 
Reference 
P-glycoprotein 3435 T 82 CL/F = - Gardner et al. 
(ABCB1) 3435 T 90 C0 =  MMR = Dulucq et al. 
 3435 T 34 CL/F ↓ - Yamakawa et al. 
 3435 T 67 C0 =  MMR =  Takahashi et al. 
 3435 T 22 CL/F ↑ - Gurney et al. 
 3435 T 229 - OS ↓ Kim et al. 
 3435 T 52 - Resistance ↑ Ni et al. 
 3435 T 46 - MMR, CMR ↓ Deenik et al. 
 3435 CC 65 - Failure ↑ Maffoli et al. 
  1236 T 90 C0 =  MMR ↑ Dulucq et al. 
 1236 T 34 CL/F = - Yamakawa et al. 
 1236 T 67 C0 =  MMR =  Takahashi et al. 
 1236 T 22 CL/F ↑ - Gurney et al. 
 1236 T 229 - CCyR, MMR = Kim et al. 
 1236 T 52 - Resistance ↑ Ni et al. 
 1236 T 46 - MMR, CMR ↓ Deenik et al. 
  2677 T/A 90 C0 =  MMR ↑ Dulucq et al. 
 2677 T/A 34 CL/F = - Yamakawa et al. 
 2677 T/A 67 C0 =  MMR =  Takahashi et al. 
 2677 T/A 22 CL/F ↑ - Gurney et al. 
 2677 T/A 229 - CCyR, MMR = Kim et al. 
 2677 A 52 - CCyR ↑ Ni et al. 
 2677 T 46 - CMR ↓ Deenik et al. 
  TTT haplotype 90 C0 ↑ MMR ↑ Dulucq et al. 
  TTT haplotype 22 CL/F ↑ - Gurney et al. 
BCRP 421 A 82 CL/F = - Gardner et al. 
(ABCG2) 421 A 34 CL/F = - Yamakawa et al. 
 421 A 67 C0 ↑ MMR =  Takahashi et al. 
 421 A 46 CL/F ↓ - Petain et al. 
  421 A 229 - MMR, CMR ↑ Kim et al. 
OCT1 480 G 229 - Loss of response Kim et al. 
(SLC22A1) 480 G 67 C0 =  MMR =  Takahashi et al. 
 1022 T 67 C0 =  MMR =  Takahashi et al. 
 1022 T 34 CL/F = - Yamakawa et al. 
  1222 G 67 C0 =  MMR ↑ Takahashi et al. 
Abbreviations: C0, plasma trough concentration; CCyR, complete cytogenetic response; CL/F, clearance; 
CMR, complete molecular response; MMR, major molecular response; PK, pharmacokinetics 
Table 5. Transporter polymorphism and effects on pharmacokinetics and the clinical 
response 
(Gschwind, et al. 2005; le Coutre, et al. 2004). Imatinib is a substrate for P-glycoprotein, 
which is encoded by the ABCB1 gene, and breast cancer-resistance protein (BCRP), which is 
encoded by the ABCG2 gene (Burger and Nooter 2004; Burger, et al. 2004; Dohse, et al. 2010; 
Ozvegy-Laczka, et al. 2004). P-Glycoprotein is a membrane efflux transporter normally 
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expressed in the small intestine, biliary canalicular front of hepatocytes, and renal 
proximal tubules (Thiebaut, et al. 1987). BCRP is widely expressed in the small intestine, 
liver, and placenta (Hirano, et al. 2005; Zhang, et al. 2006). Imatinib and its metabolites are 
excreted predominantly via the biliary–fecal route by these ATP-binding cassette (ABC) 
efflux transporters, P-glycoprotein and BCRP. Imatinib is also a substrate of the uptake 
transporter OCT1, which is encoded by SLC22A1 (Choi and Song 2008; White, et al. 2006). 
Because OCT1 is a highly expressed solute carrier in the basolateral membrane of 
hepatocytes, it facilitates the hepatocellular accumulation of imatinib before metabolism 
and biliary secretion. Further, it may play an important role in governing drug disposition 
and hepatotoxicity (Zhang, et al. 1998a; Zhang, et al. 1997; Zhang, et al. 1998b). One of the 
factors affecting interpatient variability could be polymorphism of drug transporters. 
However, the involvement of multiple transporters in imatinib pharmacokinetics hampers 
the investigation of imatinib transport mechanisms. Moreover, the level of drug 
transporter expression likely correlates with the intracellular imatinib concentration, 
because primary CML cells express the transporters on the cell surface (Burger, et al. 2005; 
White, et al. 2006). 
7. Impact of pharmacogenetic variation of drug transporters 
Pharmacogenetic research has focused on the interaction of imatinib with enzymes such as 
CYP3A4/5 and transporters such as P-glycoprotein, BCRP, and OCT1 (Table 5) (Deenik, et 
al. 2010; Dulucq and Krajinovic 2010; Gardner, et al. 2006; Kim, et al. 2009; Maffioli, et al. 
2010; Ni, et al. 2011; Petain, et al. 2008; Takahashi, et al. 2010a; Yamakawa, et al. 2011). 
7.1 CYP3A4/5 
CYP3A4/5 expression is strongly correlated with a single-nucleotide polymorphism (SNP) 
in the gene (Hustert, et al. 2001; Rodriguez-Antona, et al. 2005). Nonetheless, CYP3A4*1B (-
392A>G) and CYP3A5*3 (6986A>G) had no significant influence on the plasma 
concentration of imatinib (Gardner, et al. 2006; Gurney, et al. 2007; Takahashi, et al. 2010a). 
A drug interaction occurs upon coadministration of imatinib and rifampicin or St. John's 
wort’s CYP3A inducers, resulting in a decrease in the plasma concentration of imatinib 
(Bolton, et al. 2004; Smith, et al. 2004). In contrast, ketoconazole, a potent CYP3A4 inhibitor, 
significantly increased the Cmax and AUC0–24 of imatinib (Dutreix, et al. 2004). However, the 
effects of CYP3A4 and CYP3A5 polymorphisms are less likely to be clinically significant in 
imatinib exposure. 
7.2 P-Glycoprotein (ABCB1) 
Gurney et al. (sample size = 22) reported that oral clearance of imatinib in patients receiving 
600 mg of imatinib daily was significantly lower in those with the ABCB1 1236C/C, 
2677G/G or 3435C/C genotypes than in those with the corresponding ABCB1 1236T/T, 
2677T/T or 3435T/T genotypes (Gurney, et al. 2007). However, Gardner et al. (sample size = 
82) reported that the ABCB1 3435C>T polymorphism had no significant effect on oral 
clearance of imatinib (Gardner, et al. 2006). In another study, Takahashi et al. (sample size = 
62) reported that 1236C>T, 2677G>T/A, and 3435C>T polymorphisms had no significant 
effect on dose-adjusted imatinib C0 (Takahashi, et al. 2010a). Although other studies have 
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reported the relationship between ABCB1 polymorphisms and imatinib pharmacokinetics, 
or between ABCB1 polymorphisms and clinical response, the results are still controversial 
(Table 5). However, the 3435T polymorphism, which is associated with low expression of P-
glycoprotein, tends to correlate with poor clinical response. This finding suggests that P-
glycoprotein is involved in imatinib pharmacokinetics to a greater extent than the 
intracellular imatinib concentration in primary CML cells. 
7.3 BCRP (ABCG2) 
Five studies have reported the ABCG2 421 polymorphism and imatinib pharmacokinetics or 
clinical response. Takahashi et al. (sample size = 62) reported that the dose-adjusted 
imatinib C0 was significantly lower in Japanese patients with ABCG2 421C/C than in 
patients with C/A+A/A genotypes (Takahashi, et al. 2010a). In agreement, Petain et al. 
(sample size = 46) reported that imatinib clearance in patients carrying the ABCG2 421C/A 
genotype was significantly lower than in those with the 421C/C genotype (Petain, et al. 
2008). Moreover, ABCG2 421A/A has a significant effect on achieving MMR/CCyR (sample 
size = 229) (Kim, et al. 2009). Because the 421C>A SNP of the ABCG2 gene is associated with 
a higher imatinib exposure than is the wild-type genotype, CML patients with this SNP 
might more efficiently achieve molecular responses much more than their wild-type 
counterparts. 
7.4 OCT1 (SLC22A1) 
SLC22A1 (OCT1) expression levels likely correlate with the intracellular imatinib 
concentration, as primary CML cells expressing high levels of OCT1 have a greater drug 
uptake than those exhibiting more modest OCT1 expression (Thomas, et al. 2004; Wang, et 
al. 2008; White, et al. 2006). On the other hand, Kim et al. reported that the SLC22A1 480G/G 
genotype correlated with high rate of loss of response or treatment failure to imatinib 
therapy (Kim, et al. 2009). However, no association between dose-adjusted imatinib C0 and 
SLC22A1156T>C, 480G>C, 1022C>T, or 1222A>G polymorphisms has been observed 
(Takahashi, et al. 2010a). The SLC22A1 polymorphisms analyzed to date are therefore not 
important for imatinib exposure. OCT1 may contribute to the cellular uptake of imatinib 
rather than to imatinib exposure. 
8. Pharmacokinetics of second-generation BCR-ABL inhibitors  
Second-generation inhibitors, including nilotinib, dasatinib, and bosutinib, have been 
developed to counter imatinib resistances associated with BCR-ABL mutations, BCR-ABL 
gene amplification, increased efflux via ABC pump activation, or decreased influx via OCT1 
activation. Nilotinib is a close structural analogue of imatinib with greater binding affinity 
and selectivity for the BCR-ABL kinase than imatinib. Dasatinib and bosutinib are dual 
ABL-SRC kinase inhibitors. All these second-generation inhibitors have been evaluated in 
clinical trials (Kantarjian, et al. 2010; Keller, et al. 2009; Saglio, et al. 2010), and nilotinib and 
dasatinib have already been approved in many countries for the treatment of patients with 
CML.  
In pharmacokinetics studies with dasatinib (Christopher, et al. 2008), nilotinib (Tanaka, et al. 
2010), or bosutinib (Abbas, et al. 2011), exposures (Cmax and AUC) were shown to be linear 
and the dose proportional. Cmax was observed at 0.5, 3, and 6 h after single oral 
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expressed in the small intestine, biliary canalicular front of hepatocytes, and renal 
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factors affecting interpatient variability could be polymorphism of drug transporters. 
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the investigation of imatinib transport mechanisms. Moreover, the level of drug 
transporter expression likely correlates with the intracellular imatinib concentration, 
because primary CML cells express the transporters on the cell surface (Burger, et al. 2005; 
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7. Impact of pharmacogenetic variation of drug transporters 
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(Bolton, et al. 2004; Smith, et al. 2004). In contrast, ketoconazole, a potent CYP3A4 inhibitor, 
significantly increased the Cmax and AUC0–24 of imatinib (Dutreix, et al. 2004). However, the 
effects of CYP3A4 and CYP3A5 polymorphisms are less likely to be clinically significant in 
imatinib exposure. 
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2677G/G or 3435C/C genotypes than in those with the corresponding ABCB1 1236T/T, 
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(Table 5). However, the 3435T polymorphism, which is associated with low expression of P-
glycoprotein, tends to correlate with poor clinical response. This finding suggests that P-
glycoprotein is involved in imatinib pharmacokinetics to a greater extent than the 
intracellular imatinib concentration in primary CML cells. 
7.3 BCRP (ABCG2) 
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(sample size = 46) reported that imatinib clearance in patients carrying the ABCG2 421C/A 
genotype was significantly lower than in those with the 421C/C genotype (Petain, et al. 
2008). Moreover, ABCG2 421A/A has a significant effect on achieving MMR/CCyR (sample 
size = 229) (Kim, et al. 2009). Because the 421C>A SNP of the ABCG2 gene is associated with 
a higher imatinib exposure than is the wild-type genotype, CML patients with this SNP 
might more efficiently achieve molecular responses much more than their wild-type 
counterparts. 
7.4 OCT1 (SLC22A1) 
SLC22A1 (OCT1) expression levels likely correlate with the intracellular imatinib 
concentration, as primary CML cells expressing high levels of OCT1 have a greater drug 
uptake than those exhibiting more modest OCT1 expression (Thomas, et al. 2004; Wang, et 
al. 2008; White, et al. 2006). On the other hand, Kim et al. reported that the SLC22A1 480G/G 
genotype correlated with high rate of loss of response or treatment failure to imatinib 
therapy (Kim, et al. 2009). However, no association between dose-adjusted imatinib C0 and 
SLC22A1156T>C, 480G>C, 1022C>T, or 1222A>G polymorphisms has been observed 
(Takahashi, et al. 2010a). The SLC22A1 polymorphisms analyzed to date are therefore not 
important for imatinib exposure. OCT1 may contribute to the cellular uptake of imatinib 
rather than to imatinib exposure. 
8. Pharmacokinetics of second-generation BCR-ABL inhibitors  
Second-generation inhibitors, including nilotinib, dasatinib, and bosutinib, have been 
developed to counter imatinib resistances associated with BCR-ABL mutations, BCR-ABL 
gene amplification, increased efflux via ABC pump activation, or decreased influx via OCT1 
activation. Nilotinib is a close structural analogue of imatinib with greater binding affinity 
and selectivity for the BCR-ABL kinase than imatinib. Dasatinib and bosutinib are dual 
ABL-SRC kinase inhibitors. All these second-generation inhibitors have been evaluated in 
clinical trials (Kantarjian, et al. 2010; Keller, et al. 2009; Saglio, et al. 2010), and nilotinib and 
dasatinib have already been approved in many countries for the treatment of patients with 
CML.  
In pharmacokinetics studies with dasatinib (Christopher, et al. 2008), nilotinib (Tanaka, et al. 
2010), or bosutinib (Abbas, et al. 2011), exposures (Cmax and AUC) were shown to be linear 
and the dose proportional. Cmax was observed at 0.5, 3, and 6 h after single oral 
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administration of each inhibitor, and a mean terminal elimination half-life (t 1/2) was <4, 17, 
and 32–39 h, respectively. Absorption was rapid for dasatinib and relatively slow for 
nilotinib and bosutinib. Similarly to imatinib, they are metabolized primarily by CYP3A4. 
However, unlike imatinib, nilotinib and dasatinib are not substrates for OCT1 transporter 
(Clark, et al. 2008; Giannoudis, et al. 2008; Hiwase, et al. 2008). Nilotinib and dasatinib are 
high-affinity substrates of BCRP and also interact with P-glycoprotein (Hiwase, et al. 2008). 
However, neither P-glycoprotein nor BCRP induce resistance to bosutinib (Hegedus, et al. 
2009). 
 There are no published data on the relationship between drug plasma concentration and 
outcome or adverse events, and no clinically relevant data to suggest that dose changes are 
necessary based on sex, age, or pharmacokinetic differences that depend on the 
pharmacogenetic variation of drug transporters for second-generation inhibitors. 
9. Therapeutic drug monitoring of imatinib for CML patients 
Patients are more likely to achieve higher response rates with a satisfactory level of response 
if the 1,000 ng/mL drug plasma threshold considered as an adequate imatinib C0 is achieved 
and maintained. Because the interpatient variation of imatinib levels is influenced by 
multiple factors, including genetic polymorphisms or coadministered drugs, a routine 
therapeutic drug monitoring (TDM) service for CML patients taking imatinib might be 
useful. According to the European Leukemia Net (ELN) recommendations (Baccarani, et al. 
2009), the clinical response for CML patients receiving imatinib therapy should be evaluated 
at 3, 6, 12, and 18 months. In addition to BCR–ABL mutation analysis for CML patients, 
TDM could be also useful when making decisions related to imatinib therapy for patients 
not achieving CCyR or MMR at the above time points. If the target C0 is not reached and no 
intolerance is found, dose escalation of imatinib is recommended. On the other hand, if the 
target is achieved but the patients lack a sufficient clinical response, imatinib could be 
withdrawn and replaced by a second-line tyrosine kinase inhibitor. Moreover, among the 
above-mentioned drug transporters, BCRP seems to most strongly influence imatinib 
exposure. We have reported that the daily dose of imatinib for patients with ABCG2 421C/C 
and 421C/A or 421A/A should be 400 mg and 300 mg, respectively, to attain the 1000 
ng/mL drug plasma threshold (Takahashi and Miura 2011). If the ABCG2 421C>A 
polymorphism is detected before initiating therapy, dosing decisions may be improved to 
achieve optimal imatinib exposure immediately after intake. Further study is necessary to 
prospectively confirm the benefit of TDM of imatinib in the treatment and management of 
CML patients. 
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1. Introduction 
Therapy by drugs that block the activity of the protein Bcr-Abl, specific inhibitors of Bcr-Abl 
tyrosine kinase (TKI), significantly changed the prognosis of chronic myeloid leukemia 
(CML). Bcr-Abl gene is located on the Philadelphia chromosome (Ph'-chromosome), 
resulting from t(9;22) translocation, plays a key role in the onset and progression of CML. To 
date, the standard in the treatment of CML patients is imatinib mesylate (Gleevec, "Novartis 
Pharma AG", Switzerland). In addition, TKI 2nd generation, nilotinib and dasatinib, which 
differ in activity and impact points, also show encouraging results as first-line therapy of 
CML. According to an international multicenter study of IRIS (after 60 months of imatinib 
therapy) is shown that a complete hematologic remission was achieved in 96% of 
patients, major cytogenetic response - at 92%, complete cytogenetic response - 86% [1]. 
Imatinib treatment is well tolerated; treatment withdrawal because of intolerance is noted 
only in 5% of patients [2, 3]. The most frequent side effects are edema (peripheral edema, 
pleural or pericardial effusion, ascites, and pulmonary edema), rapid increase of body 
weight (independently from peripheral edema), nausea, vomiting, myalgia, muscle cramps, 
diarrhea, skin rash [4, 5]. 
Respiratory side effects of imatinib are rare. The most frequent among them are cough (9—
22%), dyspnea (5—16%), flu-like syndrome (11,1%), upper respiratory tract infections 
(16,5%), pneumonia (1—10%) [4, 5]. Quite infrequent complications are pulmonary fibrosis 
and drug-induced pneumonitis [6]. 
We have some cases of such complications in available literature [7, 8, 9, 10, 11, 12]. Signs 
and symptoms of pneumonitis are similar: constitutional symptoms, malaise, low-grade 
fever, dyspnea (both exertional and at rest), cough, interstitial pulmonary infiltrates [13]. 
These symptoms are nonspecific and are often seen in other disorders. Rosado M.F. et al. 
have published one of the first case reports of imatinib-induced pneumonitis in 63 year-old 
woman with CML. At month 2 of imatinib treatment she has experienced dry cough and 
moderate exertional dyspnea. At 5th month of imatinib treatment both cough and dyspnea 
have worsened and hypoxemia was found (SaO2 88%). The diagnosis was confirmed by 
results of CT scan and bronchoscopy with transbronchial needle aspiration, excluding 
bacterial, viral and fungal etiology of pneumonitis [8]. J.Rajda et al. have described drug-
induced pneumonitis in 77 year-old woman with CML during first 4 weeks of imatinib 
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treatment. The progressive exertional dyspnea has led to nearly complete disability, where 
she could feel comfortable only at rest; later on a low-grade fever occurred. SaO2 was 85% 
[13]. In other patients the disease manifestations, diagnostic approach and treatment were 
quite similar. 
Although most cases of imatinib-induced pulmonary adverse events have been reported in 
patients with early chronic phase CML (from 0.2 to 1.3%). Dyspnea during imatinib therapy 
is most often related to fluid retention and pulmonary edema. Fluid retention may be due to 
prolonged platelet-derived growth factor inhibition by imatinib. Platelet-derived growth 
factor pathways are involved in the regulation of interstitial fluid homeostasis [16]. Imatinib 
pneumonitis develops in the period from 10 to 282 days (median time, 49 days) after 
treatment with imatinib (range, 200 to 600 mg daily). Dyspnea, hypoxemia and fever are 
usually seen. The chest CT scan shows diffuse or patchy ground-glass opacity, 
consolidation, or fine nodular opacity. The lung pathology may show interstitial 
pneumonitis and fibrosis, destruction of alveolar septa, lymphocytic alveolitis, plasma cell 
infiltrates, or type II pneumocyte hyperplasia. The resolution of pneumonitis after 
corticosteroid therapy has been reported. Ohnishi et al [16] reported that pneumonitis 
developed in 4 of 11 patients with a history of imatinib-induced pneumonitis after 
reexposure to imatinib [7, 13]. Diagnose lung disease caused by taking drugs is not always 
easy due to lack of specific clinical and morphological manifestations.  
2. Clinical observations 
In 2007—2008 in Hematology Research Center (Moscow, Russia) we have observed 
(including retrospective) in CML patients 4 cases of suspected imatinib-induced 
pneumonitis (Table 1). Three female and 1 male patients aged 13, 64, 66, and 40 
correspondingly have initial diagnosis of chronic phase CML high-risk group, according to 
Sokal. The CML duration before imatinib treatment was 24, 11, 2, and 2.5 months and 
imatinib treatment duration – 73, 48, 7, and 13 months correspondingly. Pneumonitis has 
occurred at months 2, 13, 47 and 48 of imatinib treatment. 
 





















#1 F 13 XI/99 XI/2001 XII/2005 IX/2008 47 73 
#2 F 64 XII/02 XI/2004 XI/2008 XI/2008 48 48 
#3 F 66 I/08 III/2008 V/2008 XI/2008 2 7 
#4 M 40 IX/06 XI/2008 III/2008 III/2008 13 13 
Table 1. Characteristics of drug-induced pneumonitis patients. 
Here are the case reports of our patients with imatinib-induced pneumonitis. In 2 patients it 
was revealed after a short, while in another two it was associated with prolonged imatinib 
treatment. In each case, describes the stages of diagnosis lung disease that emerged while 
taking imatinib (including retrospective), and treatment. 
The first case of drug-induced pneumonitis, a 20 year-old woman, admitted to our center in 
November, 2007. At age of 13 (in November 1999) the patient was diagnosed with chronic 
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phase of CML, high-risk group by Sokal on the basis of leukocytosis (WBC 286×109/L ) with 
prominent left shift of differential count with 15% blasts, hyperthrombocytosis 2279×109/L, 
spleen +8 cm below costal margin, liver +1 cm below costal margin. It should be 
noted that under the new WHO classification of 2008, the patient was in accelerated 
phase CML. The Ph'-chromosome was found in 100% metaphases. Within two years she was 
treated with combinations of low-doses ARA-C with hydroxyurea or alpha-interferon (IFN-
α), and ARA-C + doxorubicin (7+3). The only result was temporary hematological response 
without a cytogenetic one. Moreover, the treatment was complicated by avascular necrosis 
of femoral head. Spleen began to increase gradually, up to 10% of blasts and 
basophiles (25% or more) was determined in peripheral blood . Since November, 2001 she 
was taking imatinib (400 mg daily) with restoration of complete hematological response. 
Despite the absence of cytogenetic response the imatinib dosage was increased to 600 mg 
daily only at month 32 of treatment. Since December, 2005 (after 11 months at imatinib, 600 
mg qd) for another 11 months she also received treatment for suggested disseminated 
tuberculosis with infiltration and destruction, though it was not confirmed bacteriologically. 
At the same time the daily imatinib dosage was increased to 800 mg daily because of 
increasing platelet count (up to 1800×109/L). After that she became doing worse with 
prominent weakness and exertional dyspnea. She has undergone an additional evaluation at 
Institute of tuberculosis. The CT scan has found multiple confluent areas of alveolar 
consolidation. The revision of lung biopsy, performed during antituberculosis treatment, 
revealed mild lymphoid and histiocytic infiltration of bronchioles. She was supposed to 
have exogenic allergic alveolitis of unknown origin and treated with methylprednisolon (8 mg 
daily) since May, 2007 along with imatinib. Four months of such treatment has led to further 
deterioration. The development of pulmonary complications during prolonged high-dose 
imatinib treatment, ineffectiveness of both antituberculosis drugs and methylprednisolon 
has allowed suggesting imatinib-induced alveolitis. At September, 2007 imatinib treatment 
was stopped and the patient has lost hematological response (hyperthrombocytosis, 
elevating WBC count). 
At admission to our center she was complaining of weakness, palpitations, dyspnea at 
minimal exertion, episodes of chest pain, sense of epigastral pressure, fever (up to 38,5º) 
during last 1—2 months, productive cough, pruritis in legs. At physical examination there 
was only low-grade fever and pigmentation. The chest was deformed because of scoliosis. 
Lung margins were normal, respiratory rate — 18 breaths per minute, on auscultation the 
expiratory prolongation (predominantly left-sided) with basilar rales were heard. Heart rate 
was about 120 bpm, liver and spleen were not enlarged. 
The hematological and cytogenetic resistance to imatinib treatment along with suggested 
non-hematological toxicity (alveolitis) necessitated the additional evaluation and moving 
the patient to 2nd line TKIs. 
The CT scan revealed prominent diffuse bilateral interstitial lung infiltration with 
honeycomb appearance in upper and middle parts of lungs, along with the focus of lung 
consolidation in paravertebral part of right S10 without effusion (Figure 1). This was 
considered as non-specific interstitial pneumonia with supervening infection at right S10. 
The bronchoscopy data was normal. The study of bronchoalveolar lavage excluded bacterial 
overgrowth, PCR analysis has revealed the cytomegalovirus DNA (DNA-CMV). The lavage 
sediment contained 49% alveolar macrophages, 33% segmented neutrophils, 7% eosinophils, 
and 11% lymphocytes. 
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was about 120 bpm, liver and spleen were not enlarged. 
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The CT scan revealed prominent diffuse bilateral interstitial lung infiltration with 
honeycomb appearance in upper and middle parts of lungs, along with the focus of lung 
consolidation in paravertebral part of right S10 without effusion (Figure 1). This was 
considered as non-specific interstitial pneumonia with supervening infection at right S10. 
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She has undergone the chemotherapy cycle (5+2) along with antibacterial and antiviral 
drugs; corticosteroids were stopped. The tachycardia (up to 150 bpm), probably due to 




Fig. 1. A, B. Chest CT scan of patient #1 (A — middle, B — lower parts): non-specific 
interstitial pneumonia with supervened infection. 
The serial CT scan showed some regression of interstital pneumonia with retraction of 
alveolar infiltration area (against the withdrawal of imatinib). But the infiltrative focus in 
right lower lobe has enlarged and pleural involvement appeared. The serum galactomannan 
level was increased to 2,55 ng/ml (normal < 0,5 ng/ml), permitting to diagnose invasive 
aspergillosis. In addition, the repetitive lavage evaluation has revealed Enterococcus spp. 
growth and HSV-1,2 DNA. We have added antifungal drugs (Amphotericin-B) and 
modified both antibacterial and antiviral therapy. Thus, the patient noted 
the multiple pulmonary pathology, which complicates the course of the underlying disease. 
Therapy has improved the medical condition of the patient: the fever became sub febrile and 
only few rales could be heard. Since February, 2008 she started treatment with 2nd 
generation TKI, dasatinib. 
At control evaluation (December, 2008) the medical condition of patient was good and stable 
without any fever. Dasatinib therapy allowed achieving not only complete hematological, 
but also minor cytogenetic response. The control CT scan picture has shown major 
improvement with virtually complete regression of interstitial lung infiltration (Fig. 2). 
This case demonstrates the development of complex pulmonary disease: a retrospectively 
revealed imatinib-induced pneumonitis after prolonged therapy with imatinib mesylate. 
Rapid worsening at increased dose of imatinib prompted to reevaluate the previous 
diagnosis of tuberculosis and to stop imatinib because of suggested exogenic allergic 
alveolitis. After the resolution of supervened severe pleuropneumonia mixed etiology and 
lung aspergillosis we became able to start dasatinib treatment with stabilization and 
improvement of both lung pathology and CML response. 
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In patient #2, 64 year-old woman, CML chronic phase (high-risk group) was diagnosed in 
December, 2002. At that moment she was complaining of malaise. There was splenomegaly 
(+6 cm below costal margin), liver size was normal. The peripheral blood analysis presented 
hyperleukocytosis (117×109/L), moderate thrombocytosis (669×109/L), left shift of 
differential count. Bone marrow aspirate was hypercellular, karyological examination 
revealed Ph-chromosome in 100% metaphases. In December, 2002 — November, 2004 she 
was treated with IFN-α, but achieved only hematological response without cytogenetic one. 
The next 2 years she was receiving imatinib, 400 mg daily, but didn't achieve major 
cytogenetic response. Since January, 2007 its dose was increased to 600 mg daily. In August, 
2008 she was evaluated for dry cough and dyspnea. There were no rales, or prominent 
tachypnea (respiration rate 20 per minute) and X-ray didn't find any abnormalities, but 
persistent complaints have prompted to suspect an imatinib side effect. In November, 2008 
the TKI treatment was interrupted. 
 
 
Fig. 2. Control CT scan of patient #1. Nearly complete regression interstitial lung infiltration. 
The patient was reevaluated in specialized pulmonologic center. The auscultation revealed 
basilar crepitation with respiratory rate 22 per minute and SaO2 97%. Pulmonary function 
tests showed airflow obstruction (isolated decrease of expiratory flow in distant airways). 
Static lung volumes were normal and diffusion capacity was moderately decreased. The 
lung biopsy was not performed. The chest CT scan found interstitial abnormalities with 
“ground glass” appearance. This data allowed to suggesting drug-induced pneumonitis. 
An 8-week prednisolone therapy (25 mg daily) and imatinib interruption has led to 
significant improvement with resolution of both complaints and CT scan abnormalities. 
Taking into account the imatinib intolerance (non-hematological toxicity grade 3) and 
primary cytogenetic resistance, we decided to begin treatment with 2nd generation TKI, 
nilotinib, 800 mg daily. The nilotinib treatment duration has reached now 24 months. She 
has achieved a major cytogenetic response (14% bcr/abl-positive cells by FISH). The 
complaints are absent. 
The previous experience helped us to suspect the association of drug-induced pulmonitis 
with imatinib treatment. Prompt patient evaluation, interruption of imatinib, and quick 
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response to prednisolone allowed suggesting the development of such a rare complication. 
Notably, the response to nilotinib underlines the importance of early beginning of 2nd 
generation TKI treatment in case of primary cytogenetic resistance and imatinib intolerance. 
Patient #3, 66 year-old woman, was admitted to Hematological Research Center in June, 
2008. The diagnosis of high-risk chronic phase CML was established in January, 2008. At 
diagnosis peripheral blood analysis showed high WBC count (113×109/L) with left-shifted 
differential count (blasts — 1%, myelocytes — 11%, metamyelocytes — 6,5%, bands — 24%, 
segmented — 33,5%, basophils — 8%, eosinophils — 5%, platelets — 849×109/L, Hb 103 
g/L). Bone marrow smear showed granulocytic predominance with Ph-chromosome in 98% 
metaphases. The spleen was +5 cm below costal margin. She also suffered from arterial 
hypertension, treated with lisinopril. Two months after diagnosis (since 01.03.2008) she 
began receiving imatinib at standard dose of 400 mg qd. But 2 weeks later she began doing 
worse and malaise, low-grade fever and progressive dyspnea appeared. Lung auscultation 
revealed expiratory prolongation without rales. Hemodinamically she was stable. Chest X-
ray revealed diffuse interstitial process, confirmed later by CT scan. 
The CT scan (Fig. 3) shows diffuse increase of pulmonary vascularity with its deformation 
by infiltration of intralobular paraseptal interstitium. There were also symmetrical areas of 
decreased pneumatization with “ground glass” appearance, predominantly in central parts 
of both lungs. Pleural and pericardial effusions were absent. 
 
 
Fig. 3. Chest CT scan with signs of interstitial lung disease (patient #3). 
The clinical presentation and CT scan data permitted to suspect these abnormalities to be 
an imatinib-induced pneumonitis (non-hematological toxicity grade 2). Imatinib was 
discontinued (since 01.05.2008), and corticosteroids (methylprednisolone, 40 mg daily for 
20 days with gradual dose tapering) were started. This therapy has led to significant 
dyspnea improvement with normalization of temperature and auscultatory findings. CT 
scan showed the same “ground glass” focuses, but their intensity has decreased. The 
complete resolution of signs and symptoms with delayed resolution of radiological 
findings after imatinib discontinuation and corticosteroid treatment confirmed the 
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suggested association of pneumonitis with imatinib treatment. During the treatment 
interruption (40 days) she has lost the hematological response (WBC — 25×109/L, 
platelets — 742×109/L). The patient continued treatment with imatinib in decreased dose 
(300 mg daily) and hypotensive treatment with lisinopril. Two weeks later the 
hematological response restored. The control caryological examination after 3 months of 
treatment has confirmed a major cytogenetic response (25% Ph+ metaphases). But 2 weeks 
after the treatment was resumed the dyspnea had relapsed, while control CT scan 
revealed deterioration (marked increase in size and intensity of previously seen “ground 
glass” focuses of interstitial infiltration). The increased vascularity was still remaining, 
along with paraseptal and interlobular interstitial infiltration. These findings once more 
confirmed the association of pneumonitis with CML treatment. After the imatinib 
discontinuation she has undergone 16-day methylprednisolone therapy (40 mg daily with 
gradual tapering). The treatment was discontinued and the hematological response was 
lost again, necessitating the hydroxyurea treatment (3 g daily). 
During 6 months of imatinib treatment this patient achieved optimal response, but it was 
lost shortly after the treatment interruption (due to toxicity). The non-hematological toxicity 
(imatinib-induced pneumonitis grade 2), necessitated the treatment swapping to 2nd 
generation TKIs — nilotinib or dasatinib. 
Nilotinib (Tasigna, AMN107, Novartis Pharma AG) is a structural analogue of imatinib. As 
well as imatinib, it binds ABL-tyrosine kinase in inactive conformation, but is 25—30 times 
more potent in vitro and active against the majority of its mutated forms (except T315I). 
Notably it has no cross-resistance with imatinib. Dasatinib (Sprycel, BMS-354825, Bristol 
Myers Squibb) structurally differs from imatinib. It binds ABL-tyrosine kinase in active 
conformation and also inhibits SRC-kinases superfamily; by vitro activity it is 300 times 
more potent, than imatinib and is active against all known mutated forms, except T315I. 
However, dasatinib should be used cautiously in hypertensive patients. The coexistent 
arterial hypertension in our patient led us to prefer nilotinib. 
At the moment of nilotinib treatment Ph'-chromosome was found in 100% metaphases and 
hematological response was absent too. Now the nilotinib treatment duration is 24 months; 
she has achieved stable hematological, complete cytogenetic and major molecular response. 
The control CT scan revealed nearly complete resolution of interstitial lung infiltration and 
the lung vascularity merely returned to normal pattern. No treatment interruptions needed 
and the patient noted good drug tolerability. 
Concerning the last case (#4) of 40 year-old male we have only  a brief information. The 
diagnosis of chronic phase CML, high-risk group by Sokal was established in September, 
2006 (neutrophilic leukocytosis with left-shifted of differential count, hyperthrombocytosis 
up to 2400×109/L and Ph'-chromosome by karyological examination). Two months later he 
began successfully taking imatinib (400 mg daily) for a year without side effects. However, 
in February, 2008 (13th month of treatment) low-grade fever and exertional dyspnea 
occurred. The evaluation allowed excluding infections. The CT scan has revealed “ground 
glass” lung abnormalities, with increased and deformed lung vascularity. The patient 
refused from further evaluation and treatment in specialized center. 
This case report is not representative for imatinib-induced pneumonitis. But our goal is to 
attract attention of physicians to be aware of typical complaints of patients with this 
pathology and diagnose it earlier. 
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The above-mentioned rare disease belongs to a group of interstitial lung diseases, including 
now more than 150 entries. Despite the etiological differences, including the diseases of 
unknown origin, all of them involve lung interstitium and its vasculature. This feature 
underlies their clinical, radiological and pathological similarity. 
According to CTC, both interstitial pneumonia and pneumonitis have 5 grades of severity. 
Grade 1 is asymptomatic and is revealed only radiologically (X-ray, CT scan). Grade 2 is 
characterized by signs and symptoms, not interfering activities of daily living. Typical 
clinical presentation along with disturbances of gaseous exchange and activities of daily 
living indicates a grade 3 pneumonitis. Grade 4 is a life-threatening condition with a need 
for respiratory support, and death from pneumonitis is considered as 5 grade of toxicity 
[14]. 
The pathological examination typically reveals both inflammatory infiltrates and areas of 
fibrosis. Radiological findings can't be used for differential diagnosis, because they lack 
specificity and are not only shared within this group, but also could be seen in non-related 
diseases. The high-resolution CT scan is more specific and is most useful in serial 
examinations. Equally important in differential diagnosis are arterial blood gas 
examination and bronchoscopy with transbronchial biopsies (4—6 specimens) and 
lavage. The obtained material should undergo bacteriological, virological and 
immunological examination. 
The mechanism of interstitial lung diseases is complex and has a number of distinctive 
features. It is thought to be a result of immune complex-mediated reaction with the 
principal role of T cells and cytokines. The alteration of alveolocytes leads to acute alveolitis. 
If it doesn't resolve, the inflammation extends to interstitium and its capillaries, leading to 
pneumosclerosis, alveolar deformation and disturbances of lung diffusion capacity [15]. 
The treatment of drug-induced pneumonitis consists of avoidance of allergen (here — 
imatinib) and prednisolone, 1 mg/kg body weight daily, for 2—4 weeks. The dose is then 
tapered to minimal, sufficient for good results of pulmonary function tests. If contact with 
allergen is avoided there is no need for continuous corticosteroid treatment [15]. 
Drug-induced pneumonitis is a rare complication of imatinib treatment in CML patients. In 
two cases it has developed more than 2 year after the beginning of treatment, despite its 
good tolerance earlier. In other cases it was revealed at first months of therapy, when good 
compliance is especially needed for achieving of optimal response. Unfortunately, the 
complete evaluation (bronchoscopy with transbronchial biopsy and lavage, pulmonary 
function tests, arterial blood gas examination) was not done in all patients at the time of 
pneumonitis which is associated with the rare detection of such cases, and often the 
unwillingness of patients carrying invasive research methods. For example, bronchoscopy 
with transbronchial biopsy and lavage were performed only in patient #1, the study of 
blood gases and pulmonary function tests in patient #2. Patients 
receiving outpatient treatment are often reluctant to conduct invasive research methods. 
However, the problem of doctors in clinical practice is, in particular, in explaining the 
importance and need for a comprehensive survey of every obscure case. Its data could 
elucidate the mechanism of drug-induced pneumonitis development. All of our patients had 
serial CT scan examination (with the identification of the characteristic CT picture 
of “ground glass”), the association of interstitial lung disease with imatinib treatment is 
followed up, and the effectiveness of corticosteroids is estimated. 
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These case reports illustrate the importance of search for signs of toxicity at different phases 
of treatment. Careful searching for adverse events of imatinib in CML patients and 
differential diagnosis with similar diseases allows prompt diagnosis and treatment of both 
frequent and rare side effects, including those not in onco- hematology specialist clinics, but 
also in clinical practice. Proper changing of treatment strategy can help to avoid frequent 
and prolonged interruptions of treatment due to toxicity and increase the efficacy of 
treatment, permitting to achieve optimal results. 
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Chronic myeloid leukaemia (CML) is a hematopoietic stem cell (HSC) disorder accounting 
for about 15-20% of all leukemias of the adult (Goldman & Melo, 2003; Black et al., 1997). 
The main haematological features are represented by an increase in the number of 
circulating mature granulocytes and their precursors and, subsequently, by a secondary 
evolution in acute leukaemia. 
In 1960, a major clue to the cause of CML was provided by Nowell and Hungerford who 
for the first time described an unusual small chromosome present in leukocytes from 
patients with this hematologic malignance (Nowell & Hungerford, 1960).  This “minute 
chromosome” abnormality, designed as the Philadelphia (Ph) chromosome, after the city 
in which it was discovered, was found in all malignant cells of CML patients and is now 
considered the hallmark of this neoplasia (Nowell & Hungerford, 1960). Importantly this 
discovery was the first demonstration of a chromosomal rearrangement linked to a 
specific cancer, and had sparked searches for associations of additional chromosomal 
aberrations with specific forms of cancer. In 1973, Rowley demonstrated that the Ph 
chromosome resulted from a reciprocal translocation between the long arms of 
chromosomes 9 and 22, t(9:22)(q34;q11) (Rowley, 1973). Later it was shown that this 
process fuses the c-ABL ( human homologue of the Abelson Murine Leukaemia virus), a 
tyrosine kinase encoding oncogene on chromosome 9, and BCR (Breakpoint Cluster 
Region), on chromosome 22, the function of which is still not clear (Groffen et al., 1984). 
This balanced translocation leads to a fusion gene, the product of which is a chimeric 
BCR-ABL protein equipped with cellular transforming ability which is ascribed to the 
elevated tyrosine kinase (TK) activity of the molecule compared to the native c-ABL 
(Konopka et al., 1984; Daley et al., 1990).  
The biochemical signal transduction pathways stimulated by BCR-ABL kinase activity are 
responsible for Ph+ CML oncogenesis (Ren, 2005; Calabretta & Perrotti, 2004; Krebs & 
Hilton, 2001; Neshat et al., 2000; Sattler et al., 2002; Sattler et al., 1999).  
Further studies have established BCR-ABL as a leukaemogenic oncogene since both mouse 
models and in vitro assays have shown that BCR-ABL, is able to induce leukaemia (Daley & 
Baltimore, 1988).  
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2. Molecular mechanisms of BCR-ABL 
Several BCR-ABL isoforms with different molecular weights have been reported (Melo & 
Deininger, 2004). Accordingly, while in all chimeric proteins the breakpoint within ABL 
gene is consistently located upstream of exon 2 (a2), the breakpoint in the BCR gene varies 
in its localization (Melo, 1996). A major breakpoint cluster region (M-bcr) and a minor 
breakpoint cluster region (m-bcr) have been defined (Kurzrock et al., 1988).  
The M-bcr maps to a 5.8 Kilobase (Kb) area spanning exons 12 through 16. The resulting 
fusion transcripts with ABL generate a 210-kDa protein named p210 which is the most 
common BCR-ABL form, being observed in 99% of the CML patients and in one-third of Ph-
positive B cell acute lymphoblastic leukaemia (Ph+ B-ALL) (Faderl et al., 1999). m-bcr 
localizes to a 54.4-kb area sited downstream of exon 1. It gives rise to a fusion transcript 
with ABL named p190. It is rarely observed in CML, but is the most frequent BCR-ABL 
isoform in Ph+ B-ALL. Finally, 3’ breakpoints downstream of BCR exon 19 have also been 
described and they give rise to a 230-kDa fusion protein (p230 BCR-ABL), which is typically 
found in the rare chronic neutrophilic leukaemia (CNL) (Pane et al., 1996).  
All three BCR-ABL fusion protein variants induce a similar CML-like syndrome in mice, but 
differ in their ability to induce lymphoid leukaemia (Li et al., 1999). 
3. Cellular pathways involved in oncogenic BCR-ABL signalling 
The oncogenic potential of BCR-ABL derives from its capacity to activate intracellular 
signalling cascades that lead to uncontrolled cell proliferation, altered cell adhesion, and 
apoptosis inhibition (Daley et al., 1990; Kelliher et al., 1990). To date several signalling 
pathways affected by the constitutively active BCR-ABL have been identified, as well as 
numerous binding partners and substrates that provide a link between this pathways and 
the defects that characterize CML. Increased susceptibility to proliferate derives from 
BCR-ABL’s capacity to activate the RAS-mitogen activated protein (MAP) kinase 
signalling cascade and JAK/STAT signalling; the interaction with SRC is responsible for 
increased cell motility; resistance to apoptosis is thought to result from BCR-ABL-
mediated activation of phosphatidylinositol- 3-phosphate kinase (PI3K) and thereby of 
AKT. In summary, the net effects of these molecular alterations include inhibition of 
apoptosis, increased cell proliferation, aberrant interaction with the bone marrow stroma 
and genetic instability. Importantly all these events drive disease progression (Deninger et 
al., 2000). 
Consistent with these molecular sequelae, BCR-ABL was shown to transform hematopoietic 
progenitor cells in vitro and in vivo studies (Kantarjian et al., 2006; Hehlmann et al., 2007). 
Recent reports identified a role for other signalling cascades in CML biology, including 
Hedgehog, Wnt and Ikaros, suggesting that pharmacological inhibitors of these pathways 
may find application in the treatment of CML (Chen Zhao et al., 2009; Dierks et al., 2008; 
Mullighan & Dowing, 2008; Dierks et al., 2008). Finally, also micro RNA (miRNA) 
regulation appears to apply to CML biology since miR-203, which would normally suppress 
BCR-ABL expression, is either mutated or epigenetically silenced in CML. In the latter type 
of condition, demethylating drugs such as 5-azacytidine and 4-phenylbutyrate were shown 
to restore miR-203 and to thereby decrease BCR-ABL expression and proliferation rate of 
Ph+ human CML cell lines (Faber et al., 2008; Croce & Calin, 2005).  
 




Fig. 2. Schematic view of the signal transduction pathways in cells transformed by BCR-
ABL.  
4. The CML leukaemia stem cell  
Increasing evidence suggests that only a rare subset of immature cells within the tumor, 
named "leukaemia stem cells" (LSC), are able to propagate the CML (Reya et al, 2001). This 
cell has many common features with the hematopoietic stem cells - such as self-renewal and 
pluripotency pensions- unlike these, however, are refractory to conventional chemotherapy. 
Despite the remarkable improvements in the treatment of CML, the TKIs treatment is not 
curative, suppresses the disease but is not able to eradicate the CML Achilles hell, the 
leukaemia stem cell, causing recurrence of disease (Graham et al., 2002; Copland et al., 2006) 
The relapses in CML are thought to result from the outgrowth of quiescent LSC therapy-
resistant, as the majority of leukemic cells in relapses represent (sub-) clones already present 
at diagnosis. To date the only long-term, sustainable remission derives from allogeneic bone 
marrow/peripheral blood stem cell transplantation which successfully restores normal 
hematopoiesis (Michor et al., 2005; Ljungman et al., 2009).  
Recent data suggest that aberrant self-renewal is one of the central mechanisms 
underlying the pathogenesis of chronic myeloid leukaemia - acting either at the level of 
the BCR-ABL positive pluripotential stem cell in chronic phase or at the level of a more 
differentiated progenitor to cause blastic transformation, or most probably at both levels. 
Excessive self-renewal of LSCs may be mediated via several developmental pathways, 
including the Wnt/Frizzled/beta-catenin and Musashi-Numb pathway, or TWIST-1 
oncogene and Polycomb-group protein BMI-1 (Hu et al., 2009; Ito et al., 2010; Cosset et al., 
2011). An additional candidate is the Smoothened (SMO)/Sonic Hedgehog (sHH) 
signalling pathway, which is reasonably well characterised in solid tumours but is less 
well studied in leukaemia (Dierks et al., 2008; Chen Zhao et al., 2009;). Particularly it is 
essential during embryonic development, and might play a key role in human 
malignancies when aberrantly activated. 
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5. CML treatment options 
The definition of the molecular structure of BCR-ABL tyrosine kinase domain has led to 
development of potent and specific tyrosine kinase inhibitor (TKIs) (Druker, 2008; Johnson 
et al., 2003).  TKIs such as imatinib mesylate (Gleevec™, Novartis), nilotinib ( Tasigna™, 
Novartis) and dasatinib (Sprycell™, Bristol-Myers Squibb) induce apoptosis in CML but not 
in healthy tissues, which is thought to result from addiction of CML cells to BCR-ABL 
signalling. The use of TKIs has led to remarkable improvements in disease outcome, in turn 
making TKIs the gold standard front line CML therapeutics. Importantly, although TKIs do 
induce disease remissions in most CML patients, they are not curative because of their 
incapacity to eradicate CML-LSC. Moreover, acquired resistance to TKIs is commonly 
observed and requires the prompt introduction of other TKIs that retain activity against 
BCR-ABL (Talpaz et al., 2002; Sawyers et al., 2002). Therefore, a timely and accurate follow-
up is crucial for the management of CML and for effective therapeutic decisions (Druker et 
al., 2006; Kantarjian et al., 2008; O`Brien et al., 2003; Lahaye et al., 2005; Cervantes et al., 
2003; Branford et al., 2003; Hughes & Branford, 2006). Additionally, such relapses are 
thought to result from the activation and proliferation of otherwise quiescent and therapy-
resistant LSCs (Graham et al., 2002; Copland et al., 2006). Newer molecular therapies are 
being developed to eradicate the LSC pool by targeting critical signaling molecules that are 
essential for LSC maintenance.  
6. CML monitoring  
The remarkable progress in the treatment of CML over the past decade has been 
accompanied by steady improvements in our ability to accurately and sensitively monitor 
the status of the disease with the use of molecular markers, aimed at recognizing the depth 
of remission, and by use of readings to guide the choice of strategy for therapeutic 
interventions (Hughes et al., 2006).  
However, the identification of patients that will experience a failure of TKI treatment, and 
appropriately altering the therapeutic strategy based on such monitoring, remains a 
challenge.  
Routine CML diagnostics largely relies nowadays on traditional blood cell count, 
cytogenetic analysis (standard karyotype with or without fluorescence in situ hybridization-
FISH), and real time quantitative polymerase chain reaction (RT-Q-PCR) for BCR-ABL 
messenger RNA (mRNA). These tests allow defining the haematological, cytogenetic, and 
molecular response to treatment, respectively (Kantarjian et al., 2008; Hughes et al., 2006). 
The haematological response to treatment is assessed by peripheral blood cell counts and by 
spleen size, and is classified as: 
1. Complete haematological response (CHR): normalization of peripheral blood counts with 
no immature blood cells and with disappearance of any sign of disease 
2. Partial haematological response (PHR): presence of immature blood cells and/or persistent 
splenomegaly. The next level of response is the cytogenetic one (CyR), defined as a 
decrease in the number of Ph+metaphases in a bone marrow aspirate (using ≥ 20 
metaphases). This is categorized as:   
1. Complete cytogenetic response (CCyR): 0% Ph+ metaphases 
2. Partial cytogenetic response (PCyR): 1-35% Ph+ metaphases  
3. Minor cytogenetic response: 36-65% Ph+ metaphases  
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4. Minimal cytogenetic response: 66-95% Ph+ metaphases  
CCyR or PCyR configure a major cytogenetic response (MCyR). Finally, residual leukaemia 
cells (minimal residual disease, MRD) can be detected using RT-Q-PCR. Particularly, the 
molecular response is defined as a decrease of the BCR-ABL to control gene transcript ratio 
according to the International Scale (IS) (see below):  
1. Complete molecular response (CMR): undetectable level of chimeric transcript  
2. Major molecular response (MMR): reduction in transcript levels of at least 3-log from 
standard baseline level (which represent 100% on the International Scale) or ≤1%. 
6.1 Cytogenetic and FISH  
The Ph chromosome can be detected by standard cytogenetic techniques in the vast majority 
of patients (Osarogiagbon, 1999). In patients who are cytogenetically Ph chromosome 
negative (Ph–), molecular techniques such as FISH and RT-Q-PCR may be useful in 
detecting BCR-ABL. Cytogenetic analysis is typically performed by chromosome banding of 
at least 20 bone marrow cells in metaphase allowing to identify the t(9:22) translocation 
(Haferlach et al., 2007). In addition, cytogenetic also allows to define any additional 
chromosomal abnormality (i.e. additional Ph chromosome, isochromosome 17q, trisomy 8, 
or trisomy 19), thereby providing additional prognostic information. Baccarani et al. 
recommend that, at diagnosis, two cytogenetic analyses are performed in order to increase 
the sensitivity of the method. Furthermore, if less than 20 metaphases are visualized, the 
cytogenetic analysis should be validated by FISH or by RT-Q-PCR (see below) (Baccarani et 
al., 2008). Importantly, in 5% of CML cases no cytogenetically-detectable Ph chromosome 
can be demonstrated, since the BCR-ABL fusion oncogene derives from a submicroscopic 
genetic fusion. In these cases, FISH or RT-Q-PCR will demonstrate the presence of the 
specific genetic abnormality. Traditional FISH uses 5’ BCR and 3’ ABL fluorescent probes of 
different colours while more recent FISH reagents use 3-4 probes (D-FISH). Such probes can 
detect the variant translocations leading to Ph chromosome formation and are also 
associated with low false positive rates (Dewald et al., 1998; Wang et al., 2001; Landstrom & 
Tefferi, 2006; Sinclair et al., 1997; Seong et al., 1995). Interphase or hypermetaphase FISH can 
be performed on peripheral blood specimen or bone marrow aspirates, respectively. 
Interphase FISH is applicable to a larger population of cells since does not require cycling 
cells. On the other hand, this technique is associated with a background signal greater than 
1-5% (depending on the specific probe used in the assay) (Cuneo et al., 1998; Le Gouill et al., 
2000; Lesser et al., 2002; Raanani et al., 2004). Hypermetaphase FISH is applicable only to 
dividing bone marrow cells (Schoch et al., 2002). This approach is more sensitive and can 
analyze up to 500 metaphases at a time. Usually, FISH results correlate with traditional 
cytogenetic analysis and with RT-Q-PCR results, thus remaining a convenient and sensitive 
diagnostic tool (see below).   
6.2 PCR-based approaches to CML monitoring  
Nested reverse transcriptase PCR can detect one CML cell in a background of ≥ 100.000 
normal cells (Martinelli et al., 2006). However, it remains a purely qualitative assay which is 
only capable of demonstrating the presence or absence of CML cells. Nested-PCR is 
normally only used to confirm the achievement of CMR. RT-Q-PCR methods are less 
sensitive than qualitative PCR (by 0.5-1 order of magnitude) but they have the advantage of 
determining the actual percentage of BCR-ABL transcripts and can therefore be used to 
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4. Minimal cytogenetic response: 66-95% Ph+ metaphases  
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normally only used to confirm the achievement of CMR. RT-Q-PCR methods are less 
sensitive than qualitative PCR (by 0.5-1 order of magnitude) but they have the advantage of 
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track changes in the number of leukemic cells over time (Lowemberg, 2003; Hughes et al., 
2003; Merante et al., 2005; Mauro et al., 2004; Cortes et al., 2004). Currently, RT-QPCR for 
BCR-ABL is the recommended approach for routine follow-up of CML patients and is 
considered the gold standard test for routine therapeutics decision. The BCR-ABL transcript 
levels are expressed as a percentage ratio of BCR-ABL compared to ABL transcripts. ABL 
acts as control gene to compensate for variations in the quality of the RNA and for 
differences in the efficiency of the reverse transcription reaction. The last years have seen 
numerous efforts to standardize the molecular approaches to CML monitoring as well as 
their interpretation criteria. In order to harmonize the results across laboratories worldwide, 
a standard pre-treatment baseline value for each laboratory was established. Thus, a 
molecular response is defined by reductions from an absolute baseline (common to all) 
rather than a relative baseline (individualized). This ensures that patients with the same 
level of response have the same degree of residual disease. Additionally, under- or over-
estimation of the extent of response due to individual variations is avoided by using a 
common standard baseline. According to the international reporting scale (IS) the absolute 
BCR-ABL value to define major molecular response is standardized at 0.1% (or 3 log) 
reduction from the laboratory-specific pretreatment standard baseline (Hochhaus & 
Dreyling, 2008; Hochhaus et al., 1996). A value of 1.0% is approximately equivalent to the 
achievement of a CCyR and a CMR is achieved when transcripts are undetectable (Branford 
et al., 2006; Muller et al., 2007, 2008). Because of its high sensitivity, CML monitoring by RT-
Q-PCR enables to define an early loss of response once CCyR has been achieved (Wang, 
2000, Press et al., 2006). Additionally, early molecular monitoring after initiation of 
treatment helps to identify patients at higher risk of relapse after pharmacological treatment 
onset as well as after allogeneic bone marrow transplantation ( Olavarria et al. 2002; Lange 
et al., 2004; Asnafi et al., 2006). Finally, another advantage of CML monitoring by RT-Q-PCR 
is the feasibility of this method on peripheral blood samples. In a large cohort of patients 
monitored to BCR-ABL mRNA levels after allogeneic bone marrow transplantation, we 
found that peripheral blood and bone marrow samples perform equally well in terms of 
sensitivity in relapse detection and show a very good correlation of results. Thus, molecular 
monitoring of CML with RT-Q-PCR can be performed using peripheral blood  samples 
instead of bone marrow ( Ballestrero et al., 2009). The drawbacks of this method include a 
substantial incidence of false negative tests, which on the other hand, is strongly reduced 
when serial evaluations are performed.  Nowadays, RT-Q-PCR monitoring is included as 
integral part of the management of CML patient treated with TKIs and must be performed 
every 3 months even in patients in MMR. An increase in BCR-ABL levels of 2 to 5 fold is an 
early sign of relapse, and suggests the need to switch to another type of treatment as soon as 
possible.  
6.3 Mechanisms of resistance  
A growing problem in the treatment of CML is resistance to treatment since most patients in 
chronic phase initially respond to TKIs but subsequently relapse and/or progress to 
accelerated phase or blast crisis (Talpaz et al., 2002; Sawyers et al., 2002). Primary resistance 
or, perhaps more appropriately, primary refractoriness (typically BCR-ABL independent), is 
defined as the failure to achieve initial response to therapy and is only seen in 
approximately 5% of newly diagnosed patients in chronic phase of CML. (Apperley, 2007) 
Acquired resistance, defined as the loss of previous response, is more common. About 10-
 
Towards the Cure of CML by the Molecular Approach Strategy 
 
101 
15% of patients in TKIs treatment develop treatment failure at a rate of approximately of 1-
4%/year). Resistance to TKIs may be primary or secondary and is usually classified in BCR-
ABL-dependent or -independent. The BCR-ABL-dependent mechanisms include 
reactivation of BCR-ABL signaling through mutations in the ABL kinase domain (KD), and 
increased production of BCR-ABL at the genomic (gene amplification) or transcript 
(overexpression) levels (Campbel et al., 2002, Morel et al., 2003;  Hochhaus et al., 2002). 
Conversely, BCR-ABL independent resistance mechanisms involve: i) a drop in the 
intracellular drug concentration through expression of drug efflux (such as multidrug-
resistant P-glycoprotein MDR-1) (Mahon et al., 2000;  le Coutre et al., 2000) or drug influx 
(such as hOCT1 that affects intracellular drug availability) ( Thomas et al., 2004) genes; ii) 
activation of Src family of kinases (SFKs); and iii) acquisition of additional chromosomal 
abnormalities with Ph-chromosome ( O’Dwyer et al., 2002, 2004; Schoch et al., 2003). 
Although gene amplification occurs more frequently than point mutations (10–4 per cell 
division vs. 10–9(Hochhaus A et al., 2002) clinical resistance is much more likely to be due to 
a point mutation in the BCR-ABL TK domain than to BCR-ABL amplification ( Willis et al., 
2005). To date more than 50 mutations have been identified, each of which arises at variable 
frequencies and with different consequences ( Jabbour et al., 2006; Shah et al., 2002; Branford 
et al., 2002; Hofmann et al., 2002; Roche-Lestienne et al., 2002; Deninger et al., 2000; Soverini 
et al., 2004, 2005; Chu et al., 2005; Nicolini et al., 2006; Barthe et al., 2002; Irving et al., 2004; 
Wei et al., 2006; Wang et al., 2006). Mutations may occur in various ATP-binding sites, such 
as the phosphate-binding loop (P-loop), activation site, catalytic site, or other areas in the 
BCR-ABL structure. Depending on the mutation site, resistance to imatinib will either be 
absolute or relative, or it will be clinically irrelevant. Earlier studies have associated P-loop 
mutations and the T315I mutation with the worst outcomes (Cortes et al., 2007). Mutations 
within the P-loop site are found in 30-40% of the resistant cases and reduce susceptibility to 
imatinib by 70 to 100 folds. The T315I mutation in BCR-ABL occurs in 0.16-0.32% of newly 
diagnosed patients in chronic phase, leading to substitution of threonine 315 with 
isoleucine. This “gatekeeper” mutation also affects the response to the currently existing 
second-generation TKIs. Therefore, upon its identification, patients should be considered for 
alternative pharmacological treatments or for allogeneic bone marrow transplantation.  
6.4 Mutational analysis  
A careful mutational screening allows the timely identification of potential mutant clones 
and suggests the most suitable second-line treatment based on the in vitro sensitivity of the 
specific mutation. The technologies used to identify and quantify the ABL KD mutations 
include: direct sequencing (Branford et al., 2003), subcloning and sequencing, denaturing-
high performance liquid chromatography analysis (DHPLC), pyrosequencing and allele 
specific oligonucleotide PCR. Direct sequencing represents the most widespread method 
used for routine monitoring. Its main drawback is the low detection limit (20%) which is 
responsible for false negative results. Fluorescent-based allele-specific oligonucleotide PCR 
(ASO-PCR) assays have higher detection limit (0.1%), although their main drawback is that 
the search for specific mutations does not include screening of the entire KD region of the 
BCR-ABL gene. Nowadays, numerous groups perform DHPLC to monitor CML patients, 
followed by a sequence analysis to confirm the data. DHPLC has a detection limit of 1-5% 
(Deininger et al., 2004). Mutation studies might be performed on peripheral blood or bone 
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marrow although a direct comparison of these two types of samples has not been done yet. 
The search for BCR-ABL mutations should be performed, according to NCCN CML 
guidelines (NCCN Clinical Practice Guidelines in Oncology, 2010), in the following 
conditions: 
1. Progression to accelerated or blast phase  
2. Treatment failure  
3. Suboptimal therapeutic responses  
4. Increasing BCR-ABL levels (5 to 10 fold in mRNA)  
6.5 Scheduling CML diagnostics and monitoring  
An effective CML monitoring entails an appropriate follow up-schedule (Baccarani et al., 
2006). Evidence obtained in clinical trials has prompted experts to formulate consensus 
recommendations to assess the response to treatment in patients with Ph+ CML (Quintas-
Cardama & Cortes, 2005). In the diagnostic setting, bone marrow cytogenetics is 
recommended before initiation of treatment. Additionally, a nested PCR confirms the 
diagnosis of CML and establishes the type of BCR-ABL fusion transcript present. Bone 
marrow cytogenetics is able to detect chromosomal abnormalities that FISH is not able to 
detect. However, if bone marrow collection is not feasible, FISH on peripheral blood 
specimen with dual probe (BCR and ABL genes) is a suitable tool to confirm the diagnosis. 
Subsequently, the cytogenetic evaluation is recommended at 6 and 12 months from the 
beginning of treatment. If a CCyR is achieved at 6 months, it is not necessary to repeat the 
cytogenetic evaluation at 12 months. If patients is not in a CCyR at 12 months, a cytogenetic 
evaluation should be repeated at 18 months. Once cytogenetic remission is achieved, 
residual disease should be monitored using BCR-ABL transcript levels by RT-Q-PCR, which 
is the most sensitive technique to monitor BCR-ABL. The hybrid transcript levels should be 
measured every 3 months at the beginning of treatment and then every 3-6 months since a 
CCyR is achieved. A steady decline in BCR-ABL transcripts indicates an ideal response to 
therapy. Rising level of BCR-ABL transcript (1 log increase) following the achievement of a 
MMR, mandates to repeat the molecular analysis after 1 month (Baccarani et al., 2006). If the 
result is confirmed, bone marrow cytogenetics should be performed, BCR-ABL 
quantifications by RT-Q-PCR should be scheduled every month, and a kinase domain 
mutational analysis should also be done (Wang et al., 2003). The evaluation of the 
hematologic response foresees that, starting from treatment onset, blood cell counts are 
performed every 2 weeks until a stable CHR is achieved, then every 3 months (Deininger, 
2005). If the patient fails to achieve CHR by 3 months, the treatment is generally regarded as 
a failure, indicating the need to consider alternative therapeutic strategies.  
In summary, the international guidelines recommend the following testing schedule when 
monitoring treatment of CML patients:  
1. Hematologic responses should be assessed at diagnosis, then every 2 weeks until a 
CHR has been achieved and confirmed, then every 3 months or as required.  
2. Cytogenetic responses should be assessed at diagnosis,  and every 6 months until a 
CCyR is achieved and confirmed, then every 12 to 36 months as long as MMR is stable   
3. Molecular responses should be assessed every 3 months, or monthly if an increasing 
BCR-ABL transcript level is detected. 
4. Mutational analysis in occurrences of suboptimal response or failure; recommended 
before changing to other TKIs or other therapies 
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FISH may be preferred over conventional cytogenetics as it can evaluate more cells and 
peripheral blood can be used instead of bone marrow. However it is only recommended 
prior to treatment to identify cases of Ph-, BCR-ABL CML and those with variant 
translocations, Ph amplification, or del9q+. 
 
 
Fig. 1. Proposed algorithm for CML monitoring according to the National Comprehensive 
Cancer Network guidelines.  
7. Conclusions  
Chronic myeloid leukaemia is a biological model of how the molecular understanding of a 
disease is able to provide the substrate for therapy and diagnostics. The recent molecular 
analysis of the leukaemia cell has generated an extraordinary range of discoveries about the 
anomalies developed during the cell growth, promoting the development of innovative 
therapeutic approaches for this type of hematopoietic neoplasia. In particular with the 
introduction of TKIs we have embarked on a journey aiming to reduce disease burden and 
prolonging survival.  
Additionally the molecular tools to monitor disease and characterize resistance are 
remarkably effective not only in the diagnostic evaluation but even in the management of 
CML patients. While traditional cytogenetics with or without FISH and qualitative nested-
PCR are essential for the diagnosis of CML, serial RT-Q-PCRs are the mainstay of 
therapeutic monitoring and MDR assessment (Kantarjian et al., 2008). In cases of treatment 
failure, highlighted by increasing BCR-ABL levels and/or by loss of hematologic and 
cytogenetic responses, mutational analysis to identify KD mutations should be considered in 
order to meet the better treatment decisions (i.e. use alternative TKIs or stem cell 
transplantation) (Hughes et al., 2006). Additionally, an early identification of treatment 
failure increases the chance that alternative treatments will be effective (Jabbour et al., 2009).   
However the major current impediment to cure for CML patients resides in the cancer stem 
cell population that is neither oncogene addicted nor sensitive to TKIs. Thus, one of the 
major challenges is to recognize as early as possible the patient destined to fail TKIs to revise 
the therapeutic strategy. Additionally, an early identification of treatment failure increases 
the chance that alternative treatments will be effective.  
Hence the need for increasingly sophisticated technologies for an early detection of 
molecular relapse. In this field the comprehensive analysis of the CML genome, by the 
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Additionally the molecular tools to monitor disease and characterize resistance are 
remarkably effective not only in the diagnostic evaluation but even in the management of 
CML patients. While traditional cytogenetics with or without FISH and qualitative nested-
PCR are essential for the diagnosis of CML, serial RT-Q-PCRs are the mainstay of 
therapeutic monitoring and MDR assessment (Kantarjian et al., 2008). In cases of treatment 
failure, highlighted by increasing BCR-ABL levels and/or by loss of hematologic and 
cytogenetic responses, mutational analysis to identify KD mutations should be considered in 
order to meet the better treatment decisions (i.e. use alternative TKIs or stem cell 
transplantation) (Hughes et al., 2006). Additionally, an early identification of treatment 
failure increases the chance that alternative treatments will be effective (Jabbour et al., 2009).   
However the major current impediment to cure for CML patients resides in the cancer stem 
cell population that is neither oncogene addicted nor sensitive to TKIs. Thus, one of the 
major challenges is to recognize as early as possible the patient destined to fail TKIs to revise 
the therapeutic strategy. Additionally, an early identification of treatment failure increases 
the chance that alternative treatments will be effective.  
Hence the need for increasingly sophisticated technologies for an early detection of 
molecular relapse. In this field the comprehensive analysis of the CML genome, by the 
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single nucleotide polymorphism arrays, will provide the basis for a molecular approach to 
guide therapeutic decisions. (Boultwood et al., 2010)In summary the CML represents one of 
the best examples of tumour malignancies and despite the numerous advantages of modern 
technologies, it is important to continue interpreting laboratory data within the clinical 
context of the patient in order to effectively and inexpensively utilize current and nascent 
laboratory tools. 
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1. Introduction 
Acute myeloid leukemia (AML) is the most common type of acute leukemia in adults1. Over 
the past twenty years, the studies on the pathogenesis and prognosis of AML have made 
considerable progress.  
Clinically, patients with AML typically present with signs or symptoms of bone marrow 
failure, although sometimes they can present with symptoms of leukostasis with pulmonary 
or neurological dysfunction. Rarely, patients will present with primary extramedullary 
disease, which should be approached in the same way as systemic AML.  
A certain number of factors can be involved in the etiology of AML: as an example, 
exposure to ionizing radiation and long-term exposure to benzene are known risk factors. 
AML could be part of the natural history of patients with congenital disorders of DNA 
repair, such as the Fanconi's anemias; also the myeloproliferative disorders (MPD) and 
myelodysplastic syndromes (MDS).  
AML is a heterogeneous disease; standard treatments may be applied to biologically distinct 
subgroups, resulting in different treatment outcomes. However, less than one-third of all 
adult patients with AML can be cured even to this date. The treatment of refractory, 
relapsed and elderly AML remains a major challenge. In recent years, new regimens and 
novel agents are being studied in an effort to improve complete remission (CR) rate and 
overall survival. The concept of risk-adapted therapy allows for recognition of this biologic 
diversity by incorporating key biologic features, such as cytogenetic and molecular markers, 
when formulating treatment regimens and investigating emerging targeted therapies based 
on disease characteristics. Although AML has been the focus of significant laboratory and 
clinical investigation, it remains difficult to treat, perhaps partly because of the fundamental 
nature of the disorder, which requires substantial institutional resources to adequately deal 
with the complications of bone marrow failure and sustain patients through periods of 
intensive therapy. Several large studies have helped categorize chromosomal abnormalities 
into good-, intermediate-, and poor-risk groups2-5. This hierarchical system of karyotype 
classification is predictive value across different age groups in de novo and secondary AML. 
It was also found to retain prognostic significance across the different treatment modalities 
of chemotherapy and autologous and allogeneic bone marrow transplantation. Generally, 
the poor-risk or unfavorable group includes those with complex karyotypes (> 3-5 
abnormalities), chromosome 5 or 7 abnormalities, or chromosome 3q abnormalities. The 
results for these patients are dismal, with standard chemotherapy causing some to advocate 
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patients undergoing stem cell transplantation in first remission3,5. In contrast, such an 
“aggressive” approach as allogeneic stem cell transplantation in first complete remission 
(CR) is generally not recommended in patients with good-risk or favorable cytogenetics. 
Included in this category are those with t(15;17), t(8;21), t(16;16), and inv(16) translocations6. 
Acute promyelocytic leukemia (APL), defined by the t(15;17) translocation, has a distinct 
biology, and combinations of dose-intensive anthracyclines, all-trans-retinoic acid (ATRA), 
and arsenic trioxide may be curative for most patients.  
Age was not, however, found to be the only significant factor affecting treatment outcomes. 
Although supportive measures have generally improved within the past 20 years, the drugs 
that form the backbone of standard AML chemotherapy remain essentially unchanged.  
2. Therapy 
2.1 High dose daunorubicin  
The standard induction regimen for newly diagnosed AML consists of daunorubicin (DNR) 
45 mg/m2 intravenously for 3 days and cytarabine (AraC) 100 mg/m2 by continuous 
infusion for 7 days. With this regimen 60% to 80% of young adults and 40% to 60% of older 
adults can achieve a CR7. 
Several major studies, particularly Cancer and Leukemia Group B (CALGB) 9621 and the 
French ALFA 9801 studies, have shown that higher doses of DNR (80 or 90 mg/m2) can be 
administered safely8,9. Recently, there are two major prospective studies compared DNR 
90 mg/m2 with 45 mg/m2 in the induction regimen10,11. Eastern Cooperative Oncology 
Group (ECOG) studied 657 AML patients between the age of 17 to 6010. The study showed 
significantly higher CR rate for patients receiving 90 mg/m2 (70% versus 57%). More 
importantly, overall survival (OS) was significantly prolonged (23.7 vs 15.7 months). The 
Dutch-Belgium Hemato-Oncology Cooperative Group (HOVON)/Swiss Group for 
Clinical Cancer Research (SAKK) compared DNR 90 mg/m2 versus 45 mg/m2 in 813 
patients older than 60 years11. The results showed that CR rate was 64% and 54% 
respectively, while CR rate after only one course of treatment was 52% and 35% 
respectively. The OS rate was not significantly different for the whole group. However, 
for the patients between the age of 60 to 65, the OS rate was significantly better in the high 
dose group (38% vs 23%). The rates of serious adverse events were similar in the two 
treatment groups in both studies. 
Based on historic trials and the most recent prospective studies, the 45 mg/m2 of DNR 
should no longer be the standard-dose for induction therapy. Instead, for induction therapy 
of all age groups, DNR dose should be between 60 mg/m2 to 90 mg/m2 for 3 days, but the 
exact optimal dosage remains to be established12. 
2.2 New formulations of old agents 
Liposomal encapsulation of drugs can reduce the toxicity and decrease drug doses with 
controlled-release effect. CPX-351 is a liposomal formulation that encapsulates cytarabine 
and daunorubicin at a 5:1 molar ratio. A recently completed phase 1 study13 recommended 
that 90-minute infusions of 101 u/m2 be given on days 1, 3, and 5 (1 u = 1 mg Ara-C + 0.44 
mg DNR). The results showed that liposomal encapsulation of this chemotherapy changed 
the safety profile by reducing non-hematologic toxicities including hair loss, gastrointestinal 
toxicities and hepatic toxicity, while retaining hematopoietic cytotoxicity.  
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2.3 Targeted therapy regimens 
In recent years, encouraging results have been achieved by using monoclonal antibodies for 
targeted therapy of the solid and hematologic malignancies. CD33 antigen is expressed in 
more than 90% of AML cells, while expression in normal tissue is very weak. Gemtuzumab 
ozogamycin (GO) is chemoimmunotherapy agent consisting of a monoclonal antibody 
against CD33 conjugated to calichemycin. GO triggers apoptosis when hydrolyzed in the 
leukemic blasts. GO has been approved by the U.S. FDA for the treatment of the elderly (> 
60 years) with AML in first relapse. Standard induction regimen with or with out GO were 
compared in a randomized study which enrolled 1115 younger adults with AML. The 
preliminary analysis showed a similar CR rate in both arms, but a significantly improved 
DFS among patients receiving GO--51% versus 40% at 3 years (P = .008)14. However, due to 
toxicity concern and the lack of definite survival benefit after longer follow-up, FDA has 
recently withdrawn its approval.   
A phase II study of My-FLAI aiming to assess toxicity and efficacy was done in patients 
with newly diagnosed AML aged more than 60 years15. The results showed that the four 
drug regimen My-FLAI was well tolerated in an elderly AML population, but its efficacy 
did not appear to be superior to that of standard "3+7" regimen15. 
2.4 New agents nucleoside analogues 
Nucleoside analogues transform into active metabolites (triphosphate nucleoside analogues) 
in the cells and inhibit DNA synthesis. Clofarabine is a new nucleoside analogue, a potent 
inhibitor of both ribonucleotide reductase and DNA polymerase. At the 2009 ASH meeting, 
a few studies on Clofarabine were reported16-18, either clofarabine alone or in combination 
with low-dose Ara-C, or high-dose Ara-C with the monoclonal antibody GO in the 
treatment of elderly AML or relapsed AML. Two novel nucleoside analogues, sapacitabine 
and elacytarabine, were also reported for the therapy of the elderly with refractory or 
relapsed AML19,20. 
2.5 FLT3 inhibitors (Fms-like tyrosine kinase 3 inhibitors) 
The Flt3-internal tandem duplication (ITD) can be found in approximately 30% of all AML 
patients and confers a poor risk status characterized by an increased relapse rate and poor 
overall survival21,22. Moreover, Flt3-ITD-positive AML patients relapsing after allogeneic 
stem cell transplantation (SCT) have very limited therapeutic options. Sorafenib is a 
multikinase inhibitor that is approved for the treatment of metastatic renal cell and 
hepatocellular carcinoma. Sorafenib monotherapy has significant clinical activity in Flt3-ITD 
positive relapsed and refractory AML23,24. 
In addition, combination therapy with sorafenib was shown to be effective in reducing 
mutant clones in patients with FLT3 mutations but was not able to completely eradicate 
them25. These data suggest that sorafenib can achieve temporary disease control, but should 
be integrated into induction and consolidation regimens to achieve maximal outcome  
2.6 Farnesyl-Transferase Inhibitor (FTI) 
In recent years, studies have shown that Ras gene mutation plays an important role in 
leukemogenesis26. By inhibiting farnesyl protein transferase, FTI prohibits the Ras protein 
farnesylation, schizolysis and carboxyl methylation, thus disrupting the critical Ras 
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patients undergoing stem cell transplantation in first remission3,5. In contrast, such an 
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signaling pathway. Tipifarnib (± bortezomib) may represent an important option in a subset 
of high risk/frail AML patients27. 
2.7 Histone deacetylase inhibitors 
Vorinostat is a new anti-cancer agent inhibiting histone deacetylase and has been shown to 
have some efficacy in treatment of AML28. Vorinostat in combination with idarubicin and 
ara-C has synergistic antileukemia activity in a sequence dependent fashion. Therefore, the 
combination of vorinostat, idarubicin and cytarabine is safe and active in AML. CR or CRi 
was achieved by 18% pts with MDS, 8% with relapsed/refractory AML, and 36% with 
untreated AML29. The combination of vorinostat with decitabine either concurrently or 
sequentially is possible without significant toxicity and shows activity in MDS and 
untreated AML30. 
2.8 DNA Methyl-transferase inhibitors  
The demethylating agents 5-azacytidine and Decitabine are remarkably active, even at low 
doses with mild hematologic toxicity, in patients with high-risk MDS. This disease shares 
many poor prognostic features with AML of the elderly. 
Decitabine: Decitabine inhibits DNA methyltransferase, leading to DNA 
hypomethylation and cell differentiation or apoptosis. A combination of decitabine and 
GO was found to be effective with low side effects in previously untreated or 
refractory/relapsed AML patients, especially in elderly patients31. The toxicities were 
minimal and the regimen can be safely delivered to older patients. The pioneering study 
by Pinto and coworkers32 described 12 patients with AML who received Decitabine (90-
120 mg/m2 as a 4-h infusion 3 times daily for 3 days, repeated every 4–6 weeks). Three 
patients achieved a complete remission (CR) and one a partial remission (PR) ; extra-
hematological toxicity was generally mild. Preliminary results of a trial using low-dose 
decitabine in older patients with AML were reported more recently33: Cashen and 
coworkers gave the drug over 1 h on 5 consecutive days (20 mg/m2 per day), repeated 
every 28 days. Fifty-five patients with a median age of 74 years old were enrolled and 
treated with a median of three cycles : overall response rate was 25% (complete response 
rate, 24%) and median survival was 7.7 months.   
5-Azacytidine: despite the fact that more than 100 trials of high dose 5-azacytidine were 
performed in AML in the 1970s and 1980s (mostly in combination with other 
chemotherapies), a very limited number of trials using this drug in AML have been 
published. When the CALGB compared the use of 5-Azacytidine to best supportive care in 
people with all risk groups of MDS, there was a trend toward a survival benefit in those 
patients who received the 5-Azacytidine34. There was a decrease in the P15 methylation 
associated with response. 5-azacytidine was approved by the FDA in 2004 for the treatment 
of MDS (all subtypes). Phase II studies of 5-azacytidine in MDS had been initiated by 
Silverman and the CALGB35 (7 daily administrations of 75 mg/m2, total dose 525 mg/m2, 
repeated every four weeks); overall response rate of 49% was obtained, with 12% CRs and 
median response duration of 14.7 months. A pivotal phase III study of the CALGB34 
compared subcutaneous 5-azacytidine randomized against best supportive care (BSC), with 
the possibility of “cross-over” from BSC in case of progressive disease. An overall response 
rate of 60%, with 7% CRs and 16% PRs and median response duration of 15 months was 
achieved in the experimental arm. Quality of life was also significantly improved in 5-
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azacytidine treated patients. Side effects included mainly myelosuppression and associated 
effects, particularly during the first cycles. Non-hematological toxicties, e.g. nausea and 
vomiting, were rare, but skin reactions occurred more frequently. The French ATU 
program36 performed a retrospective analysis of 184 patients with refractory or relapsed 
AML who received azacytidine. 11% of the patients responded (7%CR, 3%CRi, 1% PR). It 
appears that single agent azacytidine has only limited activity in AML patients relapsed or 
refractory to intensive frontline therapy. Combination of azacitidine with bortezomib or 
low-dose GO was also studied in relapsed or refractory AML patients37,38. In a large 
confirmatory trial39, 5-azacytidine was compared to conventional treatment as determined 
prior to randomization by the treating physician (either BSC, low-dose ara-C, or induction 
chemotherapy). Of 358 patients included, 179 were randomized to 5-azacytidine, 179 to 
conventional care (105 to BSC, 49 to low-dose ara-C, 25 to standard induction 
chemotherapy). Study drug was administered for a median of 9 cycles. 28.5% of patients in 
the experimental arm achieved CR or PR. Median survival was 24.4 months in the 5-
azacytidine group compared to 15 months in the conventional care group (P=0.0001), with a 
doubling of the 2-year survival (50.8 vs. 26%, P<0.0001). 
3. Valproic acid, an inhibitor of Histone Deacetylases (HDACs) 
Valproic acid (VPA) is an inhibitor of class I HDACs. Over the last 5 years, the drug has 
been studied as either a single agent or in combination with various drugs including ATRA. 
VPA has provided a 50% overall response rate in low-risk MDS and a lower rate of response 
in high-risk MDS40 and AML41,42. The contribution of ATRA probably was modest. Thus, the 
role of single-agent VPA may be rather limited in AML. Nevertheless, the drug in 
combination with an active drug such as decitabine, may have enhanced activity, as 
demonstrated in vitro43. A large phase II study of AML and MDS performed at the MD 
Anderson Cancer Center demonstrated the feasibility of DAC combined with 10 days of 
intravenous VPA44. 
3.1 Other agents in early clinical development 
Voreloxin: is a first-in-class anticancer quinolone derivative that intercalates DNA, inhibits 
topoisomerase II, and induces apoptosis. A preliminary report on a voreloxin trial revealed 
clinical activity in previously untreated elderly (age ≥ 60) AML patients who are unlikely to 
benefit from standard chemotherapy45 
Amonafide L-malate (AS1413): is a unique DNA intercalator, in combination with cytarabine 
produced a high complete remission rate and durable responses in both older and younger 
patients with secondary AML46. 
Ezatiostat hydrochloride: is a glutathione S-transferase P1-1 inhibitor, evaluated in 
myelodysplastic syndrome. In a phase I/II study47, trilineage responses were observed in 4 
of 16 patients (25%) with trilineage cytopenia. These responses were accompanied by 
improvement in clinical symptoms and reductions in transfusion requirements.  
Lenalidomide: (LEN) is one of the three new drugs approved by the U.S. FDA to treat 5q-low-
risk MDS. Lenalidomide has demonstrated multiple mechanisms of action48. In a recent 
phase II study49 of LEN in combination with Ara-C and daunorubicin in high risk 
MDS/AML with del 5q, 28% responded. The results show that LEN combined with 
chemotherapy in AML treatment is feasible, without significant additional toxicity.  
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Ribavirin: The eukaryotic translation factor, eIF4E, is over expressed in AML, and is 
associated with poor prognosis. Ribavirin is clinically used as an antiviral molecule, and its 
structure is similar to the m(7)G cap of mRNA, thus inhibiting eIF4E-induced export and 
translation of sensitive transcripts50.  
ARRY-520: The kinesin spindle protein (KSP) plays a major role for the assembly of a normal 
bipolar spindle and is also required for cell cycle progression through mitosis. ARRY-520 is 
a potent, selective inhibitor of KSP51.  
AZD1152: Aurora B kinase plays a major role in regulating mitosis and is over expressed in 
AML. Also it’s a highly potent and selective inhibitor of aurora B kinase. It has been shown 
to inhibit tumor growth in vivo52.  
AZD6244: is one of the orally bioavailable small molecule inhibitors of MEK kinase53-55. 
Terameprocol: The inhibitor of apoptosis protein (IAP), survivin, is a key regulator of cell 
cycles. In leukemic cells, survivin is involved in leukemia cell survival and resistance to 
chemotherapeutics and Flt-3 inhibitors56.  
3.2 Allogeneic Stem Cell Transplant (allo-SCT) 
In patients with AML, published guidelines and treatment recommendations are usually the 
basis for starting the work-up process for allo-SCT57. However, only consistent 
recommendations would allow a standardized clinical practice.  A comprehensive 
systematic literature search could allow to evaluate the best available evidence from 
controlled clinical trials. The following aspects were selected for systematic comparison: 
factors for risk assessment and categorization, role of type of donor, significance of allo-SCT 
in first or second complete remission and in relapse/progressive disease; and role of 
reduced intensity conditioning (RIC) regimens. The use of myeloablative and non-
myeloablative allogeneic stem cell transplant represents a potentially curative approach for 
patients suffering from acute and chronic leukemias such as AML. Thousands of patients 
have been treated worldwide by the transplant of hematopoietic stem cells from a related or 
unrelated donor (available at: http://www.bmdw.org). However, it is obvious that not all 
patients diagnosed with AML will benefit from allogeneic stem cell transplant. Therefore, 
the establishment of definitive, clear, evidence-based recommendations as to which patients 
are likely to benefit from transplant is needed. Several interesting findings emerge when 
comparing recommendations for transplant in key guidelines: (i) for patients with relapsed 
or refractory disease, donor availability should be explored and patients should receive 
transplant, though this is not based on reliable evidence from genetically randomized 
studies; (ii) patients in CR1 with intermediate-or high-risk disease and an available matched 
related donor should receive allogeneic stem cell transplant (intermediate-risk: allo-SCT, 
reasonable option); (iii) for patients who lack a family donor the recommendations are not 
consistent; (iv) allogeneic transplant with reduced conditioning in patients with AML is 
feasible, but the superiority over standard therapeutic regimens is not yet proven. At this 
point in time, there is no doubt that hematopoietic allogeneic stem cell transplant is an 
effective clinical procedure with a curative ability, but intensive induction and consolidation 
chemotherapy may also be sufficient for many patients. But it is likely that only well-defined 
subgroups of patients with AML will benefit from stem cell transplant. The delineation of 
these specific patient groups will be a major objective of future clinical trials. 
Transplant of patients with AML in first CR: in patients who achieved CR, the role of allo-
SCT is still under discussion. A variety of clinical studies have tried to evaluate the benefit 
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of transplant in this situation, but most studies were non-randomized, non-controlled 
trials3,5,6. Only a few trials that were analyzed based on donor availability (‘genetic’ or 
‘biological’ assignment) were useful as supporting evidence in the guideline 
recommendations, which were mainly based on cytogenetic risk factors. These methods of 
patient assignment often introduce biases. Therefore, some guidelines regard these trials as 
level II (cohort study) and not as level I evidence (randomized clinical trials). Cassileth et 
al.58 reported a study of patients with AML aged 16–55 years with complete remission after 
induction therapy who were offered allogeneic transplant if a genotypically or 
phenotypically human leukocyte antigen (HLA)-matched or single-antigen mismatched 
family donor was available (n=113). Remaining patients were randomized to autologous 
transplant (n=116) or a single course of high-dose cytarabine (n=117). The distribution of 
karyotypes did not differ significantly among treatment groups. After a median follow-up 
time of 4 years, the authors found no evidence for significant differences in disease-free 
survival (DFS) between the chemotherapy group (35%), autologous transplant group (35%), 
and allogeneic transplant group (43%). Overall survival (OS) was marginally better after 
chemotherapy than following autologous or allogeneic transplant (52% vs. 43% vs. 46%). 
Twenty five percent of patients died after allogeneic transplant as compared to 14% 
following autologous transplant and 3% after chemotherapy. The subset analysis based on 
cytogenetic risk groups showed many methodological limitations of the study: a high 
proportion of patients did not receive the assigned therapy, which tends to reduce the 
measurable treatment effect in an intention-to-treat analysis.  
The EORTC–GIMEMA (European Organization for Research and Treatment of Cancer–
Gruppo Italiano Malattie Ematologiche Maligne dell’Adulto) AML 8A trial59 showed no 
significant difference in overall survival after a median follow-up of 6 years among patients 
receiving allogeneic transplant from a sibling donor (overall survival: 48%) versus patients 
without a donor (40%, p=0.24; patients received autologous transplant or conventional 
chemotherapy). 
A higher incidence of early mortality after allogeneic transplant was counterbalanced by a 
lower incidence of late mortality. In the EORTC AML 10 trial60 these results were confirmed, 
with the exception of the high-risk group. In total, the survival rate at 4 years was 58.3% in 
the allogeneic, sibling donor group versus 50.8% in the autologous transplant group 
(p=0.18). In the high-risk group, in patients receiving allogeneic transplant the overall 
survival at 4 years (50.2%) was significantly better than after chemotherapy or autologous 
transplant (29.4%). In the standard-risk group and the low-risk group the results for overall 
survival were similar.  
However, the GOELAM (Groupe Ouest Est Leucemies Aigues Myeloblastiques) trial61 
reported no survival benefit for patients receiving an allogeneic transplant regardless of 
cytogenetic risk group. Interestingly, a trend toward better survival at 4 years following 
allogeneic transplant was more pronounced in the low-risk group (71.4% vs. 66.5%; p=0.6) 
and the high-risk group (41% vs. 30%, p=0.97) compared to the intermediate-risk group 
(40.5% vs.56.5%, p=0.08). The BGMT 87 trial62 reported overall survival only for the entire 
patient population and not stratified for risk groups. In patients receiving allogeneic 
transplant, 3-year survival was 65% in the donor group (n=36) and 50.9% in the no-donor 
group (n=60) receiving chemotherapy or autologous transplant. An analysis from all trials 
undertaken by the BGMT shows an improved survival only for the Intermediate and high-
risk population62. The MRC AML 10 trial by Burnett et al.63 evaluated 1063 patients on a 
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Ribavirin: The eukaryotic translation factor, eIF4E, is over expressed in AML, and is 
associated with poor prognosis. Ribavirin is clinically used as an antiviral molecule, and its 
structure is similar to the m(7)G cap of mRNA, thus inhibiting eIF4E-induced export and 
translation of sensitive transcripts50.  
ARRY-520: The kinesin spindle protein (KSP) plays a major role for the assembly of a normal 
bipolar spindle and is also required for cell cycle progression through mitosis. ARRY-520 is 
a potent, selective inhibitor of KSP51.  
AZD1152: Aurora B kinase plays a major role in regulating mitosis and is over expressed in 
AML. Also it’s a highly potent and selective inhibitor of aurora B kinase. It has been shown 
to inhibit tumor growth in vivo52.  
AZD6244: is one of the orally bioavailable small molecule inhibitors of MEK kinase53-55. 
Terameprocol: The inhibitor of apoptosis protein (IAP), survivin, is a key regulator of cell 
cycles. In leukemic cells, survivin is involved in leukemia cell survival and resistance to 
chemotherapeutics and Flt-3 inhibitors56.  
3.2 Allogeneic Stem Cell Transplant (allo-SCT) 
In patients with AML, published guidelines and treatment recommendations are usually the 
basis for starting the work-up process for allo-SCT57. However, only consistent 
recommendations would allow a standardized clinical practice.  A comprehensive 
systematic literature search could allow to evaluate the best available evidence from 
controlled clinical trials. The following aspects were selected for systematic comparison: 
factors for risk assessment and categorization, role of type of donor, significance of allo-SCT 
in first or second complete remission and in relapse/progressive disease; and role of 
reduced intensity conditioning (RIC) regimens. The use of myeloablative and non-
myeloablative allogeneic stem cell transplant represents a potentially curative approach for 
patients suffering from acute and chronic leukemias such as AML. Thousands of patients 
have been treated worldwide by the transplant of hematopoietic stem cells from a related or 
unrelated donor (available at: http://www.bmdw.org). However, it is obvious that not all 
patients diagnosed with AML will benefit from allogeneic stem cell transplant. Therefore, 
the establishment of definitive, clear, evidence-based recommendations as to which patients 
are likely to benefit from transplant is needed. Several interesting findings emerge when 
comparing recommendations for transplant in key guidelines: (i) for patients with relapsed 
or refractory disease, donor availability should be explored and patients should receive 
transplant, though this is not based on reliable evidence from genetically randomized 
studies; (ii) patients in CR1 with intermediate-or high-risk disease and an available matched 
related donor should receive allogeneic stem cell transplant (intermediate-risk: allo-SCT, 
reasonable option); (iii) for patients who lack a family donor the recommendations are not 
consistent; (iv) allogeneic transplant with reduced conditioning in patients with AML is 
feasible, but the superiority over standard therapeutic regimens is not yet proven. At this 
point in time, there is no doubt that hematopoietic allogeneic stem cell transplant is an 
effective clinical procedure with a curative ability, but intensive induction and consolidation 
chemotherapy may also be sufficient for many patients. But it is likely that only well-defined 
subgroups of patients with AML will benefit from stem cell transplant. The delineation of 
these specific patient groups will be a major objective of future clinical trials. 
Transplant of patients with AML in first CR: in patients who achieved CR, the role of allo-
SCT is still under discussion. A variety of clinical studies have tried to evaluate the benefit 
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of transplant in this situation, but most studies were non-randomized, non-controlled 
trials3,5,6. Only a few trials that were analyzed based on donor availability (‘genetic’ or 
‘biological’ assignment) were useful as supporting evidence in the guideline 
recommendations, which were mainly based on cytogenetic risk factors. These methods of 
patient assignment often introduce biases. Therefore, some guidelines regard these trials as 
level II (cohort study) and not as level I evidence (randomized clinical trials). Cassileth et 
al.58 reported a study of patients with AML aged 16–55 years with complete remission after 
induction therapy who were offered allogeneic transplant if a genotypically or 
phenotypically human leukocyte antigen (HLA)-matched or single-antigen mismatched 
family donor was available (n=113). Remaining patients were randomized to autologous 
transplant (n=116) or a single course of high-dose cytarabine (n=117). The distribution of 
karyotypes did not differ significantly among treatment groups. After a median follow-up 
time of 4 years, the authors found no evidence for significant differences in disease-free 
survival (DFS) between the chemotherapy group (35%), autologous transplant group (35%), 
and allogeneic transplant group (43%). Overall survival (OS) was marginally better after 
chemotherapy than following autologous or allogeneic transplant (52% vs. 43% vs. 46%). 
Twenty five percent of patients died after allogeneic transplant as compared to 14% 
following autologous transplant and 3% after chemotherapy. The subset analysis based on 
cytogenetic risk groups showed many methodological limitations of the study: a high 
proportion of patients did not receive the assigned therapy, which tends to reduce the 
measurable treatment effect in an intention-to-treat analysis.  
The EORTC–GIMEMA (European Organization for Research and Treatment of Cancer–
Gruppo Italiano Malattie Ematologiche Maligne dell’Adulto) AML 8A trial59 showed no 
significant difference in overall survival after a median follow-up of 6 years among patients 
receiving allogeneic transplant from a sibling donor (overall survival: 48%) versus patients 
without a donor (40%, p=0.24; patients received autologous transplant or conventional 
chemotherapy). 
A higher incidence of early mortality after allogeneic transplant was counterbalanced by a 
lower incidence of late mortality. In the EORTC AML 10 trial60 these results were confirmed, 
with the exception of the high-risk group. In total, the survival rate at 4 years was 58.3% in 
the allogeneic, sibling donor group versus 50.8% in the autologous transplant group 
(p=0.18). In the high-risk group, in patients receiving allogeneic transplant the overall 
survival at 4 years (50.2%) was significantly better than after chemotherapy or autologous 
transplant (29.4%). In the standard-risk group and the low-risk group the results for overall 
survival were similar.  
However, the GOELAM (Groupe Ouest Est Leucemies Aigues Myeloblastiques) trial61 
reported no survival benefit for patients receiving an allogeneic transplant regardless of 
cytogenetic risk group. Interestingly, a trend toward better survival at 4 years following 
allogeneic transplant was more pronounced in the low-risk group (71.4% vs. 66.5%; p=0.6) 
and the high-risk group (41% vs. 30%, p=0.97) compared to the intermediate-risk group 
(40.5% vs.56.5%, p=0.08). The BGMT 87 trial62 reported overall survival only for the entire 
patient population and not stratified for risk groups. In patients receiving allogeneic 
transplant, 3-year survival was 65% in the donor group (n=36) and 50.9% in the no-donor 
group (n=60) receiving chemotherapy or autologous transplant. An analysis from all trials 
undertaken by the BGMT shows an improved survival only for the Intermediate and high-
risk population62. The MRC AML 10 trial by Burnett et al.63 evaluated 1063 patients on a 
 
Myeloid Leukemia – Clinical Diagnosis and Treatment 
 
118 
donor versus no-donor basis. All patients received four courses of induction chemotherapy 
followed by consolidation chemotherapy, after which patients with an HLA-matched sibling 
donor and in appropriate condition were scheduled to receive an allogeneic transplant. The 
remainder was randomized between autologous transplant and no further therapy. Sixty-
one percent of patients with a donor underwent transplant in first remission. In a donor 
versus no-donor analysis, significant benefit in disease-free survival and overall survival 
was seen only in the standard-risk cytogenetic group (DFS: 50% vs. 39%, p=0.001; OS: 55% 
vs. 44%, p=0.01). There were twice as many deaths in first remission among patients with a 
donor than among patients with no donor (19% vs. 9%; p<0.001). 
Recently, the results of three trials from the Dutch-Belgian Hemato-Oncology Cooperative 
Group and the Swiss Group for Clinical Cancer Research (HOVON/SAKK) based on a 
donor versus no-donor analysis in patients with AML in first remission were published as 
an individual patient data (IPD) analysis64. Based on the available IPD, the study included a 
total of 1032 patients from the trials. An HLA-identical sibling donor was available for 32% 
of patients, whereas 58% of patients lacked such a donor. Following risk-group analysis, 
disease free survival was significantly better for patients with available donor and standard- 
or high-risk profile (p=0.01 and p=0.003) and also better for patients younger than 40 years 
(p<0.001). However, the improved disease-free survival in the donor group did not translate 
into significantly better overall survival (p=0.07). Treatment-related mortality was 
significantly higher in the donor group (21% vs. 4%; p<0.001). 
Three meta-analyses investigated the apparent heterogeneity of clinical study results. 
Cornelissen et al. 64 performed a meta-analysis based on published data including more than 
4000 patients with AML in first remission enrolled in the HOVON/SAKK studies, the 
Medical Research Council (MRC) studies, the trials of the EORTC, and the BGMT studies. 
Disease-free survival and overall survival were analyzed, stratified for cytogenetic risk 
profile and age. Overall, transplant from a family donor statistically significantly prolonged 
disease-free survival in patients with intermediate- and high-risk profiles, but not in patients 
with a low-risk profile. This effect was pronounced but not restricted to patients below the 
age of 35 years. However, a benefit for overall survival in patients receiving stem cell 
transplant from a related donor was seen only in patients with intermediate- and low-risk 
disease up to the age of 35 years. In this analysis there was no evidence for improved 
outcomes in the favorable-risk group. These results are in accordance with the meta-analysis 
published by Koreth et al.6 in 3638 patients with AML in first CR. However, Yanada et al.65 
identified a beneficial effect of allogeneic transplant in these patients limited to the high-risk 
group. 
In summary, there is only a limited number of phase III trials evaluating the role of allo-SCT 
in patients with AML in first remission. The results of these trials are heterogeneous, and 
often limited to matched-related donor transplant. 
Transplant in relapse/progressive disease: it is generally accepted that the overall 
prognosis of patients with relapsed or progressive disease is poor. Especially in patients 
with initial duration of remission below 1 year, the success with standard regimens for 
inducing second remission is rare. Therefore, it is not surprising that in this situation most 
treatment guidelines recommend allogeneic transplant once a patient has achieved second 
remission. However, we did not identify any randomized trial in literature search 
addressing this clinical situation. In a phase II study, Schmid et al.66 treated 103 patients 
with refractory AML using dose-reduced chemotherapy followed by allogeneic transplant 
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from a related or unrelated donor. Refractory disease was defined as primary induction 
failure, relapse within 6 months after induction, or second relapse. Overall, 1 year after 
transplant the authors reported a disease free survival of 47% and an overall survival of 
54%. After a follow-up of 4 years, disease-free survival and overall survival declined to 30% 
and 32%. The risk for treatment failure was significantly increased in patients who received 
more than two cycles of chemotherapy before stem cell transplant, in patients with primary 
induction failure, bone marrow infiltration of more than 50% blasts, and more than a 
median of 215 days from diagnosis to transplant, or in patients with low CD34 cell count in 
the graft and if stem cells from a related donor were used. While the risk for non-relapse 
mortality increased when using an unrelated donor, age, sex, and underlying karyotype 
were not predictive for outcome. Minimal residual disease (MRD), mostly defined as the 
positive detection of genetic AML-specific mutations during microscopically diagnosed 
complete remission, is often examined in the follow-up period after induction therapy for 
leukemia. In small cohort of 45 patients, Laane et al.67 claimed a benefit by allogeneic 
transplant for those patients who were identified with detectable MRD after standard 
therapy. 
Reduced intensity conditioning: reduced intensity conditioning has broadened the use of 
allogeneic stem cell transplant to elderly patients and patients with comorbidities. 
Allogeneic transplant is no longer restricted to younger, fitter patients who are better able to 
tolerate the toxicities of a myeloablative regimen. The use of a less intensive approach 
potentially results in a reduced leukemia cell kill, which in turn increases the risk for relapse 
and a higher incidence of engraftment failure. Uncertainty remains regarding the frequency 
of graft-versus-host disease (GvHD) after reduced intensity allografts. Usually, a higher 
dose of immunosuppressive agents or the use of long-acting agents is recommended to 
reduce the rate of GvHD after transplant, thereby increasing the risk of relapse. In 
conclusion, there is an urgent need to define the role of allogeneic transplant in the mixed 
chimérisme setting. Unfortunately, published literature is often based on single centre 
experience with small numbers of patients. The Seattle experience is derived from large 
multicenter studies including a high number of patients. These studies have refined the 
optimal non-myeloablative treatment procedure, but they do not compare reduced intensity 
allografts with other treatment strategies68. 
At our knowledge, two randomized controlled studies, evaluating the role of reduced 
conditioning followed by allogeneic stem cell transplant for AML, have been published. 
Mothy et al.69 assigned 95 newly diagnosed adult patients with AML in first complete 
remission on a donor versus no-donor basis. All patients had a high-risk karyotype or 
clinical profile. Based on ‘biological’ randomization, patients with a matched sibling donor 
(n=35) were assigned to a transplant arm using reduced conditioning, whereas patients 
lacking such a donor (n=60) were assigned to standard treatment procedures. In an 
intention-to-treat analysis, 4-year disease-free survival was significantly higher in the donor 
group (54%) as compared to the no-donor group (30%; p=0.01). Furthermore, overall 
survival was significantly higher in the donor group as compared to the no-donor group 
(p=0.04). Transplant-related mortality was 12%. 
Estey and colleagues70 prospectively assessed the applicability of reduced intensity 
conditioning in patients with AML or MDS. Of 99 patients who entered complete remission 
after induction chemotherapy, 14 received an allogeneic transplant (13 siblings). The authors 
conducted a matched-pair analysis, comparing patients receiving chemotherapy with 
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donor versus no-donor basis. All patients received four courses of induction chemotherapy 
followed by consolidation chemotherapy, after which patients with an HLA-matched sibling 
donor and in appropriate condition were scheduled to receive an allogeneic transplant. The 
remainder was randomized between autologous transplant and no further therapy. Sixty-
one percent of patients with a donor underwent transplant in first remission. In a donor 
versus no-donor analysis, significant benefit in disease-free survival and overall survival 
was seen only in the standard-risk cytogenetic group (DFS: 50% vs. 39%, p=0.001; OS: 55% 
vs. 44%, p=0.01). There were twice as many deaths in first remission among patients with a 
donor than among patients with no donor (19% vs. 9%; p<0.001). 
Recently, the results of three trials from the Dutch-Belgian Hemato-Oncology Cooperative 
Group and the Swiss Group for Clinical Cancer Research (HOVON/SAKK) based on a 
donor versus no-donor analysis in patients with AML in first remission were published as 
an individual patient data (IPD) analysis64. Based on the available IPD, the study included a 
total of 1032 patients from the trials. An HLA-identical sibling donor was available for 32% 
of patients, whereas 58% of patients lacked such a donor. Following risk-group analysis, 
disease free survival was significantly better for patients with available donor and standard- 
or high-risk profile (p=0.01 and p=0.003) and also better for patients younger than 40 years 
(p<0.001). However, the improved disease-free survival in the donor group did not translate 
into significantly better overall survival (p=0.07). Treatment-related mortality was 
significantly higher in the donor group (21% vs. 4%; p<0.001). 
Three meta-analyses investigated the apparent heterogeneity of clinical study results. 
Cornelissen et al. 64 performed a meta-analysis based on published data including more than 
4000 patients with AML in first remission enrolled in the HOVON/SAKK studies, the 
Medical Research Council (MRC) studies, the trials of the EORTC, and the BGMT studies. 
Disease-free survival and overall survival were analyzed, stratified for cytogenetic risk 
profile and age. Overall, transplant from a family donor statistically significantly prolonged 
disease-free survival in patients with intermediate- and high-risk profiles, but not in patients 
with a low-risk profile. This effect was pronounced but not restricted to patients below the 
age of 35 years. However, a benefit for overall survival in patients receiving stem cell 
transplant from a related donor was seen only in patients with intermediate- and low-risk 
disease up to the age of 35 years. In this analysis there was no evidence for improved 
outcomes in the favorable-risk group. These results are in accordance with the meta-analysis 
published by Koreth et al.6 in 3638 patients with AML in first CR. However, Yanada et al.65 
identified a beneficial effect of allogeneic transplant in these patients limited to the high-risk 
group. 
In summary, there is only a limited number of phase III trials evaluating the role of allo-SCT 
in patients with AML in first remission. The results of these trials are heterogeneous, and 
often limited to matched-related donor transplant. 
Transplant in relapse/progressive disease: it is generally accepted that the overall 
prognosis of patients with relapsed or progressive disease is poor. Especially in patients 
with initial duration of remission below 1 year, the success with standard regimens for 
inducing second remission is rare. Therefore, it is not surprising that in this situation most 
treatment guidelines recommend allogeneic transplant once a patient has achieved second 
remission. However, we did not identify any randomized trial in literature search 
addressing this clinical situation. In a phase II study, Schmid et al.66 treated 103 patients 
with refractory AML using dose-reduced chemotherapy followed by allogeneic transplant 
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from a related or unrelated donor. Refractory disease was defined as primary induction 
failure, relapse within 6 months after induction, or second relapse. Overall, 1 year after 
transplant the authors reported a disease free survival of 47% and an overall survival of 
54%. After a follow-up of 4 years, disease-free survival and overall survival declined to 30% 
and 32%. The risk for treatment failure was significantly increased in patients who received 
more than two cycles of chemotherapy before stem cell transplant, in patients with primary 
induction failure, bone marrow infiltration of more than 50% blasts, and more than a 
median of 215 days from diagnosis to transplant, or in patients with low CD34 cell count in 
the graft and if stem cells from a related donor were used. While the risk for non-relapse 
mortality increased when using an unrelated donor, age, sex, and underlying karyotype 
were not predictive for outcome. Minimal residual disease (MRD), mostly defined as the 
positive detection of genetic AML-specific mutations during microscopically diagnosed 
complete remission, is often examined in the follow-up period after induction therapy for 
leukemia. In small cohort of 45 patients, Laane et al.67 claimed a benefit by allogeneic 
transplant for those patients who were identified with detectable MRD after standard 
therapy. 
Reduced intensity conditioning: reduced intensity conditioning has broadened the use of 
allogeneic stem cell transplant to elderly patients and patients with comorbidities. 
Allogeneic transplant is no longer restricted to younger, fitter patients who are better able to 
tolerate the toxicities of a myeloablative regimen. The use of a less intensive approach 
potentially results in a reduced leukemia cell kill, which in turn increases the risk for relapse 
and a higher incidence of engraftment failure. Uncertainty remains regarding the frequency 
of graft-versus-host disease (GvHD) after reduced intensity allografts. Usually, a higher 
dose of immunosuppressive agents or the use of long-acting agents is recommended to 
reduce the rate of GvHD after transplant, thereby increasing the risk of relapse. In 
conclusion, there is an urgent need to define the role of allogeneic transplant in the mixed 
chimérisme setting. Unfortunately, published literature is often based on single centre 
experience with small numbers of patients. The Seattle experience is derived from large 
multicenter studies including a high number of patients. These studies have refined the 
optimal non-myeloablative treatment procedure, but they do not compare reduced intensity 
allografts with other treatment strategies68. 
At our knowledge, two randomized controlled studies, evaluating the role of reduced 
conditioning followed by allogeneic stem cell transplant for AML, have been published. 
Mothy et al.69 assigned 95 newly diagnosed adult patients with AML in first complete 
remission on a donor versus no-donor basis. All patients had a high-risk karyotype or 
clinical profile. Based on ‘biological’ randomization, patients with a matched sibling donor 
(n=35) were assigned to a transplant arm using reduced conditioning, whereas patients 
lacking such a donor (n=60) were assigned to standard treatment procedures. In an 
intention-to-treat analysis, 4-year disease-free survival was significantly higher in the donor 
group (54%) as compared to the no-donor group (30%; p=0.01). Furthermore, overall 
survival was significantly higher in the donor group as compared to the no-donor group 
(p=0.04). Transplant-related mortality was 12%. 
Estey and colleagues70 prospectively assessed the applicability of reduced intensity 
conditioning in patients with AML or MDS. Of 99 patients who entered complete remission 
after induction chemotherapy, 14 received an allogeneic transplant (13 siblings). The authors 
conducted a matched-pair analysis, comparing patients receiving chemotherapy with 
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patients who underwent transplant. Matching criteria were age, cytogenetics, and time 
between achieving CR and transplant. There was a significantly longer disease free survival 
in the transplanted patients, but the results for overall survival were similar between 
patients receiving transplant and patients receiving chemotherapy. 
In a large retrospective trial performed by the EBMT71, 315 patients with AML or MDS who 
received reduced intensity conditioning were compared with 407 patients who received a 
Myeloablative approach. In multivariate analysis, acute GvHD and transplant-related 
mortality were significantly decreased, and relapse incidence was significantly higher after 
reduced intensity conditioning. 
3.3 Autologous Stem Cell Transplantation (auto-SCT) 
For patients with AML who are unable to secure an acceptable HLA donor, the role of 
autologous stem cell transplantation (auto-SCT) has remained controversial. Its effectiveness 
remains unclear as, when analyzed on intention-to-treat strategies, a significant number do 
not undergo the procedure, whereas others seem to fail therapy from pre transplant 
recurrences. Recently, Novitzky et al.72 compared the outcome of patients in first remission 
of AML who actually underwent autologous or allogeneic transplantation. The choice for 
the type of graft was based on availability of HLA identical siblings. Patients received 
myeloablative conditioning followed by allogeneic or autologous cytokine mobilized 
peripheral blood stem cell transplantation. For prophylaxis of graft-versus-host disease 
(GVHD), grafts were incubated ex vivo with anti-CD52 antibodies and patients were 
prescribed cyclosporin until day 90. Patients were stratified by clinical and laboratory 
factors as well as cytogenetic risk. The endpoints were treatment-related mortality (TRM), 
disease-free survival (DFS), and overall survival (OS). The median presentation age for both 
transplant groups was 35 (14-60) years. Of the 112 consecutive patients achieving remission, 
autologous or allogeneic grafts were transplanted to 43 and 32 patients, respectively. There 
was no significant difference in the presentation clinical features, laboratory parameters, 
marrow morphology, or proportion of low and intermediate cytogenetic risk for both 
transplant options. Treatment mortality as well as relapse rate was similar (14% and 15%; 
39% and 27%, respectively). At a median of 1609 and 1819 post transplant days, 56% and 
63% in each group survived. In univariate analysis performance status, cytogenetic risk, 
morphologic features of dysplasia, blast count, and lactate dehydrogenase (LDH) were 
significant factors for survival. Although for the entire group there was no difference in 
survival between both modalities, all patients with unfavorable cytogenetics receiving an 
autologous graft died of disease recurrence (3-year survival 35% versus 0%; P = 0.05). They 
conclude that patients with AML who have low or intermediate cytogenetic risk undergoing 
myeloablative conditioning followed by autologous or allogeneic T cell-depleted stem cell 
transplantation appeared to have similar outcome. However, those with unfavorable 
karyotype are unlikely to be cured with autologous grafts and are candidates for 
experimental modalities.  
3.4 Other regimens for refractory /relapsed AML 
High-dose cytarabine (HiDAC) is commonly used for re-induction of relapsed or refractory 
AML. Recently, Thomas et al.73 et al reported a novel, timed-sequential regimen that takes 
advantage of synergy when mitoxantrone is given after cytarabine. Those patients received 
HiDAC/mitoxantrone regimen, with cytarabine at 3 g/m2 over four hours on days 1 and 5 
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plus mitoxantrone at 30 mg/m2 over one hour immediately following the HiDAC on days 1 
and 5. HiDAC/mitoxantrone induction was well tolerated and complete remission was 
achieved in 89%. of patients.  
To further enhance the CR rate in refractory/relapsed AML, the Japanese Adult Leukemia 
Study Group (JALSG) reported a phase II study of FLAGM (Fludarabine + High-Dose Ara-C 
+ G-CSF + mitoxantrone) in 41 patients with relapsed or refractory AML74. FLAGM yielded 
a 70% response rate in either relapsed or refractory AML patients. Although randomized 
studies are still needed, FLAGM appears to be a good option for the treatment of either 
relapsed or refractory AML patients. 
4. Conclusions: Future directions 
Achieving a cure for AML, even for younger adult patients with de novo AML, remains a 
challenge. While more than 70% of such patients will enter a first CR1 after induction 
chemotherapy, a substantial number experience disease relapse. Allo-SCT is a curative 
treatment option for younger patients with AML in CR1. However, concerns regarding allo-
SCT–related toxicity, and questions regarding its benefit, limit its use for patients who have 
attained an initial remission. Alternative therapies include intensive consolidation 
chemotherapy or auto-SCT. The current consensus, reflected in treatment guidelines of the 
National Comprehensive Cancer Network (V1.2009: available at http://www.nccn.org), is 
based on cytogenetic stratification into good-, intermediate-, and poor-risk AML. Compared 
with non-allo-SCT therapies, allo-SCT has significant relapse-free survival and overall 
survival benefit for intermediate- and poor-risk AML but not for good-risk AML in CR1. 
Prognostic markers, such as NPM1, Flt3-ITD, and cytogenetic abnormalities have made it 
possible to prospectively formulate aggressive treatment plans for unfavorable AML. If no 
Flt3-ITD mutation is present, CEBPα and NPM1 are generally associated with a favorable 
prognosis, and testing will be important in defining biologic subtypes that require less 
therapy. The presence of some of these mutations may modify the effect of others, so the 
establishment of a panel of significant markers may be needed to adequately assess risk and 
plan care. However, the long-term survival of AML with unfavorable factors remains 
unsatisfactory. Prolonged survival without curing high risk MDS/AML patients suggests 
that disease modification instead of cure of AML patients may be an alternative goal of 
treating elderly patients not suitable for aggressive therapy. New regimens and novel agents 
targeting specific pathways reviewed in this report may bring AML treatment into a new 
era. 
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mortality were significantly decreased, and relapse incidence was significantly higher after 
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For patients with AML who are unable to secure an acceptable HLA donor, the role of 
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remains unclear as, when analyzed on intention-to-treat strategies, a significant number do 
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prescribed cyclosporin until day 90. Patients were stratified by clinical and laboratory 
factors as well as cytogenetic risk. The endpoints were treatment-related mortality (TRM), 
disease-free survival (DFS), and overall survival (OS). The median presentation age for both 
transplant groups was 35 (14-60) years. Of the 112 consecutive patients achieving remission, 
autologous or allogeneic grafts were transplanted to 43 and 32 patients, respectively. There 
was no significant difference in the presentation clinical features, laboratory parameters, 
marrow morphology, or proportion of low and intermediate cytogenetic risk for both 
transplant options. Treatment mortality as well as relapse rate was similar (14% and 15%; 
39% and 27%, respectively). At a median of 1609 and 1819 post transplant days, 56% and 
63% in each group survived. In univariate analysis performance status, cytogenetic risk, 
morphologic features of dysplasia, blast count, and lactate dehydrogenase (LDH) were 
significant factors for survival. Although for the entire group there was no difference in 
survival between both modalities, all patients with unfavorable cytogenetics receiving an 
autologous graft died of disease recurrence (3-year survival 35% versus 0%; P = 0.05). They 
conclude that patients with AML who have low or intermediate cytogenetic risk undergoing 
myeloablative conditioning followed by autologous or allogeneic T cell-depleted stem cell 
transplantation appeared to have similar outcome. However, those with unfavorable 
karyotype are unlikely to be cured with autologous grafts and are candidates for 
experimental modalities.  
3.4 Other regimens for refractory /relapsed AML 
High-dose cytarabine (HiDAC) is commonly used for re-induction of relapsed or refractory 
AML. Recently, Thomas et al.73 et al reported a novel, timed-sequential regimen that takes 
advantage of synergy when mitoxantrone is given after cytarabine. Those patients received 
HiDAC/mitoxantrone regimen, with cytarabine at 3 g/m2 over four hours on days 1 and 5 
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plus mitoxantrone at 30 mg/m2 over one hour immediately following the HiDAC on days 1 
and 5. HiDAC/mitoxantrone induction was well tolerated and complete remission was 
achieved in 89%. of patients.  
To further enhance the CR rate in refractory/relapsed AML, the Japanese Adult Leukemia 
Study Group (JALSG) reported a phase II study of FLAGM (Fludarabine + High-Dose Ara-C 
+ G-CSF + mitoxantrone) in 41 patients with relapsed or refractory AML74. FLAGM yielded 
a 70% response rate in either relapsed or refractory AML patients. Although randomized 
studies are still needed, FLAGM appears to be a good option for the treatment of either 
relapsed or refractory AML patients. 
4. Conclusions: Future directions 
Achieving a cure for AML, even for younger adult patients with de novo AML, remains a 
challenge. While more than 70% of such patients will enter a first CR1 after induction 
chemotherapy, a substantial number experience disease relapse. Allo-SCT is a curative 
treatment option for younger patients with AML in CR1. However, concerns regarding allo-
SCT–related toxicity, and questions regarding its benefit, limit its use for patients who have 
attained an initial remission. Alternative therapies include intensive consolidation 
chemotherapy or auto-SCT. The current consensus, reflected in treatment guidelines of the 
National Comprehensive Cancer Network (V1.2009: available at http://www.nccn.org), is 
based on cytogenetic stratification into good-, intermediate-, and poor-risk AML. Compared 
with non-allo-SCT therapies, allo-SCT has significant relapse-free survival and overall 
survival benefit for intermediate- and poor-risk AML but not for good-risk AML in CR1. 
Prognostic markers, such as NPM1, Flt3-ITD, and cytogenetic abnormalities have made it 
possible to prospectively formulate aggressive treatment plans for unfavorable AML. If no 
Flt3-ITD mutation is present, CEBPα and NPM1 are generally associated with a favorable 
prognosis, and testing will be important in defining biologic subtypes that require less 
therapy. The presence of some of these mutations may modify the effect of others, so the 
establishment of a panel of significant markers may be needed to adequately assess risk and 
plan care. However, the long-term survival of AML with unfavorable factors remains 
unsatisfactory. Prolonged survival without curing high risk MDS/AML patients suggests 
that disease modification instead of cure of AML patients may be an alternative goal of 
treating elderly patients not suitable for aggressive therapy. New regimens and novel agents 
targeting specific pathways reviewed in this report may bring AML treatment into a new 
era. 
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Virchow to describe the blood appearance of his female patient after she died. She was a 50-
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haemorrhage, prolonged bleeding from mild skin lesions, these all reflect the 
thrombocytopenia and are common early manifestations of the disease. Bleeding of the 
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infrequently. 
According to Hu et al. the frequencies of the most important presenting features in AML are 
presented below in Table 1 (Hu et al., 2011). 
Blood transfusions may be necessary but can – in the case of hyperleukocyosis - also lead to 
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haemorrhage. The use of platelet transfusion is recommended, especially since the number 
of platelets may be overestimated due to the presence of fragments of blasts that are 
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leukaemia is most commonly associated with intravascular coagulation and bleeding 
(Tallman & Kwaan, 2004). Platelets interact with normal peripheral blood (PB) cells via 
soluble mediators of adhesion molecules and these, once released, may affect hematopoietic 
stem and progenitor cells. Recently the interactions between platelets and AML cells has 
been characterized in detail (Foss & Bruserud, 2008): blasts and platelets can affect each 
other’s functions, drugs used to treat AML can alter some platelet functions, systemic levels 
of cytokines are increased during chemotherapy, including cytokines known to affect 
platelet activation and blasts, platelet secretion of growth factors is clearly detected in 
peripheral blood of persons with stem cell autografts. 
 
Acute Myeloid Leukaemia 
Initial symptom 
Younger 
Group (age < 60) 
 % 
Elderly 
Group (age ≥ 60) 
% 
Hypodynamia 57.8 68.3 
Pale face 60.3 55.5 
Fever 40.5 33.5 
Dizziness 14.7 10.4 
Hemorrhagic dermatologic mucosa 15.5 14.0 
WBC infiltration 6.9 12.2 
Myalgias 4.3 3.0 
White cell count (109/L)   
 < 4 24.1 40.2 
 4 - 10 16.4 9.8 
 > 10 59.5 50.0 
Haemoglobin (g/L)2   
 Abnormal 93.1 95.7 
 Normal 6.9 4.3 
Platelets (109/L)   
 ≤10 29.3 21.3 
 >10 70.7 78.7 
Bone marrow cellularity   
 Severely hypercellular 53.4 30.5 
 Moderately hypercellular 21.6 34.8 
 Normocellular 13.8 20.7 
 Hypocellular 11.2 14.0 
Table 1. The frequencies of the most important presenting features in AML, according to Hu 
et al. 
Infections remain a major cause of morbidity and mortality associated with therapy in 
both adults and children with AML. Pustules or other skin infections and various skin 
lesions are the most common minor infections encountered. More serious infections like 
sinusitis, pneumonia, pyelonephritis and meningitis occur rarely in the beginning. After 
starting chemotherapy, with aggravation of neutropenia and monocytopenia, serious 
infections occur more frequently with various bacterial, fungal or viral agents. Progressive 
decline in immune function makes aged patients with AML theoretically more susceptible 
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to nosocomial infection than younger ones. However, a study in this regard indicated that 
there is no significant difference in the overall incidence of infections, such as febrile 
episodes, the pattern of nosocomial infection sites, the average duration of antimicrobial 
therapy and overall survival (Fanci et al., 2008). Gram-negative bacteria were more 
common in patients with severe sepsis (Hämäläinen et al., 2008). A case was reported in 
the literature of AML with marked hyponatremia and impaired consciousness probably 
due to treatment with linezolid, but sodium supplementation restored the natremia. 
Viridans streptococci in children with AML are a major cause of infections and 
pneumonia in cases with neutropenia. Viridans streptococci sepsis developed at different 
times after chemotherapy was initiated and patients were febrile for a median of 15 days. 
33% of the 172 children with AML included in this study had hypotension, 28% had acute 
respiratory distress syndrome and 17% had fungal infections (Okamoto et al., 2003). 
Neutropenic enterocolitis and acute appendicitis are also complications that occur in 
children with severe or prolonged neutropenia, and may endanger their lives (Alioglu et 
al., 2007). Hepatosplenic fungal infections are important infectious complications in adults 
with AML being diagnosed with computerized tomography and high levels of alkaline 
phosphatase. Mortality related to these infections is low if treatment is appropriate 
(Masood & Sallah, 2005). 
Fever is present at diagnosis in approximately 40-50% of the patients. Anorexia and weight 
reduction are also common, percentages of 25% being reported (Burns et al., 1981). 
Splenomegaly and hepatomegaly are seen in approximately one third of patients, especially 
in those with a monocytic or monoblastic morphologic subtype. Adenopathy is rare, the 
exception being the monocytic variant of AML where a frequency of more than 30% can be 
found (Burns et al., 1981; Hu et al., 2011). 
2.1 Specific organ involvement 
Blast cells are circulating and infiltrating various tissues. Occasionally, a biopsy or autopsy 
reveals infiltration with leukaemic cells at different levels. They cause disruption to the 
affected structures. Extramedullary involvement is more frequent in monocytic and 
myelomonocytic leukaemia. Recently it was demonstrated that haematopoietic progenitors 
and leukaemic cells are retained in the bone marrow (BM) microenvironment through 
chemokine receptors, such as CXCR4. A prospective study evaluated by flow cytometry the 
prognostic involvement of CXCR4 in AML. The study showed that low expression of 
CXCR4 on leukaemic cells is correlated with a better prognosis than high expression (Spoo 
et al., 2007). Different sites may be involved (Liesveld & Lichtman, 2006): 
Skin involvement. Skin injury prior to BM and blood involvement is rare and can be of three 
types: nonspecific lesions (maculae, papules, vesicles, pyoderma gangrenosum, vasculitis, 
neutrophilic dermatitis, erythema multiform or nodosa), skin leukaemia and granulocytic 
sarcomas (myeloid sarcomas), being the result of skin infiltration by blastic cells. The most 
common sites of infiltration are the scalp, trunk and extremities. 
Sensory organ involvement. Sensory organ involvement is very rare, however, infiltration of 
retina, choroids, iris and optic nerve may occur. Otitis external and internal bleeding, 
infiltration of the mastoid with VII nerve damage may be other signs of disease 
presentation. 
Gastrointestinal tract involvement. May be affected at any level, but functional disorders are 
rare. Involvement of the oral cavity, colon and anal canal most often lead to symptoms. 
Involvement of the oral cavity often means the patient goes to the dentist. Infiltration of 
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gums, periodontal abscess can cause prolonged bleeding following extractions. Enterocolitis 
may be a way of disease presentation or can occur during treatment. Fever, abdominal pain, 
bloody diarrhoea or ileus may be present and sometimes mimic appendicitis. Isolated 
gastrointestinal tract involvement is rare. Proctitis usually occurs in the monocytic variant of 
leukaemia and is a difficult problem to solve during the period with severe 
granulocytopenia. 
Respiratory tract involvement. Infiltrates may lead to laryngeal obstruction, functional 
disorders, severe symptoms and radiological changes in the case of parenchymal, alveolar 
or pleural infiltrates. 
Heart involvement. Cardiac involvement is common, but rarely causes symptoms. 
Pericardial infiltrates, ventricular transmural endocarditis can occasionally cause severe 
cardiac arrhythmias or even death. Infiltrations of the excitoconductor system and 
myocardial infarction were also cited. 
Urogenital tract involvement. The kidneys are infiltrated with leukaemic cells in a large 
number of cases, but functional disorders are rare. Bleeding into the collector is common. 
Cases have been cited with vulvar, prostatic and testicular penetration. 
Osteoarticular system involvement. Its involvement is accompanied by various degrees of 
bone and joint pain. Bone necrosis may also occur. Pseudo-gout arthritis (calcium 
pyrophosphate dehydrate) or gout arthritis (uric acid) is sometimes responsible for 
synovitis. 
Central nervous system involvement (CNS). CNS involvement is rare, although meningeal 
infiltration is seen in the monocytic type of AML. An association between CNS involvement 
and diabetes insipidus has been reported in AML with monosomy 7 and inv16 (Castagnola 
et al., 1995). 
Granulocytic sarcomas. Also known as sarcomas or chloromas, myeloid sarcomas are 
tumours composed of myeloblasts, monoblasts or megakaryocytes. These tumours can 
occur as extramedullary masses without evidence of leukaemia in BM or peripheral blood 
(nonleukaemic myeloid sarcomas) or in combination with leukaemia. When they appear as 
isolated lesions they are usually chloromas and considered extranodal lymphoma, because 
of the biopsy appearance similar to lymphoid cells. When myeloid sarcoma is the first 
manifestation of AML, the involvement of BM and blood appears after a few months. 
Theoretically myeloid sarcomas can have any location: skin, orbit, paranasal sinuses, bone, 
chest wall, breast, gastrointestinal tract, respiratory, genital-urinary, central nervous system, 
peripheral nervous system or lymph node (Hernández et al., 2002; Liesveld & Lichtman, 
2006; Paţiu et al., 2008). Abnormalities involving chromosome 8 are the most common 
cytogenetic abnormalities in nonleukaemic sarcomas (Tsimberidou et al., 2003). Initially, 
these tumours were termed chloromas because of the green colour due to the presence of 
myeloperoxidase in myeloid leukaemic cells. Patients with AML with t(8;21) have a 
propensity to develop extramedullary leukaemia with poor outcomes after treatment. 
2.2 Neonatal and childhood AML 
A study conducted between May 1988 and June 2000 that included 698 children with AML 
tried to find the relationship between the age of onset of the disease, clinical characteristics 
and evolution. AML onset was observed at a very young age and is accompanied by 
intermediate risk cytogenetics (high incidence of 11q23 translocations). French-American-
British (FAB) distribution is also based on age: types M5 and M7 are more common at 
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younger ages and types M0, M2, M3 more common in older children. In terms of clinical 
diagnosis, CNS involvement and digestive tract involvement is more common in very 
young children. Very young children develop severe diarrhoea, nausea and vomiting after 
chemotherapy (Webb et al., 2001). A recent study shows the impact of the undifferentiated 
form of AML-M0 on disease progression in children with AML with and without Down 
syndrome (DS), analyzing two clinical trials (Children's Cancer Group Clinical Trials AML). 
The main issues pursued were morphology and cytogenetics. Children with AML-M0 
without DS had a lower number of leukocytes than patients with non-M0 AML and a higher 
incidence of del5, non constitutive trisomy 21 and hypoploidy. The analysis of AML in 
children without DS showed no differences between cases and non-M0 M0. Also there was 
no difference in evolution between children with DS and M0 and those with DS and non-M0 
AML (Barbaric et al., 2007). 
Four AML related syndromes are described in newborns: 
 Transient myeloproliferative disease that may be present at birth or immediately after 
in about 10% of children with DS. The syndrome is followed shortly by acute 
leukaemia, usually myeloid (less common lymphoblastic). 
 Transient leukaemia. 25% of children with DS and transient leukaemia develop AML - 
M7 in the first 4 years of life. 
 Congenital Leukaemia.  
 Neonatal leukaemia. Children who develop leukaemia during the first weeks of life are 
often pale, with insufficient increase in weight, diarrhoea and lethargy. The presence of 
cytogenetic abnormalities involving chromosome 11 has an extremely unfavourable 
prognosis.  
The last two syndromes can occur in children without DS, but 10 times less frequently than 
in those with DS. Leukocytosis, bone marrow and blood infiltration with blasts, hepato-
splenomegaly, thrombocytopenia, anaemia, purpura and skin infiltrates are common 
manifestations. Unfortunately, these children do not survive more than a few weeks or 
months. The disease can be highlighted during the prenatal period because cytogenetic 
abnormalities appear and mark the leukaemic clone. Monocytic differentiation of leukaemia 
and t(4;11) are common features. A case was even reported of transplacental transmission of 
acute monocytic leukaemia (Liesveld & Lichtman, 2006). 
2.3 Elderly AML 
AML in the elderly is a biologically distinct clinical entity. AML is generally a disease of old 
age, because the diagnosis is usually made in the decade of 60-70 years. The unfavourable 
course of the disease is due to biological characteristics at this age and various associated co-
morbidities. In the United States the elderly population is the fastest growing segment, the 
average age at diagnosis of AML being 67 years (Melchert, 2006). Some data indicate that 
the disease develops from haematopoietic precursors that are in an early stage of maturation 
and may thus involve more than one haematopoietic line. This could explain the clinical and 
biological behaviour of the disease and prolonged neutropenia after chemotherapy. In 
addition, a large number of blasts express drug resistance glycoprotein - MDR1 and the 
incidence of unfavourable cytogenetics is high (7-, 5-). These factors, rather than age itself, 
are responsible for the unfavourable evolution of the disease. Compared to younger ages 
AML, AML in the elderly often derives from a previous haematological disease or after 
treatment for another malignancy. The morphological signs of dysplasia are frequently 
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syndrome (DS), analyzing two clinical trials (Children's Cancer Group Clinical Trials AML). 
The main issues pursued were morphology and cytogenetics. Children with AML-M0 
without DS had a lower number of leukocytes than patients with non-M0 AML and a higher 
incidence of del5, non constitutive trisomy 21 and hypoploidy. The analysis of AML in 
children without DS showed no differences between cases and non-M0 M0. Also there was 
no difference in evolution between children with DS and M0 and those with DS and non-M0 
AML (Barbaric et al., 2007). 
Four AML related syndromes are described in newborns: 
 Transient myeloproliferative disease that may be present at birth or immediately after 
in about 10% of children with DS. The syndrome is followed shortly by acute 
leukaemia, usually myeloid (less common lymphoblastic). 
 Transient leukaemia. 25% of children with DS and transient leukaemia develop AML - 
M7 in the first 4 years of life. 
 Congenital Leukaemia.  
 Neonatal leukaemia. Children who develop leukaemia during the first weeks of life are 
often pale, with insufficient increase in weight, diarrhoea and lethargy. The presence of 
cytogenetic abnormalities involving chromosome 11 has an extremely unfavourable 
prognosis.  
The last two syndromes can occur in children without DS, but 10 times less frequently than 
in those with DS. Leukocytosis, bone marrow and blood infiltration with blasts, hepato-
splenomegaly, thrombocytopenia, anaemia, purpura and skin infiltrates are common 
manifestations. Unfortunately, these children do not survive more than a few weeks or 
months. The disease can be highlighted during the prenatal period because cytogenetic 
abnormalities appear and mark the leukaemic clone. Monocytic differentiation of leukaemia 
and t(4;11) are common features. A case was even reported of transplacental transmission of 
acute monocytic leukaemia (Liesveld & Lichtman, 2006). 
2.3 Elderly AML 
AML in the elderly is a biologically distinct clinical entity. AML is generally a disease of old 
age, because the diagnosis is usually made in the decade of 60-70 years. The unfavourable 
course of the disease is due to biological characteristics at this age and various associated co-
morbidities. In the United States the elderly population is the fastest growing segment, the 
average age at diagnosis of AML being 67 years (Melchert, 2006). Some data indicate that 
the disease develops from haematopoietic precursors that are in an early stage of maturation 
and may thus involve more than one haematopoietic line. This could explain the clinical and 
biological behaviour of the disease and prolonged neutropenia after chemotherapy. In 
addition, a large number of blasts express drug resistance glycoprotein - MDR1 and the 
incidence of unfavourable cytogenetics is high (7-, 5-). These factors, rather than age itself, 
are responsible for the unfavourable evolution of the disease. Compared to younger ages 
AML, AML in the elderly often derives from a previous haematological disease or after 
treatment for another malignancy. The morphological signs of dysplasia are frequently 
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observed (Ferrara & Pinto, 2007; Hiddemann et al., 1999). Many of these patients cannot 
cope with intense chemotherapy and its complications. The acute toxicity of chemotherapy 
is greater in patients with chronic heart, lung, liver or kidney disease. For example, age-
related reduction of left ventricular ejection fraction limits the use of anthracyclines or 
mitoxantrone. Cardiotoxicity can occur at any time during mitoxantrone therapy and the 
risk increases with cumulative dose. Congestive heart failure, potentially fatal, may occur 
either during therapy with mitoxantrone or months to years after termination of therapy. 
The risk of symptomatic congestive heart failure was estimated to be 2.6% for patients 
receiving up to a cumulative dose of 140 mg/m2. Elderly patients also have reduced 
regenerative capacity of BM, even if the cytoreduction treatment was successful. Their 
inability to tolerate long periods of pancytopenia, malnutrition and toxicity of 
aminoglycosides or amphotericin are major barriers to successful treatment 
(Rathnasabapathy & Lancet, 2003). 
3. Laboratory investigations 
3.1 Complete Blood Count (CBC) 
BM infiltration by leukaemic cells is almost invariably accompanied by anaemia and 
thrombocytopenia, absolute neutrophil count being low or normal depending on the total 
number of leukocytes. 
Although CBC is a routine investigation, it has not lost its relevance in the diagnosis of 
haematological diseases and hence in AML. CBC helps to highlight the three major 
complications in AML: infections (due to neutropenia), anaemia (low value of haemoglobin, 
low red blood cells count) and bleeding (due to thrombocytopenia). 
The first clue for the diagnosis of AML is an anomalous result of the total number of 
leukocytes. Between 5-20% of patients may present with a very large number of cells (> 100 
x 109/L). Although leukocytosis is a frequent feature, AML may also present with a normal 
leukocyte count and only a low number of platelets and erythrocytes, or even leukopenia 
(aleukaemic forms of AML).  
The blast cells may be counted as lymphocytes or monocytes by the automated haematology 
analyzers and frequently not counted at all. Another important issue is that the analyzers 
cannot differentiate between myeloblasts and lymphoblasts. Eosinophilia and basophilia 
may be present in some subtypes of AML. 
CBC is used after the diagnosis to monitor disease progression and also has prognostic 
impact. It is known that the increased number of leukocytes (> 30000/microL or number of 
blasts > 15000/microL) and a very low number of platelets (< 30000/microL) are factors of 
poor prognosis in AML. 
3.1.1 Hyperleukocytosis and leukostasis 
Leukaemic cells are considerably less deformable than mature myeloid cells. With the 
increasing number of blasts in PB, leukocytosis (total leukocyte count > 10000/microL) or 
hyperleukocytosis (total leukocyte count > 100000/microL) appears and microcirculation is 
threatened by the formation of caps from these rigid cells. Local hypoxemia may be 
exacerbated by increased metabolic activity of blasts and by the production of various 
cytokines. These events lead to impaired endothelial integrity and haemorrhage occurring in 
the existing fund of hypoxia. 5% of patients with AML develop signs and symptoms due 
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hyperleukocytosis. Circulation of the central nervous system and of the lungs is the most 
susceptible to the effect of leukostasis. Cerebral haemorrhage due to vascular occlusion is 
the most aggressive manifestation.  
3.1.2 Hypoplastic leukaemia 
10% of AML patients have pancytopenia, often with no blasts in peripheral blood, without 
hepato-splenomegaly. Three quarters of these patients are men aged over 50 years. A BM 
biopsy shows a hypocellular aspect, but blasts present in a ratio of 15-90%. Hypoplastic 
leukaemia must be distinguished from aplastic anaemia and hypoplastic myelodysplastic 
syndrome. Diagnosis is made on the presence of ≥ 20% blasts in the hypocellular marrow. A 
history of toxic exposure (chemicals, alcohol or chemotherapy for another malignancy) was 
demonstrated in approximately 20% of these cases (Gladson & Naeim, 1986). 
3.1.3 Oligoblastic leukaemia 
In 10% of cases, usually in patients aged over 50 years, AML manifests with anaemia and 
thrombocytopenia, white blood cell count is low, normal or increased. The proportion of 
blasts present in peripheral blood varies from 0-19% and between 3-20% in the BM. These 
cases are classified either as oligoblastic myeloid leukaemia or myelodysplastic syndrome, 
especially refractory anaemia with blasts excess. The disease has high morbidity and 
mortality through infections and bleedings. 
3.1.4 Red blood cell count 
Anaemia is almost always present in AML, because of inadequate production of RBC in the 
BM and shortened lifespan. Anisocytosis and poikilocytosis are variously reflected in 
erythrocyte indices and Price Jones curve. A vicious chain develops when bleedings occur, 
but the BM is not able to produce new erythrocytes. The reticulocyte number is usually low. 
3.1.5 Platelet count 
The platelet count is usually low, with different degrees of thrombocytopenia. In rare cases 
the platelet number can be normal. The mechanisms of thrombocytopenia are inadequate 
production of platelets in the BM and shortened lifespan. The platelets are usually big in 
size as shown by increased medium platelet volume on CBC.  
3.2 Blood smear 
Diagnosis and classification of AML is becoming increasingly complex. Current 
classifications refer to morphological features, immunophenotype and genetics in order to 
classify the different subtypes of leukaemia. Still, a competent and rigorous microscopic 
examination remains essential for diagnosis of AML. 
Presumptive diagnosis of AML can be made by examining the peripheral smear, where 
leukaemic blasts are circulating in peripheral blood, but definitive diagnosis is made by 
examination of the aspirate or biopsy of BM. Classic May-Grunwald-Giemsa staining of 
peripheral blood and BM are used. Currently the diagnosis of AML is based on the evidence 
of 20% blasts in BM. In some cases, if the condition of patient does not allow the puncture of 
BM or biopsy and if there is evidence of 20% blasts in peripheral blood, the diagnosis can be 
made. On the other hand, we must not forget that some patients do not have blasts in their 
blood, so we could erroneously conclude it is not leukaemia. In such cases, if there is a 
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observed (Ferrara & Pinto, 2007; Hiddemann et al., 1999). Many of these patients cannot 
cope with intense chemotherapy and its complications. The acute toxicity of chemotherapy 
is greater in patients with chronic heart, lung, liver or kidney disease. For example, age-
related reduction of left ventricular ejection fraction limits the use of anthracyclines or 
mitoxantrone. Cardiotoxicity can occur at any time during mitoxantrone therapy and the 
risk increases with cumulative dose. Congestive heart failure, potentially fatal, may occur 
either during therapy with mitoxantrone or months to years after termination of therapy. 
The risk of symptomatic congestive heart failure was estimated to be 2.6% for patients 
receiving up to a cumulative dose of 140 mg/m2. Elderly patients also have reduced 
regenerative capacity of BM, even if the cytoreduction treatment was successful. Their 
inability to tolerate long periods of pancytopenia, malnutrition and toxicity of 
aminoglycosides or amphotericin are major barriers to successful treatment 
(Rathnasabapathy & Lancet, 2003). 
3. Laboratory investigations 
3.1 Complete Blood Count (CBC) 
BM infiltration by leukaemic cells is almost invariably accompanied by anaemia and 
thrombocytopenia, absolute neutrophil count being low or normal depending on the total 
number of leukocytes. 
Although CBC is a routine investigation, it has not lost its relevance in the diagnosis of 
haematological diseases and hence in AML. CBC helps to highlight the three major 
complications in AML: infections (due to neutropenia), anaemia (low value of haemoglobin, 
low red blood cells count) and bleeding (due to thrombocytopenia). 
The first clue for the diagnosis of AML is an anomalous result of the total number of 
leukocytes. Between 5-20% of patients may present with a very large number of cells (> 100 
x 109/L). Although leukocytosis is a frequent feature, AML may also present with a normal 
leukocyte count and only a low number of platelets and erythrocytes, or even leukopenia 
(aleukaemic forms of AML).  
The blast cells may be counted as lymphocytes or monocytes by the automated haematology 
analyzers and frequently not counted at all. Another important issue is that the analyzers 
cannot differentiate between myeloblasts and lymphoblasts. Eosinophilia and basophilia 
may be present in some subtypes of AML. 
CBC is used after the diagnosis to monitor disease progression and also has prognostic 
impact. It is known that the increased number of leukocytes (> 30000/microL or number of 
blasts > 15000/microL) and a very low number of platelets (< 30000/microL) are factors of 
poor prognosis in AML. 
3.1.1 Hyperleukocytosis and leukostasis 
Leukaemic cells are considerably less deformable than mature myeloid cells. With the 
increasing number of blasts in PB, leukocytosis (total leukocyte count > 10000/microL) or 
hyperleukocytosis (total leukocyte count > 100000/microL) appears and microcirculation is 
threatened by the formation of caps from these rigid cells. Local hypoxemia may be 
exacerbated by increased metabolic activity of blasts and by the production of various 
cytokines. These events lead to impaired endothelial integrity and haemorrhage occurring in 
the existing fund of hypoxia. 5% of patients with AML develop signs and symptoms due 
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hyperleukocytosis. Circulation of the central nervous system and of the lungs is the most 
susceptible to the effect of leukostasis. Cerebral haemorrhage due to vascular occlusion is 
the most aggressive manifestation.  
3.1.2 Hypoplastic leukaemia 
10% of AML patients have pancytopenia, often with no blasts in peripheral blood, without 
hepato-splenomegaly. Three quarters of these patients are men aged over 50 years. A BM 
biopsy shows a hypocellular aspect, but blasts present in a ratio of 15-90%. Hypoplastic 
leukaemia must be distinguished from aplastic anaemia and hypoplastic myelodysplastic 
syndrome. Diagnosis is made on the presence of ≥ 20% blasts in the hypocellular marrow. A 
history of toxic exposure (chemicals, alcohol or chemotherapy for another malignancy) was 
demonstrated in approximately 20% of these cases (Gladson & Naeim, 1986). 
3.1.3 Oligoblastic leukaemia 
In 10% of cases, usually in patients aged over 50 years, AML manifests with anaemia and 
thrombocytopenia, white blood cell count is low, normal or increased. The proportion of 
blasts present in peripheral blood varies from 0-19% and between 3-20% in the BM. These 
cases are classified either as oligoblastic myeloid leukaemia or myelodysplastic syndrome, 
especially refractory anaemia with blasts excess. The disease has high morbidity and 
mortality through infections and bleedings. 
3.1.4 Red blood cell count 
Anaemia is almost always present in AML, because of inadequate production of RBC in the 
BM and shortened lifespan. Anisocytosis and poikilocytosis are variously reflected in 
erythrocyte indices and Price Jones curve. A vicious chain develops when bleedings occur, 
but the BM is not able to produce new erythrocytes. The reticulocyte number is usually low. 
3.1.5 Platelet count 
The platelet count is usually low, with different degrees of thrombocytopenia. In rare cases 
the platelet number can be normal. The mechanisms of thrombocytopenia are inadequate 
production of platelets in the BM and shortened lifespan. The platelets are usually big in 
size as shown by increased medium platelet volume on CBC.  
3.2 Blood smear 
Diagnosis and classification of AML is becoming increasingly complex. Current 
classifications refer to morphological features, immunophenotype and genetics in order to 
classify the different subtypes of leukaemia. Still, a competent and rigorous microscopic 
examination remains essential for diagnosis of AML. 
Presumptive diagnosis of AML can be made by examining the peripheral smear, where 
leukaemic blasts are circulating in peripheral blood, but definitive diagnosis is made by 
examination of the aspirate or biopsy of BM. Classic May-Grunwald-Giemsa staining of 
peripheral blood and BM are used. Currently the diagnosis of AML is based on the evidence 
of 20% blasts in BM. In some cases, if the condition of patient does not allow the puncture of 
BM or biopsy and if there is evidence of 20% blasts in peripheral blood, the diagnosis can be 
made. On the other hand, we must not forget that some patients do not have blasts in their 
blood, so we could erroneously conclude it is not leukaemia. In such cases, if there is a 
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suspicion of haematologic malignancy (anaemia, thrombocytopenia) the examination of BM 
is obligatory. 
In the past 30 years the classification of AML has been done after the FAB system (French-
American-British Cooperative Group classifications of AML), based on morphological and 
cytochemical criteria and includes eight types of AML: M0-M7.  
 M0 (AML with minimal differentiation) 
 M1 (AML without maturation) 
 M2 (AML with maturation granulocyte) 
 M3 (promyelocytic) or acute promyelocytic leukaemia  
 M4 (acute myelomonocytic leukaemia) 
 M4Eo (with BM eosinophilia) 
 M5 monoblastic acute leukaemia (M5a) or acute monocytic leukaemia (M5b) 
 M6 (acute erythroid leukaemia) that includes erythroleukemia (M6a) and very rarely 
pure erythroblast leukaemia (M6b) 
 M7 (acute megakaryoblastic leukaemia) 
Blast morphology is considered of three types based on the cytoplasmic content in 
azurophilic granules: type I myeloblasts with no cytoplasmic granules, type II myeloblasts 
with less than 20 azurophilic granules and type III myeloblasts with more than 20 
azurophilic granules in their cytoplasm. Type II and III may also contain Auer rods (Naeim 
& Rao 2008). The percentage of Auer rods recognized by Wright-Giemsa (WG) staining was 
20.8%, but three times higher by peroxidase staining techniques (Jain et al., 1987). In 
peripheral blood a variable number of blasts are present and not related with the number of 
myeloblasts in the BM. Sometimes the BM is highly infiltrated, even if we have few blasts in 
the blood. Usually, blast morphology in the peripheral blood is in concordance with the BM, 
although sometimes differences may occur (differential diagnosis with acute lymphoblastic 
leukaemia, some lymphomas). So, both attentive examination of blood smear and BM are 
needed. 
Red blood cells morphology is variously affected, with large and small erythrocytes 
(anisocytosis) and different shapes especially if the leukaemia developed from a 
myelodysplastic syndrome (ovalocytes, tear drop erythrocytes). Erythroblasts and stippled 
erythrocytes may also be present.  
Thrombocytes may be giant or with granulation abnormalities (usually hypogranulated).  
Different dysplastic changes may be present if AML has undergone transformation from 
myelodysplastic syndrome: hyper/hypo granulation or hyper/hypo segmentation of 
granulocytes. 
3.3 Bone marrow examination 
Currently, the diagnosis of acute myeloid leukaemia is based on the presence of a minimum 
of 20% blasts in the BM.  
By the term blasts we understand myeloblasts, promonoblasts, monoblasts, megakarioblasts 
or promyelocytes. According to the World Health Organization (WHO) 2008, an exception 
from the 20% rule is possible, if there is evidence of AML with recurrent abnormalities: 
AML with t(8;21)(q22;q22), inv(16)(p13.1q22) or t(16;16)(p13.1;q22) and APL with 
t(15;17)(q22;q12) are considered as acute leukaemia regardless of blast count in the blood or 
BM, but in contrast to the previous edition, for AML with t(9;11)(p22;q23) or other 11q23 
abnormalities, as well as for all other subgroups (except the rare instance of some cases of 
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erythroleukemia) blasts of 20% or more of white blood cells in peripheral blood (PB) or of all 
nucleated BM cells is required for the diagnosis of AML. 
The former FAB morphologic entities are now included as acute myeloid leukaemia not 
otherwise specified: 
AML with minimal differentiation (FAB M0) 
Medium-sized blasts with no signs of differentiation, with fine nuclear chromatin and 
agranular cytoplasm. Sometimes blasts are small, resembling lymphoblasts. The BM is 
usually hypercellular and survival is poor. 
AML without maturation (FAB M1) 
In the BM we usually find above 90% myeloblasts from nonerytroid cells with few signs of 
differentiation. Blast may have azurophilic granules and/or Auer rods, but most are 
agranular blasts. Sometimes blasts look like lymphoblasts and BM is typically hypercellular. 
The literature cites cases of AML - M1 with mirror cells (although they are most commonly 
found in acute lymphoblastic leukaemia) and even with Auer rods (Casasnovas et al., 2003). 
AML with maturation (FAB M2) 
This category represents 30-45% of AML. It is also the most frequent AML in children. We 
find 20% or more myeloblasts in the blood or BM and 10% or more neutrophils in various 
stages of maturation (promyelocytes, myelocytes and metamyelocytes). Monocytes 
represent less than 20% of BM cells. Myeloblasts can be with or without azurophilic 
granules and Auer rods. Abnormal nuclear segmentation of neutrophils and increased 
number of eosinophilic precursors are frequent. The BM is usually hypercellular. In some 
cases the immature cells have abundant cytoplasm and basophilia, with a variable number 
of granules, sometimes indistinguishably, sometimes coalescent, making difficult the 
difference between M1 and M2. 
Acute promyelocytic leukaemia (FAB M3) 
In the classic form the predominant cells are abnormal promyelocytes with many primary 
granules. Auer rods are frequent and often occur in bundles. In the mycrogranular version 
(M3v), leukaemic cells have monocytic aspect with cleaved nuclei and abundant cytoplasm 
with indistinguishable granules. 
Acute myelomonocytic leukaemia (FAB M4) 
This category accounts for between 15-25% of AML. Some patients have a history of chronic 
myelomonocytic leukaemia. It is characterized by the proliferation of neutrophilic and 
monocytic precursors, 20% or more myeloblasts, monoblasts and promonocytes being 
needed in the BM nucleated cells to distinguish between chronic myelomonocytic leukaemia 
and AML, and 5 x 109/L or more blood monocytes. 
Monoblasts are large size, with round nuclei, abundant cytoplasm and prominent nucleoli, 
and sometimes have fine azurophilic granules. There is the eosinophilic variant (M4Eo), in 
which eosinophils are increased in number (>5%) and this variant is associated with 
chromosome 16 abnormalities. 
Monoblastic acute leukaemia (FAB M5a) or acute monocytic leukaemia (FAB M5b) 
This is characterized by a percentage exceeding 80% of leukaemia cells of monocytic type: 
monoblasts, promonocytes and monocytes. The two differ in the relative proportions of 
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suspicion of haematologic malignancy (anaemia, thrombocytopenia) the examination of BM 
is obligatory. 
In the past 30 years the classification of AML has been done after the FAB system (French-
American-British Cooperative Group classifications of AML), based on morphological and 
cytochemical criteria and includes eight types of AML: M0-M7.  
 M0 (AML with minimal differentiation) 
 M1 (AML without maturation) 
 M2 (AML with maturation granulocyte) 
 M3 (promyelocytic) or acute promyelocytic leukaemia  
 M4 (acute myelomonocytic leukaemia) 
 M4Eo (with BM eosinophilia) 
 M5 monoblastic acute leukaemia (M5a) or acute monocytic leukaemia (M5b) 
 M6 (acute erythroid leukaemia) that includes erythroleukemia (M6a) and very rarely 
pure erythroblast leukaemia (M6b) 
 M7 (acute megakaryoblastic leukaemia) 
Blast morphology is considered of three types based on the cytoplasmic content in 
azurophilic granules: type I myeloblasts with no cytoplasmic granules, type II myeloblasts 
with less than 20 azurophilic granules and type III myeloblasts with more than 20 
azurophilic granules in their cytoplasm. Type II and III may also contain Auer rods (Naeim 
& Rao 2008). The percentage of Auer rods recognized by Wright-Giemsa (WG) staining was 
20.8%, but three times higher by peroxidase staining techniques (Jain et al., 1987). In 
peripheral blood a variable number of blasts are present and not related with the number of 
myeloblasts in the BM. Sometimes the BM is highly infiltrated, even if we have few blasts in 
the blood. Usually, blast morphology in the peripheral blood is in concordance with the BM, 
although sometimes differences may occur (differential diagnosis with acute lymphoblastic 
leukaemia, some lymphomas). So, both attentive examination of blood smear and BM are 
needed. 
Red blood cells morphology is variously affected, with large and small erythrocytes 
(anisocytosis) and different shapes especially if the leukaemia developed from a 
myelodysplastic syndrome (ovalocytes, tear drop erythrocytes). Erythroblasts and stippled 
erythrocytes may also be present.  
Thrombocytes may be giant or with granulation abnormalities (usually hypogranulated).  
Different dysplastic changes may be present if AML has undergone transformation from 
myelodysplastic syndrome: hyper/hypo granulation or hyper/hypo segmentation of 
granulocytes. 
3.3 Bone marrow examination 
Currently, the diagnosis of acute myeloid leukaemia is based on the presence of a minimum 
of 20% blasts in the BM.  
By the term blasts we understand myeloblasts, promonoblasts, monoblasts, megakarioblasts 
or promyelocytes. According to the World Health Organization (WHO) 2008, an exception 
from the 20% rule is possible, if there is evidence of AML with recurrent abnormalities: 
AML with t(8;21)(q22;q22), inv(16)(p13.1q22) or t(16;16)(p13.1;q22) and APL with 
t(15;17)(q22;q12) are considered as acute leukaemia regardless of blast count in the blood or 
BM, but in contrast to the previous edition, for AML with t(9;11)(p22;q23) or other 11q23 
abnormalities, as well as for all other subgroups (except the rare instance of some cases of 
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erythroleukemia) blasts of 20% or more of white blood cells in peripheral blood (PB) or of all 
nucleated BM cells is required for the diagnosis of AML. 
The former FAB morphologic entities are now included as acute myeloid leukaemia not 
otherwise specified: 
AML with minimal differentiation (FAB M0) 
Medium-sized blasts with no signs of differentiation, with fine nuclear chromatin and 
agranular cytoplasm. Sometimes blasts are small, resembling lymphoblasts. The BM is 
usually hypercellular and survival is poor. 
AML without maturation (FAB M1) 
In the BM we usually find above 90% myeloblasts from nonerytroid cells with few signs of 
differentiation. Blast may have azurophilic granules and/or Auer rods, but most are 
agranular blasts. Sometimes blasts look like lymphoblasts and BM is typically hypercellular. 
The literature cites cases of AML - M1 with mirror cells (although they are most commonly 
found in acute lymphoblastic leukaemia) and even with Auer rods (Casasnovas et al., 2003). 
AML with maturation (FAB M2) 
This category represents 30-45% of AML. It is also the most frequent AML in children. We 
find 20% or more myeloblasts in the blood or BM and 10% or more neutrophils in various 
stages of maturation (promyelocytes, myelocytes and metamyelocytes). Monocytes 
represent less than 20% of BM cells. Myeloblasts can be with or without azurophilic 
granules and Auer rods. Abnormal nuclear segmentation of neutrophils and increased 
number of eosinophilic precursors are frequent. The BM is usually hypercellular. In some 
cases the immature cells have abundant cytoplasm and basophilia, with a variable number 
of granules, sometimes indistinguishably, sometimes coalescent, making difficult the 
difference between M1 and M2. 
Acute promyelocytic leukaemia (FAB M3) 
In the classic form the predominant cells are abnormal promyelocytes with many primary 
granules. Auer rods are frequent and often occur in bundles. In the mycrogranular version 
(M3v), leukaemic cells have monocytic aspect with cleaved nuclei and abundant cytoplasm 
with indistinguishable granules. 
Acute myelomonocytic leukaemia (FAB M4) 
This category accounts for between 15-25% of AML. Some patients have a history of chronic 
myelomonocytic leukaemia. It is characterized by the proliferation of neutrophilic and 
monocytic precursors, 20% or more myeloblasts, monoblasts and promonocytes being 
needed in the BM nucleated cells to distinguish between chronic myelomonocytic leukaemia 
and AML, and 5 x 109/L or more blood monocytes. 
Monoblasts are large size, with round nuclei, abundant cytoplasm and prominent nucleoli, 
and sometimes have fine azurophilic granules. There is the eosinophilic variant (M4Eo), in 
which eosinophils are increased in number (>5%) and this variant is associated with 
chromosome 16 abnormalities. 
Monoblastic acute leukaemia (FAB M5a) or acute monocytic leukaemia (FAB M5b) 
This is characterized by a percentage exceeding 80% of leukaemia cells of monocytic type: 
monoblasts, promonocytes and monocytes. The two differ in the relative proportions of 
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monoblasts and promonocytes. If most cells are monoblasts, it is M5a type (usually over 
80%), and if most cells are promonocytes, it is M5b type. 
Monoblastic acute leukaemia is characterized by large basophilic monoblasts, with 
abundant cytoplasm, with formation of pseudopods, round nuclei with one or more 
prominent nucleoli. Rarely Auer rods are observed. BM is hypercellular with an increased 
number of monoblasts. 
Monocytic acute leukaemia is characterized by the presence of promonocytes with irregular 
nuclei, with moderate basophilic cytoplasm and azurophilic granules. The erytrofagocitosis 
phenomenon can be seen. 
From a clinical point of view, M4 and M5 subtypes are accompanied with signs of 
medullary and extramedullary involvement: fever, fatigue, haemorrhage, gingival 
hyperplasia, hepato-splenomegaly, lymphadenopathy and involvement of the nervous 
system. Because the involvement of the central nervous system is frequent, the examination 
of cerebrospinal fluid is recommended, even if no clinical signs of involvement are present.  
Acute erythroid leukaemia (FAB M6)  
This includes erythroleukemia (M6a) and very rarely pure erythroblast leukaemia (M6b). 
The two types are characterized by the presence of a predominant erythroid population and 
in the case of M6a by the presence of an important myeloid component. M6 may be present 
de novo or evolve from a myelodysplastic syndrome. Occasionally, some cases of chronic 
myeloid leukaemia may develop into M6. Pancytopenia is a common feature. 
Over 50% of nucleated cells of the MO are abnormal erythroblast. Displastic changes in 
erythroblasts may be important: giant forms, multinucleated, cytoplasmic vacuolation and 
megaloblastoid change. 
Erythroleukemia (M6a) is characterized by 50% or more erythroid precursors from 
nucleated cells in the BM, 20% or more myeloblasts from non erythroid population in the 
BM, displastic erythroid precursors, with megaloblastoid nuclei and multinucleated 
erythroid cells. Dysplasia is also seen on the megakaryocytic line. Myeloblasts are of 
medium size, occasionally with Auer rods. Ringed sideroblasts can be present and the BM is 
usually hypercellular. This morphologic type represents the majority of acute erythroid 
leukaemias. Pure erythroblast leukaemia (M6b) is characterized by medium and large sized 
erythroblast with round nuclei, fine chromatin, one or more nucleoli, intense basophilic 
cytoplasm and occasionally coalescent vacuoles. 
Acute megakaryoblastic leukaemia (FAB M7) 
This represents 3-5% of AML, blast cells appertaining to the megakaryocytic line. It is 
characterized by cytopenia, displastic changes of neutrophils and platelets. 
Megakarioblasts are of medium to large size, with incised or round nuclei and with one or 
more nucleoli. Cytoplasm is basophilic, agranular with pseudopods. In some cases 
lymphoblast-like morphology (increased nuclear/cytoplasmic ratio) has been reported. We 
can frequently see in blood micromegakaryocytes circulating, fragments of megakaryocytes, 
large and displastic platelets and hypogranulated neutrophils. BM is often fibrous and BM 
puncture may be white (blinded). It presents with two peaks according to age: in children 1-
3 years old related with Down syndrome and in adults. According to 2008 WHO 
classification, myelodysplastic syndrome and AML related to Down syndrome are 
biologically identical and considered as myeloid leukaemia associated with Down 
syndrome.  
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Acute basophilic leukaemia 
This is a form of AML with primary differentiation to basophils. It is a rare, representing 1% 
of AML. It is accompanied by secondary signs of hyperhistaminemia, circulating blasts, 
organomegalia and BM failure. Morphologically it is characterized by medium-sized blasts 
with high nuclear/cytoplasmic ratio, round, oval, bilobate nucleus with one or more 
nucleoli, moderate basophilic cytoplasm containing a variable number of basophilic 
granules, red cell dysplasia and hypercellular BM. 
Acute panmyelosis with myelofibrosis  
This condition can occur at any age, de novo or after treatment with alkylating agents 
and/or radiation. There is an acute proliferation associated with fibrosis of BM. It is 
characterized by pancytopenia, marked anisocytosis, displastic change of myeloid line, 
hypercellular BM on the osteomedulary biopsy, varying degrees of hyperplasia of erythroid 
granulocytic, megakaryocytic precursors in BM, increased number of megakaryocytes with 
displastic changes and a marked increase in the number of reticulin fibres in BM. 
There are even some overlapping features with M7 subtype, the distinction is that in M7 the 
predominant population of blasts is of megakaryocytic origin and in acute panmyelosis with 
myelofibrosis it is of non-megakaryocytic origin. The prognosis is unfavourable.  
3.3.1 Particular morphological forms of acute myeloid leukaemia 
Acute myeloid leukaemia with cup-like morphology 
Various authors have attempted to characterize the morphology of AML with this special 
morphological appearance, raising questions as to whether this is a new disease entity or an 
artificial phenomenon (Barbaric et al., 2007; Benderra et al., 2005). Investigating the ’cup-
like’ morphology of 266 randomly selected patients with AML and association with 
haematological, immunological and prognostic parameters, it was found that this 
morphology was present in 21% of cases, was associated with the female sex, increased 
numbers of leukocytes and blast, normal karyotype, low expression of CD34 and HLA-DR. 
With regard to FLT3 mutations, NPM1 were found in 84.9% of cases, compared to 58.1% in 
cases without this morphology. Response to treatment and survival were not influenced in 
this study. Electronic microscopy showed that the cups contain lots of organelles. This 
particular form does not appear as a distinct category in any classification. It is sometimes 
difficult to do the differential diagnosis with acute promyelocytic leukaemia, the 
mycrogranular variant, in which neoplastic cells with prominent, bilobed nuclei can 
partially resemble blasts with cup-like nuclei. Immunophenotyping cannot identify the 
difference because both acute myeloid leukaemia with cup-like morphology and acute 
promyelocytic leukaemia are CD34- and HLA-DR-, with strong myeloperoxidase reaction. 
3.4 Biochemistry 
No specific biochemical pattern characterizes AML. Usually high activity of serum lactate 
dehydrogenase (LDH) is present. LDH is a biochemical marker reflecting tumour load and 
anaerobic glycolysis. When tissues are shifted from aerobic to the anaerobic glycolysis, LDH 
activity increases to accelerate the conversion of pyruvate to lactate, with the release of 
energy. At the molecular level, hypoxia induces expression of vascular-endothelial growth 
factor (VEGF) and fibroblasts growth factor (bFGF), and thus angiogenesis. Enhancing 
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monoblasts and promonocytes. If most cells are monoblasts, it is M5a type (usually over 
80%), and if most cells are promonocytes, it is M5b type. 
Monoblastic acute leukaemia is characterized by large basophilic monoblasts, with 
abundant cytoplasm, with formation of pseudopods, round nuclei with one or more 
prominent nucleoli. Rarely Auer rods are observed. BM is hypercellular with an increased 
number of monoblasts. 
Monocytic acute leukaemia is characterized by the presence of promonocytes with irregular 
nuclei, with moderate basophilic cytoplasm and azurophilic granules. The erytrofagocitosis 
phenomenon can be seen. 
From a clinical point of view, M4 and M5 subtypes are accompanied with signs of 
medullary and extramedullary involvement: fever, fatigue, haemorrhage, gingival 
hyperplasia, hepato-splenomegaly, lymphadenopathy and involvement of the nervous 
system. Because the involvement of the central nervous system is frequent, the examination 
of cerebrospinal fluid is recommended, even if no clinical signs of involvement are present.  
Acute erythroid leukaemia (FAB M6)  
This includes erythroleukemia (M6a) and very rarely pure erythroblast leukaemia (M6b). 
The two types are characterized by the presence of a predominant erythroid population and 
in the case of M6a by the presence of an important myeloid component. M6 may be present 
de novo or evolve from a myelodysplastic syndrome. Occasionally, some cases of chronic 
myeloid leukaemia may develop into M6. Pancytopenia is a common feature. 
Over 50% of nucleated cells of the MO are abnormal erythroblast. Displastic changes in 
erythroblasts may be important: giant forms, multinucleated, cytoplasmic vacuolation and 
megaloblastoid change. 
Erythroleukemia (M6a) is characterized by 50% or more erythroid precursors from 
nucleated cells in the BM, 20% or more myeloblasts from non erythroid population in the 
BM, displastic erythroid precursors, with megaloblastoid nuclei and multinucleated 
erythroid cells. Dysplasia is also seen on the megakaryocytic line. Myeloblasts are of 
medium size, occasionally with Auer rods. Ringed sideroblasts can be present and the BM is 
usually hypercellular. This morphologic type represents the majority of acute erythroid 
leukaemias. Pure erythroblast leukaemia (M6b) is characterized by medium and large sized 
erythroblast with round nuclei, fine chromatin, one or more nucleoli, intense basophilic 
cytoplasm and occasionally coalescent vacuoles. 
Acute megakaryoblastic leukaemia (FAB M7) 
This represents 3-5% of AML, blast cells appertaining to the megakaryocytic line. It is 
characterized by cytopenia, displastic changes of neutrophils and platelets. 
Megakarioblasts are of medium to large size, with incised or round nuclei and with one or 
more nucleoli. Cytoplasm is basophilic, agranular with pseudopods. In some cases 
lymphoblast-like morphology (increased nuclear/cytoplasmic ratio) has been reported. We 
can frequently see in blood micromegakaryocytes circulating, fragments of megakaryocytes, 
large and displastic platelets and hypogranulated neutrophils. BM is often fibrous and BM 
puncture may be white (blinded). It presents with two peaks according to age: in children 1-
3 years old related with Down syndrome and in adults. According to 2008 WHO 
classification, myelodysplastic syndrome and AML related to Down syndrome are 
biologically identical and considered as myeloid leukaemia associated with Down 
syndrome.  
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Acute basophilic leukaemia 
This is a form of AML with primary differentiation to basophils. It is a rare, representing 1% 
of AML. It is accompanied by secondary signs of hyperhistaminemia, circulating blasts, 
organomegalia and BM failure. Morphologically it is characterized by medium-sized blasts 
with high nuclear/cytoplasmic ratio, round, oval, bilobate nucleus with one or more 
nucleoli, moderate basophilic cytoplasm containing a variable number of basophilic 
granules, red cell dysplasia and hypercellular BM. 
Acute panmyelosis with myelofibrosis  
This condition can occur at any age, de novo or after treatment with alkylating agents 
and/or radiation. There is an acute proliferation associated with fibrosis of BM. It is 
characterized by pancytopenia, marked anisocytosis, displastic change of myeloid line, 
hypercellular BM on the osteomedulary biopsy, varying degrees of hyperplasia of erythroid 
granulocytic, megakaryocytic precursors in BM, increased number of megakaryocytes with 
displastic changes and a marked increase in the number of reticulin fibres in BM. 
There are even some overlapping features with M7 subtype, the distinction is that in M7 the 
predominant population of blasts is of megakaryocytic origin and in acute panmyelosis with 
myelofibrosis it is of non-megakaryocytic origin. The prognosis is unfavourable.  
3.3.1 Particular morphological forms of acute myeloid leukaemia 
Acute myeloid leukaemia with cup-like morphology 
Various authors have attempted to characterize the morphology of AML with this special 
morphological appearance, raising questions as to whether this is a new disease entity or an 
artificial phenomenon (Barbaric et al., 2007; Benderra et al., 2005). Investigating the ’cup-
like’ morphology of 266 randomly selected patients with AML and association with 
haematological, immunological and prognostic parameters, it was found that this 
morphology was present in 21% of cases, was associated with the female sex, increased 
numbers of leukocytes and blast, normal karyotype, low expression of CD34 and HLA-DR. 
With regard to FLT3 mutations, NPM1 were found in 84.9% of cases, compared to 58.1% in 
cases without this morphology. Response to treatment and survival were not influenced in 
this study. Electronic microscopy showed that the cups contain lots of organelles. This 
particular form does not appear as a distinct category in any classification. It is sometimes 
difficult to do the differential diagnosis with acute promyelocytic leukaemia, the 
mycrogranular variant, in which neoplastic cells with prominent, bilobed nuclei can 
partially resemble blasts with cup-like nuclei. Immunophenotyping cannot identify the 
difference because both acute myeloid leukaemia with cup-like morphology and acute 
promyelocytic leukaemia are CD34- and HLA-DR-, with strong myeloperoxidase reaction. 
3.4 Biochemistry 
No specific biochemical pattern characterizes AML. Usually high activity of serum lactate 
dehydrogenase (LDH) is present. LDH is a biochemical marker reflecting tumour load and 
anaerobic glycolysis. When tissues are shifted from aerobic to the anaerobic glycolysis, LDH 
activity increases to accelerate the conversion of pyruvate to lactate, with the release of 
energy. At the molecular level, hypoxia induces expression of vascular-endothelial growth 
factor (VEGF) and fibroblasts growth factor (bFGF), and thus angiogenesis. Enhancing 
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angiogenesis is a phenomenon which was observed in AML. Studies have shown that the 
activity of serum LDH and not the concentrations of two growth factors (VEGF, bFGF) may 
be used as a parameter predictor for BM angiogenesis in AML (Teng et al., 2006). Another 
value of this marker is the prediction of tumour lysis syndrome (TLS), which usually occurs 
in patients with hyperleukocytosis. Despite the prophylactic use of allopurinol, morbidity 
and mortality related to tumour lysis syndrome (TLS) still occurs in some patients with 
AML. The criteria for tumour lysis syndrome are serum creatinine level over 1.4 mg/dL 
(normal range 0.5 to 1.4 mg/dL) and an increase of at least one of the following parameters: 
potassium > 5 mEq/L (normal range 3.7 to 5.0 mEq/L.), uric acid > 7.5 mg/dL (normal 
range 3.0 to 7.0 mg/dL), phosphate > 5 mg/dL (normal range 2.4 to 4.1 mg/dL) and calcium 
< 8 mg/dL (normal range 8.4 to 10.2 mg/dL). TLS can be a life-threatening complication in 
patients during induction therapy in AML. Characteristic laboratory changes may occur 
spontaneously before initiation of induction therapy due to catabolism and to increased 
turnover of leukaemic cells, but is most commonly induced by intensive chemotherapy. Yet 
few studies have focused upon TLS in AML, so the incidence and development of TLS in 
these patients are not well defined. A study that included 772 patients with AML treated 
with allopurinol and intense hydration showed that 17% of patients developed TLS. 
Multivariate analysis showed that pretreatment levels of LDH above the normal range, 
creatinine over 1.4 mg/dl, uric acid over 7.5 mg/dl and WBC count 25x109/L, were 
independent prognostic factors for TLS (Montesinos et al., 2008). In children with AML, life-
threatening pulmonary complications were cited in combination with TLS and mimic 
systemic inflammatory response syndrome (SIRS). Severe SRSI is more common in 
association with monocytic and myelomonocytic AML (M4, M4Eo, M5), especially in M4Eo.  
A mild or moderate increase of uric acid plasma level is frequent, especially in monocytic 
and myelo-monocytic AML. 
Changes of ions concentrations (sodium, potassium, calcium, hydrogen) are mild or 
moderate and infrequent. Hypokalemia is the most frequent finding at presentation, related 
to renal tubular dysfunction, and artifactual increase of potassium is associated in vitro in 
patients with hyperleukocytosis. Hypocalcaemia can appear as a result of multiple 
mechanisms, as direct skeletal invasion by malignant cells, ectopic parathyroid hormone 
(PTH) production or bone-resorbing cytokines. Hypophosphataemia as a result of 
leukaemic cell up-take, also can occur. Hyponatremia and lactic acidosis as presenting 
features of AML are rare. Hyponatremia is proposed to be due to inappropriate production 
of antidiuretic hormone by the leukaemic cells. There has been no well defined cause for 
lactic acidosis due to leukaemia per se, but probable explanations are due to anaerobic 
glycolysis by leukaemic cells and due to increased blast count with its attendant leukostasis 
(Udayakumar et al., 2006). 
Various abnormalities of coagulation are met in AML: decrease in α2 antiplasmin, 
antithrombin III and fibrinogen. Especially in promyelocytic acute leukaemia, there is a high 
risk for disseminated intravascular coagulation, because of procoagulants released from the 
cytoplasmic granules.  
3.5 Cytochemical stains 
Cytochemical stains with full analysis of blood and careful morphological examination of 
peripheral smear and BM help to classify most cases of AML. Research into signs of 
dysplasia is important work and it is hard to quantify cell dysplasia when the line is poorly 
represented (Braham-Jmili et al., 2006). 
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Cytochemical stains that characterize each morphological subtype are the following: 
M0 (AML with minimal differentiation) 
 Myeloperoxidase staining is negative (MPO) 
 Sudan Black staining is negative (SBB) 
 Naphthol chloroacetate esterase staining is negative (<3% positive blasts) 
 Alpha naphthyl acetate and butyrate esterase staining are negative 
 Periodic acid Schiff (PAS) staining is negative 
 This subtype can only be diagnosed using flow cytometry 
M1 (AML without maturation) 
 3% or more of the blasts positive for MPO and SSB 
 PAS is usually negative 
M2 (AML with maturation granulocyte) 
 A large number of blasts are MPO positive  
 PAS is usually negative 
M3 (promyelocytic) or acute promyelocytic leukaemia 
 Blasts are MPO and chloroacetate esterase positive 
 The hypogranular variant behave similarly regarding the cytochemical stains 
M4 (acute myelomonocytic leukaemia) 
 MPO positive in at least 3% of blasts 
 Monoblasts, promonocytes and monocytes are typically nonspecific esterase (NSE) 
positive 
Monoblastic M5 acute leukaemia (M5a) or acute leukaemia monocytic (M5b) 
 Typically NSE is strongly positive 
 MPO is negative, but the MPO may occasionally be positive in M5b 
 Lysozyme is positive 
M6 (erythroid acute leukaemia) 
 Red cell precursors are PAS positive  
 Blasts are MPO, SSB negative, but may be positive for NSE 
M7 (acute megakaryoblastic leukaemia) (23) 
 Stains are negative for MPO and SSB 
 Blasts can be PAS and NSE positive 
 This subtype can only be diagnosed using flow cytometry 
Acute basophilic leukaemia (26) 
 Blasts are acid phosphatase positive 
 MPO, SBB, NSE are negative 
Acute panmyelosis with myelofibrosis 
 In some cases blasts may be MPO positive 
Granulocytic sarcoma 
 Tumour cells may express myeloid associated molecules in the biopsies, such as MPO, 
NSE or lysozyme. 
3.6 Immunophenotyping 
Flow cytometry is a technique used for counting, examining and sorting microscopic 
particles suspended in fluid. It also allows multiparametric analysis of the physical and/or 
chemical characteristics of a single cell passing through an optical and/or electronic 
detection device. Immunophenotyping is an essential technique for the diagnosis, 
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angiogenesis is a phenomenon which was observed in AML. Studies have shown that the 
activity of serum LDH and not the concentrations of two growth factors (VEGF, bFGF) may 
be used as a parameter predictor for BM angiogenesis in AML (Teng et al., 2006). Another 
value of this marker is the prediction of tumour lysis syndrome (TLS), which usually occurs 
in patients with hyperleukocytosis. Despite the prophylactic use of allopurinol, morbidity 
and mortality related to tumour lysis syndrome (TLS) still occurs in some patients with 
AML. The criteria for tumour lysis syndrome are serum creatinine level over 1.4 mg/dL 
(normal range 0.5 to 1.4 mg/dL) and an increase of at least one of the following parameters: 
potassium > 5 mEq/L (normal range 3.7 to 5.0 mEq/L.), uric acid > 7.5 mg/dL (normal 
range 3.0 to 7.0 mg/dL), phosphate > 5 mg/dL (normal range 2.4 to 4.1 mg/dL) and calcium 
< 8 mg/dL (normal range 8.4 to 10.2 mg/dL). TLS can be a life-threatening complication in 
patients during induction therapy in AML. Characteristic laboratory changes may occur 
spontaneously before initiation of induction therapy due to catabolism and to increased 
turnover of leukaemic cells, but is most commonly induced by intensive chemotherapy. Yet 
few studies have focused upon TLS in AML, so the incidence and development of TLS in 
these patients are not well defined. A study that included 772 patients with AML treated 
with allopurinol and intense hydration showed that 17% of patients developed TLS. 
Multivariate analysis showed that pretreatment levels of LDH above the normal range, 
creatinine over 1.4 mg/dl, uric acid over 7.5 mg/dl and WBC count 25x109/L, were 
independent prognostic factors for TLS (Montesinos et al., 2008). In children with AML, life-
threatening pulmonary complications were cited in combination with TLS and mimic 
systemic inflammatory response syndrome (SIRS). Severe SRSI is more common in 
association with monocytic and myelomonocytic AML (M4, M4Eo, M5), especially in M4Eo.  
A mild or moderate increase of uric acid plasma level is frequent, especially in monocytic 
and myelo-monocytic AML. 
Changes of ions concentrations (sodium, potassium, calcium, hydrogen) are mild or 
moderate and infrequent. Hypokalemia is the most frequent finding at presentation, related 
to renal tubular dysfunction, and artifactual increase of potassium is associated in vitro in 
patients with hyperleukocytosis. Hypocalcaemia can appear as a result of multiple 
mechanisms, as direct skeletal invasion by malignant cells, ectopic parathyroid hormone 
(PTH) production or bone-resorbing cytokines. Hypophosphataemia as a result of 
leukaemic cell up-take, also can occur. Hyponatremia and lactic acidosis as presenting 
features of AML are rare. Hyponatremia is proposed to be due to inappropriate production 
of antidiuretic hormone by the leukaemic cells. There has been no well defined cause for 
lactic acidosis due to leukaemia per se, but probable explanations are due to anaerobic 
glycolysis by leukaemic cells and due to increased blast count with its attendant leukostasis 
(Udayakumar et al., 2006). 
Various abnormalities of coagulation are met in AML: decrease in α2 antiplasmin, 
antithrombin III and fibrinogen. Especially in promyelocytic acute leukaemia, there is a high 
risk for disseminated intravascular coagulation, because of procoagulants released from the 
cytoplasmic granules.  
3.5 Cytochemical stains 
Cytochemical stains with full analysis of blood and careful morphological examination of 
peripheral smear and BM help to classify most cases of AML. Research into signs of 
dysplasia is important work and it is hard to quantify cell dysplasia when the line is poorly 
represented (Braham-Jmili et al., 2006). 
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Cytochemical stains that characterize each morphological subtype are the following: 
M0 (AML with minimal differentiation) 
 Myeloperoxidase staining is negative (MPO) 
 Sudan Black staining is negative (SBB) 
 Naphthol chloroacetate esterase staining is negative (<3% positive blasts) 
 Alpha naphthyl acetate and butyrate esterase staining are negative 
 Periodic acid Schiff (PAS) staining is negative 
 This subtype can only be diagnosed using flow cytometry 
M1 (AML without maturation) 
 3% or more of the blasts positive for MPO and SSB 
 PAS is usually negative 
M2 (AML with maturation granulocyte) 
 A large number of blasts are MPO positive  
 PAS is usually negative 
M3 (promyelocytic) or acute promyelocytic leukaemia 
 Blasts are MPO and chloroacetate esterase positive 
 The hypogranular variant behave similarly regarding the cytochemical stains 
M4 (acute myelomonocytic leukaemia) 
 MPO positive in at least 3% of blasts 
 Monoblasts, promonocytes and monocytes are typically nonspecific esterase (NSE) 
positive 
Monoblastic M5 acute leukaemia (M5a) or acute leukaemia monocytic (M5b) 
 Typically NSE is strongly positive 
 MPO is negative, but the MPO may occasionally be positive in M5b 
 Lysozyme is positive 
M6 (erythroid acute leukaemia) 
 Red cell precursors are PAS positive  
 Blasts are MPO, SSB negative, but may be positive for NSE 
M7 (acute megakaryoblastic leukaemia) (23) 
 Stains are negative for MPO and SSB 
 Blasts can be PAS and NSE positive 
 This subtype can only be diagnosed using flow cytometry 
Acute basophilic leukaemia (26) 
 Blasts are acid phosphatase positive 
 MPO, SBB, NSE are negative 
Acute panmyelosis with myelofibrosis 
 In some cases blasts may be MPO positive 
Granulocytic sarcoma 
 Tumour cells may express myeloid associated molecules in the biopsies, such as MPO, 
NSE or lysozyme. 
3.6 Immunophenotyping 
Flow cytometry is a technique used for counting, examining and sorting microscopic 
particles suspended in fluid. It also allows multiparametric analysis of the physical and/or 
chemical characteristics of a single cell passing through an optical and/or electronic 
detection device. Immunophenotyping is an essential technique for the diagnosis, 
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classification, staging and monitoring of leukaemia. In the last 10 years, expanding 
monoclonal antibodies (MoAb) and flurochromes allow differentiation of normal cell 
populations, of leukaemic cells, defining the state of maturation and recognition of aberrant 
phenotypes. 
Despite recommendations for standardization for multiparametric flow cytometry (Bene et 
al., 1995; Rothe & Schmitz, 1996; Stewart et al., 1997; Bain et al., 2002), the number, 
specificity and combination of reagents used for diagnosis and classification of acute 
leukaemia in different laboratories are varied. A study showed that using combinations of 
four MoAb from a minimum panel of 13 MoAb and CD45/sideward scatter gating strategy, 
achieved the correct classification in 97.2% of cases of acute leukaemia (155 patients), of 
which 79 were AML (Ratei et al., 2007).  
To monitor minimal residual disease (MRD), application of five-colour flow cytometry is 
more appropriate, enhancing sensitivity and precision of the method (Bacârea et al., 2007; 
Voskova et al., 2007). Another study also demonstrated that multiparametric flow cytometry 
in five colours is useful for the detection of leukaemia associated phenotypes in BM of 
patients with de novo AML and detection of MRD. Another study showed that the six-
colour cytometry allowed for the identification of leukaemia associated phenotypes that are 
not expressed in normal BM or postchimiotherapy and can be used successfully to monitor 
the MRD. The practical relevance of the multicolour approach is the ability to detect patients 
at high risk of relapse (Olaru et al., 2008). 
Immunophenotyping of acute leukaemia cells after density gradient separation is currently 
the gold standard, but the destruction of red blood cells after whole blood lysis and direct 
marking is a widespread and used procedure. In addition, data show that for both methods, 
the mean expression of antigens being tested was similar: CD4, CD7, CD11b, CD11c, CD13, 
CD14, CD15, CD33, CD34, CD65s, glycophorin A, HLA-DR (Schwonzen et al., 2007). For 
manual counting, blasts represent the percentage of total nucleated cells. For flow-
cytometric studies, the lysis step for removing erythrocytes, removes a variable number of 
red cell precursors. So, the obtained values determined by flow cytometry are a percentage 
of all analyzed cells or all nonerytroid cells. These differences also affect the use of flow 
cytometry to assess erythroleukemia, the erythroid/myeloid type, where the criteria require 
more than 50% red cell precursors of the total population of nucleated cells and above 20% 
myeloblasts from the nonerytroid population. Using cell separation with Ficol also leads to 
alteration of cell proportions and is strongly discouraged. On the other hand, blasts can be 
difficult to recognize on morphological examination, or are destroyed during preparation of 
blood or BM smears. So it is prudent to perform both immunophenotyping and 
morphological blast count (Craig & Foon, 2008). 
Usually, the expression of an antigen is considered positive if 20% or more blasts react with 
a specific antibody. Blast cells can be distinguished from myeloid precursors through the 
expression of immature markers CD34, CD117 and lack of maturity markers CD11b, CD15, 
CD16. Some blasts are negative for CD34 and CD117, and are difficult to distinguish from 
more mature cells. For example, it is difficult to distinguish mature monocytes from CD34 
negative monoblasts. Therefore, even if it is tempting, it is preferable not to make the 
selection of blasts according to CD34. CD117 antigen is expressed on the blasts, but also on 
mast cells. Mature myeloid cells when hypogranulated may fall below on the side scatter 
and may fall into the blasts window on CD45/side blasts scatter plot.  
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The advantages of flow cytometry are given by the possibility of quick analysis of several 
thousand cells, multiparametric analysis. It also allows the assessment of aberrant markers 
and mixed phenotypes and investigation of MRD. Disadvantages are the costs (an expensive 
device and antibodies), the panels that can change, problems of interpretation and the fact 
that the technique does not allow diagnosis of acute leukaemia, which is cytological. 
To standardize the work in specialized laboratories it is recommended an initial assessment 
of the line and then a secondary assessment. In the attempt to define the optimal number of 
markers to determine the immunophenotype in acute leukaemia with a sensitivity of 95%, 
some recommended markers for AML are: myeloperoxidase (MPO), CD33, CD13, CD14, 
CD15, CD117, CD34 (Lee et al., 2006). Other authors recommend wider panels with specific 
antibodies: CD13, CD14, CD15, CD33, CD64, CD117, CD36, MPO and antigens associated 
with haematopoietic cell maturation (CD34, CD38, TDT) and myeloid antigens (CD16, 
CD66). In addition, it is recommended to use other auxiliary markers in determining non-
specific antigens: CD7, CD19 and CD56 are very useful to monitor residual disease 
(Woźniak & Kopeć-Szlęzak, 2008). 
AML is regarded as a stem cell disease. In AML CD34 + leukaemic stem cells are recognized 
as CD38-. This CD34 + CD38- population survives chemotherapy and is most likely the 
cause of residual disease (MRD - with poor prognosis), which will then lead to relapse. 
Thus, by showing CD34 + CD38- malignant cells after chemotherapy, detection of MRD at 
stem cell level is possible (van Rhenen et al., 2007). 
Based on antigen positivity we can establish different immunological profiles: 
 Myeloblastic – CD13, CD33, CD117, CD15, HLA-DR usually positive 
 Myelomonocytic – CD11, CD13, CD33, CD14, HLA-DR usually positive 
 Erythroblastic – Glycophorin, spectrin, carbonic anhidrase I, HLA-DR usually positive 
 Promyelocytic – CD11, CD13, CD33, CD15 usually positive 
 Monocytic – CD11, CD13, CD33, CD14, HLA-DR usually positive 
 Megakaryoblastic – CD34, CD41, CD42, CD61, von Willebrand factor  
For practical reasons it is necessary that FAB classification and immunological profile 
correspond. 
M0 (AML with minimal differentiation) 
 CD 34 and HLA-DR usually positive, but CD38 is negative in most cases 
 Myeloid associated antigens often positive – CD13, CD33, CD117 
 About half of the cases express TdT and/or CD7 
 Monocytic markers are usually negative 
 Occasionally the blasts may aberrantly express CD10, CD19, CD2, CD56 
 Lack of lymphoid antigen expression: cyCD3 for T line, cyCD79 and cyCD22 for B line 
M1 (AML without maturation)  
 Myeloid associated antigens often positive – CD13, CD33 and CD117 
 CD34, HLA-DR. cyMPO are often positive 
M2 (AML with maturation granulocyte) 
 Myeloid associated antigens often positive – CD13, CD33 and CD117 
 CD34, HLA-DR, cyMPO are often positive 
 Occasionally the blasts may aberrantly express CD56, CD19 
 Monocytic markers are usually negative 
M3 (promyelocytic) or acute promyelocytic leukaemia 
 Leukaemic promyelocytes express strongly for MPO and SSB, and also for CD9, CD13, 
CD33 
 
Myeloid Leukemia – Clinical Diagnosis and Treatment 
 
142 
classification, staging and monitoring of leukaemia. In the last 10 years, expanding 
monoclonal antibodies (MoAb) and flurochromes allow differentiation of normal cell 
populations, of leukaemic cells, defining the state of maturation and recognition of aberrant 
phenotypes. 
Despite recommendations for standardization for multiparametric flow cytometry (Bene et 
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patients with de novo AML and detection of MRD. Another study showed that the six-
colour cytometry allowed for the identification of leukaemia associated phenotypes that are 
not expressed in normal BM or postchimiotherapy and can be used successfully to monitor 
the MRD. The practical relevance of the multicolour approach is the ability to detect patients 
at high risk of relapse (Olaru et al., 2008). 
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CD14, CD15, CD33, CD34, CD65s, glycophorin A, HLA-DR (Schwonzen et al., 2007). For 
manual counting, blasts represent the percentage of total nucleated cells. For flow-
cytometric studies, the lysis step for removing erythrocytes, removes a variable number of 
red cell precursors. So, the obtained values determined by flow cytometry are a percentage 
of all analyzed cells or all nonerytroid cells. These differences also affect the use of flow 
cytometry to assess erythroleukemia, the erythroid/myeloid type, where the criteria require 
more than 50% red cell precursors of the total population of nucleated cells and above 20% 
myeloblasts from the nonerytroid population. Using cell separation with Ficol also leads to 
alteration of cell proportions and is strongly discouraged. On the other hand, blasts can be 
difficult to recognize on morphological examination, or are destroyed during preparation of 
blood or BM smears. So it is prudent to perform both immunophenotyping and 
morphological blast count (Craig & Foon, 2008). 
Usually, the expression of an antigen is considered positive if 20% or more blasts react with 
a specific antibody. Blast cells can be distinguished from myeloid precursors through the 
expression of immature markers CD34, CD117 and lack of maturity markers CD11b, CD15, 
CD16. Some blasts are negative for CD34 and CD117, and are difficult to distinguish from 
more mature cells. For example, it is difficult to distinguish mature monocytes from CD34 
negative monoblasts. Therefore, even if it is tempting, it is preferable not to make the 
selection of blasts according to CD34. CD117 antigen is expressed on the blasts, but also on 
mast cells. Mature myeloid cells when hypogranulated may fall below on the side scatter 
and may fall into the blasts window on CD45/side blasts scatter plot.  
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The advantages of flow cytometry are given by the possibility of quick analysis of several 
thousand cells, multiparametric analysis. It also allows the assessment of aberrant markers 
and mixed phenotypes and investigation of MRD. Disadvantages are the costs (an expensive 
device and antibodies), the panels that can change, problems of interpretation and the fact 
that the technique does not allow diagnosis of acute leukaemia, which is cytological. 
To standardize the work in specialized laboratories it is recommended an initial assessment 
of the line and then a secondary assessment. In the attempt to define the optimal number of 
markers to determine the immunophenotype in acute leukaemia with a sensitivity of 95%, 
some recommended markers for AML are: myeloperoxidase (MPO), CD33, CD13, CD14, 
CD15, CD117, CD34 (Lee et al., 2006). Other authors recommend wider panels with specific 
antibodies: CD13, CD14, CD15, CD33, CD64, CD117, CD36, MPO and antigens associated 
with haematopoietic cell maturation (CD34, CD38, TDT) and myeloid antigens (CD16, 
CD66). In addition, it is recommended to use other auxiliary markers in determining non-
specific antigens: CD7, CD19 and CD56 are very useful to monitor residual disease 
(Woźniak & Kopeć-Szlęzak, 2008). 
AML is regarded as a stem cell disease. In AML CD34 + leukaemic stem cells are recognized 
as CD38-. This CD34 + CD38- population survives chemotherapy and is most likely the 
cause of residual disease (MRD - with poor prognosis), which will then lead to relapse. 
Thus, by showing CD34 + CD38- malignant cells after chemotherapy, detection of MRD at 
stem cell level is possible (van Rhenen et al., 2007). 
Based on antigen positivity we can establish different immunological profiles: 
 Myeloblastic – CD13, CD33, CD117, CD15, HLA-DR usually positive 
 Myelomonocytic – CD11, CD13, CD33, CD14, HLA-DR usually positive 
 Erythroblastic – Glycophorin, spectrin, carbonic anhidrase I, HLA-DR usually positive 
 Promyelocytic – CD11, CD13, CD33, CD15 usually positive 
 Monocytic – CD11, CD13, CD33, CD14, HLA-DR usually positive 
 Megakaryoblastic – CD34, CD41, CD42, CD61, von Willebrand factor  
For practical reasons it is necessary that FAB classification and immunological profile 
correspond. 
M0 (AML with minimal differentiation) 
 CD 34 and HLA-DR usually positive, but CD38 is negative in most cases 
 Myeloid associated antigens often positive – CD13, CD33, CD117 
 About half of the cases express TdT and/or CD7 
 Monocytic markers are usually negative 
 Occasionally the blasts may aberrantly express CD10, CD19, CD2, CD56 
 Lack of lymphoid antigen expression: cyCD3 for T line, cyCD79 and cyCD22 for B line 
M1 (AML without maturation)  
 Myeloid associated antigens often positive – CD13, CD33 and CD117 
 CD34, HLA-DR. cyMPO are often positive 
M2 (AML with maturation granulocyte) 
 Myeloid associated antigens often positive – CD13, CD33 and CD117 
 CD34, HLA-DR, cyMPO are often positive 
 Occasionally the blasts may aberrantly express CD56, CD19 
 Monocytic markers are usually negative 
M3 (promyelocytic) or acute promyelocytic leukaemia 
 Leukaemic promyelocytes express strongly for MPO and SSB, and also for CD9, CD13, 
CD33 
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 CD34, HLA-DR are negative 
 Sometimes it is difficult to make a differential diagnosis between acute promyelocytic 
leukaemia, the hypogranular variant and acute myeloid leukaemia with cup-like 
morphology, because it is also characterized by the immunophenotype: CD34-, HLA-
DR-. Also, CD7 is usually negative and myeloid markers are often positive (CD13, 
CD33, CD117, myeloperoxidase). 
M4 (acute myelomonocytic leukaemia) 
 Myeloid antigens CD13, CD33 are often positive 
 Partial expression of CD34, MPO, CD11c, CD36, CD64, CD117, HLA-DR 
 Aberrant expression of CD2, CD7, CD56 
 CD14 may have partial expression or sometimes may be negative 
M5 (monoblastic acute leukaemia - M5a or acute monocytic leukaemia - M5b) 
 Monocytic markers are usually positive: CD11c, CD36, CD64, CD14 
 HLA-DR is positive 
 A small proportion of blasts express CD13, CD33, CD117, MPO (weak) 
 CD34 is usually negative 
 Aberrant expression of CD56 
 High levels of CD64 expression distinguish AML subtype - M5, but low expression of 
CD64 by itself does not distinguish between subtypes of AML M4 and M5. Some 
authors consider the association of CD68 and CD11b useful to differentiate M5a and 
M5b FAB subtypes, given that CD68 and CD11b expression are much higher in M5a 
than in M5b (Pagano et al., 2005). 
 When immuphenotyping cannot be done successfully (inadequate smears, white 
puncture) immunohistochemistry can identify the monocytoid component. The 
usefulness of CD163 (scavenger for haemoglobin molecule present on 
monocytes/macrophages) is well established (Garcia et al., 2008). 
M6 (erythroid acute leukaemia) 
 Erythroid precursors are usually positive: glycophorin, CD71 
 CD34, HLA-DR are negative 
 Myeloid, monocytic markers are negative 
M7 (acute megakaryoblastic leukaemia) 
 Platelet glycoproteins are positive both on the surface and intracytoplamatic – CD41, 
CD42, CD62 
 Sometimes megakaryoblasts may express CD36, CD7 
 HLA-DR is often negative 
Acute basophilic leukaemia  
 Some myeloid markers may be positive – CD13, CD33 
 CD34, HLA-DR are usually positive  
Acute panmyelosis with myelofibrosis  
 CD34 and myeloid antigens CD13, CD33, CD117, MPO are often positive 
 A small proportion of blasts express platelets associated antigens 
Granulocytic sarcoma 
 Sarcomas are a mixture of immature and mature myeloid cells. The marker’s presence 
is based on the balance between the two. 
Phenotype in myeloid leukaemia associated with Down syndrome 
 Usually Down syndrome is associated with megakaryoblastic acute leukaemia, being 
CD41, CD42, CD62 positive. 
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Different studies have tried to correlate immunophenotype with cytogenetic profile and 
clinical manifestations, showing that karyotype abnormalities and clinical manifestations are 
closely related to abnormal antigen expression in AML (Plesa et al., 2008; Thalhammer-
Scherrer et al., 2002; Zheng et al., 2008): 
 Co-expression of CD19 was found in subtypes M0, M1 and M2. 
 The expression of CD14 is associated with subtypes M4, M4Eo, M5b, accompanied by 
poor outcome, low complete remission rate and shorter survival. 
 Expression of CD7 was found in subtypes M0, M1, M2, M4 and most frequently in M5a. 
 Expressions of CD22, CD56, TDT were correlated with the presence of abnormal 
karyotype. 
 t(8;21) was present in M2 and strongly associated with expression 
CD15/CD19/CD34/CD56. 
 In the M3, although lymphoid markers were detected in a considerable number of 
cases, they were not highlighted in any patient with t(15;17).  
 In M4, CD2 and CD34 expression was associated with abnormal karyotype. CD2 
expression was higher in the M4Eo version, but had no correlation with inv(16). Other 
studies indicate the presence of CD2 in M4Eo and M3variant. 
 In M5 there was a higher expression of CD14 and CD56. 
 The expressions of CD4, CD7, CD14, CD56, TDT were correlated with clinical features: 
increased numbers of leukocytes, platelets and patient age. 
 The few studies investigating AML-M7 confirm the high heterogeneity of this subtype. 
Cytogenetic abnormalities in adults are frequently those of secondary leukaemia and 
few of them have a history and morphology with dishematopoesis. In children, besides 
the famous Down syndrome (DS) associated M7, t(1;21) is characterized by young age 
of onset, female sex, tumour presentation and low percentage of blasts in BM, 
sometimes without megakaryoblastic marrow involvement, but always with 
dismegakaryopoesis associated with micromegakaryocytes. It appears that these 
children generally respond well to intensive chemotherapy (Duchayne et al., 2003). 
3.6.1 Flow cytometry and minimal residual disease (BMR) 
It is known that flow cytometry can be used not only for diagnosis of AML, but also to 
monitor the BMR. Two highly sensitive methods, multiparametric flow cytometry and real-
time quantitative PCR (RQ-PCR), are widely used to monitor the BMR and disease 
management. Multiparametric flow cytometry is particularly useful for investigating the 
early clearance of blasts, and blast count after consolidation therapy. Later, BMR levels 
quantified by RQ-PCR in cases of AML with fusion gene had the highest prognostic power, 
the sensitivity of RQ-PCR being between 10-4 - 10-7. Both methods are able to detect early 
disease relapse. Multiparametric flow cytometry may be used for most patients, however, to 
be successfully applied, two concepts have emerged which should be carefully weighed up: 
to include only those leukaemia associated phenotypes that are absent in normal BM, 
respectively do not consider cases with less aberrant immunophenotypes for MRD 
monitoring. In most cases the phenotype at diagnosis is the same at relapse. But, this may be 
true for only a part of the leukaemic cells and the intensity of expression and aberrantly 
expressed antigens may change (Kern et al., 2008): 
 Lymphoid antigen expression (e.g. CD33+/CD2+/CD34+, CD34+/CD13+/CD19+) 
 Antigenic overexpression  
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Different studies have tried to correlate immunophenotype with cytogenetic profile and 
clinical manifestations, showing that karyotype abnormalities and clinical manifestations are 
closely related to abnormal antigen expression in AML (Plesa et al., 2008; Thalhammer-
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increased numbers of leukocytes, platelets and patient age. 
 The few studies investigating AML-M7 confirm the high heterogeneity of this subtype. 
Cytogenetic abnormalities in adults are frequently those of secondary leukaemia and 
few of them have a history and morphology with dishematopoesis. In children, besides 
the famous Down syndrome (DS) associated M7, t(1;21) is characterized by young age 
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sometimes without megakaryoblastic marrow involvement, but always with 
dismegakaryopoesis associated with micromegakaryocytes. It appears that these 
children generally respond well to intensive chemotherapy (Duchayne et al., 2003). 
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monitor the BMR. Two highly sensitive methods, multiparametric flow cytometry and real-
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(e.g. HLA-DR++/CD33++/CD34++, CD64++/CD4++/CD45++) 
 Lack of antigens (e.g. HLA-DR-/CD33+/CD34+) 
 Asynchronous antigen expression  
(e.g. CD15+/CD33+/CD34+, CD65+/CD33+/CD34+) 
3.7 Secondary acute myeloid leukaemia 
Secondary AML is a poorly defined term that usually refers to the AML that develops after 
a history of myelodysplastic syndrome (MDS), myeloproliferative neoplasm or 
myelodysplastic/myeloproliferative neoplasm (MDS/MPN). The 2008 WHO classification 
defined the cases with a history of MDS or MDS/MPN and have evolved to AML, or cases 
that have a myelodysplasia-related cytogenetic abnormality, or at least 50% of cells in two or 
more myeloid lineages that are dysplastic as myelodysplasia-related changes. Some cases 
previously assigned to the subcategory of AML not otherwise specified as acute erythroid 
leukaemia or acute megakaryoblastic leukaemia may be reclassified as AML with 
myelodysplasia-related changes (Vardiman et al., 2009). Secondary AML may occur after 
chemotherapy with alkylating agents or topoisomerase II inhibitors, after radiation or 
exposure to environmental carcinogens. The 2008 WHO classification classifies cases after 
use of alkylating agents or topoisomerase II inhibitors as therapy-related myeloid 
neoplasms. The question is whether secondary AML itself is associated with poor prognosis 
or whether this is due to association with some morphological and biological characteristics. 
Dysplasia in de novo AML is related to unfavourable prognosis, but has no prognostic 
relevance under intensive therapy. Since there is no correlation between cytogenetic risk 
subgroups and dysplasia, cytogenetics continues to have proven impact in both de novo 
AML and secondary AML. Cytogenetic abnormalities spectrum in secondary AML is similar 
to de novo AML, but the frequency of unfavourable cytogenetic abnormalities associated 
with high risk and intermediate risk (complex karyotype, trisomy 8, monosomy 7 and 
others) is higher in secondary AML. Survival of patients with therapy-induced AML is 
shorter than those with de novo AML within the same cytogenetic risk group. Genetic and 
molecular differences that determine the phenotype and prognosis of secondary AML still 
require several additional studies (Larson, 2007). 
3.8 Acute leukaemias of ambiguous lineage 
According to WHO 2008, the classification encompasses the following entities: 
 Acute undifferentiated leukaemia 
 Mixed phenotype acute leukaemia with t(9;22)(q34;q11.2); BCR-ABL1 
 Mixed phenotype acute leukaemia with t(v;11q23); MLL rearranged 
 Mixed phenotype acute leukaemia, B-myeloid, NOS 
 Mixed phenotype acute leukaemia, T-myeloid, NOS 
 Provisional entity: natural killer (NK) cell lymphoblastic leukaemia/lymphoma: 
This is a rare subtype of acute leukaemia, which is much debated. Although the nature of 
NK cells is questionable, is a variant of leukaemia with distinct morphological features and 
immunophenotype (blasts express CD56, CD2, CD7 and are negative for B or myeloid 
antigens). The cases previously classified as ‘blastic natural killer cell leukaemia/lymphoma’ 
are now ‘myeloid related blastic plasmacytoid dendritic neoplasm’ (Vardiman et al., 2009). 
The requirements for assigning more than one lineage to a single blast population in mixed 
phenotype acute leukaemia (MPAL) are presented in Table 2. 
 






Myeloperoxidase (flow cytometry, immunohistochemistry or 
cytochemistry) or monocytic differentiation (at least two of the 
following: nonspecific esterase, CD11c, CD14, CD64, lysozyme) 
For T lineage Cytoplasmic CD3 (flow cytometry with antibodies to CD3 epsilon 
chain; immunohistochemistry using polyclonal anti-CD3 antibody 
may detect CD3 zeta chain which is not T cell–specific) or surface 
CD3 (rare in mixed phenotype acute leukaemia) 
For B lineage 
(multiple antigens 
required) 
Strong CD19 with at least one of the following strongly expressed: 
CD79a, cytoplasmic CD22, CD10 or weak CD19 with at least two of 
the following strongly expressed: CD79a, cytoplasmic CD22, CD10 
Table 2. The requirements for assigning more than one lineage to a single blast population in 
mixed phenotype acute leukaemia (MPAL). 
The former European Group of Immunological Markers for Leukaemia (EGIL) scoring 
system to evaluate biphenotypic acute leukaemia (BAL) had limitations because of over-
diagnosis of BAL, plus it ignored the cytogenetic data. Because of this, well defined genetic 
abnormalities could be classified as BAL. The new classification includes cytogenetics in the 
evaluation of MPAL. A lot of studies showed that when applying the 2008 WHO 
classification the number of MPAL decreased (BAL became ALL with aberrant myeloid 
markers or AML with aberrant lymphoid markers). The pitfall still remains the over-
diagnosis of MPAL, because of misinterpretation of immunological studies (e.g. 
immunophenotyping for MPO). Regarding MPO, it is preferable, if possible, to have both 
immunophenotyping and cytochemistry to consider it positive. Care must be taken, for 
example, not to consider as MPAL the patients with t(9;22) in blast crisis with former 
chronic myeloid leukaemia (CML). Cases of BCR-ABL1 positive and MLL positive acute 
leukaemias may meet the criteria for MPAL (Vardiman et al., 2009). 
3.9 Cytogenetics 
Compared with the 2001 WHO classification, the number of recognized recurrent genetic 
abnormalities has grown. The current 2008 WHO classification recognizes the importance of 
recurrent genetic abnormalities, which are crucial for correct diagnosis and treatment of AML: 
 AML with t(8;21)(q22;q22); RUNX1-RUNX1T1 
 AML with inv(16)(p13.1q22) or t(16;16)(p13.1;q22); CBFB-MYH11 
 APL with t(15;17)(q22;q12); PML-RARA 
 AML with t(9;11)(p22;q23); MLLT3-MLL 
 AML with t(6;9)(p23;q34); DEK-NUP214 
 AML with inv(3)(q21q26.2) or t(3;3)(q21;q26.2); RPN1-EVI1 
 AML (megakaryoblastic) with t(1;22)(p13;q13); RBM15-MKL1 
 Provisional entity: AML with mutated NPM1 
 Provisional entity: AML with mutated CEBPA  
The detection of recurrent genetic abnormalities requires cytogenetics - karyotyping, 
fluorescence in situ hybridization (FISH) and molecular analysis - reverse transcriptase 
polymerase chain reaction (RT-PCR). 
The new classification is helpful for clinicians because data can provide more prognostic 
significance. Cytogenetics currently provides the most important prognostic information 
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both at diagnosis and at relapse. Given the progress made in recent years on understanding 
disease pathogenesis, given the profile of the genes, new therapeutic targets will develop, 
with the hope that this new agents potentially will improve the disease (Avivi & Rowe, 
2005). Cytogenetic abnormalities have a frequency of 85% in de novo AML and 95-100% in 
secondary AML, consistent abnormalities being classified as specific (constant) and 
nonspecific (random). They can be balanced (translocations or chromosomal 
rearrangements) and unbalanced (chromosome loss or acquisitions). The specific, balanced 
abnormalities are present with a higher frequency in a given morphological FAB subtype. 
There are evidences for more than 80 balanced chromosomal rearrangements: [t(8:21) in 
AML2, inv16 in AML4 eosinophilic variant, t(9:11) in AML5, t(11:19) in AML4]. Constant 
unbalanced abnormalities (-7, -5) appear in all morphological subtypes. Some of these 
abnormalities are good prognostic factors [t(8; 21) (Q22, Q22 - fusion AML1-ETO), t(15; 17) 
(Q22, Q12 ~ 21 - fusion PML-RARA), inv (16 )(p13q22) / t (16; 16) (p13; Q22 - CBFB-MYH11 
fusion)], and others poor prognostic factors (5 -, 7 -, 5q-, 7q-, trisomy 8, trisomy 11, t (6, 9) or 
combinations). AML with t(8;21)(q22;q22); RUNX1-RUNX1T1 is a common leukaemia 
usually associated with AML with maturation morphology and sometimes with 
myelomonocytic morphology. Auer rods are frequent. Eosinophilia and basophilia are 
common features. Displastic changes and association with myeloid sarcomas may also been 
seen. AML with inv(16)(p13.1q22) or t(16;16)(p13.1;q22); CBFB-MYH11 may be associated 
with other cytogenetic abnormalities like trisomy 21, 8, loss or deletion of Y chromosome. It 
is associated with BM eosinophilia and lymphadenopathy. APL is one variant of AML 
associated with t(15;17). It is the retinoic acid receptor α gene (RARα) that is affected. In 
acute promyelocytic leukaemia, the variant RARA translocations with other partner genes 
should be considered separately, because of different features and different responses to 
treatment. Generating chimerical fusion proteins from chromosomal translocations results 
in blocking cell differentiation and contributes to the biological characteristics of different 
subtypes of leukaemia, representing the primary event in the pathogenesis of AML. In 
recent years it has become clear that other mutations have a role in pathogenesis: 
 Mutations of genes encoding transcription factors involved in haematopoiesis (often in 
AML1-M0, CEPBA - common in M1, M2) 
 Mutations of genes that encode components of the signal translation pathways, 
mutations in the tyrosine kinase receptor (FLT3 gene - confers proliferative advantage) 
 Mutations in genes that encode nucleophosmin (NPM1 - nucleocytoplasmatic protein 
involved in regulating gene expression - 35% of cases of AML) (Dohner et al., 2005; 
Falini et al., 2005; Schnittger et al., 2005) 
Extensive studies have proposed a system of risk stratification based on cytogenetics in 
AML patients who fall into three risk categories: favourable, intermediate and poor. The 
information obtained from diagnosis is used to further stratify therapy. For patients with 
abnormal karyotype before treatment, cytogenetic analysis has been recommended to 
document complete remission (CR), based on data showing that the persistence of even a 
single metaphase with an abnormality present at diagnosis leads to significantly higher 
incidence of relapse (Cheson et al., 2003). Because multilineage dysplasia is not associated 
with independent prognostic significance when cytogenetics is taken into account, the 2008 
WHO classification named this group ‘AML with myelodysplasia-related changes’. The 
cytogenetic abnormalities sufficient for diagnosis of AML with myelodysplasia-related 
changes when 20% or more PB or BM blasts are present are shown in Table 3: 
 




Complex karyotype  
Unbalanced abnormalities  Balanced abnormalities  
-7 or del(7q)  
-5 or  
i(17q) or t(17p)  
-13 or del(13q)  
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Table 3. Cytogenetic abnormalities sufficient for diagnosis of AML with myelodysplasia-
related changes 
Even if we have patients with therapy-related AML or with myelodysplasia-related 
changes, it is better to classify them according to their cytogenetic abnormalities. Still, 
because the outcome in patients with therapy related AML is worse than in those with de 
novo AML, it is important to correctly classify the therapy related AML, because it could 
bring important pathogenetic information and as it well known that not all patients taking 
such treatment develop AML (Vardiman at al., 2009). 
As is known, patients with AML with normal karyotype are the largest group and are 
classified as intermediate risk. They should be analyzed for FLT3, NPM1 and CEBPA 
mutations, and, if present, the abnormality should be noted in the diagnosis. FLT3 gene 
encodes a member of the class III receptor tyrosine - kinase, which is expressed on the 
surface of haematopoietic progenitors from BM, with a role in the survival and 
differentiation of pluripotent stem cells. FLT3 - ITD encodes a protein that causes abnormal 
activation and stimulates autophosphorylation of the receptor, activating the pathway 
below. Results of studies show the FLT3-ITD as a strongly independent negative prognostic 
factor influencing remission duration and survival in the group with normal karyotype, 
located in the intermediate cytogenetic risk group. Mutation is found in 28-33% of cases. 
Additional mutations that occur in the signal transduction molecules (receptor tyrosine 
kinase - c-kit and FLT3, NRAS and KRAS) are required to generate the disease. FLT3 is 
overexpressed in most cases of AML and is mutated in approximately 35% of cases of AML. 
These mutations lead to activation of FLT3 with activation of anti–apoptotic pathways. In 
addition, it activates MAPK (mitogen activated protein kinase), AKT and Stat5 (signalling 
molecules) leading to activation of Pim-1 (proto-oncogene which encodes a cytoplasmic 
serine - threonine kinase) and overexpression of Bcl-XL (protein inhibiting cell death and 
inhibiting caspase activation, thereby inhibiting apoptosis). Simultaneous blockage of both 
caspase pathways predict poor response to chemotherapy and is prognostic for decreased 
overall patient survival (Schimmer et al., 2003).  
Nucleophosmin mutations have been reported in 46-62% of cases of AML with normal 
karyotype, as the most frequent gene alteration in this group of AML cytogenetics. NPM1 
mutations have been associated with pre-treatment characteristics such as female sex, higher 
percentage of blasts in MO, elevated levels of lactate dehydrogenase (LDH), increased 
number of leukocytes, platelets and low or absent expression of CD34 marker. 
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Approximately 40% of patients with NPM1 mutations also harbour FLT3-ITDs, which 
together with the tyrosine kinase domain mutations (FLT3-TKD), are twice as common in 
NPM1 positive patients as those with wild-type NPM1. CEBPA mutations occur with 
similar frequency in patients with and without NPM1 mutations. Many studies have shown 
that NPM1 mutation is associated with clinical outcome. Cytoplasmic localization of 
nucleophosmin is a favourable prognostic factor for achieving CR (Schnittger et al., 2005). 
CEBPA mutations (enhancer binding protein - the gene encodes a myeloid transcription 
factor and plays an important role in normal granulopoesis) were detected in 15-20% of 
cases of AML with normal karyotype. These cases, compared to wild-type mutation, have a 
higher percentage of blasts in peripheral blood and decreased numbers of platelets, but 
lymph and extramedullary involvement is much rarer and less likely to carry FLT3-ITD, 
FLT3-TKD and MLL-PTD. Regarding MLL, although the t(9;11)(p22;q23) is clearly named in 
the classification, it is recommended that variant MLL translocation also be specified in the 
diagnosis, for example, AML with t(11;19)(q23;p13.3); MLL-ENL. MLL-PTD should not be 
classified in this category (Gaidzik & Döhner, 2008; Marcucci et al., 2008; Mrózek et al., 2007; 
Vardiman et al., 2009). Cytogenetically normal AML with CEBPA mutations is associated 
with favourable prognosis. Some recent studies suggest that there is a heterogeneity among 
mutated CEBPA AML and just the cases with double, biallelic mutations have a favourable 
outcome (Barjesteh van Waalwijk van Doorn-Khosrovani et al., 2003; Fröhling et al., 2004; 
Preudhomme et al., 2002; Schlenk et al., 2008). The question of whether the presence of a 
FLT3-ITD has an impact on prognosis in patients with CEBPA mutations remains open 
(Renneville et al., 2009; Schlenk et al., 2008). 
Down related AML harbour the same molecular abnormality – GATA1 mutation and also 
other features (clinical, morphological and immunophenotypical) and this was the reason 
for their separation in the myeloid proliferations related with the Down syndrome category. 
4. Differential diagnosis 
Regarding the distinction between subtypes of AML, the most important and with 
consequences for treatment is that between APL and other AML subtypes. APL, especially the 
hypogranular variant, may look like AML with monocytic differentiation. Leukaemic 
promonocytes often have Auer rods and are MPO strongly positive. The immunophenotype is 
different, leukaemic promonocytes being negative for CD34, HLA-DR and monocytic markers. 
AML with multilineage dysplasia must be distinguished from refractory anaemia with 
blasts excess (RAEB). The presence of 20% blasts in peripheral blood or BM makes the 
difference. In order to have the diagnosis of AML with multilineage dysplasia, patients must 
have 20% or more blasts in the PB or BM and evolve from previously MDS or MDS/MPN, 
specific myelodysplasia-related cytogenetic abnormalities (see Table 3), or present dysplasia 
in 50% or more of the cells in two or more myeloid lineages. 
The differential diagnosis of acute megakaryoblastic leukaemia includes AML without 
differentiation, idiopathic myelofibrosis, acute panmyelosis with myelofibrosis and 
metastases of BM. The presence of Down syndrome, megakarioblasts in peripheral blood, 
the positivity of CD41, CD42 and CD61 pleads for the diagnosis of acute megakarioblastic 
leukaemia. In acute panmyelosis with myelofibrosis, the blasts are of non megakaryocytic 
origin. Care must be taken in patients with hypoplastic and oligoblastic leukaemia when 
examining specimens of BM, where the diagnosis is made on the presence of ≥ 20% blasts in 
the hypocellular marrow. 
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The difference between AML and ALL is easy to assess using immunophenotyping. 
Chronic myeloid leukaemia (CML) in myeloid blast crisis can mimic AML, but the presence 
of the Philadelphia chromosome, splenomegaly and myeloid cells at all levels of 
differentiation distinguish CML from AML. Acute basophilic leukaemia is another entity to 
consider, knowing the characteristic basophilia. Care must be provided for example not to 
consider as MPAL the patients with t(9;22) in blast crisis with former CML. The 2008 WHO 
classification shows that there is the atypical CML category, that is BCR-ABL1–negative, and 
it is not a variant of CML, BCR-ABL1–positive. On the other hand, cases of BCR-ABL1–
positive AML have been reported, but because it is difficult to distinguish it from CML in 
blastic crisis, the 2008 classification does not recognize it (Vardiman et al., 2009). 
Leukaemoid reactions and nonleukaemic pancytopenia can be differentiated from AML 
because the blasts are missing in blood or BM. Sometimes in infections, such as tuberculosis, 
the proportion of blasts in the marrow may increase, but it does not reach the proportion of 
blasts required for a diagnosis of AML.  
Pseudoleukaemia is a condition usually met after administration of granulocyte colony 
stimulating factor. Attentive observation of patients clarifies the problem, because in a short 
time the morphological appearance of BM will normalize. In the beginning it is manifested 
with severe leukopenia and usually normal thrombocytes. 
Agranulocytosis is an acute condition involving severe leukopenia most commonly 
neutropenia in the circulating blood. The concentration of granulocytes falls below 100 
cells/mm³ of blood. When infection and bleeding are present the diagnosis is more 
complicated. With examination of BM, a history of drug use helps in giving the correct 
diagnosis. 
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1. Introduction 
The last four decades have witnessed major transformations in the approach to the 
diagnostic work-up and therapeutics in the field of hematology. The identification of the 
Philadelphia chromosome in Chronic Myelogenous Leukemia has served as a prototype for 
diagnosis and subsequent monitoring of response. This discovery has led to the 
understanding of the pathogenesis and subsequent developments in therapeutic targeting 
the pathways. These principles have helped evolve therapeutic strategies aimed at 
molecular pathways in several disorders. Acute leukemias were classified based on 
morphology and cytochemistry supplemented by immunophenotyping, as proposed by the 
French–American–British (FAB) group. Following advances and greater access to 
immunophenotyping techniques and simultaneous refinements in cytogenetic methods, the 
MIC groups proposed the classification of acute leukemias incorporating morphology, 
immunologic typing and cytogenetic analysis. MIC–M classification granted recognition to 
molecular genetic information by formally incorporating it into the classification (Bain BJ, 
1998).  
In 2001, the World Health Organization (WHO), in collaboration with the Society for 
Hematopathology and the European Association of Haematopathology, published a 
Classification of Tumors of the Hematopoietic and Lymphoid Tissues as part of its 3rd 
edition of the series, WHO Classification of Tumors (Jaffe ES et al, 2001). This 
classification system was a worldwide consensus classification system for hematological 
malignancies. It stratified neoplasms according to the lineage. Within each category 
distinct entities are defined based on morphology, immunophenotype, genetic features 
and clinical syndromes. The classification reflected a paradigm shift from previous 
schemes as for the first time, genetic information was incorporated. A revised 
classification was published in 2008 as the 4th edition of the WHO monograph series 
(Swerdlow SH et al, 2008). The revision incorporates new scientific and clinical 
information. Refined diagnostic criteria for previously described neoplasms and newly 
recognized distinct entities have been defined. The new classification defines 108 new 
diagnostic entities in hematopathology, including 50 new or provisional leukemia entries 
and also recognizes provisional entities that have a definite prognostic significance (Arber 
DA, 2010; Betz BL & Hess JL, 2010; Swerdlow SH et al, 2008).  
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2. WHO 2008 recommendations for work-up of AML 
WHO 2008 is one of the most scientifically devised systems to diagnose, prognosticate and also 
accordingly treat the haematological malignancies. The objectives are to work-up a case to 
obtain the information on all variables, which affect the outcome. However, for much of the 
world population where funding options are restricted, stringent diagnostic algorithms are a 
major deterrent in the management of acute leukemias. Resources are spread between 
diagnostic and therapeutic needs. We present here a workable and practical approach to 
address the need for important diagnostic parameters in AML with the focus on identifying 
potentially curable ones in the resource-constrained areas. 
3. Diagnostic work-up 
There is no single “gold standard” protocol for the diagnosis and classification as per the 
WHO 2008 system which broadly categorises AML as follows -  
a. AML with recurrent genetic abnormalities 
b. AML with myelodysplasia-related changes 
c. Therapy related myeloid neoplasms 
d. AML (not otherwise categorized) 
e. Myeloid sarcoma 
f. Myeloid proliferations related to Down syndrome 
g. Blastic plasmacytoid dendritic cell neoplasm (BPDC) 
The categories A, B, C, and F require genetic studies and/or clinical history to classify. 
Morphology is always essential and sometimes it is diagnostic. Common ancillary studies 
relevant to bone marrow diagnosis are: cytogenetics, FISH studies, molecular studies 
(typically PCR or RT-PCR) for antigen receptor gene rearrangements and/or to detect 
specific translocations, immunophenotyping and immunohistochemistry. These tests will 
confirm the diagnosis of AML, subcategorize them, add to prognostication and more 
importantly differentiate from the related malignancies. The latter include acute leukemias 
of ambiguous lineage – acute undifferentiated leukemia (AUL) and mixed phenotypic acute 
leukemia (MPAL); non-Hodgkin lymphomas, round cell tumors and other metastases. Such 
information derived at the time of diagnosis is at the discretion of the treating physician and 
the pathologist subject to availability of expertise and affordability of the patient. 
3.1 Morphology 
The starting point for diagnosis of leukemia is morphologic examination of bone marrow or 
blood to document the presence of at least 20% blasts. Rarely the diagnosis is based on 
trephine biopsy or tissue biopsy. 
3.1.1 Peripheral blood and bone marrow aspirate 
The blasts were earlier categorized as type I and II based on criteria proposed by the FAB 
group (Bain BJ, 2003; Mufti GJ et al, 2008). Type I blasts lack granules and have 
uncondensed chromatin, a high nucleocytoplasmic (N:C) ratio and usually prominent 
nucleoli (Figure 1a). Type II blasts resemble type I blasts except for the presence of a few 
azurophilic granules and a slightly lower N:C ratio (Figure 1b). Goasguen et al defined type 
III blasts, which had more than 20 azurophilic granules, otherwise with typical blast 
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morphology (Goasguen JE et al, 1991; Mufti GJ et al, 2008). The WHO 2001 classification 
lacked specific definition of blasts. However, in the WHO 2008 classification, the blasts are  
 
   
1(a)    1(b) 
   
1(c)    1(d) 
   
1(e)    1(f) 
   
1(g)    1(h) 
Fig. 1. Different types of blasts in AML (1000x; Giemsa) 
(a) Type 1 Blasts with scant agranular cytoplasm (b)Type 2 blasts showing moderate 
granular cytoplasm (c) Type 2 blasts with perinuclear hof, characteristic of t(8;21) , a single 
blast shows Auer rod [arrow] (d) Abnormal promyelocytes with hypergranular cytoplasm 
and convoluted nucleus (e) Abnormal promyelocytes of Microgranular variant type of APL 
(f) Monoblasts with abundant blue-grey cytoplasm (g) Promonocytes with convoluted 
nuclei (h) Megakaryoblasts with characteristic cytoplasmic blebs 
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morphology (Goasguen JE et al, 1991; Mufti GJ et al, 2008). The WHO 2001 classification 
lacked specific definition of blasts. However, in the WHO 2008 classification, the blasts are  
 
   
1(a)    1(b) 
   
1(c)    1(d) 
   
1(e)    1(f) 
   
1(g)    1(h) 
Fig. 1. Different types of blasts in AML (1000x; Giemsa) 
(a) Type 1 Blasts with scant agranular cytoplasm (b)Type 2 blasts showing moderate 
granular cytoplasm (c) Type 2 blasts with perinuclear hof, characteristic of t(8;21) , a single 
blast shows Auer rod [arrow] (d) Abnormal promyelocytes with hypergranular cytoplasm 
and convoluted nucleus (e) Abnormal promyelocytes of Microgranular variant type of APL 
(f) Monoblasts with abundant blue-grey cytoplasm (g) Promonocytes with convoluted 
nuclei (h) Megakaryoblasts with characteristic cytoplasmic blebs 
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defined according to the criteria proposed by the International Working Group on 
Morphology of Myelodysplastic Syndrome (Mufti GJ et al, 2008; Swerdlow SH et al, 2008; 
Vardiman JW et al, 2009). 
Myeloblasts were defined as the cells with high N:C ratio, easily visible nucleoli and usually 
fine nuclear chromatin, however, with a variable nuclear shape. Cytoplasmic features are 
variable in terms of basophilia, granules and Auer rods. Golgi zones are not detected except 
in cases of AML with t(8;21), where these are prominent and seen as perinuclear clearing or 
hofs (Figure 1c). The agranular blasts corresponded to FAB type I blasts and the granular 
blasts included both type II blasts of FAB and type III blasts of Goasguen JE et al (Mufti GJ 
et al, 2008; Goasguen JE et al 1991; Swerdlow SH et al, 2008). The promyelocytes of acute 
promyelocytic leukemia (APL) with PML-RARA are the blast equivalents and these are 
morphologically of two types – the classical or hypergranular and the microgranular or 
hypogranular types (Vardiman JW et al, 2002). The hypergranular promyelocytes are 
characterized by kidney-shaped or bilobed nuclei, although the shape may greatly vary 
(Liso V & Bennett J, 2003; Sainty D et al, 2000). The cytoplasm is marked by densely-packed 
granules, sometimes may obscure nuclear margins, and variable presence of Auer rods 
(Figure 1d). Some cells may be characterized by bundles of Auer rods (faggot cells). The 
promyelocytes of microgranular variant have bilobed, multilobed, or reniform nucleus and 
under usual staining are devoid of granules or contain fine azurophilic granules (Figure 1e) 
(Golomb HM et al, 1980; Sainty D et al, 2000). There are few cases of variant RARA 
translocations; of these those associated with ZBTB16 fusion partner at 11q23 have a 
characteristic morphology. These cells have regular nuclei, many granules, usual absence of 
Auer rods, and an increased number of Pelgeroid neutrophils (Corey SJ et al, 1994; Melnick 
A & Licht JD, 1999; Sainty D et al, 2000) . Monoblasts are large cells with abundant 
cytoplasm, which is light grey to deeply blue and may show pseudopod formation (Figure 
1f). The nuclei are round to oval with delicate lacy chromatin and prominent nucleoli. 
Promonocytes are counted as monoblast equivalents (Vardiman JW et al, 2002). These cells 
have a delicate convoluted, folded or grooved nucleus with finely dispersed chromatin, a 
small indistinct or absent nucleolus, and finely granulated cytoplasm (Figure 1g). 
Distinction of promonocytes from abnormal monocytes is essential but very difficult on 
morphological basis as the diagnosis of acute monocytic or acute myelomonocytic leukemia 
versus chronic myelomonocytic leukemia depends on this distinction; therefore, flow 
cytometry and other methods are needed to improve specificity. The abnormal monocytes 
are characterized by more clumped chromatin, variably indented, folded nuclei and grey 
cytoplasm with more abundant lilac colored granules.  
Megakaryoblasts are usually medium to large in size with a round, indented or irregular 
nucleus with finely reticular chromatin and one to three nucleoli. Cytoplasm is basophilic, 
agranular, and may show cytoplasmic blebs (Figure 1h) (Bennett JM, 1985). Small dysplastic 
megakaryocytes and micromegakaryocytes, seen in various myeloid neoplasms, are not 
blasts. Erythroid precursors (erythroblasts) are not counted as blasts, except in cases of pure 
erythroleukemia (a variant of AML-M6), where these are considered as blast equivalents. 
The cells are basically proerythroblasts, which are medium to large-sized, with round 
nuclei, fine chromatin and one or more nucleoli. The cytoplasm is deeply basophilic, 
agranular and frequently contains poorly demarcated vacuoles (Swerdlow SH et al, 2008). 
Acute leukemias with FLT3 mutations have characteristic blasts with nuclear invaginations 
spanning more than 25% of the nuclear diameter or a prominent ‘‘fishmouth’’ nucleus (Chen 
W et al, 2006; Kussick SJ et al, 2004; McCormick et al 2010).  
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2(a)    2(b) 
Fig. 2. AML with myelodysplasia related changes (Giemsa stain,1000x) (a) Erythropoiesis is 
megaloblastoid with multinucleate erythroblasts and blasts in the background (b) 
Dyspoietic dwarf megakaryocytes with megaloblastoid erythropoiesis. 
The blasts are expressed as the percentage of nucleated cells and the count is typically 
based on a 200-cell count in peripheral blood and 500-cell count in the bone marrow. If 
there are more than 50% erythroid precursors, the erythroid progenitors are also excluded 
from the blast count. This is quite important in the diagnosis of acute erythroleukemia, 
where the erythroid precursors are > 50% of the total nucleated cells and the myeloblasts 
are > 20% of the non-erythroid marrow nucleated cells (Swerdlow SH et al, 2008). Pure 
erythroid leukemia consists of precursors committed exclusively to erythroid lineage, 
which are > 80% of marrow nucleated cells without evidence of a significant myeloblast 
component. In rare cases, the diagnosis of acute leukemia can be made with low marrow 
blast count (< 20%) when associated with recurring genetic abnormalities as 
t(8;21)(q22;q22), inv(16)(p13.1q22), or t(16;16)(p13.1;q22) or t(15;17)(q22;q12) (Vardiman 
JW et al, 2002). These entities not only define unique disease with characteristic 
morphology, clinical features and biology but also have a significant prognostic 
implications. In AML with t(8;21), many neoplastic cells have abundant granules that may 
be mistaken as promyelocytes. 
Relevance of non-blast myeloid precursors: The evaluation of other precursors may give 
important information. The presence of immature eosinophilic granules in the promyelocyte 
and myelocyte stages is an important diagnostic feature of cases of AML with 
inv(16)(p13.1q22), or t(16;16)(p13.1;q22). These granules are often larger than those normally 
present in immature eosinophils, purple-violet in color, and in some cases are so dense that 
they obscure the cell morphology. It is important to assess the degree of dysplasia in the 
different lineages. Dysplasia in at least 50% of the cells in 2 or more hematopoietic lineages 
is essential for the morphological diagnosis of AML with myelodysplasia related changes, 
which has adverse prognostic implications (Figures 2a and 2b) (Arber DA et al, 2003; 
Vardiman JW et al, 2009; Weinberg OK et al, 2009; Yanada M et al, 2005). The dysplastic 
features are also seen in cases of therapy-related myeloid neoplasms, AML with 
t(6;9)(p23;q34), and AML with inv(3)(q21q26.2) or t(3;3)(q21;q26.2) (Swerdlow SH et al, 
2008).  
Bone Marrow Biopsy 
It is done when the aspirate is a dry tap to evaluate for the presence of blasts (Figure 3a), 
especially in AML-M7 and in situations where there are significant stromal changes (Figure 
3b) (Bennett JM, & Orazi A, 2009; Lorand-Metze I et al, 1991).  
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3(a)    3(b) 
Fig. 3. Bone marrow biopsy in AML: (a) Paratrabecular collection of blasts with large 
vesicular nucleus (H&E stain, 400x) (b) Hypoplastic AML with prominence of fat spaces, 
interstitial blast prominence and dyspoietic megakaryocytes in the background (H&E stain, 
100x)  
3.1.3 Myeloid sarcomas 
These may sometimes be preceeding or associated acute leukemias. The differentiation from 
lymphoblastic leukemia and round cell tumors is essential. These can involve almost any 
site of the body (Figure 4). These need to be differentiated from other malignancies – as 
lymphoblastic leukemia, lymphomas, round cell tumor, carcinomas, round cell melanomas, 
etc. Immunohistochemistry is done to resolve these issues. Molecular studies may be 
performed– FISH or PCR to further look for specific genetic abnormalities. These are a 
common occurence in AML with t(8;21). Usually these patients need allogeneic /autologous 
transplantation and have better survival rates as compared to other modalities as high dose 
chemotherapy, radiation or surgery (Pileri SA et al, 2007). 
 
 
Fig. 4. Lymph node section shows sheets of large cells. These have granular cytoplasm and 
large convoluted nuclei. (H&E, 400x) 
3.2 Cytochemistry 
The role of cytochemistry has become redundant in WHO 2008 with the regular use of flow 
cytometry for the lineage determination (Arber DA, 2010; Betz BL & Hess JL, 2010). The 
stains generally used for identifying lineage type are myeloperoxidase (MPO), Sudan black 
B, nonspecific esterases (NSE), chloro-acetate esterase and periodic acid- Schiff. The MPO 
stain is most specific indicator of myeloid differentiation (Figure 5a), however, negativity 
does not rule out myeloblasts. NSE is still used as one of the identifiers for monocytic 
differentiation. The stain that still has a definite role is the Perl’s stain not only to evaluate 
 
Diagnostic Approach in Acute Myeloid Leukemias in Line with WHO 2008 Classification 
 
163 
iron stores, but also for identification of ringed sideroblasts (Figure 5b) (Mufti GJ et al, 
2008). These stains are adjunct to morphology and useful for defining the subtypes of AML-
NOS. There is a need for these stains in places where access to flow cytometry is difficult 
and rational decisions may still be taken through diligent practices (Scott C.S et al, 1993). 
 
      
5(a)       5(b) 
Fig. 5. Cytochemistry in AML: (a)Myeloperoxidase stain shows  golden brown granules in 
myeloblasts (Hematoxylin counterstain, 1000x) (b) Perl’s stain demonstrates ring 
sideroblasts, characteristically showing Prussian blue dots around the nucleus (Eosin 
counterstain, 1000x) 
3.3 Flow cytometry 
Flow cytometry in hematological malignancies is based on the principle that neoplastic cells 
frequently show nonrandom expression of antigens in a manner that deviates from the 
tightly regulated patterns of antigen expression seen in normal maturation (Wood BL, 2007). 
Flow cytometric immunophenotyping (FCI) plays a well-established role in the diagnosis of 
acute leukemia, including AML, principally for blast enumeration, lineage assignment, and 
identification of immunophenotypic abnormalities suitable for post-therapeutic disease 
monitoring (Casasnovas RO et al, 1998; Orfao A et al, 2004; Peters JM & Ansari MQ, 2011; 
Weir EG & Borowitz MJ, 2001; Wood BL, 2007). It is mandatory to perform FCI to diagnose 
AML-M0, AML-M6, AML-M7, and acute leukemias of ambiguous lineage that include acute 
undifferentiated leukemia and mixed phenotypic leukemia. A three- or 4-color flow 
cytometer is good enough for routine diagnostic work-up, although  there are some centers 
using  9- to 10- color flow cytometers (Kussick SJ & Wood BL, 2003; Wood BL, 2006). Various 
panels have been recommended according to the type of flow cytometer, regional 
requirements, available resources, and personal preferences (Bene MC et al, 1995; Gujral S et 
al, 2008; Nguyen D et al, 2003). There is no universal consensus on the panel design. Each 
has its merits and limitations, undoubtedly the panels with more number of antibodies 
yields better results. Either bone marrow aspirate or peripheral blood containing good 
number of blasts can be processed for lineage typing. However, bone marrow aspirate is 
recommended for subtyping. In special situations, when the aspirate is a dry tap, BM core 
scraping suspensions can be utilized for FCI. However, because of lack of preservation of 
architectural features and the potential for artifactual alterations of the relative frequency of 
abnormal cells, the FCI data must always be correlated with histologic sections of the BM 
biopsy.  
Recognizing a Hematopoietic Origin: The blasts express CD45, albeit have a weak 
expression as compared to lymphocytes, thus favoring an immature process and the 
differential diagnosis includes lymphoblasts, or myeloblasts. It is important to note that 
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CD45 negativity does not exclude AL as some cases of B-ALL/B-LBL and all cases of AML 
with erythroid and megakaryocytic lineages are CD45 negative (Nguyen D et al, 2003). This 
feature is of vital importance. 
Markers of Immaturity: CD34 is the most commonly used marker to identify a precursor 
stage (Table 1). CD117 demonstrates a similar expression pattern and is more sensitive than 
CD34 in AML (Rizzatti EG et al, 2002). Flow cytometry should not be taken as an alternative 
to morphology for blast enumeration as blast is a morphological definition. The percentages 
of CD34 positive population equivalent to blasts can vary; may be falsely decreased due to 
hemodilution or falsely increased due to loss of erythroid precursors (the denominator for 
morphologic counts includes nucleated erythroid cells). CD117 strongly favors a myeloid 
blast lineage because it is not seen in B-ALL and is reported only very rarely in T-ALLs 
(<2%) (Paietta E et al, 2005). TdT is expressed in 20% of AML cases, especially those with 
t(8;21) (Porwit-MacDonald A et al, 1996; Wood BL, 2007). CD133 and CD38 are useful 
markers whenever CD34 and CD117 are non-contributory. 
 
Lineage Markers Positive 
Precursor stage CD34, CD117, CD133, HLA-DR, CD38, TdT 
Granulocytic markers  
 
CD13, CD15, CD16, CD33, CD65, cytoplasmic 
myeloperoxidase (cMPO) 
Monocytic markers Nonspecific esterase (NSE), CD11c, CD14, CD64, 
lysozyme, CD4, CD11b, CD36 
Megakaryocytic markers CD41 (glycoprotein IIb/IIIa), CD61 (glycoprotein IIIa), 
CD42 (glycoprotein 1b) 
Erythroid markers CD235a (glycophorin A), CD71 
B-lymphoid markers CD19, CD10, CD22 
T-lymphoid markers cytoplasmic CD3, CD2, CD5, CD7 
NK cell markers CD16, CD56 
Table 1. Usual antigens associated with stage and lineages of blasts 
HLA-DR in AML: HLA-DR is expressed in most AML and is characteristically negative in 
APL and AML-M6 and up to half of AML-M7. HLA-DR negativity once thought to be 
characteristically associated with APL has now been found to be present in a subset of AML 
with cup-shaped nuclei and FLT-3 gene internal tandem duplication (Bain BJ et al, 2002; 
Craig FE & Foon KA, 2008; Kussick SJ et al, 2004; Nguyen D et al, 2003). 
Myeloid lineage Antigens: Myeloblasts are well recognized for demonstrating marked 
immunophenotypic heterogeneity. Thus, multiple lineage-specific antibodies may be 
necessary to confirm the AML classification. CD13 and CD33 are the most sensitive myeloid 
markers. The assigning of myeloid lineage relies on identifying the expression of antigens 
characteristic of early myelomonocytic differentiation, including CD13, CD15, CD33, CD64, 
CD117, and cytoplasmic myeloperoxidase (Bain BJ et al, 2002; Chang CC et al, 2000; Cohen 
PL et al 1998; Craig FE & Foon KA, 2008; Wood BL, 2007). CD64 is expressed in AML 
subtypes M0 to M5 in varying intensities: strong expression characterizes AML M5, whereas 
heterogeneous, dim, or moderate expression is seen in M0 through M4 subtypes. However, 
the pattern of any CD64 expression when associated with strong CD15 expression 
distinguishes AML-M4 or M5, from other AML subtypes (Dunphy CH & Tang W, 2007). 
Promonocytes are characterized by the expression of high CD64, low CD13, intermediate 
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CD15 and CD36, and high HLA-DR without significant CD34, minimal CD117, and, 
importantly, with low to absent CD14 (Wood BL, 2007). These are distinguished from more 
mature monocytes by more uniform high expression of HLA-DR, lower CD13 and CD36, 
higher CD15, and low to absent CD14. This demarcation is important when one objectively 
needs to differentiate AML-M5 from CMML. The current WHO 2008 recommendation is the 
expression of myeloperoxidase for assigning the cells as myeloblasts and presence of at least 
two of the following parameters to assign as monoblasts – NSE, CD11c, CD14, CD64, and 
lysozyme (Swerdlow SH et al, 2008). Erythroid lineage is identified by the expression of 
Glycophorin A, CD71, CD36 with CD117 in absence of CD64. Megakaryocytic lineage is 
characterized by the expression of CD41 and CD61 (Bain BJ et al, 2002; Craig FE & Foon KA, 
2008; Wood BL, 2007).  
Lymphoid Antigens in AML: Aberrant expression of lymphoid antigens, such as CD2, CD5, 
CD7, CD19, and CD56, is common and generally does not indicate bilineal or mixed lineage 
differentiation (Auger MJ et al, 1992; Baer MR et al, 1997; Khalidi HS et al, 1998; Kita K et 
al,1992; Wood BL, 2007). The presence of cytoplasmic or surface CD3 is essential to 
designate blasts as that of T-lineage. For categorizing B-lineage blasts, when these cells 
express strong CD19 with one of the following- CD79a, cytoplasmic CD22 or CD10 and 
when the CD19 is weak, then these should express two of the above antibodies.  
3.3.1 Immunoprofiles in AMLs 
AML, Not otherwise specified: The characteristic immunoprofile of various entities (AML-
M0 to AML-M7) is described above. In acute basophilic leukemia, the blasts usually 
express CD13 and/or CD33 with CD123, CD203c, CD11b, CD9, CD34, and HLA-DR. These 
are usually negative for CD117 and CD25 (Swerdlow SH et al, 2008). 
AML with recurrent genetic abnormalities: There is a strong correlation of certain 
immunophenotypes in AML with specific cytogenetic and molecular abnormalities (Hrusak 
O & Porwit-MacDonald A, 2002; Wood BL, 2007). AML with t(8;21) has a high incidence of  
aberrant expression of CD19, high CD34, CD56, and TdT (Figure 6) (Porwit-MacDonald A et 
al, 1996; Wood BL, 2007). t(15;17) AML demonstrates an immunophenotype typical of 
promyelocytes, including a variable increase in side scatter, lack of  significant CD34, 
expression of variable CD13 and CD117, aberrantly high CD33, and aberrantly low to absent 
CD15 (Orfao A et al, 1999; Wood BL, 2007). AML with inv (16) or t(16;16) generally displays 
myelomonocytic differentiation and sometimes is associated with CD2 expression 
(Adriaansen HJ et al, 1993). 
AML with myelodysplasia-related changes: The immunophenotyping results vary 
according to the cytogenetic abnormality. Those with abnormalities of chromosomes 5 and 7 
show a high incidence of CD34, TdT and CD7 expression. CD56 and / or CD7 are seen 
aberrantly in cases of antecedent MDS. Most noticeable is a decrease in side scatter on 
mature neutrophils, the flow cytometric equivalent of morphologic hypogranularity (Wells 
DA et al, 2003; Wood BL, 2007). However, one has to keep in mind that aged samples also 
give rise to hypogranularity (Wood BL, 2007). 
Myeloid leukemia associated with Down’s syndrome: The blasts usually are of 
megakaryocytic lineage with a phenotype showing positivity for CD117, CD13, CD33, CD7, 
CD4 (dim), CD42, CD36, CD41, CD61, CD71 and negative for MPO, CD15, CD14 and 
glycophorin A (Swerdlow SH et al, 2008; Xavier AC & Taub JW, 2009). CD34 is seen in 50% 
cases only.  
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CD45 negativity does not exclude AL as some cases of B-ALL/B-LBL and all cases of AML 
with erythroid and megakaryocytic lineages are CD45 negative (Nguyen D et al, 2003). This 
feature is of vital importance. 
Markers of Immaturity: CD34 is the most commonly used marker to identify a precursor 
stage (Table 1). CD117 demonstrates a similar expression pattern and is more sensitive than 
CD34 in AML (Rizzatti EG et al, 2002). Flow cytometry should not be taken as an alternative 
to morphology for blast enumeration as blast is a morphological definition. The percentages 
of CD34 positive population equivalent to blasts can vary; may be falsely decreased due to 
hemodilution or falsely increased due to loss of erythroid precursors (the denominator for 
morphologic counts includes nucleated erythroid cells). CD117 strongly favors a myeloid 
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t(8;21) (Porwit-MacDonald A et al, 1996; Wood BL, 2007). CD133 and CD38 are useful 
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Lineage Markers Positive 
Precursor stage CD34, CD117, CD133, HLA-DR, CD38, TdT 
Granulocytic markers  
 
CD13, CD15, CD16, CD33, CD65, cytoplasmic 
myeloperoxidase (cMPO) 
Monocytic markers Nonspecific esterase (NSE), CD11c, CD14, CD64, 
lysozyme, CD4, CD11b, CD36 
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designate blasts as that of T-lineage. For categorizing B-lineage blasts, when these cells 
express strong CD19 with one of the following- CD79a, cytoplasmic CD22 or CD10 and 
when the CD19 is weak, then these should express two of the above antibodies.  
3.3.1 Immunoprofiles in AMLs 
AML, Not otherwise specified: The characteristic immunoprofile of various entities (AML-
M0 to AML-M7) is described above. In acute basophilic leukemia, the blasts usually 
express CD13 and/or CD33 with CD123, CD203c, CD11b, CD9, CD34, and HLA-DR. These 
are usually negative for CD117 and CD25 (Swerdlow SH et al, 2008). 
AML with recurrent genetic abnormalities: There is a strong correlation of certain 
immunophenotypes in AML with specific cytogenetic and molecular abnormalities (Hrusak 
O & Porwit-MacDonald A, 2002; Wood BL, 2007). AML with t(8;21) has a high incidence of  
aberrant expression of CD19, high CD34, CD56, and TdT (Figure 6) (Porwit-MacDonald A et 
al, 1996; Wood BL, 2007). t(15;17) AML demonstrates an immunophenotype typical of 
promyelocytes, including a variable increase in side scatter, lack of  significant CD34, 
expression of variable CD13 and CD117, aberrantly high CD33, and aberrantly low to absent 
CD15 (Orfao A et al, 1999; Wood BL, 2007). AML with inv (16) or t(16;16) generally displays 
myelomonocytic differentiation and sometimes is associated with CD2 expression 
(Adriaansen HJ et al, 1993). 
AML with myelodysplasia-related changes: The immunophenotyping results vary 
according to the cytogenetic abnormality. Those with abnormalities of chromosomes 5 and 7 
show a high incidence of CD34, TdT and CD7 expression. CD56 and / or CD7 are seen 
aberrantly in cases of antecedent MDS. Most noticeable is a decrease in side scatter on 
mature neutrophils, the flow cytometric equivalent of morphologic hypogranularity (Wells 
DA et al, 2003; Wood BL, 2007). However, one has to keep in mind that aged samples also 
give rise to hypogranularity (Wood BL, 2007). 
Myeloid leukemia associated with Down’s syndrome: The blasts usually are of 
megakaryocytic lineage with a phenotype showing positivity for CD117, CD13, CD33, CD7, 
CD4 (dim), CD42, CD36, CD41, CD61, CD71 and negative for MPO, CD15, CD14 and 
glycophorin A (Swerdlow SH et al, 2008; Xavier AC & Taub JW, 2009). CD34 is seen in 50% 
cases only.  
 





Fig. 6. Flow cytometry on the peripheral blood showed blasts (painted red) in the blast 
region in the CD45 /side scatter plot. These cells are CD45 dim and express CD13, CD117, 
CD33, CD19, CD38, CD34, and HLA-DR. These were negative for CD10, CD2, CD5, CD14 
and CD7. Normal lymphocytes are painted green. 
Blastic plasmacytoid dendritic cell neoplasm: Earlier known as agranular CD4+/CD56+ 
hematodermic neoplasm or blastic NK cell lymphoma, is characterized by the expression of 
CD4, CD43, CD56 and CD45RA by the blasts (Miwa H et al, 1998). These express CD123 and 
may sometimes express CD68, CD7, and CD33. These are negative for CD34, CD117, MPO, 
T-lineage and other monocytic lineage markers. 
3.3.2 Acute leukemia of ambiguous lineage 
This group includes the acute undifferentiated leukemia (AUL) and mixed phenotypic 
leukemias (MPAL) (Swerdlow SH et al, 2008). AUL is characterized by the absence of T- 
and myeloid lineage specific markers, i.e. cytoplasmic CD3 and MPO as well as cCD22, 
cCD79a or strong CD19. These leukemias lack erythroid, megakaryocytic and 
plasmacytoid dendritic cell lineage markers. These cells may express CD34, HLA-DR, and 
/or TdT. MPAL can show combinations of myeloid with B- or T- lineage specific antigens. 
Sometimes these are associated with specific chromosomal abnormalities as MPAL with 
t(9;22)(q34;q11.2); BCR-ABL1 and MPAL with t(v;11q23); MLL rearranged, where these 
blasts are commonly categorized as B-lymphoblasts with a high frequency of myeloid 
lineage antigen expression. 
 
Diagnostic Approach in Acute Myeloid Leukemias in Line with WHO 2008 Classification 
 
167 
   
7(a)    7(b) 
Fig. 7. IHC on trephine biopsy section (a) Blasts show strong membranous CD34 positivity 
(Hematoxylin counterstain, 400x) (b) Myeloperoxidase positivity in blasts (Hematoxylin 
counterstain, 400x) 
3.4 Immunohistochemistry (IHC) 
Although various studies have shown that FCI is the preferred method of 
immunophenotyping acute leukemias, certain situations where FCI is unavailable, 
immunohistochemistry (IHC) is an alternate or sometimes adjunct to flow cytometry. In 
situations where an appropriate specimen with adequate cellularity is not available, as in a 
‘‘dry tap’’, the diagnostic cells are low in yield, FCI is usually less informative. FCI may not 
be routinely requested if leukemia is not an initial diagnostic consideration, especially in 
extramedullary or extranodal site biopsies. Similarly, fresh cells may not be consistently 
submitted for consultation cases, and the technology may not be immediately accessible in 
community settings (Olsen RJ, 2008). The main objective of IHC is to confirm a hematologic 
malignancy, differentiating ALs from high grade NHLs, round cell tumors and other non-
hematologic malignancies. These help categorize ALs into B-ALL, T-ALL and AML. To an 
extent these can also subtype AMLs (Dunphy CH, 2004). Comparison of IHC results with 
FCI suggests that there is significant concordance in the results for markers that can be used 
with both techniques, indicating that the sensitivity and specificity of both methods is 
comparable (Manaloor EJ, 2000). 
IHC is useful in confirming the blast lineage and in categorizing the following AML groups 
- AML-NOS, which is subdivided based on the traditional FAB classification, myeloid 
sarcoma and BDPC neoplasm. AML may not be definitively classified with IHC. However, 
differentiation toward myeloid, monocytic, erythroid or megakaryocytic lineages can be 
demonstrated with appropriate staining panels. Certain staining characteristics may guide 
genetic testing such as fluorescence in situ hybridization studies on the paraffin-embedded 
tissue according to the type of blasts present (Olsen RJ, 2008). The commonly available 
antibodies for AML include CD45 (LCA) (marker for hemopoietic origin), CD117, CD34, 
TdT, HLA-DR (markers of precursor stage), MPO (specific myeloid marker), CD68, 
lysozyme, CD163 (markers for monocytic lineage), CD41, CD61, factor VIII (FVIII) (markers 
for megakaryocytic lineage), hemoglobin A1, glycophorin A (markers for erythroid lineage), 
and CD15 (marker for myeloid maturation). . The fact that various antibodies have variable 
reactivity in FC and IHC has to be kept in mind while interpreting the results. Although 
most studies found a better detection of CD34 by flow, some did not find any difference. 
CD15 and CD117 are better detected by FC analysis and MPO is better detected by IHC 
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immunohistochemistry (IHC) is an alternate or sometimes adjunct to flow cytometry. In 
situations where an appropriate specimen with adequate cellularity is not available, as in a 
‘‘dry tap’’, the diagnostic cells are low in yield, FCI is usually less informative. FCI may not 
be routinely requested if leukemia is not an initial diagnostic consideration, especially in 
extramedullary or extranodal site biopsies. Similarly, fresh cells may not be consistently 
submitted for consultation cases, and the technology may not be immediately accessible in 
community settings (Olsen RJ, 2008). The main objective of IHC is to confirm a hematologic 
malignancy, differentiating ALs from high grade NHLs, round cell tumors and other non-
hematologic malignancies. These help categorize ALs into B-ALL, T-ALL and AML. To an 
extent these can also subtype AMLs (Dunphy CH, 2004). Comparison of IHC results with 
FCI suggests that there is significant concordance in the results for markers that can be used 
with both techniques, indicating that the sensitivity and specificity of both methods is 
comparable (Manaloor EJ, 2000). 
IHC is useful in confirming the blast lineage and in categorizing the following AML groups 
- AML-NOS, which is subdivided based on the traditional FAB classification, myeloid 
sarcoma and BDPC neoplasm. AML may not be definitively classified with IHC. However, 
differentiation toward myeloid, monocytic, erythroid or megakaryocytic lineages can be 
demonstrated with appropriate staining panels. Certain staining characteristics may guide 
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tissue according to the type of blasts present (Olsen RJ, 2008). The commonly available 
antibodies for AML include CD45 (LCA) (marker for hemopoietic origin), CD117, CD34, 
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lysozyme, CD163 (markers for monocytic lineage), CD41, CD61, factor VIII (FVIII) (markers 
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reactivity in FC and IHC has to be kept in mind while interpreting the results. Although 
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analysis (Dunphy CH et al, 2001). Some of the antibodies as CD13 and CD33 are not 
available or not standardized well by IHC. 
LCA positivity recognizes a hemopoietic malignancy; however, it can be negative in AML-
M6 and M7. CD34 (QBEND10) is less sensitive by IHC than by FC and is detected in only 
50% of cases (Figure 7a) (Manaloor EJ, 2000; Olsen RJ, 2008). CD117 (c-Kit) is a much more 
sensitive marker of immaturity than CD34 and is also a marker for myeloid lineage (Rizzatti 
EG et al, 2002). TdT is expressed in cases of AML with t(8;21). Myeloperoxidase is the most 
specific marker for assigning myeloid lineage (Figure 7b); however, is negative in AML-M0 
and blasts of monocytic, erythroid, and megakaryocytic lineages. Hemoglobin A1 and 
glycophorin A are positive in 90% to 100% of erythroid lineage cells, and FVIII is positive in 
90% of megakaryocytic cells, but rare cases demonstrating inadequate lineage maturation 
(early megakaryoblasts) may be negative (Chuang SS & Li CY, 1997; Manaloor EJ, 2000). 
CD41 and CD61 expression favor megakaryoblastic lineage; however, CD41 expression can 
be sometimes observed in other subtypes of AML. As in FCI, IHC can also demonstrate 
lymphoid lineage reactivity – as with CD2, CD7, CD4 and PAX-5. The expression of PAX-5 
correlates highly with AML showing the t(8;21) abnormality.  
The results of IHC should be evaluated carefully keeping in mind the limitations of the 
technique. Where there is unequivocal demonstration of immaturity, i.e. CD34 and/or CD117 
expression, with MPO staining in the blasts, a diagnosis of AML can be made confidently. 
However, it is a challenge to interpret MPO negative AL cases. In such cases of AL, one has to 
first ensure that the B- and T- lymphoblastic lineages have been ruled out by a negative 
staining for CD79a, PAX-5, CD20, and CD3 (should detect CD3 epsilon chain and not zeta 
chain by a polyclonal antibody, which is non-specific) (Swerdlow SH et al, 2008). Monocytic 
lineage can be established using the CD68 (both KP-1 and PG-M1 epitopes) and lysozyme. 
Possibilities of AML-M6 or AML-M7 should be ruled out; these may be more challenging as 
they may be LCA negative. If the blasts express CD117 and TdT without CD79a, PAX-5, 
CD79a, MPO, and CD3 possibility of AML-minimally differentiated may be suggested. In the 
LCA negative cases, work-up towards other possibilities should be done before making a 
diagnosis of AL. Ancillary techniques should be appropriately used before a final conclusion. 
The role of IHC in the diagnosis of AL of ambiguous lineage is questionable. The possibility 
of AUL can be suggested when the blasts fail to express the immunophenotypic features of 
either lymphoid or myeloid differentiation. It is important to consider non-hemopoietic 
malignancies. BDPC neoplasm is a diagnosis usually based on tissue biopsy, most often a skin 
lesion (Petrella T et al, 1999). Morphologically suspected as leukemia cutis, the primary panel 
is usually inconclusive - weakly positive for LCA/CD45, variably and focally positive for 
CD68. The pattern may be confusing because of the absence of lineage-specific markers. The 
diagnosis should be suspected and a further panel should be done for a conclusive opinion. 
The cells are positive for CD4, CD43, CD56, and CD123 (plasmacytoid dendritic cell marker) 
and the expression of CD2 and CD7 is variable. This pattern may be seen in myeloid sarcoma 
(AML- M4 or M5). These entities are distinguished by the clinical presentation, and more 
importantly by CD13, and CD33 expression, which are readily available by FC. CD13 and 
CD33 are present in AMLs and are usually absent in BDPC (Jacob MC et al, 2003).  
3.5 Cytogenetics 
Conventional cytogenetic analysis is now an integral component of the diagnostic 
evaluation of a patient with suspected acute leukemia. This is done best at the time of 
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diagnosis before initiating therapy. Chromosome abnormalities are detected in 
approximately 55% of adult AML (Döhner H et al, 2010; Grimwade D et al, 1998). There are 
seven recurrent balanced translocations and inversions, and their variants recognized in the 
WHO category – AML with recurrent genetic abnormalities. Several cytogenetic 
abnormalities are considered sufficient to establish the WHO diagnosis of AML with 
myelodysplasia-related features, when 20% or more blood or marrow blasts are present. A 
minimum of 20 metaphase cells analyzed from bone marrow is considered mandatory to 
establish the diagnosis of a normal karyotype, and also to define an abnormal karyotype. 
Abnormal karyotypes may be diagnosed from blood specimens, or the biopsy core 
scrapings, when the marrow aspirate is scanty or insufficient. Leukemic blasts carrying 
AML-associated chromosome aberrations can constitute only a fraction of cells dividing in 
vitro. Moreover, a blood specimen can sometimes be cytogenetically normal when the 
marrow is abnormal. In the CALGB database, this was found in approximately 5% of AML 
patients whose marrow and blood specimens were studied simultaneously (Grimwade D et 
al, 1998; Mrózek K et al, 2001, 2007). 
Acquired genetic alterations, both those detectable microscopically as structural and 
numerical chromosome aberrations, and those detected as submicroscopic gene mutations 
and changes in gene expression, are commonly seen in AML. At present, cytogenetic 
aberrations detected at the time of AML diagnosis constitute the most common basis for 
predicting clinical outcome (Byrd JC et al, 2002; Mrózek K &Bloomfield CD, 2006; Slovak M 
L et al, 2000). Acquired clonal chromosome abnormalities are defined as a structural 
aberration or a trisomy observed in at least 2 and monosomy found in at least 3 metaphase 
cells. These are detected in the pretreatment marrow of 50% to 60% of adults with de novo 
AML. In 10% to 20% of patients, the abnormal karyotype is complex, defined as the presence 
of more than 3 abnormalities in karyotypes not including the abnormalities seen in the 
recurrent genetic abnormalities group, i.e. t(8;21), inv(16), t(16;16), t(15;17) or t(9;11) 
(Swerdlow SH et al, 2008). In around 40% to 50% of patients no cytogenetic abnormality can 
be detected using standard banding methods (Byrd JC et al, 2002; Farag SS et al, 2006; 
Grimwade D et al, 1998; Mrózek K et al, 2001, 2007; Slovak M L et al, 2000). The role of 
cytogenetics is of paramount importance in the diagnosis of AML with recurrent genetic 
abnormalities – those associated with balanced translocations and inversions, and AML 
with myelodysplasia-related changes.  
3.5.1 AML with balanced translocations/ inversions 
This group is composed of ALs with detection of balanced translocations between 
chromosomes and are usually associated with a specific prognosis. All large cytogenetic 
studies of AML have shown that patients with t(15;17)(q22;q12- 21) have an excellent 
outcome and those with t(8;21)(q22;q22) or inv(16)(p13q22)/ t(16;16)(p13;q22) a relatively 
favorable prognosis. Those with inv(3)(q21q26)/ t(3;3)(q21;q26), –7 and a complex karyotype 
have an unfavourable outcome (Mrózek K &Bloomfield CD, 2006) . 
3.5.1.1 Core-Binding Factor (CBF) AML 
CBF-AML is a relatively frequent subtype of adult de novo AML, with t(8;21) being detected 
in 7% and inv(16)/t(16;16) in 8% of patients (Byrd JC et al, 2002; Marcucci G et al, 2005; 
Mrózek K & Bloomfield CD, 2006). As in APL both these leukemias have a characteristic 
morphology based on which these cytogenetic abnormalities are predicted and specifically 
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analysis (Dunphy CH et al, 2001). Some of the antibodies as CD13 and CD33 are not 
available or not standardized well by IHC. 
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90% of megakaryocytic cells, but rare cases demonstrating inadequate lineage maturation 
(early megakaryoblasts) may be negative (Chuang SS & Li CY, 1997; Manaloor EJ, 2000). 
CD41 and CD61 expression favor megakaryoblastic lineage; however, CD41 expression can 
be sometimes observed in other subtypes of AML. As in FCI, IHC can also demonstrate 
lymphoid lineage reactivity – as with CD2, CD7, CD4 and PAX-5. The expression of PAX-5 
correlates highly with AML showing the t(8;21) abnormality.  
The results of IHC should be evaluated carefully keeping in mind the limitations of the 
technique. Where there is unequivocal demonstration of immaturity, i.e. CD34 and/or CD117 
expression, with MPO staining in the blasts, a diagnosis of AML can be made confidently. 
However, it is a challenge to interpret MPO negative AL cases. In such cases of AL, one has to 
first ensure that the B- and T- lymphoblastic lineages have been ruled out by a negative 
staining for CD79a, PAX-5, CD20, and CD3 (should detect CD3 epsilon chain and not zeta 
chain by a polyclonal antibody, which is non-specific) (Swerdlow SH et al, 2008). Monocytic 
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Possibilities of AML-M6 or AML-M7 should be ruled out; these may be more challenging as 
they may be LCA negative. If the blasts express CD117 and TdT without CD79a, PAX-5, 
CD79a, MPO, and CD3 possibility of AML-minimally differentiated may be suggested. In the 
LCA negative cases, work-up towards other possibilities should be done before making a 
diagnosis of AL. Ancillary techniques should be appropriately used before a final conclusion. 
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diagnosis before initiating therapy. Chromosome abnormalities are detected in 
approximately 55% of adult AML (Döhner H et al, 2010; Grimwade D et al, 1998). There are 
seven recurrent balanced translocations and inversions, and their variants recognized in the 
WHO category – AML with recurrent genetic abnormalities. Several cytogenetic 
abnormalities are considered sufficient to establish the WHO diagnosis of AML with 
myelodysplasia-related features, when 20% or more blood or marrow blasts are present. A 
minimum of 20 metaphase cells analyzed from bone marrow is considered mandatory to 
establish the diagnosis of a normal karyotype, and also to define an abnormal karyotype. 
Abnormal karyotypes may be diagnosed from blood specimens, or the biopsy core 
scrapings, when the marrow aspirate is scanty or insufficient. Leukemic blasts carrying 
AML-associated chromosome aberrations can constitute only a fraction of cells dividing in 
vitro. Moreover, a blood specimen can sometimes be cytogenetically normal when the 
marrow is abnormal. In the CALGB database, this was found in approximately 5% of AML 
patients whose marrow and blood specimens were studied simultaneously (Grimwade D et 
al, 1998; Mrózek K et al, 2001, 2007). 
Acquired genetic alterations, both those detectable microscopically as structural and 
numerical chromosome aberrations, and those detected as submicroscopic gene mutations 
and changes in gene expression, are commonly seen in AML. At present, cytogenetic 
aberrations detected at the time of AML diagnosis constitute the most common basis for 
predicting clinical outcome (Byrd JC et al, 2002; Mrózek K &Bloomfield CD, 2006; Slovak M 
L et al, 2000). Acquired clonal chromosome abnormalities are defined as a structural 
aberration or a trisomy observed in at least 2 and monosomy found in at least 3 metaphase 
cells. These are detected in the pretreatment marrow of 50% to 60% of adults with de novo 
AML. In 10% to 20% of patients, the abnormal karyotype is complex, defined as the presence 
of more than 3 abnormalities in karyotypes not including the abnormalities seen in the 
recurrent genetic abnormalities group, i.e. t(8;21), inv(16), t(16;16), t(15;17) or t(9;11) 
(Swerdlow SH et al, 2008). In around 40% to 50% of patients no cytogenetic abnormality can 
be detected using standard banding methods (Byrd JC et al, 2002; Farag SS et al, 2006; 
Grimwade D et al, 1998; Mrózek K et al, 2001, 2007; Slovak M L et al, 2000). The role of 
cytogenetics is of paramount importance in the diagnosis of AML with recurrent genetic 
abnormalities – those associated with balanced translocations and inversions, and AML 
with myelodysplasia-related changes.  
3.5.1 AML with balanced translocations/ inversions 
This group is composed of ALs with detection of balanced translocations between 
chromosomes and are usually associated with a specific prognosis. All large cytogenetic 
studies of AML have shown that patients with t(15;17)(q22;q12- 21) have an excellent 
outcome and those with t(8;21)(q22;q22) or inv(16)(p13q22)/ t(16;16)(p13;q22) a relatively 
favorable prognosis. Those with inv(3)(q21q26)/ t(3;3)(q21;q26), –7 and a complex karyotype 
have an unfavourable outcome (Mrózek K &Bloomfield CD, 2006) . 
3.5.1.1 Core-Binding Factor (CBF) AML 
CBF-AML is a relatively frequent subtype of adult de novo AML, with t(8;21) being detected 
in 7% and inv(16)/t(16;16) in 8% of patients (Byrd JC et al, 2002; Marcucci G et al, 2005; 
Mrózek K & Bloomfield CD, 2006). As in APL both these leukemias have a characteristic 
morphology based on which these cytogenetic abnormalities are predicted and specifically 
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looked for. Both t(8;21) and inv(16) are related at the molecular level as they disrupt the α 
and β subunits of CBF, respectively.  
AML with t(8;21)(q22;q22); RUNX1-RUNX1T1: This abnormality detected in 20% adult and 
40% children de novo AML cases is associated usually with FAB AML-M2, rarely with other 
subtypes (Figure 8). Over 70% are associated with secondary chromosome aberrations – as loss 
of a sex chromosome (–Y in men and –X in women) and del(9q) with loss of 9q22 being the 
most frequent. Despite good prognosis relapse is a major problem, especially in first 2 years of 
remission (Marcucci G et al, 2005; Mrózek K & Bloomfield CD, 2006; Schlenk RF et al, 2004). 
 
 
Fig. 8. Karyotype showing balanced translocation of 46,XY, t(8;21)(q22;q22) 
AML with inv(16)(p13.1q22) / t(16;16) (p13.1q22); CBFB-MYH11: These are associated with 
characteristic FAB M4Eo morphology, higher WBCs, percentages of PB and BM blasts, more 
often showing extramedullary involvement, lymphadenopathy, splenomegaly, gingival 
hypertrophy and skin/mucosa involvement and characteristic cytogenetic features. 
Approximately two thirds of patients with inv(16)/t(16;16) have this rearrangement as a 
sole chromosome abnormality. Most frequent secondary chromosome aberrations in 
inv(16)/t(16;16)-positive patients are +22, +8, del(7q) and +21. These studies identified 
additional cytogenetic prognostic factors differentiating the two cytogenetic subsets of CBF 
AML. Among patients with inv(16)/t(16;16), those who harbored +22 as a secondary 
abnormality were found to have a significantly lower cumulative incidence of relapse 
compared with patients with inv(16)/t(16;16) as a sole abnormality in the CALGB study and 
longer relapse free survival than patients without +22 in the German Acute Myeloid 
Leukemia Intergroup study(Marcucci G et al, 2005; Mrózek K & Bloomfield CD, 2006; 
Schlenk RF et al, 2004). 
3.5.1.2 AML associated with RARA translocation including variant translocations 
APL constitutes 5-8% of AML (Swerdlow SH et al, 2008). In 1977 Rowley and colleagues 
identified the t(15;17) balanced reciprocal chromosomal translocation as the karyotypic 
hallmark of the disease (Rowley J et al, 1997 as cited in Sirulnik A et al, 2003). In the early 
1990s it was discovered that in classical APL this reciprocal translocation involves a fusion 
between the RARA gene on chromosome 17 and a previously unknown locus named 
promyelocytic leukemia (PML) on chromosome 15 (Kakizuka A et al, 1991 as cited in 
Sirulnik A et al, 2003). Other additional chromosomal abnormalities can be found in 30 to 
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40% of patients with APL in addition to t(15;17). The most common of these are trisomy 8 
and isochromosome 17. Additional chromosomal abnormalities do not have a negative 
effect on the overall prognosis (Johannson B et al, 1994; Schoch C et al. 1996; Slack JL, 1997). 
However, there have been cases morphologically reported as APL without a detectable 
t(15;17) on a conventional karyotype. Some of these have a cryptic PML/RARA 
translocation, i.e. these are submicroscopic and not detected by conventional method and 
require ancillary techniques as the FISH or PCR for a confirmation. Others have 
translocations not involving the t(15;17) (Goyal M et al, 2010; Grimwade DF et al, 1997).  
AML with Variant RARA translocations: The current WHO categorizes morphologically 
diagnosed cases of APL into those associated with t(15;17)(q22;q21)/ PML-RARA 
rearrangement, and those lacking PML/RARA rearrangements based on the cytogenetic 
and molecular studies (Swerdlow SH et al, 2008). The latter group is separately categorized 
as variant RARA translocations due to refractory / variable response to ATRA. Instead of 
PML the partner genes in this group could be ZBTB16/ PLZF at 11q23, NUMA1 at 11q13, 
NPM1 at 5q35 and STAT5B at17q11.2.  
3.5.1.3 AML with t(9;11)(p22;q23); MLLT3-MLL and variant MLL translocations in AL  
The MLL gene on chromosome 11 band q23 is frequently involved in chromosome 
translocations in acute lymphoblastic leukemia and acute myeloid leukemia. The MLL gene 
located at 11q23 has been described as a ‘promiscuous’ gene due its involvement with a 
large number of genetic partners (Moorman AV et al, 1998). More than 80 different partner 
chromosome regions have been described till date. The translocation results in the formation 
of a fusion gene on the derivative 11 chromosome consisting of the 5’ part of the MLL gene 
and the 3’ part of another gene. MLL gene rearrangements generally correlate with a poor 
prognosis; however AML with t(9;11)(p22;q23) is associated with intermediate prognosis. 
Therefore, the presence of 11q23 aberration has direct implications for treatment 
stratification, making early and rapid detection of utmost importance (van der Burg et al, 
1999). AML with t(9;11) are associated with acute monocytic and myelomonocytic leukemias 
(Baer MR et al, 1998; Sorensen PHB et al, 1994; Swansbury GJ et al, 1998). This entity 
involves MLLT3 (AF9), which is the most common MLL translocation in AML. Secondary 
chromosomal abnormalities as +8 are commonly seen, however, these do not affect the 
prognosis.  
AML with variant MLL translocations: Various other partner chromosomes are known to 
be associated with the MLL gene (Moorman AV et al, 1998). 19p13.1 is involved almost only 
with AML, others can be seen both in ALL and AML, and all have been categorized in 
variant MLL translocations in acute leukemia. The WHO 2001 encompassed all MLL related 
translocations into the category of AML with 11q abnormalities. However, the WHO 2008 
now separates AML with t(9;11) from other MLL related translocations, which are placed in 
the category variant MLL translocations in acute leukemia. It is imperative to mention the 
specific abnormality associated with MLL to place in the latter category. Cases of AML with 
specific MLL translocations as t(11;16)(q23;p13.3) and t(2;11)(p21;q23) if not associated with 
cytotoxic chemotherapy should be considered as AML with myelodysplasia-related changes 
and not variant translocation of 11q23 (Swerdlow SH et al, 2008). 
3.5.1.4 AML with t(6;9)(p23;q34); DEK-NUP214 
Morphologically these are AML with or without monocytic features, usually associated with 
basophilia and multilineage dysplasia. The t(6;9)(p23;q34) results in fusion of DEK on 
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looked for. Both t(8;21) and inv(16) are related at the molecular level as they disrupt the α 
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40% of patients with APL in addition to t(15;17). The most common of these are trisomy 8 
and isochromosome 17. Additional chromosomal abnormalities do not have a negative 
effect on the overall prognosis (Johannson B et al, 1994; Schoch C et al. 1996; Slack JL, 1997). 
However, there have been cases morphologically reported as APL without a detectable 
t(15;17) on a conventional karyotype. Some of these have a cryptic PML/RARA 
translocation, i.e. these are submicroscopic and not detected by conventional method and 
require ancillary techniques as the FISH or PCR for a confirmation. Others have 
translocations not involving the t(15;17) (Goyal M et al, 2010; Grimwade DF et al, 1997).  
AML with Variant RARA translocations: The current WHO categorizes morphologically 
diagnosed cases of APL into those associated with t(15;17)(q22;q21)/ PML-RARA 
rearrangement, and those lacking PML/RARA rearrangements based on the cytogenetic 
and molecular studies (Swerdlow SH et al, 2008). The latter group is separately categorized 
as variant RARA translocations due to refractory / variable response to ATRA. Instead of 
PML the partner genes in this group could be ZBTB16/ PLZF at 11q23, NUMA1 at 11q13, 
NPM1 at 5q35 and STAT5B at17q11.2.  
3.5.1.3 AML with t(9;11)(p22;q23); MLLT3-MLL and variant MLL translocations in AL  
The MLL gene on chromosome 11 band q23 is frequently involved in chromosome 
translocations in acute lymphoblastic leukemia and acute myeloid leukemia. The MLL gene 
located at 11q23 has been described as a ‘promiscuous’ gene due its involvement with a 
large number of genetic partners (Moorman AV et al, 1998). More than 80 different partner 
chromosome regions have been described till date. The translocation results in the formation 
of a fusion gene on the derivative 11 chromosome consisting of the 5’ part of the MLL gene 
and the 3’ part of another gene. MLL gene rearrangements generally correlate with a poor 
prognosis; however AML with t(9;11)(p22;q23) is associated with intermediate prognosis. 
Therefore, the presence of 11q23 aberration has direct implications for treatment 
stratification, making early and rapid detection of utmost importance (van der Burg et al, 
1999). AML with t(9;11) are associated with acute monocytic and myelomonocytic leukemias 
(Baer MR et al, 1998; Sorensen PHB et al, 1994; Swansbury GJ et al, 1998). This entity 
involves MLLT3 (AF9), which is the most common MLL translocation in AML. Secondary 
chromosomal abnormalities as +8 are commonly seen, however, these do not affect the 
prognosis.  
AML with variant MLL translocations: Various other partner chromosomes are known to 
be associated with the MLL gene (Moorman AV et al, 1998). 19p13.1 is involved almost only 
with AML, others can be seen both in ALL and AML, and all have been categorized in 
variant MLL translocations in acute leukemia. The WHO 2001 encompassed all MLL related 
translocations into the category of AML with 11q abnormalities. However, the WHO 2008 
now separates AML with t(9;11) from other MLL related translocations, which are placed in 
the category variant MLL translocations in acute leukemia. It is imperative to mention the 
specific abnormality associated with MLL to place in the latter category. Cases of AML with 
specific MLL translocations as t(11;16)(q23;p13.3) and t(2;11)(p21;q23) if not associated with 
cytotoxic chemotherapy should be considered as AML with myelodysplasia-related changes 
and not variant translocation of 11q23 (Swerdlow SH et al, 2008). 
3.5.1.4 AML with t(6;9)(p23;q34); DEK-NUP214 
Morphologically these are AML with or without monocytic features, usually associated with 
basophilia and multilineage dysplasia. The t(6;9)(p23;q34) results in fusion of DEK on 
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chromosome 6 with NUP214 on chromosome 9. Usually it is an isolated abnormality. Very 
occasional reports of complex karyotype are known (Chi Y et al, 2008; Slovak ML et al, 
2006). These are frequently associated with FLT3-ITD mutations and a poor prognosis. 
3.5.1.5 AML with inv(3)(q21q26.2) or t(3;3)(q21q26.2); RPN1-EVI1 
These are morphologically AML with multilineage dysplasia and characterized by the 
translocation involving EVI1 or MDS-1EVI1 located at 3q26.2 and RPN1 at 3q21 
respectively. Other abnormalities involving the 3q26.2, seen in therapy related AML are not 
included in this category. This group is frequently associated with secondary karyotypic 
abnormalities – monosomy 7, 5q deletions, and complex karyotypes. AML with 
inv(3)(q21q26.2) or t(3;3)(q21q26.2) is an aggressive disease with a short survival (Lugthart S 
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Table 2. Types of cytogenetic abnormalities defining AML with myelodysplasia related 
changes and Therapy related AML (t-AML) 
 
 
Fig. 9. Case of a t-AML, post treatment for carcinoma breast showing a complex karyotype: 
44,XX,del(5q),del(7q),der(9)add(9p),der(15)add(15p),-16,-20 
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3.5.1.6 AML with t(1;22)(p13;q13); RBM15-MKL1 
These are morphologically acute megakaryoblastic leukemia associated with a very poor 
prognosis. Usually t(1;22)(p13;q13) is the sole abnormality. However, cytogenetics may not 
always be successful to depict this abnormality due to poor bone marrow aspirate yield and 
one may need to resort to molecular analysis as well. When a morphological diagnosis of 
AML-M7 is suspected, this chromosomal/ molecular abnormality should be looked for 
(Swerdlow SH et al, 2008). 
3.5.2 AML with myelodysplasia related changes and therapy related AML 
The chromosomal abnormalities are similar to those found in MDS and often involve gain or 
loss of major segments of certain chromosomes with complex chromosomal abnormalities. 
Various balanced and unbalanced abnormalities are known to occur (Table 2). Some 
abnormalities as t(11;16)(q23;p13.3) and t(3;21)(q26.2;q22.1) seen in AML with 
myelodysplasia-related changes, also occur commonly in t-AML and clinical details should 
be evaluated to differentiate between the two (Secker-Walker LM et al, 1998). Trisomy 8, del 
20q and loss of Y are common in MDS, however, are not considered disease-specific. Hence, 
their isolated presence is not sufficient to consider a case as AML with myelodysplasia-
related changes. Cases of AML with myelodysplastic changes in bone marrow may show 
t(6;9)(p23;q34), inv(3)(q21q26.2) or t(3;3)(q21q26.2) on a karyotype and should be 
categorized as such and not in AML with myelodysplasia-related changes. In t-AML 
unbalanced chromosomal aberrations are seen in 70% cases (Figure 9). These are associated 
with longer latent period, myelodysplastic changes and alkylating agent and/ or radiation 
therapy. Balanced translocations seen in 20-30% are associated with shorter latency, absence 
of myelodysplasia and prior therapy with topoisomerase inhibitors. The prognosis for t-
AML is dependent on the karyotype – is generally poor, except in cases associated with 
balanced translocations as t(15;17) and inv(16)(p13q22), which is also poorer as compared to 
de novo cases (Swerdlow SH et al, 2008). 
3.5.3 AML- not otherwise specified  
There are no specific chromosomal abnormalities associated with different subtypes. 
However, higher frequency of few abnormalities is seen in certain subtypes. Cuneo A et al, 
1995 compared cases of AML-M0 and AML-M1 and showed that abnormal karyotypes, 
complex karyotypes, unbalanced chromosome changes (-5/5q- and/or -7/7q- and +l3) were 
more frequent in AML-M0 than in AML-M1. However, many cases were regrouped in the 
AML with myelodysplasia-related changes. Trisomy 8 may be seen in acute 
myelomonocytic leukemia and t(8;16)(p11.2;p13.3) may be seen in acute monocytic or 
myelomonocytic leukemia. Cases of AML-M7 associated with mediastinal germ cell tumors 
have shown several cytogenetic abnormalities of which i(12p) is the most characteristic. 
There are no specific abnormalities documented in other subtypes. 
3.5.4 Down’s syndrome related AML  
In addition to trisomy 21, trisomy 8 is a common cytogenetic abnormality seen in DS-
AML (13-44%). More importantly the focus should be on detecting GATA1 mutations, 
which are commonly seen in children below 5 years (Swerdlow SH et al, 2008; Xavier AC 
& Taub JW, 2009). 
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3.5.1.6 AML with t(1;22)(p13;q13); RBM15-MKL1 
These are morphologically acute megakaryoblastic leukemia associated with a very poor 
prognosis. Usually t(1;22)(p13;q13) is the sole abnormality. However, cytogenetics may not 
always be successful to depict this abnormality due to poor bone marrow aspirate yield and 
one may need to resort to molecular analysis as well. When a morphological diagnosis of 
AML-M7 is suspected, this chromosomal/ molecular abnormality should be looked for 
(Swerdlow SH et al, 2008). 
3.5.2 AML with myelodysplasia related changes and therapy related AML 
The chromosomal abnormalities are similar to those found in MDS and often involve gain or 
loss of major segments of certain chromosomes with complex chromosomal abnormalities. 
Various balanced and unbalanced abnormalities are known to occur (Table 2). Some 
abnormalities as t(11;16)(q23;p13.3) and t(3;21)(q26.2;q22.1) seen in AML with 
myelodysplasia-related changes, also occur commonly in t-AML and clinical details should 
be evaluated to differentiate between the two (Secker-Walker LM et al, 1998). Trisomy 8, del 
20q and loss of Y are common in MDS, however, are not considered disease-specific. Hence, 
their isolated presence is not sufficient to consider a case as AML with myelodysplasia-
related changes. Cases of AML with myelodysplastic changes in bone marrow may show 
t(6;9)(p23;q34), inv(3)(q21q26.2) or t(3;3)(q21q26.2) on a karyotype and should be 
categorized as such and not in AML with myelodysplasia-related changes. In t-AML 
unbalanced chromosomal aberrations are seen in 70% cases (Figure 9). These are associated 
with longer latent period, myelodysplastic changes and alkylating agent and/ or radiation 
therapy. Balanced translocations seen in 20-30% are associated with shorter latency, absence 
of myelodysplasia and prior therapy with topoisomerase inhibitors. The prognosis for t-
AML is dependent on the karyotype – is generally poor, except in cases associated with 
balanced translocations as t(15;17) and inv(16)(p13q22), which is also poorer as compared to 
de novo cases (Swerdlow SH et al, 2008). 
3.5.3 AML- not otherwise specified  
There are no specific chromosomal abnormalities associated with different subtypes. 
However, higher frequency of few abnormalities is seen in certain subtypes. Cuneo A et al, 
1995 compared cases of AML-M0 and AML-M1 and showed that abnormal karyotypes, 
complex karyotypes, unbalanced chromosome changes (-5/5q- and/or -7/7q- and +l3) were 
more frequent in AML-M0 than in AML-M1. However, many cases were regrouped in the 
AML with myelodysplasia-related changes. Trisomy 8 may be seen in acute 
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myelomonocytic leukemia. Cases of AML-M7 associated with mediastinal germ cell tumors 
have shown several cytogenetic abnormalities of which i(12p) is the most characteristic. 
There are no specific abnormalities documented in other subtypes. 
3.5.4 Down’s syndrome related AML  
In addition to trisomy 21, trisomy 8 is a common cytogenetic abnormality seen in DS-
AML (13-44%). More importantly the focus should be on detecting GATA1 mutations, 
which are commonly seen in children below 5 years (Swerdlow SH et al, 2008; Xavier AC 
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3.5.5 Blastic Plasmacytoid Dendritic Cell neoplasm 
Chromosomal abnormalities are found in two-thirds of BPDC patients, although a specific 
karyotype is lacking. Complex karyotypes are common and six major recurrent 
chromosomal abnormalities are found: 5q21 or 5q34, 12p13, 13q13-21, 6q23-qter, 15q and -9.  
3.5.6 Cytogenetically normal AML (CN-AML) 
The proportion of adults with de novo CN-AML has varied between 40% and 49% in the 
largest cytogenetic studies (Byrd JC et al, 2002; Grimwade D et al, 2001; Mrózek K et al, 2007; 
Slovak ML et al, 2000). A patient is defined karyotypically normal when full analysis of at least 
20 metaphase cells originating from a marrow sample cultured in vitro for 24 to 48 hours is 
performed (Mrózek K et al, 2007). There are patients who, despite having a normal karyotype 
on standard cytogenetic investigation, carry 1 of the fusion genes identical to those generated 
by recurrent translocations (eg, PML-RARA/t(15;17), RUNX1-RUNX1T1 (AML1-ETO)/ t(8;21)) 
or inversions (CBFB-MYH11/inv(16)) and categorized in AML with recurrent genetic 
abnormalities. In most instances, these fusion genes are created by cryptic insertions of very 
small chromosome segments that do not alter the chromosome morphology (Grimwade D et 
al, 2000; Mrózek K et al, 2007; Rowe D et al, 2000). Both RT-PCR and FISH can be used to 
detect the presence of the aforementioned hidden rearrangements. Such testing is definitely 
warranted in CN-AML patients with FAB M2, M3, M3v, and M4Eo marrow morphology but 
is otherwise not routinely recommended outside of a clinical trial (Mrózek K et al, 2007; 
National Comprehensive Cancer Network (NCCN), 2006). 
3.5.7 Prognosis associated with chromosomal abnormalities 
The risk stratification with regards to cytogenetics is based on studies performed on patients 
below 60 years of age (Byrd JC et al, 2002; Grimwade D et al, 1998; Mrózek K & Bloomfield 
CD, 2006; Slovak ML et al, 2000). The favourable risk group have only balanced 
translocations – include t(15;17)(q22;q12-21), t(8;21)(q22;q22) and with inv(16)(p13.1q22) / 
t(16;16) (p13.1q22) (Table 3). The CN-AML is included in the intermediate-risk group. The 
unfavourable risk group includes complex karyotype, various balanced translocations, 
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Table 3. Known cytogenetic abnormalities with associated favourable, intermediate and 
unfavourable prognosis. 
 
Diagnostic Approach in Acute Myeloid Leukemias in Line with WHO 2008 Classification 
 
175 
of patients above 60 years with fewer than 5 abnormalities, regardless of the presence of 
abnormalities involving chromosomes 5, 7 and 3q, to be comparable to the intermediate-risk 
category. They included only those patients with a complex karyotype with 5 or more 
aberrations in the adverse risk category (Grimwade D et al, 2001). A CALGB study 
confirmed that older AML patients with a complex karyotype with 5 or more aberrations 
have particularly poor disease free survival (DFS) and overall survival (OS), with no patient 
surviving 5 years after diagnosis (Farag SS et al, 2006). 
3.6 Fluorescent-In-Situ Hybridisation (FISH) 
FISH is an improvisation of cytogenetic technique used to detect and localize the presence or 
absence of specific DNA sequences on chromosomes. Karyotype analysis has an advantage 
that the entire genome can be analyzed however, is applicable to actively dividing cells, and 
the resolution is limited to chromosomal rearrangements that are >3Mb in size. In addition 
technical aspects of sample collection, storage, transport, and culture may lead to 
suboptimal results. Poorly spread or contracted metaphases, low mitotic index and highly 
complex cytogenetic abnormalities may also lead to faulty results. This technique is labour-
intensive and time-consuming. FISH is capable of detecting aberrations of sizes between 
10kb to 5Mb. These are accurate, rapid, however, targeted analysis of the genomes. FISH 
provides increased resolution, thus elucidating submicroscopic deletions, cryptic or subtle 
duplications and translocations, complex rearrangements, involving many chromosomes 
and marker chromosomes. Interphase FISH has advantages of screening more number of 
cells, and also that both proliferating and not proliferating cells can be analyzed. The test 
can be performed on fixed bone marrow suspensions, paraffin-embedded tissue sections, 
bone marrow or blood smears, and touch preparations of cells from tissues. The test can be 
reliably used for routine diagnostic screening and whenever the patient’s material is not 
sufficient or suitable for cytogenetic/RT-PCR analysis.  
Role of FISH in AML: The main applications in AML are detection of recurrent cytogenetic 
abnormalities, whenever the cytogenetic analysis fails or in a CN-AML case, where 
morphology is suggestive of AML with recurring cytogenetic abnormalities. Dual color 
dual- fusion probes specific for the abnormality are used when a reciprocal translocations 
are suspected, e.g. t(8;21), t(15;17), etc (Figure 10). The presence of a translocation is  
 
 
Fig. 10. Interphase FISH analysis showing 1red– 1green– 1yellow fusion signal pattern; as 
compared to the normal cells which show a pattern of 0red– 0green– 2yellow (not shown). 
The splitting of yellow signal into 1red and 1green indicates translocation involving 
chromosome 16 in the region of CBFB (DAPI counterstain, ×1000) 
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detected by the formation of a red-green or yellow fusion signal. MLL gene is involved in 
more than 80 different translocations. To detect AL with MLL gene involvement break-apart 
probes complimentary to MLL gene are useful. This approach has an advantage that it 
detects all types of MLL gene translocations, independent of the partner gene (van der Burg 
et al, 1999). However, for detecting specific abnormality, dual color dual-fusion specific 
probes are used to detect the balanced translocations. In cases of AML with myelodysplasia 
associated changes, where numerical aberrations are more common CEPs are used to detect 
+8, -5, -7, etc. 
3.7 PML nuclear bodies immunofluorescence test 
An immunofluorescence based test is developed for rapid diagnosis of APL, using 
antibodies directed against the amino terminal portion of the human PML gene product, 
PG-M3 monoclonal antibody (Falini B et al, 1997). The wild type PML produces a 
characteristic nuclear speckled pattern that is due to localization of the protein into discrete 
dots (5 to 20 per nucleus), named PML nuclear bodies. The architecture of PML nuclear 
bodies appears to be disrupted in APL cells that bear the t(15; 17), thus resulting in 
abnormal (micropunctate) pattern of the PML/RARA fusion protein (usually ≥50 small 
granules/per nucleus). These are characteristically seen in APL with PML/RARA 
translocation and not in PLZF/RARA APL and other AMLs. Immunocytochemical labeling 
with PG-M3 represents a rapid, sensitive, and highly-specific test for the diagnosis of APL 
that bears the t(15; 17) and allows an easy and correct diagnosis of this subtype of acute 
leukemia to any laboratory provided with a minimal equipment for immunocytochemistry 
work.  
3.8 Polymerase chain reaction 
Nucleic acid amplification studies have become an integral part of diagnostic and 
prognostic work-up in the field of hematology. These include detection of DNA or the RNA 
by a process known as polymerase chain reaction (PCR). A marrow or peripheral blood 
specimen is routinely taken for molecular diagnostics. Ideally, DNA and RNA should be 
extracted and viable cells stored; if sample quantity is limited, RNA extraction should be a 
priority, because RNA is suitable for molecular screening for fusion genes and leukemia-
associated mutations.  
3.8.1 PCR in the diagnosis of recurrent genetic abnormalities 
Molecular diagnosis by RT-PCR for the recurring gene fusions, such as RUNX1-RUNX1T1, 
CBFB-MYH11, MLLT3-MLL, DEK-NUP214, can be useful in certain circumstances. RT-PCR 
is an option to detect these rearrangements, if chromosome morphology is of poor quality, 
or if there is typical marrow morphology but the suspected cytogenetic abnormality is not 
present and for a rapid diagnosis (Mrózek K et al, 2001). The standardized protocols are 
published by the BIOMED-1 group (van Dongen JJM et al, 1999). 
Acute Promyelocytic Leukemia with PML/RARA translocation: Five different chromosomal 
translocation partners have been identified in patients with APL, and all involve the RARA 
gene on chromosome 17q21 fused to one of the partners, PML on chromosome 15q22 being the 
most common. This results in fusion PML/RARA, mRNA transcription and a chimeric 
protein. RT- PCR amplification of the PML/RARA fusion transcript is now widely used for 
both diagnostic and monitoring studies (Sirulnik A et al, 2003).  
 





Fig. 11. The upper left panel shows a schematic representation of possible break-points in 
the PML and RARA genes, thus generating the isoforms – bcr1, bcr2 or bcr3 of PML-RARA 
fusion transcript. (Idea adapted from van Dongen JJM et al, 1998). The bcr1 and bcr2 
breakpoint regions are juxtaposed in intron 6 and exon 6, respectively. The upper right 
panel shows presence of bcr1 form of PML-RARA transcript (red arrow) with an internal 
control (black arrow). The lower panel gives a reference chart for the location of various 
PML-RARA transcripts and their relative sizes based on the number of base pairs 
The exact type of breakpoint on the PML gene can be determined. RT-PCR allows the 
detection of minimal residual disease at high sensitivity levels. Some pitfalls include poor 
RNA yield and stability, as well as the low expression of the hybrid PML/RARA gene. The 
chromosome 17 breakpoints are localized within a 15 kb DNA fragment of the RARA intron 
2. The PML gene spans 35 kb of genomic DNA and contains nine exons (Chen Z & Chen SJ, 
1992; Sirulnik A et al, 2003). Three regions of the PML locus are involved in the translocation 
breakpoints: intron 6 (bcr1; 55% of cases), exon 6 (bcr2; 5%), and intron 3 (bcr3; 40%). Bcr1 
and bcr2 are considered as long (L) forms and bcr3 is considered as short (S) form (Figure 
11). Because bcr2 (also referred to as ‘variant’ or V form) and bcr1 are located in PML exon 6 
and intron 6, respectively, sequencing of all L transcript cases would be needed to clearly 
distinguish these two isoforms. There is no difference in the clinical features of various 
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isoforms (Lo-Coco F et al, 1999, 2003; van Dongen JJM et al, 1999). Recognition of the 
infrequent PLZF/RARA subtype is clinically relevant in the light of its presumed 
unresponsiveness to ATRA and other agents such as arsenic trioxide (Lo-Coco F et al, 2003). 
Acute myeloid leukemia with RUNX1-RUNX1T1 or AML-ETO: The t(8;21) fuses the 
RUNX1 or AML1 or CBFA2 gene on chromosome 21 to the RUNX1T1 or ETO gene on 
chromosome 8. RUNX1-RUNX1T1/ AML1-ETO fusion transcripts are found by RT-PCR in 
virtually all cases of t(8;21)-positive AML, including those with complex translocations and 
also in a significant proportion of t(8;21)-negative AML (van Dongen JJM et al, 1999). 
Transcripts of this fusion gene can be specifically and sensitively detected by RT-PCR. They 
generate predominant PCR products of a constant size, corresponding to an in-frame fusion 
of AML1 exon 5 to ETO exon 2 (Downing JR et al, 1993; Liu Yin JA, 2002).  
Acute myeloid leukemia with CBFB-MYH11:  This translocation involves fusion of CBFB 
gene located on16q22 with MYH11 gene located on 16p13. There is marked heterogeneity in 
the fusion transcripts, arising from variable genomic breakpoints in both CBFB and MYH11 
genes and alternative splicing. Ten different CBFB-MYH11 fusion transcripts have been 
reported and have been designated as types A to J (Liu Yin JA, 2002; van Dongen JJM et al, 
1999). More than 85% of the positive patients have type A transcript; two other transcripts 
(D and E) represent nearly 5% each, whereas all others represent unique cases (Liu PP et al, 
1995; Liu Yin JA, 2002).  
Other cytogenetic abnormalities: There are primers directed to diagnose other recurring 
genetic abnormalities, especially those involving MLL gene, the partners being MLLT3 
/AF9, AF6, AF10, ENL, etc. In addition PCR can be used to diagnose DEK-CAN related to 
t(6;9)(q23;q34), EVI-1 associated with inv 3(q21;q26)/ t(3;3) (q21;q26), AML1-EVI-1, 
t(3;21)(q26;q22) and rarely the BCR-ABL1, i.e. t(9;22)(q24;q11) (Swerdlow SH et al, 2008; 
Vardiman JW et al, 2009). Although BCR-ABL1–positive AML has been reported, criteria for 
its distinction from CML initially manifesting in a blast phase are not entirely convincing, 
and for this reason, BCR-ABL1–positive AML is not recognized in this classification. Many 
cases of BCR-ABL1– related AL will meet the criteria for ALL or MPAL, provided that a 
blast phase of a previously unrecognized CML can be excluded (Vardiman JW et al, 2009). 
GATA 1 mutations are detected in children less than 5 years in cases of AML associated 
with Down’s syndrome. (Swerdlow SH et al, 2008; Xavier AC & Taub JW, 2009) 
3.8.2 Cytogenetically Normal AML 
According to the various cytogenetic classifications mentioned above around 50% to 70% of 
AML patients are considered to be a part of an intermediate-risk group. Most of these 
patients have a normal karyotype (40-50% of all AML patients), but the heterogeneity is 
most pronounced in this group (Schlenk RF et al, 2008). Somatically acquired mutations 
have been identified in several genes, the notable ones are the NPM 1, CEBPA, and FLT3, 
which have been proven to have prognostic implications. AML with mutations in NPM1 or 
CEBPA have been incorporated in the WHO classification as provisional entities. The FLT3 
internal tandem duplication (ITD) mutation was detected and found to be the most common 
gene mutation in AML. Subsequent research shows that mutations of the NPM1 gene can 
occur in up to 60% of patients with AML and are most common in patients with a normal 
karyotype. The European Leukemia Net panel recommends that mutations of NPM1, 
CEBPA and FLT3 be analyzed at least in patients with CN-AML who will receive treatment 
other than low-dose chemotherapy or best supportive care (Döhner H et al, 2010; Döhner K 
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& Döhner H, 2008). There are few more as MLL, BAALC, WT1, etc which have also an 
impact on the prognosis.  
 
                                       1                2              Reference 
         
Fig. 12. A patient showing FLT3 – ITD in lane 2 (arrow) as a distinct band from the wild type 
of FLT-3. Lane 1 shows 100bp markers. The reference gel on the right panel shows the 
various locations of the wild and mutant products. 
Mutations of the nucleophosmin, member 1 (NPM1) gene: Mutations of NPM1 gene, 
which codes for a nuclear/cytoplasmic shuttling protein, are found in 50–60% of CN-AML 
cases (Schiffer CA, 2008). Heterozygous mutations in exon 12 of the NPM1 gene, results in 
abnormal cytoplasmic expression of its protein product, nucleophosmin. The presence of 
NPM1 mutations has been associated with pretreatment features as female sex, increased 
bone marrow blast percentages, LDH levels, WBC and platelet counts, and low or absent 
CD34 expression. In many studies, the presence of NPM1 mutation in CN-AML has been 
associated with good prognosis. 40% of patients with NPM1 mutations also harbor FLT3- 
ITDs (Döhner K et al, 2005; Falini B et al, 2006; Schnittger S et al, 2005; Thiede C et al, 2006). 
Mutations of the CCAAT/enhancer-binding protein alpha (CEBPA) gene: CEBPA protein 
is critical for normal hematopoietic differentiation and loss of activity either by mutation or 
epigenetic silencing can result in a block in normal differentiation. The incidence varies 
between 7% and 20% in various studies (Schiffer CA, 2008). Those with CEBPA mutations 
present with higher percentages of peripheral blood blasts, lower platelet counts, less 
lymphadenopathy and extramedullary involvement, and are less likely to also carry FLT3-
ITD, FLT3-TKD and MLL-PTD. CEBPA mutations confer favorable prognosis. CEBPA 
mutations are best studied by DNA sequencing, and hence are not available on a routine 
basis. 
FLT 3 mutations: FLT3 is a transmembrane tyrosine kinase receptor with important roles in 
hematopoietic stem/progenitor cell survival and proliferation. FLT3 is the most frequently 
mutated gene in AML. Different mutations of the gene exist. Most common are the internal 
tandem duplications (ITDs) in the juxta membrane domain (JMD) and found in 23% of AML 
patients (Figure 12). FLT3-ITD can be detected in all subtypes of AML but contradictory 
results have been published concerning its relationship with FAB type (Bacher U et al, 2008; 
Boissel N et al, 2006; Cairoli R et al, 2006; Frohling S et al, 2002; Gale RE et al, 2008; 
Kottaridis PD et al, 2001; Schnittger S et al, 2002). Its incidence is associated with 
hyperleukocytosis and age (Cairoli R et al, 2006). The frequency is higher in elderly patients 
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& Döhner H, 2008). There are few more as MLL, BAALC, WT1, etc which have also an 
impact on the prognosis.  
 
                                       1                2              Reference 
         
Fig. 12. A patient showing FLT3 – ITD in lane 2 (arrow) as a distinct band from the wild type 
of FLT-3. Lane 1 shows 100bp markers. The reference gel on the right panel shows the 
various locations of the wild and mutant products. 
Mutations of the nucleophosmin, member 1 (NPM1) gene: Mutations of NPM1 gene, 
which codes for a nuclear/cytoplasmic shuttling protein, are found in 50–60% of CN-AML 
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NPM1 mutations has been associated with pretreatment features as female sex, increased 
bone marrow blast percentages, LDH levels, WBC and platelet counts, and low or absent 
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ITD, FLT3-TKD and MLL-PTD. CEBPA mutations confer favorable prognosis. CEBPA 
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tandem duplications (ITDs) in the juxta membrane domain (JMD) and found in 23% of AML 
patients (Figure 12). FLT3-ITD can be detected in all subtypes of AML but contradictory 
results have been published concerning its relationship with FAB type (Bacher U et al, 2008; 
Boissel N et al, 2006; Cairoli R et al, 2006; Frohling S et al, 2002; Gale RE et al, 2008; 
Kottaridis PD et al, 2001; Schnittger S et al, 2002). Its incidence is associated with 
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and lower in children. FLT3 is highly expressed in infant MLL gene re-arranged ALL and 
offers an interesting target for this high-risk group of patients (Döhner H et al, 2010). In 
addition to FTL3-ITD, point mutations in the FLT3 gene involving aspartic acid 835 of the 
kinase domain (KD), may also lead to constitutive activation of the receptor. FLT3-KD point 
mutations in other sites are found less frequently. FLT3-KD point mutations are seen in 8-
12% of AML patients. Both types of mutation constitutively activate FLT3. Many studies in 
AML have shown that the presence of ITD mutations portends a poor prognosis. Thiede et 
al showed that the outcome of AML patients is dependent on the ratio of mutant and wild-
type FLT3 (Thiede C et al, 2002). In most studies the KD point mutants do not seem to have 
the same unfavorable prognostic effect. FLT3 mutations can also be detected in other types 
of AML including those with t (6;9) and APL (Schiffer CA. 2008). Testing for FLT3 mutations 
in younger patients, i.e. less than 60 years of age, with de novo AML is now recommended 
by the NCCN Practice Guidelines in Oncology. Testing for FLT3-ITD and for the other 
molecular markers is available mostly at only the large university centers and is performed 
as part of clinical trials (NCCN, 2006). 
Overexpression of WT1 (Wilm’s Tumor 1) gene: The levels of WT1 were found to be 102 – 
103 times higher in AML than in normal bone marrow, where it is either undetectable or 
expressed at very low levels. WT1 is over-expressed in approximately 90% of AML patients, 
except in FAB AML-M5, where its expression is lower (Gaidzik VI et al, 2009; Inoue K et al, 
1994; King-Underwood L et al, 1996; Liu Yin JA, 2002; Paschka P et al, 2008). Many studies 
show that levels of WT1 transcript are prognostically valuable and can predict early relapse 
in AML.  
Miscellaneous 
Partial tandem duplication (PTD) of the MLL (mixed lineage leukemia) gene was the first 
molecular alteration shown to impact on clinical outcome of CN-AML patients. It is detected 
in approximately 5% to 10% of these patients. Patients with MLL-PTD have a poorer 
prognosis than patients without the MLL-PTD (Mrózek K, & Bloomfield CD, 2006). 
Overexpression of the BAALC gene in PB at diagnosis was detected in adults under the age 
of 60 years. These are associated with lower WBC, less frequent diagnosis of FAB M5 AML 
and an unfavourable prognosis (Mrózek K, & Bloomfield CD, 2006). ERG overexpression is 
a recently identified molecular marker predicting adverse outcome (Mrózek K, & 
Bloomfield CD, 2006). Mutations of the C- KIT proto-oncogene, a tyrosine kinase receptor, 
result in a constitutive proliferative signal, have been described in patients with CBF- AML, 
with data suggesting a poorer outcome in patients with this additional mutation (Mrózek K, 
& Bloomfield CD, 2006; Schiffer CA, 2008). 
3.9 Electron microscopy 
The role of electron microscopy has diminished ever since the introduction of flow 
cytometry in the diagnostic work-up. Currently the WHO recognizes its role in the 
diagnosis of acute basophilic leukemia, which is characterized by the presence of granules 
containing structures characteristic of basophil precursors. These structures are electron 
dense particulate substance, are internally bisected, or contain crystalline material arranged 
in pattern of scrolls or lamellae (Swerdlow SH et al, 2008). The demonstration of 
metachromatic granules with toluidine blue stain and flow cytometry are enough to make 
the diagnosis. 
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3.10 Role of clinical history 
The role of clinical evaluation cannot be undermined for any diagnosis and evaluation of 
etiology and other prognostic factors. However, in the diagnostic algorithm of AML, clinical 
history is a vital component. A past history of receiving chemotherapy or radiation is of 
paramount importance to categorize therapy related AML. Similarly past history of 
myelodysplasia is important for the diagnosis of AML with myelodysplasia related changes. 
In a known scenario of Down’s syndrome AML should be separately grouped. Usually all 
these entities require cytogenetics supplementation. 
 
Factors Good Poor 
Clinical Parameters ECOG < 1 
No CNS  or extramedullary 
tumors  
Age < 2 and > 60 years 
ECOG > 1 
AML with prior 





TLC < 25000/ cu.mm TLC  > 100,000/ cu.mm 
Elevated LDH 
Morphology FAB AML-M3, M2, M4Eo FAB AML-M0, M6, M7 
Immunophenotype CD19, CD2 expression CD56, CD7 expression 
Cytogenetics t(15;17);  t(8;21) 
inv(16)/ t(16;16) 
Complex karyotype 
inv (3) or t (3;3), t(6;9), t(6;11), 
t(11;19), monosomy 5, or 7 
Molecular Presence of fusion 
PML/RARA; RUNX1-
RUNX1T1; CBFB-MYH11; 
Presence of NPM-1 mutation 




tandem duplication; BAALC, 
WT-1, ERG-2 over-
expression; mutations of C-
KIT;  
Response to treatment MRD negative MRD positive 
Table 4. Factors that influence prognosis 
4. Prognostic work-up 
There is a marked heterogeneity in the behavior of AML patients in terms of their response 
to the treatment and their survival rates. Various factors were found to have an effect on the 
prognosis in AML (Table 4) (Frohling S et al, 2006; Reinhardt D et al, 2000; Saxena A et 
al,1998). Several groups have published studies using cytogenetics to stratify patients into 
different risk groups (Byrd JC et al, 2002; Slovak ML et al, 2000). AML cytogenetic 
subgroups can be identified using molecular profiling with the potential for further 
subdividing patients to begin to explain the heterogeneity in outcome among patients of the 
same cytogenetic type. Cytogenetics and molecular studies are very important in the 
prognostication of acute leukemias. In cytogenetically favorable CBF-AML, the presence of a 
KIT mutation has been shown to have an unfavorable influence on outcome in retrospective 
studies (Boissel N et al, 2006; Cairoli R et al, 2006; Schnittger S et al, 2006). Numerous 
molecular markers are known to have impact on prognosis (Preudhomme C et al, 2002; 
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and lower in children. FLT3 is highly expressed in infant MLL gene re-arranged ALL and 
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kinase domain (KD), may also lead to constitutive activation of the receptor. FLT3-KD point 
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al showed that the outcome of AML patients is dependent on the ratio of mutant and wild-
type FLT3 (Thiede C et al, 2002). In most studies the KD point mutants do not seem to have 
the same unfavorable prognostic effect. FLT3 mutations can also be detected in other types 
of AML including those with t (6;9) and APL (Schiffer CA. 2008). Testing for FLT3 mutations 
in younger patients, i.e. less than 60 years of age, with de novo AML is now recommended 
by the NCCN Practice Guidelines in Oncology. Testing for FLT3-ITD and for the other 
molecular markers is available mostly at only the large university centers and is performed 
as part of clinical trials (NCCN, 2006). 
Overexpression of WT1 (Wilm’s Tumor 1) gene: The levels of WT1 were found to be 102 – 
103 times higher in AML than in normal bone marrow, where it is either undetectable or 
expressed at very low levels. WT1 is over-expressed in approximately 90% of AML patients, 
except in FAB AML-M5, where its expression is lower (Gaidzik VI et al, 2009; Inoue K et al, 
1994; King-Underwood L et al, 1996; Liu Yin JA, 2002; Paschka P et al, 2008). Many studies 
show that levels of WT1 transcript are prognostically valuable and can predict early relapse 
in AML.  
Miscellaneous 
Partial tandem duplication (PTD) of the MLL (mixed lineage leukemia) gene was the first 
molecular alteration shown to impact on clinical outcome of CN-AML patients. It is detected 
in approximately 5% to 10% of these patients. Patients with MLL-PTD have a poorer 
prognosis than patients without the MLL-PTD (Mrózek K, & Bloomfield CD, 2006). 
Overexpression of the BAALC gene in PB at diagnosis was detected in adults under the age 
of 60 years. These are associated with lower WBC, less frequent diagnosis of FAB M5 AML 
and an unfavourable prognosis (Mrózek K, & Bloomfield CD, 2006). ERG overexpression is 
a recently identified molecular marker predicting adverse outcome (Mrózek K, & 
Bloomfield CD, 2006). Mutations of the C- KIT proto-oncogene, a tyrosine kinase receptor, 
result in a constitutive proliferative signal, have been described in patients with CBF- AML, 
with data suggesting a poorer outcome in patients with this additional mutation (Mrózek K, 
& Bloomfield CD, 2006; Schiffer CA, 2008). 
3.9 Electron microscopy 
The role of electron microscopy has diminished ever since the introduction of flow 
cytometry in the diagnostic work-up. Currently the WHO recognizes its role in the 
diagnosis of acute basophilic leukemia, which is characterized by the presence of granules 
containing structures characteristic of basophil precursors. These structures are electron 
dense particulate substance, are internally bisected, or contain crystalline material arranged 
in pattern of scrolls or lamellae (Swerdlow SH et al, 2008). The demonstration of 
metachromatic granules with toluidine blue stain and flow cytometry are enough to make 
the diagnosis. 
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3.10 Role of clinical history 
The role of clinical evaluation cannot be undermined for any diagnosis and evaluation of 
etiology and other prognostic factors. However, in the diagnostic algorithm of AML, clinical 
history is a vital component. A past history of receiving chemotherapy or radiation is of 
paramount importance to categorize therapy related AML. Similarly past history of 
myelodysplasia is important for the diagnosis of AML with myelodysplasia related changes. 
In a known scenario of Down’s syndrome AML should be separately grouped. Usually all 
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Response to treatment MRD negative MRD positive 
Table 4. Factors that influence prognosis 
4. Prognostic work-up 
There is a marked heterogeneity in the behavior of AML patients in terms of their response 
to the treatment and their survival rates. Various factors were found to have an effect on the 
prognosis in AML (Table 4) (Frohling S et al, 2006; Reinhardt D et al, 2000; Saxena A et 
al,1998). Several groups have published studies using cytogenetics to stratify patients into 
different risk groups (Byrd JC et al, 2002; Slovak ML et al, 2000). AML cytogenetic 
subgroups can be identified using molecular profiling with the potential for further 
subdividing patients to begin to explain the heterogeneity in outcome among patients of the 
same cytogenetic type. Cytogenetics and molecular studies are very important in the 
prognostication of acute leukemias. In cytogenetically favorable CBF-AML, the presence of a 
KIT mutation has been shown to have an unfavorable influence on outcome in retrospective 
studies (Boissel N et al, 2006; Cairoli R et al, 2006; Schnittger S et al, 2006). Numerous 
molecular markers are known to have impact on prognosis (Preudhomme C et al, 2002; 
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Renneville A et al, 2009; Wouters BJ et al, 2009b). However, one needs to remember that it is 
the interaction of these factors, which are responsible for the ultimate prognosis, including 
the post-therapy remission status (Preisler H, 1993). 
5. Assessing the status of the therapeutic targets 
Ever since the introduction of all-trans retinoic acid and the Arsenic trioxide in the 
treatment of APL, imatinib in CML and rituximab in non-Hodgkin lymphomas of mature 
B-cell type, focus has been on developing specific drugs that would target those molecules 
and proteins that are specific to the leukemic cells and not affecting the normal 
hemopoietic cells. The various targets identified and worked upon in cases of AML are 
CD33, FLT3-ITD, enzymes as farnesyl transferase, histone deacetylase, P-glycoprotein, 
bcl-2 protein, and vascular endothelial growth factor (Stone RM, 2007). Of these the most 
widely are evaluated are CD33 and FLT3-ITD and its downstream pathway. Gemtuzumab 
ozogamicin (Mylotarg, CMA 676) is a monoclonal humanized anti-CD33 antibody 
chemically linked to the cytotoxic agent calicheamicin that inhibits DNA synthesis and 
induces apoptosis (Döhner H et al, 2010). It has shown significant activity in patients with 
relapsed acute myeloid leukemia, in elimination of minimal residual disease and in 
patients with APL who had evidence of disease only at the molecular level. Several FLT3-
selective tyrosine kinase inhibitors (e.g., midostaurin, lestaurtinib, sunitinib) have in vitro 
cytotoxicity to leukemia cells. A number of FLT3 inhibitors have reached clinical trials as 
monotherapy in relapsed or refractory AML patients, some or all of whom had FLT3 
mutations (Döhner H et al, 2010; Small D, 2006). Keeping these facts in mind assessment 
of the potential targets should be undertaken before starting these drugs, best at the time 
of diagnosis. 
6. Evaluation of the baseline parameters useful during follow-up 
Post-treatment assessment of residual disease is an important prognostic marker. 
Conventional morphology, karyotyping and FISH have not proven to be of any practical 
utility. Currently the best parameters at the time of diagnosis which can be used as follow-
up markers of disease are molecular transcripts and antigenic profile of the blasts. The 
practical guidelines are that: for patients with t(15;17), t(8;21) and inv(16), which are about 
30% of AML cases, it is recommended to quantify MRD by real-time RT-PCR (Liu Yin JA, 
2002; Lo-Coco F et al, 1999, 2003). For patients without a molecular marker, the options are 
multiparameter flow-cytometry or assessment of the WT1, whichever is appropriate for a 
particular patient (Inoue K et al, 1994; Wood BL, 2007). 
7. Parameters to assess baseline general health and detect comorbidities 
The general health and comorbidities should be assessed at the time of diagnosis before the 
patient undertakes the treatment. These will be baseline results based on which the 
complications will be monitored during the treatment. The following tests should be 
performed - complete blood counts, biochemical analysis, coagulation tests (especially in 
APL), urine analysis, serum pregnancy test in women with child bearing potential, 
screening for Hepatitis A, B, C virus and HIV-1 and 2, chest radiograph and 12-lead EKG, 
ECHO cardiography and lumbar puncture, whenever indicated. 
 
Diagnostic Approach in Acute Myeloid Leukemias in Line with WHO 2008 Classification 
 
183 
8. Planning for future 
Although not recommended on a routine basis, however, these tests should be planned in 
advance to avoid subsequent confounding results. If the patient is an ideal subject for 
allogeneic stem cell transplant, HLA typing and cross-matching of the patient and potential 
donors should be performed at the outset and the results be sent to the Bone marrow 
transplant registry. The patients’ pretreatment leukemic marrow and blood should be stored 
within a biobank.  
Genome-wide studies - The Probable Future: In recent years, DNA microarrays 
(complementary DNA (cDNA) and oligonucleotide), together with the availability of the 
complete nucleotide sequence of the human genome, have spurred the search for 
abnormalities in cancer, including AML (Wouters BJ et al, 2009a). There is enough data to 
support the fact that there is heterogeneity within established AML subtypes. The studies 
pertaining to the CBF-AMLs, each could be split into subgroups merely based on the GEP 
data (Wouters BJ et al, 2009a). Further validation of the generated data is necessary for 
assessing biologic significance. 
9. Approach in an ideal set-up 
The ideal work-up contains all elements described above with the aim of planning for 
future. The focus is to adopt whatever is clinically significant and proven in terms of 
diagnosis, prognosis, therapy, and disease monitoring at that point of time. It also involves 
archiving the necessary samples for future research and the data obtained thereafter may be 
available to incorporate newer information into clinical practice. The algorithms for this may 
be as illustrated in Figures 13, 14 & 15. 
Approach in resource limited areas 
WHO 2008 is the most appropriate classification in terms of prognostication and 
pathogenesis. This is however, a resource intensive process and liable to deviations in large 
parts of the world. The constraints on men, machine and material required to adhere to the 
current WHO classification are very real. It becomes necessary to devise methods that 
simplify the steps of diagnosis, prognosis, and monitoring treatment response. We find in 
our experience that it is possible to provide meaningful laboratory support for our under-
resourced patient population. Morphology combined with cytochemistry forms the basis of 
identifying entities that are potentially curable [ALL, APL, AML with t(8;21) and AML with 
inv(16)] and those which are less likely to yield good response to treatment (AML-M0, AML 
with dyspoiesis, AML-NOS ). With this objective work-up is planned. If treatment is a 
definite choice, baseline markers for monitoring response are necessary. The lack of 
resources including finances, infrastructure, expertise and socio-cultural factors that hinder 
treatment options are considerable. In such a situation diagnosing acute leukemia and 
recognizing AML in itself is an important step in patient management. Hence, the approach 
needs to be tailored to individual patient. The work-up designed in these circumstances may 
not always be in accordance with WHO 2008 guidelines. However, the information derived 
from this classification has improved our approach. The important end-points in this 
approach are to distinguish AML from ALL, identify the good-prognostic categories among 
AML. The algorithm for the same is proposed here (Figure 16). 
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1. Introduction  
Over the last decade, considerable effort has gone into defining global gene expression 
profiles (GEP) in many different types of malignancies. There is a dual aim behind these 
studies: on the one hand, to identify molecular signatures that correlate with clinically 
useful parameters and, on the other hand, to increase knowledge concerning the biology of 
the respective diseases. Some of these studies yielded molecular classifications of specific 
cancer types that better correlate with disease progression and/or response to therapy, 
whereas others revealed yet unknown biological properties of cancer cells that may 
represent the starting point for novel therapeutic approaches. 
Acute myeloid leukemias (AML) represent a highly heterogeneous set of malignancies 
whose pathogenesis is linked to specific genetic abnormalities, including chromosome 
translocations and point mutations that involve genes encoding for key regulators of 
hematopoiesis (Marcucci, Haferlach, & Dohner 2011). Genetic information is the most 
relevant parameter for the correct classification of AML patients at diagnosis into three 
prognostic risk groups (favorable, intermediate and adverse) and, consequently, for 
directing therapeutic choices (Lo-Coco et al. 2008; Dohner et al. 2010). In fact, current 
diagnostic approaches include cytogenetic and molecular analyses for correct stratification 
of AML patients according to the World Health Organization (WHO) recommendations 
(Vardiman et al. 2009). However, these approaches are not fully satisfactory, particularly 
within the significant group of cytogenetically normal AML (CN-AML), where known 
prognostic markers are lacking. This likely reflects the genetic heterogeneity of the CN-AML 
group, the existence of yet unidentified genetic lesions and the co-existence of different 
genetic mutations in a significant number of cases.  
AML was the first type of malignancy to be studied with a GEP approach, and hundreds of 
reports addressing specific clinical issues (classification, prognosis, response to therapy) 
have been published. An equally significant number of studies have addressed the 
molecular pathogenesis of AML by analyzing GEP in functionally characterized AML model 
systems, including transgenic mice, primary or established cell lines expressing 
leukemogenic oncogenes. The analysis of their specific target genes has been exploited to 
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unravel the functional consequences of AML-associated oncogene expression, including the 
arrest of myeloid differentiation and enhanced cell survival.  
In recent years, the analysis of AML has been extended to other genomic approaches, 
including microRNA profiling and epigenetic studies. The rapid technological 
advancement, and in particular the advent of next-generation sequencing has imposed a 
dramatic change of outlook to the molecular basis of cancer, including AML, and it is likely 
that GEP approaches so far used will become obsolete, favoring more focused, clinically 
relevant expression studies.  
What have GEP studies taught us about AML? We here propose an overview of the 
progress that has been made through GEP both in terms of clinical utility and of insight to 
the biology of the disease, and discuss future perspectives (Figure 1). 
  
 
Fig. 1. Main points covered in this review. 
2. Clinical utility of GEP analysis in AML  
The first evidence that GEP could be employed as a tool for the correct classification of 
cancer was reported by Golub and collaborators in 1999, using acute leukemias as a test case 
(Golub et al. 1999). The authors were able to discriminate AML samples from acute 
lymphoblastic leukemia (ALL) samples without prior knowledge concerning the respective 
diagnosis, and suggested two important applications for GEP: “class discovery”, which 
refers to the identification of new prognostically relevant tumor subtypes, and “class 
prediction”, which assigns tumor samples to already known subtypes on the basis of their 
specific gene expression signature. Successive studies introduced the possibility to exploit 
GEP for predicting response to therapy (“outcome prediction”) (Theilgaard-Monch et al. 
2011). Technically, class discovery implies the search for significant similarities and 
differences in a cohort of samples, assuming that similar gene expression signatures will 
correspond to the same disease subtype, and relies on an unsupervised approach (i.e. no 
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prior knowledge of patient characteristics, such as age, cytogenetics, molecular 
abnormalities, etc.). Class prediction, instead, takes into account patient information to 
derive gene expression signatures that are specific for given parameters, which can then be 
used for predicting disease subtypes in samples of unknown status (i.e. supervised 
approach).  
In de novo AML, chromosomal abnormalities can be detected at diagnosis in approximately 
55% of cases by cytogenetics analysis, and specific genetic mutations can be identified in 
85% of the remaining CN-AML. The most frequent chromosomal rearrangements include 
reciprocal translocations and inversions, such as t(8;21), which fuses the AML1 and ETO 
genes, inv(16), which results in the CBFβ/MYH11 chimeric gene, t(15;17), which generates 
the PML/RARα fusion specific of acute promyelocytic leukemia (APL), and a variety of 
translocations involving the MLL gene on chromosome 11q23, the most frequent being 
t(9;11) (Look 1997). The resulting fusion proteins possess oncogenic properties and 
frequently function as transcriptional regulators (Alcalay et al. 2001). It is therefore perhaps 
not surprising that AML blasts bearing such rearrangements display specific gene 
expression signatures, as demonstrated by several studies (Bullinger et al. 2004; Debernardi 
et al. 2003; Schoch et al. 2002; Valk et al. 2004). In fact, GEP can actually predict favorable 
cytogenetic AML subtypes, i.e. t(8;21), t(15;17) and inv(16), with 100% accuracy, and with 
>90% accuracy for AML with MLL rearrangements (Haferlach et al. 2005b; Ross et al. 2004), 
whereas the correlation is less stringent for other molecular subtypes (Verhaak et al. 2009).  
The function of group-specific genes often reflects characteristics of the corresponding 
disease: for example, the t(15;17) signature of APL, which is clinically characterized by a 
hemorrhagic diathesis and a response to treatment with Retinoic Acid (RA), includes genes 
involved in hemostasis and suggests an impairment in the response to RA-induced 
differentiation (Bullinger et al. 2004). Interestingly, GEP can segregate APL cases (M3 
subtype) from variant cases (M3v), which are characterized by a specific morphology of 
blasts and by a more severe prognosis (Haferlach et al. 2005a). The genes that are 
differentially expressed between APL-M3 and APL-M3v encode for functions such as 
granulation and maturation of blood cells, which are coherent with the morphological and 
clinical observations. 
Specific somatic mutations are frequent events in AML, particularly in CN-AML, which are 
classified in the group with intermediate risk even though there are important differences. 
Currently, only mutations of the NPM1, CEBPA and FLT3 genes have an impact on the 
clinics because of their correlation with prognosis. Other recurrent mutations in AML 
include N-RAS, KIT, IDH1, IDH2, WT1, RUNX1 and MLL, but their clinical significance is 
either controversial or unknown, and their identification is at the moment not used for 
guiding therapeutic choices. Although these mutations are prevalent in CN-AML, they can 
also be found in association to other cytogenetic abnormalities (Marcucci, Haferlach, & 
Dohner 2011).  
Specific GEP signatures have been described for AML that carry mutations, but their 
predictive accuracy appears to be lower than the one described for the recurrent cytogenetic 
rearrangements described above (Verhaak et al. 2009), likely due to the frequent co-
occurrence of different genetic abnormalities or to the presence of other yet unknown 
mutations. Mutations in the NPM1 gene represent the most frequent genetic abnormality in 
CN-AML (Falini et al. 2005), and are associated to mutations of the FLT3 gene in a 
significant proportion of cases. AML with mutated NPM1 without concurrent FLT3 
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predictive accuracy appears to be lower than the one described for the recurrent cytogenetic 
rearrangements described above (Verhaak et al. 2009), likely due to the frequent co-
occurrence of different genetic abnormalities or to the presence of other yet unknown 
mutations. Mutations in the NPM1 gene represent the most frequent genetic abnormality in 
CN-AML (Falini et al. 2005), and are associated to mutations of the FLT3 gene in a 
significant proportion of cases. AML with mutated NPM1 without concurrent FLT3 
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mutations are characterized by a better response to induction therapy and a favorable 
prognosis (Falini et al. 2007). These cases present a gene expression signature characterized 
by over-expression of HOX and TALE genes (Alcalay et al. 2005; Verhaak et al. 2005). Other 
genes involved in maintenance of hematopoietic stem cells, such as the NOTCH ligand 
JAG1, are also over-expressed, suggesting that the cell of origin of AML with mutated NPM1 
may be an early hematopoietic progenitor, as further indicated by frequent multilineage 
involvement (Alcalay et al. 2005; Pasqualucci et al. 2006). 
AML with CEBPA mutations are also associated with a favorable outcome. Generally, AML 
in this group carry mutations in both CEBPA alleles, whereas heterozygous mutations are 
less frequent. A specific GEP signature has been described for AML with biallelic CEBPA 
mutations, while no discriminating gene expression pattern was detectable in AML carrying 
single mutations (Wouters et al. 2009). Of note, in this study, only AML with biallelic 
CEBPA mutations correlated with a favorable outcome, whereas single mutations did not, 
suggesting a prognostic value for the specific gene expression signature. Interestingly, in a 
group of CN-AML patients displaying a GEP signature resembling that of AML with 
mutant CEBPA, but lacking such mutations, the CEBPA gene was found to be silenced as a 
consequence of promoter hypermethylation (Wouters et al. 2007). This result suggests that 
GEP may actually be more efficient than mutational analysis in identifying functional 
pathways that are perturbed in specific AML cases, and may be a useful tool for correct 
molecular classification of AML . 
Two types of mutations involving FLT3 can be found in AML: internal tandem duplications 
(FLT3-ITD), which are present in 20% of AML, and point mutations within the tyrosine 
kinase domain (FLT3-TKD) that can be detected in an additional 5-10% of cases. FLT3-ITD 
are associated with a poor prognosis in CN-AML, whereas the prognostic relevance of FLT3-
TKD is not clear (Marcucci, Haferlach, & Dohner 2011; Mrozek et al. 2007). GEP analyses in 
AML with mutated FLT3 have yielded controversial results. One study described an 
accurate separation of samples with FLT3-ITD from those with FLT3-TKD (Neben et al. 
2005), while another study reported a specific gene expression signature that discriminates 
between FLT3-TKD and FLT3-wild type CN-AML (Whitman et al. 2008). On the other hand, 
other studies reported difficulties in predicting FLT3 mutations from GEP results (Valk et al. 
2004; Verhaak et al. 2009). Such conflicting results may reflect the frequent coincidence of 
FLT3 mutations with other mutations in CN-AML (Dohner et al. 2010), where the co-
occurrence of several genetic abnormalities is likely to impact on the phenotype and the 
specific GEP. Interestingly, however, a specific gene expression signature derived from 
FLT3-ITD CN-AML, although not highly accurate in predicting the FLT3-ITD genotype, 
proved to be extremely accurate in predicting clinical outcome (Bullinger et al. 2008), 
suggesting that activation of the FLT3 pathway may be mediated by other yet unidentified 
genetic alterations. 
In summary, GEP has proven to be extremely reliable in identifying AML cases with 
recurrent chromosomal abnormalities, but less predictive in identifying specific gene 
mutations in CN-AML (Verhaak et al. 2009), and this raises doubts as to its applicability in a 
clinical setting. However, a recent multicenter study involving 11 laboratories that use 
different microarray platforms (MILE – Miocrarray Innovations in Leukemia) demonstrated 
that GEP is a robust technology for the diagnosis of hematologic malignancies with high 
accuracy (Haferlach et al. 2010), and that in some cases GEP outperformed routine 
diagnostic procedures. The analysis of larger cohorts of AML cases, in particular of the less 
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frequent molecular subtypes, will likely be necessary for the identification of reliable gene 
expression signatures of clinical utility. Whether GEP-derived predictors can be of use for 
prognosis, and in particular whether GEP presents a concrete advantage over standard 
cytogenetic or molecular markers in terms of prognostic value, remains an open question. 
Different studies have identified specific gene expression signatures that correlate with 
clinical outcome in AML (Bullinger et al. 2004; Metzeler et al. 2008; Radmacher et al. 2006), 
suggesting that GEP may, in fact, yield diagnostic and prognostic information 
simultaneously.  
3. GEP and the biology of AML 
As discussed above, GEP results derived from AML patients have been exploited to 
derive information concerning the biology underlying the disease. For the purpose of 
identifying specific functional pathways relevant to leukemogenesis, this approach is, 
however, partially hampered by properties that are intrinsic to patient-derived material, 
including individual genetic variability and the presence of heterogeneous cellular 
populations in each sample. It is, therefore, possible to exploit different experimental 
model systems, including purified cellular subpopulations, cell lines or animal models, 
with the aim of unraveling the molecular mechanisms underlying leukemic 
transformation. Such approaches have been widely proved to be reliable by extensive 
validation through a variety of independent methods. A significant number of reports 
have identified transcriptional targets deregulated in specific types of AML, and it is not 
possible to discuss all the data and their implications in due detail. We will instead briefly 
review specific aspects that emerged from these studies, focusing on their possible 
relevance to AML pathogenesis and management. 
3.1 Common functions: Myeloid differentiation and stem cell maintenance 
A general feature of AML-associated oncogenes is the capacity to block the process of 
myeloid differentiation and to promote self-renewal of hematopoietic precursor/stem cells. 
A variety of model systems have been employed for GEP analyses with the aim of 
identifying specific genes and pathways underlying these properties. Some of these studies 
have highlighted the existence of target genes that are common to several AML-associated 
oncogenes, suggesting that diverse genetic mutations can lead to the deregulation of 
overlapping downstream functional pathways. This observation is of potential clinical 
importance, since it suggests the existence of common therapeutic targets, regardless of the 
specific initiating oncogenic lesion. For example, expression of AML fusion proteins such as 
AML1/ETO, PML/RAR, and PLZF/RAR in the U937 hematopoietic cell line resulted in 
deregulation of a large set of common targets (Alcalay et al. 2003). These included a 
decreased expression of genes involved in myeloid differentiation, such as GFI1, CSF3R, 
STAT5A and others, and the activation of pathways leading to increased stem cell renewal 
(in particular, the Jagged1/Notch pathway). A similar approach led to the identification of 
Wnt signaling activation by diverse AML oncogenes, through upregulation of plakoglobin 
expression (Muller-Tidow et al. 2004). The existence of common leukemogenic functions is 
further suggested by the observation that a specific cellular subpopulation derived from 
CEBPA-deficient leukemia, which is capable of transferring AML to recipient mice, revealed 
a GEP signature shared with MLL-AF9-transformed AML (Kirstetter et al. 2008). 
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The identification of overlapping functions deregulated by AML oncogenes is perhaps to be 
expected. In fact, the genetic lesions underlying AML pathogenesis mostly involve 
transcriptional regulators that function during myeloid differentiation in an orchestrated 
manner, and are physiologically cross-regulating each other’s expression. For example, 
CEBPA is a crucial factor in myeloid differentiation, and its expression is often attenuated or 
repressed by oncogenic transcription factors such as AML1/ETO (Pabst et al. 2001). 
Therefore, part of the transcriptional response elicited by AML1/ETO may be due to a 
decrease in CEBPA activity. Overexpression of CEBPA in human CD34+ hematopoietic 
precursors induces the expression of genes involved in myeloid differentiation (Cammenga 
et al. 2003), which are presumably targets of deregulation not only in AML with mutated 
CEBPA, but also in all AML that present decreased levels of CEBPA expression. 
Interestingly, mutations involving genes that do not directly regulate gene expression, such 
as FLT3 or NPM1, are associated to alterations in global gene expression that partially 
overlap with those described for oncogenic transcription factors. Expression of FLT3 
mutants in murine 32Dcl3 cells resulted in repression of genes involved in myeloid 
differentiation, including CEBPA, and in the activation of a transcriptional program that 
partially overlaps with that induced by IL-3, a potent hematopoietic cytokine (Mizuki et al. 
2003). Recently, the expression of an NPM1 mutant allele in mouse HSC was shown to result 
in HOX gene overexpression, reproducing the situation of primary AML with mutated 
NPM1 (Vassiliou et al. 2011). The molecular mechanisms through which these mutants elicit 
a transcriptional response remain to be elucidated. 
3.2 Characterization of Leukemic Stem Cells 
AML derives from the transformation of a single hematopoietic progenitor/stem cell, 
known as leukemic stem cell (LSC), which shares important properties with normal 
hematopoietic stem cells (HSC), including unlimited self-renewal and the capacity to give 
origin to a hierarchy of hematopoietic cells. The molecular characterization of LSC and the 
identification of functions that are specific of LSC with respect to normal HSC are clearly 
instrumental for designing novel therapeutic strategies aimed at eradicating AML. 
The transforming genetic event does not necessarily occur in HSC, but may take place in 
more differentiated progenitors that reacquire stem cell characteristics (Passegue et al. 2003). 
In favor of the latter possibility, Krivtsov et al. isolated leukemic stem cells (LSC) from a 
mouse model of AML generated by the MLL-AF9 fusion protein, which revealed a GEP that 
was reminiscent of normal granulocyte/macrophage progenitors (Krivtsov et al. 2006). 
However, a subset of genes that is highly expressed in normal HSC appeared to be re-
activated in LSC, including several HOXA genes, STAT1 and CD44. Another study 
conducted on CD34+ AML revealed two distinct subpopulations of LSC, the more mature 
resembling normal granulocyte-macrophage progenitors in terms of GEP, and the immature 
LSC population reminiscent of lymphoid-primed multipotent progenitors (Goardon et al.). 
Taken together, these studies and the ones discussed in the previous section suggest that 
AML initiates in progenitor cells that re-acquire specific stem cell characteristics, such as 
activation of Notch and/or Wnt signaling and/or over-expression of HOX genes, which are 
tightly linked to the acquisition of an unlimited self-renewal capacity and cause an arrest in 
the differentiation program.  
However, the identification of functions that are specific of LSC with respect to normal HSC 
is clearly of importance for the identification of novel therapeutic strategies aimed at 
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eradicating AML. In terms of global gene expression, LSCs are not simply characterized by 
the re-activation of stem cell pathways and maintenance of self-renewal. A direct 
comparison of the GEP of highly enriched normal human HSC and LSC from AML of 
diverse subtypes revealed differences in relevant functional pathways, including Wnt 
signaling, MAP Kinase signaling, and Adherens Junction (Majeti et al. 2009). The latter is 
particularly intriguing, since it suggests specific abnormalities in the relationship between 
LSCs and the microenvironment (“niche”).  
3.3 Response to therapy 
AML are characterized by a heterogeneous response to therapy, and although there has 
been notable progress in the past decades, most patients still succumb to the disease. The 
search for new therapeutic strategies is therefore of paramount importance, and GEP studies 
have also been exploited to dissect the molecular basis underlying the response to AML 
therapy.  
One way to identify genes/pathways that may determine response to therapy is to compare 
GEP of treated versus untreated AML cells. Among AML, APL represents an exception in 
that its exquisite sensitivity to RA and arsenic trioxide treatment has dramatically changed 
its prognosis to a 5-year survival rate of 90%. Several studies have described specific 
transcriptional programs that are modulated by RA in APL cells, with the aim of identifying 
targets that may be of wider use in AML treatment. GEP analysis of APL blasts and 
PML/RAR-expressing U937 cells treated with RA in vitro revealed that the transcriptional 
response to RA is characterized by regulation of genes involved in the control of 
differentiation, stem cell self-renewal and chromatin remodeling, suggesting that specific 
structural changes in local chromatin domains may be required to promote RA-mediated 
differentiation (Meani et al. 2005).  
Another possible approach is to compare the GEP of sensitive versus resistant AML cells 
after treatment with drugs. Tagliafico et al. derived a molecular signature that predicts the 
resistance or sensitivity to differentiation induced by RA or vitamin D in six myeloid cell 
lines, and proved its validity in a set of primary AML blasts using an in vitro differentiation 
assay (Tagliafico et al. 2006). Similarly, Zuber at al., described the differences between a 
chemosensitive and a chemoresistant AML model: murine AML expressing the AML1/ETO 
fusion protein, which show a dramatic response to chemotherapy, displayed activation of 
the p53 tumor suppressor function. Murine AML expressing MLL fusion proteins are 
instead drug-resistant and present an attenuated p53 response. It appears, therefore, that the 
p53 network has a central role in the response to chemotherapy in AML (Zuber et al. 2009). 
Importantly, GEP information can also be exploited for the identification of new therapeutic 
options. Corsello et al. defined an AML1/ETO GEP signature by comparing a t(8;21) bearing 
cell line before and after siRNA-mediated inhibition of the fusion protein, and used the 
resulting signature to screen a set of drug-induced expression profiles (Corsello et al. 2009). 
In a recent study, publicly available GEP data sets derived from APL patients were 
exploited for the identification of an “APL signature”, which was then compared to a 
collection of expression profiles for more than 1300 bioactive compounds for the discovery 
of relevant drug candidates (Marstrand et al. 2010). Although these studies have not yet 
been transferred to the clinics, they open a concrete possibility for exploiting GEP data 
alongside chemical genomics approaches for the in silico identification of molecularly 
targeted drugs. 
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4. Conclusion and perspectives 
Have GEP studies truly had an impact on the management of AML? Currently, no GEP-
based diagnostic/prognostic tests are available for AML in clinical practice. However, tests 
that reliably predict the outcome for cancer patients based on the expression pattern of a 
selected subset of genes identified through GEP are available for other malignancies, such as 
breast cancer (van't Veer&Bernards 2008), and available evidence suggests that a reliable set 
of prognostic predictors could be established for AML as well. Furthermore, GEP can 
accurately sub-classify most AML according to the underlying genetic abnormality even 
when histopatholgical data are ambiguous, and outperforms routine diagnostic tests in 
certain cases, raising the possibility to introduce GEP-derived approaches in a diagnostic 
setting. A particularly exciting perspective is to exploit GEP data in combination with 
chemical genomics for the design of novel therapeutic strategies aimed at molecular targets. 
Many factors concur in determining the AML phenotype, and in recent years there has been 
a growing interest in high-throughput approaches other than GEP to analyze microRNA 
(miRNA) expression, epigenetic modifications and whole-genome DNA sequencing in 
AML. MiRNAs are small non coding RNAs that can regulate the expression levels of 
numerous target mRNAs both at the transcriptional and post-transcriptional level. Similarly 
to what has been observed for mRNAs, specific miRNA signatures have been associated 
with AML subtypes (Garzon et al. 2008; Li et al. 2008; Marcucci et al. 2008), and may 
therefore represent an additional option for the development of clinically useful tools. 
Epigenetic modifications including DNA methylation and covalent histone modifications, 
such as acetylation, methylation and ubiquitination, are known to play a crucial role in the 
regulation of gene expression, and different epigenetic alterations have been described in 
leukemias (Plass et al. 2008). Recently, specific DNA methylation profiles have been 
described for distinct cytogenetic and molecular AML subtypes, and a 15-gene methylation 
classifier was found to be predictive of overall patient survival (Figueroa et al. 2010). 
Interestingly, the integration of DNA methylation data with GEP was shown to further 
improve prognostication in AML, suggesting that integration of genomic approaches may 
prove of clinical importance (Bullinger et al. 2010). 
The advent of next-generation sequencing technology has opened the possibility to 
investigate the complexity of cancer genomes, and the first complete sequence of a human 
malignancy reported was that of an AML genome (Ley et al. 2008). The authors identified 
ten somatic mutations, two of which had already been described (NPM1 and FLT3), while 
the other eight were novel. None of the latter were, however, detected in a cohort of 187 
AML cases, casting serious doubts as to their relevance in determining the leukemic 
phenotype. Successive studies using the same approach identified novel mutations in the 
IDH1 and DNMT3 genes that are instead recurrent in AML, underlining the power of this 
approach for the discovery of genetic alterations in cancer (Ley et al. 2010; Mardis et al. 
2009). However, these studies also highlighted the relevant genetic heterogeneity among 
AML patients within the same subtype, since most of the mutations described were actually 
specific to the single patient under analysis, and their contribution to AML progression 
remains to be defined. One distinct possibility is that they represent “passenger” mutations 
that arise as a consequence of cancer-associated genomic instability, and bear no functional 
relevance to the malignant phenotype. On the other hand, such mutations may instead 
involve different players within complex functions (for example, regulators of proliferation 
or differentiation), and although the mutated genes are different, the functional 
 
Clinical and Biological Relevance of Gene Expression Profiling in Acute Myeloid Leukemia 
 
205 
consequence(s) may be the same. In any case, the co-existence of several genetic alterations 
within the same cell is bound to have an impact on gene expression, and  it will therefore be 
necessary to integrate GEP data with the corresponding results from mutational analyses. 
Finally, microarray technology has inherent limitations, and with the advancement of 
current sequencing approaches may rapidly become obsolete. The possibility to sequence 
entire transcriptomes (RNA-seq) has several advantages over microarray-based GEP, 
including transcription start site mapping, gene fusion detection, small RNA identification 
and detection of alternative splicing events (Ozsolak & Milos 2011). The first RNA-seq 
analysis of an AML model reported an unexpected level of transcriptome variation between 
phenotypically similar LSC, including a large number of structural differences such as 
alternative splicing and promoter usage (Wilhelm et al. 2011). These results suggest a broad 
transcriptional heterogeneity in AML that is not limited to differences in mRNA levels. 
In the next few years there will inevitably be an explosion of genomic data in AML, 
describing yet unknown molecular mechanisms underlying the disease. The large amount 
of already available GEP data will have to be integrated with the new findings to increase its 
value in generating knowledge that can ultimately be translated into clinically useful tools. 
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suggested that the treatment outcome of t(8;21)AML may differ depending on race 
(Marcucci et al, 2005). This indicates that the knowledge from past research in Western 
countries cannot necessarily be directly transferred to Japanese patients, but the reality is 
that research related to the clinical features of Japanese t(8;21)AML is very limited. Of these 
publications, the best summarized report is the analysis of patients participating in a clinical 
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2003). This report reveals that the overall 5-year survival rate was 52%. However, this report 
mainly focuses on the additional chromosome abnormality of t(8;21)AML. Many clinicians 
felt the need for new research in order to clarify the clinical features of t(8;21)AML in 
Japanese patients, such as prognosis and treatment outcomes. 
The research group of the authors appealed to clinicians and researchers aware of such 
issues, arranged participation of institutes for which approval was obtained, and conducted 
a retrospective study with the purpose of clarifying clinical features in Japanese patients. 
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2. Japanese t(8;21)AML patients have a favorable survival rate 
The authors retrospectively investigated clinical features of 46 adult t(8;21)AML patients 
newly diagnosed at facilities participating in the research from 2000 to 2005 as the subjects 
(Narimatsu et al, 2008b). The comparison of its outcome with prior researches (Appelbaum 
et al, 2006; Marcucci et al, 2005; Nguyen et al, 2002; Schlenk et al, 2004) is shown in Table 1. 
First off, the 3-year overall survival rate of Japanese t(8;21)AML patients reported by the 
authors was 70%. A definite conclusion cannot be drawn due to the short follow-up period, 
but close to 70% were estimated to have a 5-year survival rate. This is a good number 
compared to past reports from Western countries, in which 5-year survival rate ranged from 
45% to 59% (Appelbaum et al, 2006; Marcucci et al, 2005; Nguyen et al, 2002). On the other 
hand, age, which is the greatest risk factor for the survival of leukemia patients, was older in 
reports from Japan compared to reports from Western countries. Moreover, white blood cell 
counts and blood platelet counts at the initial visit, which are also believed to be risk factors, 
were the same in reports from Japan and reports from Western countries. From these 
comparisons, it was suggested that the prognosis of Japanese t(8;21)AML patients was better 
than the prognosis of Westerners, and a possibility that racial differences may be involved 
as its cause, rather than the inclusion of background factors such as age and white blood cell 
count at initial visit, was suggested. 
The authors also compared the survival rate of t(8;21)AML patients and leukemia patients 
that were diagnosed in each institute at the same time as AML(M2) having no t(8;21) 
abnormality(Narimatsu et al, 2008b). As a result, the overall survival rate of t(8;21)AML 
patients was significantly better than AML(M2) patients without t(8;21) (70% vs. 43% for 3-
year overall survival rate). However, the age of AML(M2) patients without t(8;21) was 
significantly higher compared to t(8;21)AML, so the overall survival rate was compared by 
limiting patients to those 60-years old or younger. As a result, the 3-year survival rate was 
71%(n=35, patients with t(8;21)) and 58% (n=49, patients without t(8;21)), respectively, 
narrowing the difference, with no significant difference observed between the two groups. 
Furthermore, when prognosis factor analysis was conducted with all these patients as 
subjects, the presence of t(8;21) was not a significant prognosis factor(Narimatsu et al, 
2008b). These results suggest that young age is the main reason for good prognosis in 
t(8;21)AML patients, which is very interesting. 
3. Prognosis factor 
It was revealed from the investigation of Japanese t(8;21)AML patients by the authors that 
the older the age, the higher the white blood cell count at the initial visit, and the worse 
the survival rate. This, as shown in Table 1, can be said to be almost the same as the 
outcome of the research in Western countries. However, chromosome abnormalities 
additionally occurring in t(8;21), such as the deficiency of a sex chromosome and/or 
chromosome-9-abnormality that have been pointed out in much prior research, was not 
an apparent prognosis factor. This is the same finding as the research by Nishii et al. from 
JALSG, and there is a possibility that this may be the difference with Western patients 
(Nishii et al, 2003). 
Moreover, although not included in the research by the authors, the report by Nishi et al. 
showed that the prognosis of patients with an addition of trisomy 4 is extremely poor, and  
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clinicians should make note of this fact. In one of those patients, Nishii et al showed c-kit 
mutation of the leukemia cells (Langabeer et al, 2003). KIT mutation may related to this 
unfavorable outcome, which needs to be clarified in further large study. 
4. Is high dose cytarabine therapy effective? 
It has been reported by prior research in Western countries that high dose cytarabine 
therapy can improve the treatment outcome of t(8;21)AML patients(Byrd et al, 1999; Ferrara 
& Del Vecchio, 2002). The authors also investigated whether or not the same can be said of 
Japanese patients. As a result, the survival rate of 14 patients who underwent consolidation 
therapy with a standard dose of cytarabine and that of 19 patients who underwent 
consolidation therapy with a high-dose cytarabine was approximately the same. However, 
numbers of those patients are small and the consolidation regimen of these patients covered 
various grounds, and it is difficult to discuss the efficacy of high dose cytarabine therapy 
from this result. Increased fatal side effects such as infectious diseases are a concern with 
high dose cytarabine therapy, but from this result, it is suggested that high-dose cytarabine 
can also be conducted in Japanese patients. 
Recently, the outcome of a randomized controlled trial of consolidation therapy with high 
dose cytarabine therapy and multi-drug therapy was reported by a JALSG group. 
According to their report, although high dose cytarabine therapy shows a better outcome for 
disease free survival and overall survival compared to multi-drug therapy at a standard 
dosage, the results did not have any apparent significant differences (Miyawaki et al, 2011). 
This differs from the research report accounting for the usefulness of high-dose cytarabine 
in Western countries represented by the research by Bloomfield et al (Bloomfield et al, 1998). 
On the other hand, documented severe infections are common in high-dose cytarabine 
groups. This difference is presumed to be related to the difference in the incidence of 
tyrosine kinase such as KIT, etc., which is believed to affect the prognosis, and there is a 
need to clarify this in future research. 
Taking the above outcomes into account, at this point, the decision regarding whether or not 
to apply high-dose cytarabine to Japanese t(8;21)AML patients must be determined by the 
on-site clinician. 
5. The significance of measuring minimal residual disease 
RUNX1 (AML1)/MTG8 (ETO) transcript occurs as a result of t(8;21)(q22;q22) 
translocation. The minimal residual disease can be evaluated by qualitatively and 
quantitatively measuring this transcript by the PCR method. In some small scale research 
from Western countries, it has been reported that patients with a high risk for relapse can 
be determined by evaluating minimal residual disease. (Krauter et al, 2003; Leroy et al, 
2005; Perea et al, 2006; Tobal et al, 2000) (Weisser et al, 2007) Therefore, in the same way, 
the authors also investigated the clinical significance of minimal residual disease in 
Japanese t(8;21)AML patients by collecting the outcome of RUNX1/MTG8 quantitative 
tests from the clinical records of 26 t(8;21)AML patients that reached complete remission 
(Narimatsu et al, 2008a). As a result, between the group that reached less than 1,000 copies 
of RUNX1/MTG8 transcript when remission was reached (n=13) and the group that did 
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not (n=7), the relapse-free survival rate was better in the latter group. This shows that in 
contrast to reports from Western countries, in Japanese patients, the number of copies of 
RUNX1/MTG8 transcript when remission is reached does not necessarily reflect 
prognosis; however, number of study patients are small and it is difficult to make a 
definite conclusion. On the other hand, relapse is expected in patients in whom 
RUNX1/MTG8 transcript increased during the remission period, and monitoring 
RUNX1/MTG8 transcript during the remission period was suggested to have significance 
in terms of early prediction of relapse. 
6. Conclusion - Issues to be solved in the future 
The motivation for the group of the authors to initiate research was the hypothesis of the 
authors, “Reports on t(8;21)AML from Western countries do not match the feeling of actual 
clinical practice.” Outcomes actually investigated also suggested a possibility of clinical 
features differing between Western t(8;21)AML patients and Japanese t(8;21)AML patients. 
It will be necessary to conduct large-scale research and/or a prospective study on Japanese 
patients as well in the future, in order to create evidence for Japanese t(8;21)AML patients. 
The following are listed in concrete terms. 
1. It is necessary to conduct a large-scale retrospective study to compare the survival rate 
of t(8;21)AML to that of AML with other chromosome abnormalities or AML without 
any. Furthermore, it is necessary to clarify if t(8;21) translocation is a significant 
prognosis factor of AML (as in the research by the authors, if the young age of 
t(8;21)AML patients is responsible for good prognosis). 
2. It is necessary to clarify the molecular biological characteristics of t(8;21)AML in 
Japanese patients. Particularly, investigation into whether or not the frequency of 
tyrosine kinase mutation, N-Ras mutation,,which are believed to have an effect on 
prognosis, is different between t(8;21)AML in Japan and Western countries, should be 
useful. 
3. It is also necessary to reinvestigate the clinical significance of minimal residual disease 
by research designed so as to unify when specimens were retrieved and the method of 
examination with patients treated, using the same regimen as the subject. 
The clarification of clinical features of t(8;21)AML in Japanese and Western patients and 
the establishment of optimum therapy customized for every ethnicity is hoped for in the 
near future. 
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by research designed so as to unify when specimens were retrieved and the method of 
examination with patients treated, using the same regimen as the subject. 
The clarification of clinical features of t(8;21)AML in Japanese and Western patients and 
the establishment of optimum therapy customized for every ethnicity is hoped for in the 
near future. 
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1. Introduction 
Acute promyelocytic leukemia (APL) is a subtype of acute myeloid leukemia (AML) 
characterized by the reciprocal translocation t(15;17)(q22;q12) resulting in the fusion gene 
PML-RARA and an oncoprotein that impairs myeloid differentiation (Arber et al., 2008; de 
The et al., 1990; Rowley et al., 1977). Morphological and clinical characteristics include 
hypergranular leukemic promyelocytes, Auer rods, and coagulopathy. The use of all-trans 
retinoic acid (ATRA) has revolutionized the management of this disease that has become the 
most curable form of AML in adults (Castaigne et al., 1990; Tallman et al., 1997). In relapsed 
APL, arsenic trioxide can induce complete morphological, cytogenetic and molecular 
remission (Douer and Tallman, 2005; Soignet et al., 1998).  
Cases lacking the classic t(15;17) are divided into two separate groups that behave 
differently and are now considered different disease entities (Arber et al., 2008). The first 
group represents cryptic and complex APL where t(15;17) is absent on routine cytogenetic 
studies but PML-RARA is present on molecular studies (Grimwade et al., 2000). This group 
shares the same phenotype, prognosis, and sensitivity to ATRA as classic APL, and is thus 
managed similarly. The second group, “AML with a variant RARA translocation”, is no 
longer considered part of APL and includes acute myeloid leukemias with translocations 
involving RARA and a variety of partner genes other than PML (Arber et al., 2008). 
Compared to classic APL, these leukemias often exhibit significant differences in malignant 
phenotype and sensitivity to ATRA which will be further explored in this chapter.  
2. Clinical characteristics 
APL represents less than 10% of all AML, but seems to be over-represented in Hispanics 
(Yamamoto and Goodman, 2008). The median age of presentation is approximately 40 years 
(Vickers et al., 2000). Leukocytosis is only seen in about 25% of patients, and organomegaly 
is rarely found on diagnosis. The most common presenting signs are pancytopenia, fever, 
anemia, and bleeding. The latter can be fatal especially if occurring in the central nervous 
system (CNS), and is due to the combination of thrombocytopenia and the dreaded 
coagulopathy of APL (Warrell et al., 1993).  
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Abnormal promyelocytes are larger than their normal counterparts, with a nucleus that is 
often bilobed or kidney-shaped. 75% of APL cases are hypergranular (M3) with densely-
packed cytoplasmic granules that are bright pink, red, or purple, in addition to Auer rods in 
bundles called “faggot cells”. The remaining 25% of cases are microgranular or 
hypogranular (M3v), the granules being visualized by electron microscopy but not light 
microscopy, and the cytoplasm may contain a few fine azurophilic granules.  
In APL, myeloperoxidase (MPO) is strongly positive in all leukemic promyelocytes, and this 
can be especially helpful in microgranular APL which is sometimes confused with acute 
monocytic leukemia (Arber et al., 2008).  
4. Immunophenotype 
APL cells are usually CD13 positive and especially CD33 positive, but are characterized by 
low or absent expression of HLA-DR, CD34, CD11a, CD11b, CD18, and CD117 (Paietta et 
al., 2004). Hypogranular APL frequently coexpresses CD34 and CD2 (Exner et al., 2000). 
Expression of CD56 has been observed in about 20% of cases and confers a worse outcome 
(Ferrara et al., 2000). 
5. Pathogenesis 
APL is caused by the reciprocal translocation t(15;17)(q22;q12) that results in the fusion gene 
PML-RARA and an oncoprotein that impairs myeloid differentiation (Grignani et al., 1993). 
PML and RARA are both involved in normal hematopoiesis, and disruption of their 
physiologic roles by the formation of PML-RARA is essential to leukemogenesis. 
PML possesses physiologic growth suppressor and proapoptotic properties that are 
disrupted by PML-RARA, possibly by the abnormal positioning of PML away from the 
nuclear body structure, thus contributing to leukemic transformation (Wang et al., 1998). 
Following this logic, treatment with ATRA restores the normal localization of PML, 
allowing the resumption of its physiologic functions. 
On the other hand, RARA normally binds to response elements at the promoter region of 
target genes through heterodimerization with the retinoid X receptor (RXR). RARA-RXR 
results in the recruitment of nuclear corepressors (N-CoR) and histone deacetylase (HDAC) 
that repress transcription and inhibit differentiation (Grignani et al., 1993). This is thought to 
take place through epigenomic changes including histone deacetylation or methylation 
(Licht, 2009) and could have therapeutic implications in the future, especially as to the 
efficacy  of histone deacetylase inhibitor in APL refractory to conventional treatment with 
ATRA. Physiologic amounts of retinoid acid (RA) unbind the N-CoR from RAR-RXR, 
allowing for activation of transcription of RARA target genes and myeloid differentiation. In 
the presence of PML-RARA, normal concentrations of RA are not enough for that separation 
and pharmacologic doses of ATRA are needed to allow myeloid differentiation (Warrell et 
al., 1993). Arsenic trioxide (ATO) can also lead to differentiation, but it does so by inducing 
degradation of the PML-RARA fusion transcript. Both drugs have recently been shown to 
also work on an entirely different level in APL by eradicating “leukemia-initiating cells” or 
“leukemic stem cells” (Nasr et al., 2009), leading to think that their combination in induction 
regimens could result in higher rates of prolonged remissions and cure. 
 




6.1 Classic t(15;17) APL 
Around 92% of APL patients have the balanced t(15;17), leading to the fusion of the retinoic 
acid receptor-alpha (RARA) gene on chromosome 17 and the promyelocytic leukemia (PML) 
gene on chromosome 15 (Grimwade et al., 2000) (Fig. 1). FISH uses a dual color dual fusion 
probe to detect PML-RARA rearrangements. The typical normal FISH pattern for the dual 
color, dual fusion probe is 2 red signals (2R) and 2 green signals (2G) for the PML and RARA 
loci respectively. When t(15;17) is present, the  characteristic FISH pattern is one red, one 
green and two fusion signals (Fig. 2). 
Whereas the breakpoints in RARA are invariably at intron 2, those in PML can occur at any 
one of three breakpoint cluster regions (Bcr): intron 6 (Bcr1), exon 6 (Bcr2), and intron 3 
(Bcr3) (Pandolfi et al., 1992). The 3 respective ensuing mRNA types, long (L)-form, variable 
(V)-form, and short (S)-form, can exhibit different phenotypes but do not affect complete 
remission (CR) rate or disease-free survival (DFS). The S-form, for example, is associated 
with increased leukocytosis which by itself is an adverse risk factor in APL, but after 
adjusting for that, does not independently influence CR rate and OS (Gallagher et al., 1997). 
The V form, originally thought to be less sensitive to ATRA, was later shown to be as 
equally sensitive to it as the other two types (Slack et al., 2000).  
6.2 Cryptic and complex APL  
As mentioned before, t(15;17) is absent in around 8% of patients diagnosed with APL 
(Grimwade et al., 2000), which should lead to the adoption of PML-RARA as the hallmark of 
APL. Cases lacking t(15;17) are divided into two separate disease entities: on one hand, 
cryptic and complex APL that share the same phenotype, prognosis, and sensitivity to 
ATRA as classic APL; and on the other hand, AML with a variant RARA translocation 
(Arber et al., 2008) which will be discussed later in this chapter. 
In cryptic and complex APL, the classic t(15;17) is absent on routine cytogenetic studies but 
PML-RARA is present on molecular studies; the leukemia is morphologically and clinically 
similar to t(15;17) positive APL and is treated as such. The European working party was 
crucial in characterizing the rare APL cases lacking the classic t(15;17) on routine cytogenetic 
studies. 4% of the cases represented cryptic/masked APL with submicroscopic insertion of 
RARA into PML leading to the expression of the PML-RARA transcript, while 2% had 
complex variant translocations involving chromosomes 15, 17 and an additional 
chromosome, and were sub-classified as: (a) complex variant t(15;17) due to a 3-way 
balanced translocation involving 15q22, 17q21, and another chromosome; (b) simple variant 
t(15;17) involving 15q22 or 17q21 with another chromosome; and (c) very complex cases 
(Grimwade et al., 2000). 
In these unusual cases, the diagnosis can be missed by conventional cytogenetic studies, and 
molecular methods are needed such as fluorescence in situ hybridization (FISH) (Fig. 2), 
reverse transcriptase polymerase chain reaction (RT-PCR) and direct sequencing. FISH is often 
not sensitive enough to detect small cryptic insertions (Han et al., 2007; Kim et al., 2008; Wang 
et al., 2009), while RT-PCR can also face technical challenges such as atypical PML-RARA 
rearrangement with new breakpoints in the PML gene that cannot be amplified with 
conventional primers (Barragan et al., 2002; Park et al., 2009), insertions of the PML gene to the 
RARA but too far apart to permit elongation and amplification of the PML-RARA sequence 
(Tchinda et al., 2004), or submicroscopic deletions of the 3’ RARA (Han et al., 2009).  
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efficacy  of histone deacetylase inhibitor in APL refractory to conventional treatment with 
ATRA. Physiologic amounts of retinoid acid (RA) unbind the N-CoR from RAR-RXR, 
allowing for activation of transcription of RARA target genes and myeloid differentiation. In 
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Fig. 1. G-banded karyotype with t(15;17)(q22;q21) at arrows. 
 
 
Fig. 2. Dual color dual fusion break apart probe for detection of PML-RARA rearrangement. 
Panel A shows a normal FISH pattern (2R,2G), whereas panel B reveals fusion of the PML 
and RARA loci at arrows. 
6.3 AML with a variant RARA translocation  
This term is now used by the WHO (World Health Organization) to designate a subset of 
acute myeloid leukemias morphologically similar to APL, but lacking both t(15;17) by 
cytogenetics and PML-RARA by FISH and RT-PCR (Arber et al., 2008). They do, however, 
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show different variant translocations involving RARA and 1 of 7 partner genes: ZBTB16 
(previously known as promyelocytic leukemia zinc finger gene or PLZF) on chromosome 
11q23 (Licht et al., 1995), NUMA1 (nuclear matrix-mitotic apparatus protein 1 gene) on 
chromosome 11q13 (Wells et al., 1996), NPM1 (nucleophosmin gene) on chromosome 5q35 
(Corey et al., 1994; Hummel et al., 1999), STAT5B (signal transducer and activator of 
transcription 5 beta) on chromosome 17q21.1-21.2 (Zelent et al., 2001), PRKAR1A (protein 
kinase, cAMP-dependent, regulatory, type I, alpha) on chromosome 17q24 (Catalano et al., 
2007), FIP1L1 (factor interacting with PAP 1-like 1) on chromosome 4q12 (Buijs and Bruin, 
2007), and BCOR (BCL6 corepressor gene) on chromosome X (Yamamoto et al., 2010). Of the 
partner genes, the first 4 were included in the latest WHO classification, while the last 3 
have been described since. As with other hematological malignancies, partner genes affect 
both neoplastic phenotype and response to treatment including ATRA, making their 
identification crucial in the evaluation of these patients. 
6.3.1 ZBTB16-RARA 
The ZBTB16 or PLZF gene encodes for a zinc finger transcription factor of 673 amino acids 
(Chen et al., 1993). Its expression may play a role in the life of hematopoietic stem cells and 
seems to be down-regulated with differentiation (Shaknovich et al., 1998). Like PML, it 
possesses tumor suppressor activity that seems to be disturbed by t(11;17)(q23;q21) (Zelent 
et al., 2001). The European working party on APL found the t(11;17)(q23;q21) translocation 
in 0.8% of APL patients (Grimwade et al., 2000). The first case was identified in a Chinese 
patient from Shanghai (Chen et al., 1993), and more than 16 cases have been described since. 
The clinical presentation is usually indistinguishable from APL, with a low peripheral WBC 
count and a preponderance of promyelocytes in the bone marrow. The leukemic cells are 
usually microgranular, have a regular nucleus instead of bilobed, no Faggot cells, and there 
is often an increased number of Pelger-Huet-like cells (Sainty et al., 2000). The blasts are 
typically HLA-DR and CD34 negative, CD13 and CD33 positive. Several cases were strongly 
positive for the CD56 NK cell antigen.  
The tumor suppressor properties of ZBTB16 are thought to be inhibited by the ZBTB16-
RARA fusion protein in t(11;17)(q23;q21). Except for anecdotal reports, patients with 
ZBTB16-RARA are resistant to ATRA since pharmacological doses of the drug fail to 
dissociate ZBTB16 from the co-repressors (Licht et al., 1995).  
6.3.2 NUMA1-RARA 
The nuclear matrix-mitotic apparatus protein 1 gene (NUMA1) on chromosome 11q13 is a 
236 kDa protein that serves in the completion of mitosis, is thought to be involved in the 
regulation of transcription and is affected by post-translational changes (Harborth et al., 
2000; Saredi et al., 1996). So far, there’s only been a single report of a patient with NUMA1-
RARA, a 6 month-old boy who was diagnosed with APL with atypical features, received 
ATRA and was in complete remission (CR) more than 24 months following a bone marrow 
transplant (Wells et al., 1997; Wells et al., 1996). The pathogenesis of this leukemia is not 
well understood, but is thought to share several features with PML-RARA APL.  
6.3.3 NPM1-RARA 
The nucleophosmin gene (NPM1) plays a role in several important cell functions from the 
transportation of ribosomal precursors between cytoplasm and nucleolus (Szebeni et al., 
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2007), and BCOR (BCL6 corepressor gene) on chromosome X (Yamamoto et al., 2010). Of the 
partner genes, the first 4 were included in the latest WHO classification, while the last 3 
have been described since. As with other hematological malignancies, partner genes affect 
both neoplastic phenotype and response to treatment including ATRA, making their 
identification crucial in the evaluation of these patients. 
6.3.1 ZBTB16-RARA 
The ZBTB16 or PLZF gene encodes for a zinc finger transcription factor of 673 amino acids 
(Chen et al., 1993). Its expression may play a role in the life of hematopoietic stem cells and 
seems to be down-regulated with differentiation (Shaknovich et al., 1998). Like PML, it 
possesses tumor suppressor activity that seems to be disturbed by t(11;17)(q23;q21) (Zelent 
et al., 2001). The European working party on APL found the t(11;17)(q23;q21) translocation 
in 0.8% of APL patients (Grimwade et al., 2000). The first case was identified in a Chinese 
patient from Shanghai (Chen et al., 1993), and more than 16 cases have been described since. 
The clinical presentation is usually indistinguishable from APL, with a low peripheral WBC 
count and a preponderance of promyelocytes in the bone marrow. The leukemic cells are 
usually microgranular, have a regular nucleus instead of bilobed, no Faggot cells, and there 
is often an increased number of Pelger-Huet-like cells (Sainty et al., 2000). The blasts are 
typically HLA-DR and CD34 negative, CD13 and CD33 positive. Several cases were strongly 
positive for the CD56 NK cell antigen.  
The tumor suppressor properties of ZBTB16 are thought to be inhibited by the ZBTB16-
RARA fusion protein in t(11;17)(q23;q21). Except for anecdotal reports, patients with 
ZBTB16-RARA are resistant to ATRA since pharmacological doses of the drug fail to 
dissociate ZBTB16 from the co-repressors (Licht et al., 1995).  
6.3.2 NUMA1-RARA 
The nuclear matrix-mitotic apparatus protein 1 gene (NUMA1) on chromosome 11q13 is a 
236 kDa protein that serves in the completion of mitosis, is thought to be involved in the 
regulation of transcription and is affected by post-translational changes (Harborth et al., 
2000; Saredi et al., 1996). So far, there’s only been a single report of a patient with NUMA1-
RARA, a 6 month-old boy who was diagnosed with APL with atypical features, received 
ATRA and was in complete remission (CR) more than 24 months following a bone marrow 
transplant (Wells et al., 1997; Wells et al., 1996). The pathogenesis of this leukemia is not 
well understood, but is thought to share several features with PML-RARA APL.  
6.3.3 NPM1-RARA 
The nucleophosmin gene (NPM1) plays a role in several important cell functions from the 
transportation of ribosomal precursors between cytoplasm and nucleolus (Szebeni et al., 
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1997), to cell growth control (Zelent et al., 2001) and activation of transcription (Shi et al., 
1997). It had been implicated in hematological malignancies including anaplastic lymphoma 
(Morris et al., 1994) and myelodysplastic syndrome (Yoneda-Kato et al., 1996). The NPM1-
RARA fusion is a rare variant translocation (less than 0.5%) and has so far been reported in 
pediatric patients, with absent Auer rods but otherwise variable morphology. In contrast to 
classic APL, CD13 is negative, but the rest of the immunophenotype is similar to classic APL 
including absence of CD56. The reported cases have been very sensitive to treatment with 
ATRA (Corey et al., 1994; Grimwade et al., 2000; Hummel et al., 1999; Redner et al., 1996).  
6.3.4 STAT5B-RARA 
STAT5B is one of many latent cytosolic transcription factors to be activated by janus kinase 
(JAK) tyrosine kinases, allowing it to move to the nucleus where it regulates gene 
transcription (Arnould et al., 1999). To date, only 4 cases of AML with STAT5B-RARA have 
been reported, all men in their fourth to sixth decade of life, with a predilection for 
disseminated intravascular coagulation (DIC) but otherwise heterogeneous clinical, 
morphologic and immunophenotypic characteristics. Finally, STAT5B-RARA is resistant to 
ATRA, similarly to ZBTB16-RARA. (Arnould et al., 1999; Iwanaga et al., 2009; Kusakabe et 
al., 2008).  
6.3.5 PRKAR1A-RARA 
PRKAR1A refers to protein kinase, cAMP-dependent, regulatory, type I, alpha. 
Protein kinase A (PKA) is a multimeric protein which activity is dependent on cyclic 
adenosine monophosphate (cAMP). Downregulation of PKA occurs when 
phosphodiesterase, one of the substrates activated by the kinase, converts cAMP to AMP, 
effectively decreasing cAMP that can activate PKA. There’s only one reported case of AML 
with PRKAR1A-RARA in a 66 year-old man. He presented with a normal WBC count, had a 
hypercellular marrow with 88% hypergranular promyelocytes, regular nuclei, and absent 
Auer rods and faggot cells. MPO was strongly positive, but expression of CD13, CD33, and 
CD11b was weak. The cells were negative for CD2, CD19, CD34, CD56, CD117, and HLA-
DR (Catalano et al., 2007).  
6.3.6 FIP1L1-RARA 
Human FIP1 is an integral subunit of cleavage and polyadenylation specificity factor (CPSF), 
and plays a significant role in poly(A) site recognition and cooperative recruitment of poly(A) 
polymerase to the RNA (Kaufmann et al., 2004). Only 2 cases of FIP1L1-RARA have been 
described, and the entity seems to be sensitive to ATRA. The first case involved a 90 year-old 
woman who was clinically diagnosed with APL and achieved a complete remission by oral 
administration of ATRA alone. No further details were described in the paper as to clinical 
presentation, morphology, or immunophenotypic analysis (Kondo et al., 2008). 
The second case involved a 20 month-old boy who was diagnosed with juvenile 
myelomonocytic leukemia after presenting with leukocytosis and anemia. Bone marrow 
aspirate showed hypercellularity including 11% promyelocytes, 25% myelocytes, 12% 
metamyelocytes, and 8% myelomonoblasts. These cells were hypergranular but had regular 
nuclei and no Auer rods. Immunophenotypic analysis was not published. Unfortunately, 
the patient did not receive ATRA, had an allogeneic stem cell transplant but died from 
relapse a few months later. 
 




As its name implies, BCOR is a corepressor of transcription through the oncoprotein BCL6, 
and its activity could be disrupted by the formation of BCOR-RARA (Huynh et al., 2000). 
There’s only one such case reported in the literature of a 45 year-old male patient who 
presented with leukocytosis and coagulopathy. Leukemic cells were MPO positive and less 
granular than classic APL. Interestingly, the cytoplasm contained periodic acid–Schiff 
rectangular and round cytoplasmic inclusion bodies and lacked Auer bodies and faggot 
cells. Immunophenotypic analysis showed HLA-DR negativity but positivity for CD33, 
CD13 and CD56. The patient was clinically responsive to ATRA but had several relapses 
with chemotherapy and ATRA (Yamamoto et al., 2010).  
7. Treatment 
In the previous section, we depicted the reported cases of AML with a variant RARA 
translocation, their response to treatment, and their varying sensitivity to ATRA depending 
on the partner gene. We will now discuss the management of classic APL, and cryptic and 
complex APL; these all share the same phenotype, prognosis, and sensitivity to ATRA, and 
therefore are treated similarly.  
7.1 Induction therapy 
When left untreated, APL is the deadliest form of AML with a median survival of less than 
30 days (Hillestad, 1957). The introduction of ATRA in 1980 (Breitman et al., 1980) 
completely revolutionized the management of this disease that now boosts complete 
remission rates of 80 to 95% and cure rates of around 80% (Sanz and Lo-Coco, 2011). ATRA 
sets off the differentiation of malignant promyelocytes into mature granulocytes, improves 
homeostasis and shortens the duration of the dreaded coagulation syndrome of APL. It also 
generates the eradication of “leukemia-initiating cells” or “leukemic stem cells”, a property 
shared by arsenic trioxide (ATO). In mice, a combination of both drugs can actually result in 
the elimination of leukemia-initiating cells and effectively “cure” APL (Nasr et al., 2009), 
opening the door to future trials combining ATRA and ATO without the use of 
chemotherapy. As mentioned before, if APL is suspected clinically and cytologically, ATRA 
should be promptly started even if cytogenetic and molecular confirmations of the diagnosis 
are pending.  
Because of the short duration of CR with ATRA alone, and the known sensitivity of APL to 
anthracyclines (Head et al., 1995), the current standard induction regimen in APL is the 
administration of ATRA with anthracycline-based chemotherapy. This combined approach 
has been shown to be superior to a previously adopted sequential treatment of ATRA 
followed by chemotherapy (Fenaux et al., 1999). The median time to CR ranges from 38 to 44 
days but could be as long as 90 days. In addition to its effect on CR, chemotherapy controls 
leukocytosis that is common when ATRA is used alone. In patients who have 
contraindications to anthracycline chemotherapy, the combination of ATRA and arsenic 
trioxide (ATO) for induction treatment should be considered (Sanz et al., 2009). The current 
standard chemotherapy regimens use daunorubicin with cytarabine or idarubicin alone, 
while there’s a lack of experience and data with other anthracyclines. These 2 regimens have 
indirectly yielded comparable CR rates (Fenaux et al., 1999; Mandelli et al., 1997). When 
daunorubicin was used without cytarabine in one randomized prospective trial of young 
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leukocytosis that is common when ATRA is used alone. In patients who have 
contraindications to anthracycline chemotherapy, the combination of ATRA and arsenic 
trioxide (ATO) for induction treatment should be considered (Sanz et al., 2009). The current 
standard chemotherapy regimens use daunorubicin with cytarabine or idarubicin alone, 
while there’s a lack of experience and data with other anthracyclines. These 2 regimens have 
indirectly yielded comparable CR rates (Fenaux et al., 1999; Mandelli et al., 1997). When 
daunorubicin was used without cytarabine in one randomized prospective trial of young 
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patients with APL, the CR rates were similar but there were more relapses and lower overall 
survival in patients who did not get cytarabine (Ades et al., 2006). The additional benefit 
conferred by cytarabine, however, did not apply to all patients and was only observed in 
those with WBC > 10x109/L (Ades et al., 2008) who are high-risk patients by Sanz’s risk 
stratification (Table 1) (Sanz et al., 2000; Sanz et al., 2004). Based on these results and the 
findings of other trials suggesting a similar role for cytarabine in consolidation (Sanz and 
Lo-Coco, 2011), we recommend that APL patients younger than 60 years old with WBC > 
10x109/L receive cytarabine in addition to ATRA and an anthracycline. Other indicators of 
relapse, such as CD56 positivity, do not currently alter treatment decisions (Ferrara et al., 
2000).  
7.2 Consolidation therapy  
Five to six weeks following induction, patients should be re-evaluated with bone marrow 
aspirate/biopsy and cytogenetics, while RTC-PCR for PML-RARA is not required since the 
transcript will still be detectable in about half of patients. Those in remission (> 90% of 
patients) will proceed with consolidation treatment to prevent relapse. This involves the use 
of an anthracycline (± cytarabine in high-risk patients), in addition to ATRA (Sanz et al., 
2004; Sanz et al., 2008), but different regimens are still being prospectively studied.  
7.3 Maintenance therapy 
Molecular remission is required at the end of consolidation treatment, after which 
maintenance ATRA will increase disease-free survival and improve the 10-year cumulative 
incidence of relapse (Ades et al., 2010; Tallman et al., 2002). The most commonly used 
maintenance regimen lasts for 1 year and encompasses ATRA 45 mg/m2 orally daily for 15 
days every 3 months or 7 days every 2 weeks, 6-mercaptopurine 60 mg/m2 orally every 
evening, and methotrexate 20 mg/m2 orally every 7 days (Avvisati G, 2003). Patients 
require close surveillance for toxicities, myelosuppression, and abnormal liver function 
tests, in addition to RTC-PCR every 3 months to monitor for disease relapse. 
 
Risk stratification  3-year DFS 
Low risk WBC ≤ 10x109/L, PLT > 40x109/L  97% 
Intermediate risk WBC ≤ 10x109/L, PLT ≤ 40x109/L  97% 
High risk WBC > 10x109/L  77% 
Table 1. Risk stratification of APL patients based on WBC and Platelet (PLT) counts, and 
corresponding 3-year disease-free survival (DFS) following induction and consolidation 
therapies with ATRA + anthracycline-based chemotherapy, followed by standard 
maintenance (Sanz et al., 2000; Sanz et al., 2004)  
8. Refractory and relapsed disease 
8.1 Arsenic trioxide 
Patients who do not achieve cytogenetic remission after induction therapy and/or 
molecular remission after consolidation are considered to have refractory disease, while 
those in remission who suddenly have detectable PML-RARA by RTC-PCR have relapsed 
APL. In both situations, salvage treatment is needed and arsenic trioxide (ATO) can induce 
CR in 85 to 88% of patients, and this can be followed by stem cell transplantation (Soignet et 
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al., 2001; Soignet et al., 1998). ATO not only induces degradation of the PML-RARA fusion 
transcript, leading to differentiation of malignant promyelocytes, but also leads to the death 
of “leukemia-initiating cells” (Nasr et al., 2009).  
So far reserved for the treatment of refractory or relapsed disease, in addition to some use in 
patients with contraindications to anthracyclines (Sanz et al., 2009), ATO has and is 
currently being studied for use in first-line induction therapy alone or in combination with 
ATRA without any chemotherapy (Hu et al., 2009; Mathews et al., 2006). This, however, has 
not yet become standard of care.  
ATO is usually given at 0.15 mg/kg/day intravenously until hematologic remission or for a 
maximum of 60 days. The major side-effects of this drug are fluid retention, differentiation 
syndrome and QT prolongation (Unnikrishnan et al., 2004).  
8.2 Other agents 
Repeat treatment with ATRA and chemotherapy in refractory and relapsed APL has had 
disparate success, and other agents that might be of benefit in this setting are still under 
investigation including gemtuzumab, Hum195 which is an anti-CD33 antibody, sodium 
phenylbutyrate, and calcitriol. 
Of special note, tamibarotene, a synthetic retinoid synthesized by the University of Tokyo in 
1984 and 10 times more potent than ATRA, seems to be especially promising. Tamibarotene 
is approved in Japan for use in relapsed and refractory acute APL, and was successfully 
used at our institution (University of Texas Southwestern Medical Center) in a patient with 
relapsed and refractory extra-medullary APL (Naina et al., 2011). Tamibarotene is currently 
being compared to ATRA for maintenance therapy in the ongoing APL204, a randomized 
phase III trial of the Japan Adult Leukemia Study Group.  
9. Other considerations 
9.1 Coagulopathy 
Within the first 10 days of treatment, 5-10% of APL patients will develop fatal hemorrhage, 
especially in the central nervous system (CNS) and lungs (Rodeghiero et al., 1990). This is 
secondary to a characteristic coagulation disorder combining disseminated intravascular 
coagulation (DIC) and fibrinolysis that is not well understood. Platelets and cryoprecipitate 
should be transfused to maintain platelet counts more than 30-50x109/L, and fibrinogen 
level more than 150 mg/dL, respectively (Tallman et al., 2005). ATO and ATRA have both 
been shown to quickly correct this coagulation disorder, and the initiation of the latter has 
become a true emergency in any new APL patient. ATRA should be promptly started when 
APL is clinically and cytologically suspected even if cytogenetic and molecular 
confirmations of the diagnosis are pending (Sanz et al., 2009).  
9.2 Central Nervous System (CNS) prophylaxis 
The CNS is the most common site of extramedullary disease and relapse in APL (Evans and 
Grimwade, 1999), with elevated WBC count > 10x109/L being the only significant risk factor 
in a multivariate analysis (de Botton et al., 2006). There are no guidelines as to the systematic 
CNS prophylaxis of APL patients with leukocytosis. Groups who include intrathecal 
chemotherapy in their regimens administer it during consolidation, not during induction 
when the risk of fatal bleeding is high. ATO crosses the blood-brain barrier and is being 
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aspirate/biopsy and cytogenetics, while RTC-PCR for PML-RARA is not required since the 
transcript will still be detectable in about half of patients. Those in remission (> 90% of 
patients) will proceed with consolidation treatment to prevent relapse. This involves the use 
of an anthracycline (± cytarabine in high-risk patients), in addition to ATRA (Sanz et al., 
2004; Sanz et al., 2008), but different regimens are still being prospectively studied.  
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Molecular remission is required at the end of consolidation treatment, after which 
maintenance ATRA will increase disease-free survival and improve the 10-year cumulative 
incidence of relapse (Ades et al., 2010; Tallman et al., 2002). The most commonly used 
maintenance regimen lasts for 1 year and encompasses ATRA 45 mg/m2 orally daily for 15 
days every 3 months or 7 days every 2 weeks, 6-mercaptopurine 60 mg/m2 orally every 
evening, and methotrexate 20 mg/m2 orally every 7 days (Avvisati G, 2003). Patients 
require close surveillance for toxicities, myelosuppression, and abnormal liver function 
tests, in addition to RTC-PCR every 3 months to monitor for disease relapse. 
 
Risk stratification  3-year DFS 
Low risk WBC ≤ 10x109/L, PLT > 40x109/L  97% 
Intermediate risk WBC ≤ 10x109/L, PLT ≤ 40x109/L  97% 
High risk WBC > 10x109/L  77% 
Table 1. Risk stratification of APL patients based on WBC and Platelet (PLT) counts, and 
corresponding 3-year disease-free survival (DFS) following induction and consolidation 
therapies with ATRA + anthracycline-based chemotherapy, followed by standard 
maintenance (Sanz et al., 2000; Sanz et al., 2004)  
8. Refractory and relapsed disease 
8.1 Arsenic trioxide 
Patients who do not achieve cytogenetic remission after induction therapy and/or 
molecular remission after consolidation are considered to have refractory disease, while 
those in remission who suddenly have detectable PML-RARA by RTC-PCR have relapsed 
APL. In both situations, salvage treatment is needed and arsenic trioxide (ATO) can induce 
CR in 85 to 88% of patients, and this can be followed by stem cell transplantation (Soignet et 
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al., 2001; Soignet et al., 1998). ATO not only induces degradation of the PML-RARA fusion 
transcript, leading to differentiation of malignant promyelocytes, but also leads to the death 
of “leukemia-initiating cells” (Nasr et al., 2009).  
So far reserved for the treatment of refractory or relapsed disease, in addition to some use in 
patients with contraindications to anthracyclines (Sanz et al., 2009), ATO has and is 
currently being studied for use in first-line induction therapy alone or in combination with 
ATRA without any chemotherapy (Hu et al., 2009; Mathews et al., 2006). This, however, has 
not yet become standard of care.  
ATO is usually given at 0.15 mg/kg/day intravenously until hematologic remission or for a 
maximum of 60 days. The major side-effects of this drug are fluid retention, differentiation 
syndrome and QT prolongation (Unnikrishnan et al., 2004).  
8.2 Other agents 
Repeat treatment with ATRA and chemotherapy in refractory and relapsed APL has had 
disparate success, and other agents that might be of benefit in this setting are still under 
investigation including gemtuzumab, Hum195 which is an anti-CD33 antibody, sodium 
phenylbutyrate, and calcitriol. 
Of special note, tamibarotene, a synthetic retinoid synthesized by the University of Tokyo in 
1984 and 10 times more potent than ATRA, seems to be especially promising. Tamibarotene 
is approved in Japan for use in relapsed and refractory acute APL, and was successfully 
used at our institution (University of Texas Southwestern Medical Center) in a patient with 
relapsed and refractory extra-medullary APL (Naina et al., 2011). Tamibarotene is currently 
being compared to ATRA for maintenance therapy in the ongoing APL204, a randomized 
phase III trial of the Japan Adult Leukemia Study Group.  
9. Other considerations 
9.1 Coagulopathy 
Within the first 10 days of treatment, 5-10% of APL patients will develop fatal hemorrhage, 
especially in the central nervous system (CNS) and lungs (Rodeghiero et al., 1990). This is 
secondary to a characteristic coagulation disorder combining disseminated intravascular 
coagulation (DIC) and fibrinolysis that is not well understood. Platelets and cryoprecipitate 
should be transfused to maintain platelet counts more than 30-50x109/L, and fibrinogen 
level more than 150 mg/dL, respectively (Tallman et al., 2005). ATO and ATRA have both 
been shown to quickly correct this coagulation disorder, and the initiation of the latter has 
become a true emergency in any new APL patient. ATRA should be promptly started when 
APL is clinically and cytologically suspected even if cytogenetic and molecular 
confirmations of the diagnosis are pending (Sanz et al., 2009).  
9.2 Central Nervous System (CNS) prophylaxis 
The CNS is the most common site of extramedullary disease and relapse in APL (Evans and 
Grimwade, 1999), with elevated WBC count > 10x109/L being the only significant risk factor 
in a multivariate analysis (de Botton et al., 2006). There are no guidelines as to the systematic 
CNS prophylaxis of APL patients with leukocytosis. Groups who include intrathecal 
chemotherapy in their regimens administer it during consolidation, not during induction 
when the risk of fatal bleeding is high. ATO crosses the blood-brain barrier and is being 
 
Myeloid Leukemia – Clinical Diagnosis and Treatment 
 
228 
evaluated for use in first-line induction therapy; it is conceivable that such induction 
regimens will result in lower rates of CNS relapse.  
9.3 Differentiation syndrome 
Also known as the retinoic acid syndrome or cytokine storm, it is seen in around 25% of 
APL patients in the first 3 weeks following treatment with ATRA or arsenic trioxide (Vahdat 
et al., 1994). The differentiation syndrome is caused by the release of cytokines from 
neoplastic promyelocytes as they differentiate in response to treatment. Usual symptoms 
include fever, shortness of breath, peripheral edema, pulmonary infiltrates, hypoxemia, 
respiratory distress and hypotension. Patients can also develop renal and hepatic 
dysfunction, in addition to pleural and pericardial effusions. The syndrome can be fatal and 
prompt recognition is vital, leading to the initiation of intravenous dexamethasone 10 mg 
twice daily until clinical resolution, followed by slow steroid taper. Patients with WBC > 
10x109/L are suspected to be at increased risk, and some recommend treating this group 
prophylactically with steroids (Wiley and Firkin, 1995).  
10. Conclusion 
Over the last 2 decades, we have witnessed a change in acute promyelocytic leukemia from 
the most malignant form of AML to the most curable one; a remarkable medical 
achievement that did not rely on advances in chemotherapy, but rather on molecular 
targeted therapy in the form of differentiation agents. This innovative approach to the 
treatment of malignant neoplasms was later emulated by the use of tyrosine kinase 
inhibitors in chronic myeloid leukemia. The latest scientific breakthrough in APL is the 
discovery that ATRA and ATO not only induce differentiation but also eradicate “leukemia-
initiating cells” or “leukemic stem cells” (Nasr et al., 2009), leading to think that their 
combination in induction regimens could result in higher rates of prolonged remission and 
cure. This has opened the door to new clinical trials in APL and a rational that might prove 
one day applicable in other hematologic malignancies. 
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evaluated for use in first-line induction therapy; it is conceivable that such induction 
regimens will result in lower rates of CNS relapse.  
9.3 Differentiation syndrome 
Also known as the retinoic acid syndrome or cytokine storm, it is seen in around 25% of 
APL patients in the first 3 weeks following treatment with ATRA or arsenic trioxide (Vahdat 
et al., 1994). The differentiation syndrome is caused by the release of cytokines from 
neoplastic promyelocytes as they differentiate in response to treatment. Usual symptoms 
include fever, shortness of breath, peripheral edema, pulmonary infiltrates, hypoxemia, 
respiratory distress and hypotension. Patients can also develop renal and hepatic 
dysfunction, in addition to pleural and pericardial effusions. The syndrome can be fatal and 
prompt recognition is vital, leading to the initiation of intravenous dexamethasone 10 mg 
twice daily until clinical resolution, followed by slow steroid taper. Patients with WBC > 
10x109/L are suspected to be at increased risk, and some recommend treating this group 
prophylactically with steroids (Wiley and Firkin, 1995).  
10. Conclusion 
Over the last 2 decades, we have witnessed a change in acute promyelocytic leukemia from 
the most malignant form of AML to the most curable one; a remarkable medical 
achievement that did not rely on advances in chemotherapy, but rather on molecular 
targeted therapy in the form of differentiation agents. This innovative approach to the 
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1. Introduction 
Among patients with acute myeloid leukemia (AML), treatment regimens and outcomes 
may differ among younger and older adults. Although there is no clear dividing line when 
considering age in AML, in most studies, "older adults" was defined as over age 60.The 
management of older patients with AML is a difficult challenge [1]. Older adults are more 
likely to have comorbidities that can limit treatment options; the disease tends to be more 
aggressive biologically; and outcomes are worse than in younger patients.  
Decisions regarding the optimal treatment of acute myelogenous leukemia in the elderly 
patient requires the consideration of multiple factors. Population-based studies have 
demonstrated that, for all age groups, aggressive therapy results in improved survival and 
quality of life when compared with palliative care. The optimal induction and post 
remission regimen for older patients has yet to be determined. Furthermore, not all patients 
are candidates for such therapy. Consideration of patient and disease-related factors can 
help to determine the appropriateness of intensive therapy in a given patient. For those 
patients for whom aggressive induction therapy does not seem to be in their best interest, 
novel agents are being investigated that will hopefully address the issues of induction death 
and early relapse associated with these patient populations. This topic review will discuss 
the treatment of older adults with AML. 
Most question that must be answer. 
1. How Is Acute Myeloid Leukemia in the Elderly Different?  
2. What Is the Standard Therapy for the Older Patient With AML? 
3. Who Should Not Receive Intensive Therapy? 
4. What Treatment Options Are Available for Patients Who Are Not Candidates for 
Intensive Induction Therapy? 
Acute myeloid leukemia (AML) presents at all ages, but is mainly a disease of the elderly, 
with a median age of 69 years in the white US population[93]. In the Swedish Acute 
Leukemia Registry, 68% of patients diagnosed with AML since 1973 were over age 60 years; 
between 1997 and 2005, 75% was aged 60 years or more[94]. Prognosis worsens every 
decade beginning at age 30 to 40 [93,95]. A report by the German Acute Myeloid Leukemia 
Cooperative Group looked at patients 16 to 85 years of age enrolled in two consecutive trials 
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Leukemia Registry, 68% of patients diagnosed with AML since 1973 were over age 60 years; 
between 1997 and 2005, 75% was aged 60 years or more[94]. Prognosis worsens every 
decade beginning at age 30 to 40 [93,95]. A report by the German Acute Myeloid Leukemia 
Cooperative Group looked at patients 16 to 85 years of age enrolled in two consecutive trials 
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in 1992 and 1999 with no upper age limit who had AML[96]. In a multivariate analysis of 
prognostic factors, age ≥ 60 years was a statistically significant poor prognostic factor for 
complete remission (CR), overall survival (OS), remission duration, and relapse-free 
survival (RFS). Population-based studies have reported 3- and 5-year survival rates of only 
9% to 10% and 3% to 8%, respectively, in patients over age 60, compared with 5-year 
survival rates of up to 50% for younger patients[94,96,97]. Poorer outcome has traditionally 
been considered to be the result of less intensive therapy in this population, concurrent 
comorbidities, a higher likelihood of underlying hematopoietic disorders, and biologically 
poor risk disease. Moreover, because of the perception that older adults are less likely to do 
well with standard therapy, clinicians are less likely to treat these patients aggressively or 
refer them to centers that do so. As such, lower levels of aggressive treatment may 
compound underlying prognostic differences associated with patient factors and disease 
biology. 
2. Pretreatment evaluation 
General — The assessment of an older adult with AML includes those studies used for the 
pretreatment evaluation of younger adults with AML in addition to more specific 
investigations of physical functioning, nutrition, and comorbid conditions. Testing specific 
for older adults is presented in the following sections. The detailed pretreatment evaluation 
of all patients with AML is presented separately, as is an overview of the comprehensive 
geriatric assessment of cancer patients.  
Physical functioning — The patient's performance status and ability to perform activities of 
daily living are measures of physical function that can help to predict the ability to 
withstand rigorous chemotherapy regimens. 
Performance status — Several studies have supported the use of the Eastern Cooperative 
Oncology Group (ECOG) and Karnofsky performance status as measures of physical 
functioning and prognosis in patients with AML (table-1) 
A retrospective study of data from five Southwestern Oncology Group (SWOG) trials that 
included 968 patients with AML found that the mortality rate within 30 days of initiation of 
induction therapy is dependent upon both the patient's age and ECOG performance status 
(PS) at diagnosis.  
Thirty-day mortality rates were 2 to 3 percent for patients under the age of 55 years 
regardless of the PS.For patients over age 55 years, mortality rates ranged from 5 to 18 
percent for patients with a PS of zero or 1. Patients 55 to 65 years old with a PS of 2 had a 
similar mortality rate (18 percent).Patients over age 55 years with a PS of 3 and those over 
age 65 with a PS of 2 or 3 had much higher mortality rates that ranged from 29 to 82 
percent.The proportion of patients with poorer performance status increased with age. PS of 
2 or 3 was observed in 15, 24, 26, and 32 percent in those under age 56, 56 to 65, 66 to 75, and 
>75 years of age, respectively. 
Activities of daily living — Geriatricians commonly measure functional status by evaluating 
basic activities of daily living (ADLs) and instrumental activities of daily living (IADLs). 
ADLs are the skills that are necessary for basic living, and include feeding, grooming, 
transferring, and toileting. IADLs are required to live independently in the community and 
include activities such as shopping, managing finances, housekeeping, preparing meals, and 
taking medications. Assessment of ADLs and IADLs may add to the functional status 
obtained from the ECOG or Karnofsky performance status. 
 




Table 1. Karnofsky performance status scale 
Comorbid conditions — Comorbid conditions are poor prognostic factors in older patients 
with AML [8-10]. Patients with age-related chronic cardiac, pulmonary, hepatic or renal 
disorders or diabetes suffer greater acute toxicity from chemotherapy. 
Older patients may also have decreased bone marrow regenerative capacity, even after 
successful leukemia cytoreduction. Inability to tolerate long periods of pancytopenia and 
malnutrition or the nephrotoxicity of drugs such as aminoglycosides or amphotericin 
remains a major barrier to successful treatment. 
Frequently used measures of comorbidity include a modified Charlson comorbidity index 
(CCI) and the hematopoietic cell transplantation-specific comorbidity index (HCT-CI), 
neither of which was originally designed for older adults with AML. 
Other comorbidity scores have incorporated information on infections prior to treatment 
and antecedent hematologic disorders. Assessment of other patient-related variables (eg, 
advanced age, performance status, organ function, karyotype, leukocytosis, CD34 
expression) with or without a modified comorbidity index may be helpful for predicting 
such outcomes as attainment of complete remission, early mortality, and overall survival 
[3,4,11,12]. 
Charlson comorbidity index — The original Charlson comorbidity index (CCI) was devised 
as a measure of comorbidities in older adults. A revised version has been developed for use 
in older adults with AML with mixed results. (table 2). 
A retrospective study evaluated the use of this modified CCI in 133 patients age 70 or older 
who received induction chemotherapy for AML [11]. CCI scores of zero, 1, and more than 1 
were seen in 68, 13, and 19 percent of patients, respectively. When compared with those 
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with a CCI score of 1 or less, patients with a CCI score greater than 1 had a significantly 
lower rate of obtaining a complete response (35 versus 63 percent) and had a nonsignificant 
trend towards higher eight-week mortality rates (30 versus 19 percent) and lower two-year 
overall survival (24 versus 30 percent). 
 
 
Table 2. Charlson comorbidity index (CCI) 
HCT comorbidity index — The hematopoietic cell transplantation specific comorbidity 
index (HCT-CI) was designed to predict outcomes in patients undergoing hematopoietic cell 
transplantation (HCT) (table 3). It has had mixed results in predicting outcome in older 
adults with AML. 
 
 
Table 3. Hematopoietic cell transplantation specific comorbidity index 
A retrospective study of 177 patients over 60 years of age receiving induction chemotherapy 
for AML reported HCT-CI scores of zero, 1 to 2, and greater than 2 in 22, 30, and 48 percent 
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of patients, respectively [14]. Corresponding early death rates were 3, 11, and 29 percent, 
respectively. The same groups had median overall survival times of 45, 31, and 19 weeks, 
respectively.A second retrospective study evaluated the use of the HCT-CI in 92 patients age 
80 or above with newly diagnosed AML offered induction chemotherapy [13]. Intensive 
therapy was given to 64 percent while the remainder elected supportive care. HCT-CI scores 
of zero to 1, 2 to 3, and 4 or greater were seen in 20, 35, and 45 percent, respectively. Patients 
with a HCT-CI score greater than 4 had a similar median survival when compared to those 
with a HCT-CI score of zero or 1 whether they received supportive care (1.9 versus 1.4 
months) or intensive chemotherapy (3.5 versus 4.2 months). 
Family discussions — A discussion with the patient and family members should include a 
review of the following 
Prognostic information allowing them to make informed decisions on the type of treatment 
to be pursued [12]. Regardless of treatment choice, patients and their family members often 
report not being offered alternative treatment options and tend to overestimate the chance 
of cure [15]. Written consent forms required for clinical trials may serve an educational role, 
even for those who do not desire to enter into a formal study. Who has durable power of 
attorney for health issues if the patient becomes unable to make decisions? Does the patient 
have an updated will? Do other members of the family know where this information is 
kept? Will the family have access to adequate funds while the patient is hospitalized?A 
discussion concerning "code" status and the possibility that the patient might need to be 
transferred to an intensive care unit, with its attendant morbidity and mortality [16]. This 
should include issues related to "do not resuscitate" and "do not intubate" orders, such that 
the patient and family can make properly informed decisions on these matters. (See "Ethics 
in the intensive care unit: Informed consent; withholding and withdrawal of life support; 
and requests for futile therapies".)The effect on the patient's employment. Most patients will 
not be able to return to even part-time work until the completion of induction and 
consolidation chemotherapy. 
3. Outcomes in older compared to younger patients 
Overview — Overall survival rates for AML decrease as age increases (figure 1). Most series of 
older patients with newly diagnosed AML have noted CR rates between 40 and 60 percent 
[2,4,5,8,12,17-21]. While suitably selected older patients given aggressive induction therapy 
may achieve CR at a rate approximating that of younger patients [12], others may spend a 
significant proportion of their remaining life in a hospital setting receiving treatment. 
Older age, defined in most studies as over age 55, 60, or 65, is an independent poor 
prognostic factor in AML. Such patients have, in comparison with younger patients. 
Poorer performance status Higher incidence of multidrug resistance Lower percentage of 
favorable cytogenetics Higher percentage of unfavorable cytogenetics Higher treatment-
related morbidity and mortality Higher incidence of treatment-resistant disease Lower 
complete remission rates, shorter remission durations, and shorter median overall survival 
Fewer opportunities for allogeneic hematopoietic cell transplantation. 
An analysis of Medicare claims for 2657 older patients with AML diagnosed between 1991 
and 1996 underscored the grim prognosis for AML in the older patient.  
Median survival for all patients was two months, with a two-year overall survival of 6 
percent. For patients ≥85 years of age, median survival was only one month.Only 30 percent 
of patients received chemotherapy; when compared with those not receiving chemotherapy, 
 
Myeloid Leukemia – Clinical Diagnosis and Treatment 
 
238 
with a CCI score of 1 or less, patients with a CCI score greater than 1 had a significantly 
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they tended to be younger (average age 73 versus 78 years) and live longer (median survival 
seven versus one month).Of those older patients dying from AML during the follow-up 
period of the study (94 percent of the sample), 31 percent of their remaining days had been 





Fig. 1. Overall survival rates for AML decrease as age increases. 
The outcomes might be better if more patients were offered induction chemotherapy. A 
retrospective analysis of 2767 patients with non-APL AML from the Swedish acute leukemia 
registry reported that early death rates (ie, death within 30 days of diagnosis) were 
considerably lower in patients receiving intensive induction chemotherapy when compared 
with those who received palliative therapy, even when stratified for performance status, 
however it remains possible that patients with a better prognosis were more likely to be 
 
Treating the Elderly Patient with Acute Myelogenous Leukemia 
 
241 
offered induction chemotherapy [4]. The difference between 30-day mortality rates for the 
two groups ranged from 16 to 35 percent. Patients who had de novo AML, were "fit" for 
intensive chemotherapy, had an ECOG performance status of zero to 2, and were age 16 to 
55, 56 to 65, 66 to 75, and 76 to 89 had median overall survival times of 7 years, 18 months, 
14 months, and 6 months, respectively. 
Prognostic factors — A number of risk factors have been identified which occur more 
frequently in the older patient and appear to contribute to the worse outcome. The major 
independent prognostic factors in older adults with AML are Age Cytogenetics Performance 
status Secondary leukemia White blood cell count at diagnosis Multidrug resistance-1 (P-
glycoprotein) expression. 
The cytogenetic abnormalities most often associated with treatment failure in young 
patients with AML (eg, abnormalities of chromosomes 5 or 7 or complex karyotypes) are 
considerably more common in older patients, occurring in 32 to 57 percent of patients in two 
series [25,27-30]. Conversely, all of the "favorable" cytogenetic abnormalities, such as t(8;21), 
t(15;17), or inv(16), are more common in younger subjects and are responsible in part for 




Fig. 2. Overall survival in aml according to the cytogenetic study. 
4. Overview of treatment 
Goals — The goal of remission induction chemotherapy is the rapid restoration of normal 
bone marrow function and attainment of complete remission.  
Induction therapy aims to reduce the total body leukemia cell population from 
approximately 10 12 to below the cytologically detectable level of about 10 9 cells. It is 
generally assumed, however, that a substantial burden of leukemia cells persists undetected 
(ie, minimal residual disease), leading to relapse within a few weeks or months if no further 
therapy were administered. 
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Postinduction or "remission consolidation" therapy usually comprises one or more courses 
of chemotherapy or hematopoietic cell transplantation (HCT). It is designed to eradicate 
residual leukemia, allowing the possibility of cure. Rates of relapse and death are quite low 
after three to four years in remission, and most such patients are long-term disease-free 
survivors. 
Decision to treat — After the diagnosis of AML has been established, the physician and staff 
must present the goals of therapy, as well as the side effects of treatment, to the patient and 
family. For almost all patients, this discussion can emphasize the potential benefits of 
intensive treatment with regard to both the short and long term outcome. Remission 
induction, even if short-lived, is an appropriate goal for most patients with AML.  
Patients who achieve a remission have an improved quality of life compared with those 
patients who receive palliative therapy likely because they require fewer hospitalizations, 
transfusions, and antibiotics [4].Attainment of CR following intensive chemotherapy is 
required in order to assure meaningful prolongation of life.   
Occasionally, intensive treatment with the intent to achieve CR may be less advisable 
because of advanced patient age, debility, presence of significant co-existing medical 
problems, and/or prior chemotherapy. Patients unlikely to survive treatment can be 
identified by their poor performance status using the Karnofsky or ECOG (Zubrod) 
performance.  
In addition, there are a few patients with "acute leukemia" by the usual quantitative criteria 
of >20 percent bone marrow blast cells whose disease has a much more smoldering course. 
These patients suffer from bone marrow failure and pancytopenia more than 
hyperleukocytosis. Their survival may be equally long and their quality of life better, using 
transfusion support and antibiotics rather than intensive chemotherapy. This may be 
particularly true for the "hypoplastic/hypocellular" variant of AML. Supportive care may 
also be beneficial in acutely infected patients with advanced myelodysplastic syndromes. 
Occasionally, the clinical picture mimics AML, but resolves following treatment of the 
infection. 
For otherwise healthy (ECOG performance status of two or less and few comorbidities) 
older adults with newly diagnosed AML, we suggest remission induction treatment, ideally 
on a clinical trial.For older patients with indolent AML, severe comorbidity, or high risk 
disease, we suggest the use of supportive care rather than standard induction 
chemotherapy. 
It is frequently appropriate and necessary to repeat this discussion and counseling later 
during the patient's course, as a diagnosis of acute leukemia often leaves the patient and 
family unable to cope with the longer term consequences of this diagnosis until the patient 
has successfully passed through the initial weeks of chemotherapy and recovery. 
INDUCTION — The best treatment strategy for older patients with AML remains 
controversial . Among the treatment options that have been evaluated are various forms of 
intensive or less-intensive chemotherapy, the administration of colony-stimulating factors to 
enhance neutrophil recovery, supportive therapy, low-dose cytarabine, high- or 
intermediate-dose cytarabine-based consolidation therapy, prolonged consolidation 
therapy, and maintenance treatment with interferon. Most of these studies have been 
disappointing. 
Intensive chemotherapy — The best induction chemotherapy for older patients with AML 
remains to be identified . Intensive chemotherapy may be appropriate for selected patients 
with low or intermediate risk disease in whom the complete remission (CR) rate can be as 
 
Treating the Elderly Patient with Acute Myelogenous Leukemia 
 
243 
high as 70 to 80 percent . With this approach, median survival is approximately eight 
months, but 9 to 12 percent of patients will be alive at five years. Although pilot studies 
have used more intensive initial chemotherapy, a reasonable standard regimen for many 
older patients who are medically fit is seven days of continuous infusion cytarabine (ara-C, 
100 mg/m2 per day) plus three days of daunorubicin (60 or 90 mg/m2 per day).  
Randomized trials have investigated various modifications of cytarabine plus an 
anthracycline for the treatment of older adults with AML. In general, the choice of 
anthracycline (eg, daunorubicin, mitoxantrone, or idarubicin) does not appear to affect 
overall outcome. However, higher doses of anthracyclines may result in superior rates of 
complete remission (CR) without an apparent increase in toxicity. 
For most older adults with favorable or intermediate risk AML and an ECOG performance 
status of two or less and few comorbidities, we suggest remission induction treatment with 
a combination of an anthracycline such as daunorubicin for three days and "standard" dose 
cytarabine for seven days rather than other chemotherapy regimens or supportive care 
alone. When induction treatment is chosen, it should be applied at sufficient dose intensity 
to provide the best chance of success. Further details on the administration of this regimen 
are presented separately as are recommendations for evaluation after completion of 
induction therapy. 
Use of growth factors — Several groups have evaluated the effects of colony-stimulating 
factors (eg, GM-CSF, G-CSF, and glycosylated G-CSF) as an adjunct to intensive 
chemotherapy with largely disappointing results. The rationale for this approach is that 
older patients are particularly susceptible to infection and experience a higher infectious 
mortality rate during episodes of neutropenia. Shortening the duration of neutropenia 
might have a beneficial effect and improve the rate of complete remission. 
What Treatment Options Are Available for Patients Who Are Not Candidates for Intensive 
Induction Therapy? 
For those patients who are not considered to be candidates for intensive induction therapy, 
one would hope to identify agents and regimens that are more effective and less toxic to 
address the concerns regarding early induction death, inadequate response rate, and high 
risk of relapse. The NCRI AML 14 study was designed to allow for randomization of 
patients between intensive and nonintensive therapy, but only eight patients agreed to 
randomization[117,147]. As such, data available on novel agents comes from a variety of 
pilot and phase II studies with differing eligibility criteria. When evaluating the outcomes, it 
is important to also look at the characteristics of patients who were ultimately enrolled.  
reviews available data from some of these studies . 
As part of the NCRI AML 14 study, 212 patients who were deemed unfit for intensive 
treatment options by the local investigator were randomized to receive supportive care 
alone with hydroxyurea or cytarabine 20 mg twice daily by subcutaneous injection for 10 
days every 4 to 6 weeks [95].  Outcome was improved for the low-dose (LD) cytarabine arm 
when compared with supportive care with hydroxyurea alone. CR was 18% versus 1%, and 
median survival was 575 days for those who achieved CR, compared with 66 days in 
nonresponders. DFS for responders was 8 months. Survival benefit was seen in all age 
groups, even those over age 75. As none of the patients with adverse cytogenetics achieved a 
CR, no survival benefit was, however, seen in that group. The early death rate was 
39% at 8 weeks. Although no criteria were used to define unfit patients, 78% were over age 
70, 27% had secondary AML, 30% had PS _ 2, 27% had heart disease, 49% had other 
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comorbidities, and 59% had a poor risk score by the Wheatley Risk Index [90].  Based on this 
study, LD cytarabine became the standard of care for the treatment of patients felt to be 
unfit for intensive chemotherapy, although one could argue that it should not be given to 
those with poor risk cytogenetics. 
The DNA methyltransferase inhibitors have been the subject of several recent studies. In a 
multicenter phase II study of 55 patients over age 60 with untreated AML, decitabine was 
administered for 5 days monthly until disease progression. [96].  With a median of three 
cycles, the overall response rate was 24%, median survival was 7.7 months, and 30-day 
mortality was 7%. Responses were seen in all cytogenetic risk groups, as well as in those 
patients with prior MDS. An alternate schedule of decitabine was reported by Blum et 
al[97,98].  Patients received an initial one to two courses of 10 days of decitabine, followed 
by a course over 3 to 5 days every 4 weeks for 1 year. Of the 53 patients with a median age 
of 74, 36% had secondary AML, and 34% had a complex karyotype. 
Eighteen patients had a HCTCI score of _ 3. There was a 64% response rate after a median of 
three cycles of therapy. CR occurred in all subsets, regardless of age, karyotype, presenting 
WBC, and prior AHD. One-year survival of poor risk patients was 30% (compared with 10% 
in patients with a similar Wheatley risk score in the AML 11 trial) [90].   
In a study of azacitidine in AML with 20% to 30% blasts, patients who were deemed unfit 
for standard induction chemotherapy were randomized against either supportive care or LD 
cytarabine[99]. OS survival was superior in the azacitidine arm. There was a statistically 
significant difference seen in OS for patients with poor risk cytogenetics in favor of 
azacitidine, compared with conventional care regimens (12.3 vs 5.3 months, respectively, 
with 2-year OS of 38% vs 0%). 
Gemtuzumab ozogamicin (GO) has been the subject of a recent study by the EORTC and 
GIMEMA leukemia groups (AML 19) [100].   
In this randomized multicenter study, 84 patients were randomizedto receive one of two 
schedules of GO at attenuated doses or best supportive care. The proportion of patients 
either achieving a response or maintaining stable disease was greater in patients who 
receive GO at a dose of 6 mg/m2 on day 1 and 3 mg/m2 on day 8, when compared with a 
schedule of GO 3 mg/m2 on days 1, 3, and 5 (63% vs 38%, respectively). Results of the 
comparison with patients who were randomized to standard care are not yet available, and 
a phase III trial is ongoing. 
Clofarabine has been studied as an agent in elderly patients with AML. In a phase II study 
of the agent in 112 patients over age 60 with untreated AML with at least one unfavorable 
baseline prognostic factor, there was a 46% response rate[101]. The median age of the 
patients was 71. Twenty-two percent of patients had a baseline PS of 2, 47% had a prior 
hematologic disorder (AHD) or secondary AML,55% had an unfavorable karyotype, and 
62% were _ age 70. 
Overall response rate (ORR) was 39 % for patients _ 70, 32% for PS 2, 51% for patients with 
AHD, 54% for intermediate karyotype and 42% for unfavorable karyotype, and 38% for 
patients with three risk factors. Median DFS was 37 weeks, and median OS was 41 weeks for 
all patients, 59 weeks for patients with CR/complete remission with incomplete platelet 
recovery (CRp), and 72 weeks for patients with CR. Early death rate (within 60 days) was 
16%. 
In two consecutive European studies of 106 untreated older patients with AML who were 
considered unfit for chemotherapy, participants were given four to six 5-day courses of 
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clofarabine[70,102]. In the UWCM (University of Wales College of Medicine)-001 study, 
patients who were either over age 70 (68%) or over age 60, with a PS of 2 or cardiac 
comorbidity, were treated with clofarabine for 5 days every 28 days for 2 to 4 courses. In the 
BIOV-121 study, patients were treated for 5 days every 4 to 6 weeks for up to six courses. All 
patients were age _ 65 and deemed unfit for chemotherapy. 
Overall, 36% of patients had a PS _ 2, 30% had adverse risk cytogenetics, 46% had Wheatley 
poor risk disease, and 65% were age _ 70. The ORR was 48%, and the median OS was 19 
weeks for all and 45 weeks for those who attained a CR/completeremission with incomplete 
blood count recovery (CRi). Responses were seen in patients with adverse cytogenetics (44% 
ORR), patients with secondary AML (31%), and patients age _ 70 (49%). 
The death rate within 30 days was 18%. A novel agent, laromustine (VNP40101M), a 
sulfonylhydrazine alkylatingagent, has been studied in 85 patients with poor risk AML 
age_60 years.51 Patients received one to two cycles of laromustine at a doseof 600 mg/m2, 
followed by one cycle of cytarabine. Seventy-eightpercent of patients were age _ 70, 47% had 
an adverse karytype, 41%had a PS of 2, 77% had pulmonary disease, 73% had cardiac 
disease,and 3% had hepatic disease. All patients with unfavorable karyotype orECOG PS 
had at least one other risk factor at the time of enrollment.Seventy-five percent of patients 
had _ 3 risk factors. The ORR was32% and was similar in patients over age 70 (32%), with a 
PS of 2 (32%), with baseline pulmonary or cardiac dysfunction (27%–34%). 
There was a 14% 30-day mortality. OS was 3.2 months (12.4 months for those with 
CR/CRp), and 1-year survival was 21% (52% for those with CR/CRp). 
These phase II studies are encouraging, in that responses are seen in all poor risk categories, 
and early death rates are acceptable.Randomized trials are needed. Although randomized 
trials ofintensive versus nonintensive therapy have not been successful, theongoing AML 16 
trial was designed to randomize patients who areconsidered not fit for intensive treatment 
to LD cytarabine versusLD cytarabine with GO, LD cytarabine with arsenic trioxide or 
tipifarnib, or LD clofarabine.52 The arsenic arm has been closed because of ineffectiveness 
with CR/CRi of 29%, compared with 24% and a 12-month OS of 27%, compared with 41%. 
The other arms continue to accrue patients.  
POST REMISSION THERAPY — While a substantial percentage of older adults will attain a 
complete remission (CR) with induction chemotherapy, virtually all of these patients will 
relapse within a median of four to eight months unless given additional cytotoxic therapy. 
Even with post-remission therapy, relapses are common. Only about 10 percent of older 
adults, and generally only those with favorable or intermediate risk disease, attain long-
term survival after the administration of post-remission therapy. 
Post-remission therapy aims to destroy leukemia cells that survived induction 
chemotherapy but are undetectable by conventional studies. There are two generally 
accepted options for post-remission therapy: consolidation chemotherapy and allogeneic 
hematopoietic cell transplantation (HCT). Consolidation chemotherapy is less intensive and 
has a lower early mortality rate, but allogeneic HCT provides a graft-versus-tumor effect 
that decreases relapse rates. In younger patients, consolidation chemotherapy is usually 
given to patients with favorable risk disease while HCT is used for patients with 
unfavorable risk disease. The optimal treatment for intermediate risk disease is unknown. 
Evidence regarding the therapeutic benefit of any consolidation therapy in older patients 
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comorbidities, and 59% had a poor risk score by the Wheatley Risk Index [90].  Based on this 
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baseline prognostic factor, there was a 46% response rate[101]. The median age of the 
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clofarabine[70,102]. In the UWCM (University of Wales College of Medicine)-001 study, 
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followed by one cycle of cytarabine. Seventy-eightpercent of patients were age _ 70, 47% had 
an adverse karytype, 41%had a PS of 2, 77% had pulmonary disease, 73% had cardiac 
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These phase II studies are encouraging, in that responses are seen in all poor risk categories, 
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POST REMISSION THERAPY — While a substantial percentage of older adults will attain a 
complete remission (CR) with induction chemotherapy, virtually all of these patients will 
relapse within a median of four to eight months unless given additional cytotoxic therapy. 
Even with post-remission therapy, relapses are common. Only about 10 percent of older 
adults, and generally only those with favorable or intermediate risk disease, attain long-
term survival after the administration of post-remission therapy. 
Post-remission therapy aims to destroy leukemia cells that survived induction 
chemotherapy but are undetectable by conventional studies. There are two generally 
accepted options for post-remission therapy: consolidation chemotherapy and allogeneic 
hematopoietic cell transplantation (HCT). Consolidation chemotherapy is less intensive and 
has a lower early mortality rate, but allogeneic HCT provides a graft-versus-tumor effect 
that decreases relapse rates. In younger patients, consolidation chemotherapy is usually 
given to patients with favorable risk disease while HCT is used for patients with 
unfavorable risk disease. The optimal treatment for intermediate risk disease is unknown. 
Evidence regarding the therapeutic benefit of any consolidation therapy in older patients 
with AML is limited and its value has remained uncertain. Newly discovered genetic 
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markers are helping to refine the risk stratification. A detailed description of these options in 
younger adults is presented separately. Post-remission therapy in older adults is 
complicated by high rates of treatment related toxicity. Older adults are generally not 
candidates for a fully myeloablative allogeneic HCT, but a subset may be able to undergo 
nonmyeloablative HCT after reduced intensity conditioning regimens. A choice among 
these strategies is generally made based upon the risk stratification of the patient's tumor 
and the patient's performance status and comorbidities that might affect tolerance of 
intensive therapy. A phase III trial demonstrated that post-remission therapy with single 
agent gemtuzumab ozogamicin did not improve clinical outcomes (probability of relapse, 
overall survival, or disease free survival), but added toxicities[75]. 
Consolidation chemotherapy — High dose cytarabine (HiDAC) is the standard 
consolidation chemotherapy for younger adults with AML of a favorable risk, but is 
associated with unacceptably high rates of severe toxicity and early death in older adults 
that counteract any improvement in efficacy over standard dose cytarabine. Instead, 
consolidation therapy with two cycles of daunorubicin (30 to 45 mg/m2 for two days) and 
cytarabine (ara-C, 100 mg/m2 per day for five days) for older adults is preferred. The use of 
consolidation chemotherapy in younger adults is presented separately. 
Nonmyeloablative transplantation — Allogeneic hematopoietic cell transplantation (allo-
HCT) is the preferred treatment for younger adults with unfavorable risk AML because of 
its graft-versus-leukemia effect. However, allo-HCT is associated with a very high 
treatment-related mortality rate in older patients that precludes its general use. Instead, 
various reduced intensity  or nonmyeloablative [85] allo-HCT regimens have been 
employed in fit older adults. However, the comparable efficacy of this approach remains to 
be proven and a randomized, multinational trial by the European Group for Blood and 
Marrow Transplantation evaluating alloSCT versus conventional consolidation therapy in 
elderly patients is currently accruing patients. The use of allo-HCT in younger adults is 
presented separately, as is additional information on nonmyeloablative allo-HCT. 
The development of less toxic and better tolerated nonmyeloablative regimens capable of 
inducing a state of mixed chimerism may allow allo-HCT to be performed in patients with 
AML and advanced age or co-morbidity, with the hope that such regimens would result in 
lower rates of treatment-related mortality without sacrificing relapse-free and overall 
survival, and with a reasonable balance between GVHD and the graft-versus-tumor effect. 
Additional experience with this approach is awaited. 
SUPPORTIVE CARE — For older patients with indolent AML, severe comorbidity, or high 
risk disease, we suggest the use of supportive care rather than induction chemotherapy. 
Supportive care can include the use of red blood cell and platelet transfusions, antibiotics, 
and control of leukocytosis with agents such as low-dose cytarabine or hydroxyurea. 
Low-dose cytarabine — While not curative, many committees, including the British 
Committee for Standards in Hematology, consider low-dose cytarabine to be the standard 
against which other palliative treatments for AML in the older patient should be evaluated.  
A number of trials have investigated the use of low-dose cytarabine in older subjects with 
AML, both for induction and later for maintenance of remission .As an example, investigators 
in France randomly assigned 87 patients >65 to receive either intensive chemotherapy with 
cytarabine and rubidazone (a daunorubicin analogue) or low-dose subcutaneous cytarabine 
(10 mg/m2 every 12 hours for 21 days) .Although the number of complete remissions was 
greater with intensive chemotherapy, the early death rate was also higher.  
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Other supportive measures — Other measures of supportive care include the use of 
leukocyte-depleted, irradiated red blood cell and platelet transfusions as needed and the use 
of antibiotics to treat infections. As described above, patients treated with supportive care 
alone spend a similar amount of time in the hospital compared with those who receive 
intensive chemotherapy. 
5. Approach to the elderly patient with AML 
AML is a disease of the elderly, with the majority of patients over age 60. As our population 
ages, that percentage will only increase. 
Unfortunately, the standard regimens that are successful in treating younger patients with 
AML are not as beneficial in the majority of older patients with the disease. Figure 3 outlines 
my approach to the elderly patient with AML. Understanding of the disease biology, as well 
as the prognostic factors associated with the host, allows us to better determine which 
patients are likely to benefit from standard therapy and which require alternative 
approaches. Objective scoring systems are being developed that allow us to define patients 
unfit for intensive chemotherapy on the basis of increased risk of induction death, low 
response rate, and/or low long-term DFS. Optimal induction and postremission therapy for 
patients appropriate for intensive therapy have yet to be defined, again, because results are 
not satisfactory with our current regimens, even in those patients who do not have definable 
poor prognostic factors. When compared with young patients with similar disease-related 
features, outcomes are inferior. For patients who are not candidates for intensive therapy 
because of comorbid conditions, low-intensity therapies appear to be superior to palliative 
care alone. Whenever possible, patients should be enrolled in clinical trials that will allow us 
to address these issues. 
 
 
Fig. 3. Outlines my approach to the elderly patient with AML. 
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1. Introduction  
Progress in understanding the prognosis and survival in acute myelogenous leukemia 
(AML) has been dramatic over the last few decades. Traditionally, clinical risk factors such 
as age and performance status have been the main prognostic factors in AML. However, 
recent advances in cytogenetic studies and molecular markers in AML have revolutionized 
our approach to this disease. These have changed our understanding of AML as a 
heterogeneous group of diseases rather than a single disease, provided greater insight not 
only in understanding disease biology but also into predicting response to therapy and 
helped in the development of risk stratification-based treatment approach. 
 In 2010, there are about 12,330 new cases in the United States which represent about 0.8% 
and 29% of all new cancer and leukemia cases respectively. With about 8,950 estimated 
deaths related to AML, this represents about 1.6% of cancer related deaths in 2010. 
(American Cancer Society, 2010)  
Although there has been some improvement in survival for AML patients over the last few 
decades, mainly in younger age groups as shown in figure 1, AML long term survival is still a 
big challenge. In the United States, data from Surveillance Epidemiology and End Results 
(SEER) dataset for 2001 to 2007 showed 5-year overall survival (OS) of 22.6% for all AML 
patients. There is still a lot to be done especially in the oldest age group (>65 years), that is 
showing a dismal 5-year OS of less than 5%, See Figure 2. This is of particular concern as more 
than half of the patients diagnosed in 2000-2004 were over 65 years old. (Howlader et al., 2011). 
2. Clinical prognostic factors  
2.1 Age 
AML is seen more commonly in the elderly with median age at diagnosis of 66 with 
incidence increases dramatically after age of 55, See figure 3. Data from SEER (see figure 2) 
as well as from major studies of the largest cooperative groups including the Medical 
Research Council (MRC), the Southwest Oncology Group/Eastern Cooperative Oncology 
Group (SWOG/ECOG), AML cooperative group (AMLCG) and the Cancer and Leukemia 
Group B (CALGB) that included elderly patients have shown consistently worse outcome in 
this patient population, See figure 4. (Slovak et al., 2000; Byrd et al., 2002; Schoch et al., 
2004a; Grimwade & Hill., 2009) 
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Fig. 1. Period estimates of 5-year relative survival of patients with AML by major age groups 





Fig. 2. Age and sex-associated with 5-year relative survival in patients with AML in the 
United States, 1996–2003 (From SEER cancer statistics, National Cancer Institute, 2007.) 
 









(a)     (b) 
Fig. 4. Survival curves according to age groups. a: Patients treated in MRC AML trials 
(AML10, 11, 12, 14 and 15) (Smith et al. , 2011). b: Patients treated in AMLCG trials (AMLCG 
1992, AMLCG 1999 and AMLCG APL trials) (Schoch et al., 2004a) 
The worse outcome in elderly population is related to two components: resistance to 
treatment and treatment-related death. It is believed that most of treatment failure in elderly 
is related to the first component. This is mainly related to distinct biological and clinical 
features such as higher percentage of poor cytogentics, higher incidence of multidrug 
resistance protein (MDR) and preceding hematological disease, all of which are associated 
independently with worse prognosis in AML. (Lieth et al., 1997; Estey 2007). For example, in 
retrospective analysis from five SWOG clinical trials more than 50% of patients >75 years 
old had poor cytogenetics which translated into complete remission (CR) rate of 33%, See 
figure 5, table 1. (Appelbaum et al., 2006a) 
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Fig. 5. Percentage of patients in the different cytogenetic risk groups by age category in five 
SWOG clinical trials (Appelbaum et al., 2006a). 
 
 
Table 1. CR rates in different age groups in the same patient population (Appelbaum et al., 
2006a). 
The second component of treatment failure is treatment-related death. This is mainly related 
to the worse performance status and organ function in this age group. Multiple studies have 
shown age along with poor performance status as very strong predictors of early post-
induction mortality in AML, See table 2, Figure 6. (Appelbaum et al., 2006a; Juliusson et al., 
2009).  
This has motivated researchers to develop different prognostic and predictive models 
including clinical and laboratory variables that can help physicians deciding treatment in 
this challenging patient population. (Krug et al., 2010; Kantarjian et al., 2010)  
Even after accounting for the above factors, elderly patients tend to have worse outcome 
with less CR rate and higher mortality rate. In two different reports from SWOG and 
AMLCG, elderly patients with favorable cytogenetic have worse outcome compared to 
younger patients. (Schoch et al,. 2004a; Appelbaum et al., 2006a) 
The dismal prognosis in elderly population has another component which is 
undertreatment. While AML is more common in elderly, a large number of these patients do 
not receive intensive chemotherapy. This is because they are more likely to have poor 
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performance status and comorbidities at diagnosis and therefore less frequently judged to 
be fit for induction therapy. Menzin et al,. reviewed SEER data of AML in elderly patients. 
Among 2657 patients age > 65 years reviewed, only 30% of patients underwent intensive 
chemotherapy. Juliusson et al reported similar numbers from the Swedish Acute Leukemia 
Registry with only 45% of patients in age group 70-74 offered treatment as compared to 92% 
in 60-64 age group and 98% in <50 age group (Juliusson et al., 2009).  
 
 
Table 2. Mortality within 30 days of induction treatment according to age group and 
performance status in 5 clinical SWOG trials (Appelbaum et al., 2006a).  
 
 
Fig. 6. Mortality within 30 days of induction treatment according to age group and 
performance status the Swedish acute leukemia registry (Juliusson et al., 2009). 
So when interpreting data from various clinical trials we have to keep in our minds that the 
patient population in clinical trials includes only a subset of elderly patients with AML and 
survival numbers achieved could be an overestimate in this patient population. In the same 
report from Menzin et al including treated and untreated AML patients, patients older than 
65 years had a median survival of two months with two-year OS of 6% (Menzin et al., 2002).  
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2.2 Performance status 
Different clinical trials have consistently showed worse outcome in patients with poor 
performance. It is considered the strongest predictor of 30-day mortality after induction 
therapy, See table 2, Figure 6. (Appelbaum et al., 2006a; Juliusson et al., 2009). Poor 
performance usually reflects comorbidities and organ dysfunction. Assessing this parameter 
in elderly patients can be difficult. Acute infection or decompensation can easily change 
performance status and confuse our assessment of baseline performance status. Clinical 
trials exclude patients with poor performance status, so when reviewing data from any 
clinical trial we have to keep in our minds that it excludes a major part of patients who are 
rendered ineligible. This selection bias is more pronounced in elderly population as fit 
elderly are more likely to receive treatment.  
2.3 Prior hematological disease 
The prior diagnosis of myelodysplastic (MDS) or myeloproliferative (MPD) disease is well 
established as a poor prognostic factor in AML patients. While the poor survival is more 
associated with high prevalence of advanced age and poor cytogenetics in this patient 
population, it is still an independent prognostic factor after adjusting for both variables. 
Longer interval from onset of MDS or MPD disease to AML negatively affected outcomes in 
this patient population. One explanation is that a protracted history of prior hematological 
disease may select for higher rates of chemotherapy resistance after AML develops. Prior 
treatment for MDS is another poor prognostic factor in this patient population. (Bello et al., 
2011). 
2.4 Therapy-related AML 
People exposed to cytotoxic agents are at higher risk of developing AML among other 
myeloid neoplasms. Therapy-related AML (t-AML) represents about 10-15% of all cases of 
AML (Schoch et al., 2004b). it is considered a poor prognostic factor. Goldstone et al. 
reported OS of 30% compared to 44% in de novo AML (Goldstone et al., 2002). In another 
report from Kayser et al, Outcome of patients with t-AML was significantly inferior with 4-
year OS of 25.5% compared to 37.9% in de novo AML. (Kayser et al., 2011) 
The risk is highest after exposure to two classes of cytotoxic agents: topoisomerase II 
inhibitors and alkylating agents. The current WHO classification does not subcategorize t-
AML based on agents involved. This is mainly due the fact that most patients developing t-
AML have been exposed to both types and it is not feasible to discriminate according to the 
previous therapy. (Swerdlow et al., 2008) 
Each class related-AML has certain characteristics. While alkylating agents related-AML 
frequently is preceded by myelodysplastic phase and a long interval between exposure and 
development of AML (36-72 months), topoisomerase II related-AML usually presents 
without myelodysplastic phase and has an interval of usually 6 to 36 months. While 
alkyalting agents are usually associated with unbalanced cytogenetic abnormalities 
involving chromosome 5 and 7 as well as complex karyotype, patients with topoisomerase II 
inhibitors related t-AML are more likely to have balanced translocations involving MLL at 
11q23, NUP98 at 11p15, RUNX1 at 21q22 and RARA at 17q21. 
t-AML is commonly associated with abnormal karyotype ranging between 69 to 96%. 
Cytogenetic abnormalities in t-AML are the same described in de novo AML but with 
different frequencies. In one report, 46% of t-AML patients had unfavorable cytogenetic 
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profile as compared to 20% in de novo AML and only 10% had normal cytogenetics versus 
40% in de novo AML. Similar distribution has been observed in other trials as well. (Schoch 
et al., 2004b ; Grimwade & Hill 2009; Kayser et al., 2011)  
Patients with t-AML tend to be older than de novo AML patients. In one report , median age 
of t-AML was 57.8 years versus 53.2 years in de novo AML. (Kayser et al., 2011) 
While the above factors contribute to the worse outcome seen in t-AML, inferior survival 
and response rate has been observed in all age and cytogenetic subgroups (Grimwade & 
Hill 2009; Borthakur et al., 2009), See figure 7.  
 
 
Fig. 7. Survival curves according to cytogenetics subgroups for patients treated in MRC 
AML trials (AML10, 11, 12, 14 and 15) with t-AML and de novo AML (Grimwade & Hill 
2009). 
2.5 Others 
Clinical markers of high tumor burden like high LDH , high peripheral white blood cell 
(WBC) count and need for cytoreduction therapy are reported to be of adverse impact on 
prognosis. As will be discussed later in details, certain molecular abnormalities (FLT3 or KIT 
mutations) are more associated with high WBC count which could be the actual factor 
contributing to the prognosis. So much of the prognostic impact of leukocytosis may reflect 
the molecular abnormalities driving the proliferation. (Dalley et al., 2001; Martin et al., 2000; 
Burnett et al., 1999) Extramedullary involvement has been associated with worse outcome as 
well. (Change et al., 2004)  
3. Karyotype 
50 to 60 % of adult patients with de novo AML have karyotype abnormalities. Cytogenetics 
is the most powerful prognostic factor in AML. This has been illustrated in several analyses 
from small single institution studies as well as large multi-institutional trials from various 
research groups. Its importance has exceeded other variables by consistently showing strong 
prognostic value in predicting CR, risk of relapse as well as survival, See figure 7 
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(Grimwade & Hill 2009; Byrd et al., 2002; Slovak et al., 2000). Therefore it is the single most 
important factor that provides a framework for the current risk-stratified treatment 
approach in AML. This is clearly reflected on the current WHO classification of AML in 
which different groups are specified according to the cytogenetic abnormalities. (Swerdlow 
et al., 2008) 
While there is agreement among different groups on defining the favorable cytogenetics 
group, there is variation on assigning the rest of karyotype abnormalities in the other two 
groups (i.e. intermediate and adverse). This could be related to variation in patient 
characteristics, treatment protocols among various trials, as well as the relatively small 
number of patients having a certain cytogenetic abnormalities in each trial. Table 3 is 
showing different cytogenetics risk groups in major cooperative groups clinical trials. 
 
 
Table 3. Classification of different cytogenetics risk groups in major cooperative groups 
clinical trials. (Grimwade & Hill , 2009). 
3.1 Favorable risk 
Acute promyelocytic leukemia (APL) with t(15;17) translocation as well as AML with core 
binding factor (CBF) abnormalities [t(8;21) and inv(16)/t(16;16)] fall in the favorable risk 
group. They represent around 15% of all AML cases in adults. The favorable outcome in 
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presentation, and treatment regimen that incorporates all trans retinoic acid (ATRA). Different 
clinical trials have reported excellent outcomes with CR rates of more than 90 %. If an ATRA-
based regimen of induction, consolidation, and maintenance is used, rates of 3-year OS exceed 
85 %. In one report from European APL group 10-year OS rate was 77%. (Ades et al. 2010; Lo-
Coco et al. 2010; Sanz et al. 2010) While it carries a good prognosis in general, it is important to 
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notice that patients with age less than 30 years and WBC count less than 10,000/microL at 
presentation have superior event-free survival. (Asou et al., 1998) 
About 40% of patient with APL have associated chromosomal abnormalities. These 
additional abnormalities have no impact on treatment outcome. (De Botton et al., 2000; Slack 
et al., 1997) 
3.1.2 t(8;21) 
It has been consistently reported to be of favorable prognosis with with CR rates exceeding 
87-90% and a 5-year survival of at least 40-65% (Grimwade et al., 2010; Appelbaum et al., 
2006a). Along with AML with Inv(16)/ t(16;16), AML with t(8;21) comprise CBF leukemias. 
In addition to sharing similar pathogenesis, the CBF leukaemias share the characteristics of 
sensitivity to high-dose cytarabine (HDAC) (Grimwade et al., 1998; Slovak et al., 2000; Byrd 
et al., 2002). Furthermore, the outcome can be improved substantially by post-remission 
therapy with HDAC. (Byrd et al., 1999; Palmieri et al., 2002) 
While there is agreement on prognosis in AML with isolated t(8;21), there has been 
inconsistently when defining the prognostic significance of additional cytogenetic 
abnormalities. Three different small trials have showed poor prognosis with the presence of 
deletions of the long arm of chromosome 9 (del(9q)) (Schoch et al., 1996) and karyotype 
complexity (Appelbaum et al., 2006b). On the other side, one large cohort showed no 
negative impact on prognosis; on the contrary, loss of the Y chromosome in male subjects 
was associated with a trend for better overall survival (Grimwade et al., 2010).  
On the other hand, adverse prognostic significance has been linked to high WBC or 
absolute granulocyte count, the presence of granulocytic sarcomas, expression of the 
neural cell adhesion molecule CD56 on leukemic blasts and high WBC index. (Nguyen et 
al., 2002)  
3.1.3 Inv(16)/ t(16;16) 
While it is commonly grouped with AML associated with t(8;21) due to similar pathogenesis 
and outcome, there are few differences. AML associated with inv(16) has different 
morphological features usually of FAB M4Eo morphology and is less likely to have 
secondary cytogenetic changes (Byrd et al., 1999, 2004; Nguyen et al., 2002; Delaunay et al., 
2003). The presence of such abnormalities, particularly +22, predicted a better outcome in 
AML associated with inv(16), t(16;16). (Schlenk et al., 2004; Marcucci et al., 2005) 
As with t(8;21), the outcome of adults with AML with Inv(16)/ t(16;16) can be improved 
substantially by intensive post-remission therapy with HDAC. Byrd et al reported the 5-year 
relapse rate was significantly decreased in patients with inv(16)/t(16;16) receiving 3–4 cycles 
of HDAC as compared with those receiving one HDAC course (43% versus 70%) (Byrd et 
al., 2004) 
Inferior outcome has been reported in patients presenting with high WBC counts (Martin et 
al., 2000) and older age. (Delaunay et al., 2003) 
3.2 Intermediate risk 
This comprises the largest cytogenetics group of AML patients. This is because it includes 
patients excluded from favorable and adverse groups. This translates in wide variation of 
CR and survival rates. It is believed to be molecularly heterogeneous and advances in 
molecular analyses of leukemic cell helped identifying subgroups in this large 
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(Grimwade & Hill 2009; Byrd et al., 2002; Slovak et al., 2000). Therefore it is the single most 
important factor that provides a framework for the current risk-stratified treatment 
approach in AML. This is clearly reflected on the current WHO classification of AML in 
which different groups are specified according to the cytogenetic abnormalities. (Swerdlow 
et al., 2008) 
While there is agreement among different groups on defining the favorable cytogenetics 
group, there is variation on assigning the rest of karyotype abnormalities in the other two 
groups (i.e. intermediate and adverse). This could be related to variation in patient 
characteristics, treatment protocols among various trials, as well as the relatively small 
number of patients having a certain cytogenetic abnormalities in each trial. Table 3 is 
showing different cytogenetics risk groups in major cooperative groups clinical trials. 
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heterogeneous group. This is particularly important in the largest subset of this group, 
patient with normal cytogentics AML.  
3.2.1 Normal karyotype  
The proportion of adults with de novo AML with normal cytogenetics (AML-NC) has 
varied between 40% and 49% in various clinical trials which makes the largest 
cytogenetically defined group of patients. 
 
 
Fig. 8. Survival curves according to different cytogenetic aberrations for patients treated in 
MRC AML trials (AML10, 11, 12, 14 and 15) with t-AML and de novo AML (Grimwade & 
Hill , 2009). 
While it is considered as one category in the intermediate risk group, AML-NC represents a 
heterogeneous group of patients as evident by the wide range of OS rates from 24% to 42%. 
(Gregory et al., 2009). While certain molecular abnormalities have been identified in AML-
NC with prognostic significance that identify distinct subgroups of patients, further efforts 
are needed to subcategorize the rest of the patients in this heterogeneous group.  
3.2.2 Trisomy 8 
The prognosis of AML patients with trisomy 8 alone or with other aberrations is still a 
controversial issue. CR rates of patients with trisomy 8 have differed widely, from 29% to 
91% (Schiffer et al., 1989; Dastugue et al., 1995). As a result, some groups such as the MRC 
and SWOG have assigned these patients to a intermediate risk group whereas the GALGB 
group consider trisomy 8 in the an unfavorable risk group, See table 3. The differences in 
prognosis of patients with trisomy 8 reported indicate that this population of patients is 
heterogeneous and identification of additional prognostic factors are needed.  
 




AML with other non-complex aberrations has been categorized in intermediate risk group 
due to CR and survival rates that fall between the other two major risk groups. MRC data 
showed a 10 year survival rate of 37% in patients with less than three aberrations not 
classified in other risk groups as compared to 38% in patients with normal karyotype, see 
figure 9b.(Grimwade et al.,2010)  
3.3 Adverse risk 
10-20% of AML patient have adverse risk cytogenetics. These patients tend to be older, often 
with a prior history of MDS or exposure to chemotherapy . Different trials have reported CR 
rates of less 60% and a 5-year survival of around 10%. (Grimwade et al., 2010; Byrd et al., 
2002; Slovak et al., 2000) 
While there is some variability in additional karyotypes defining unfavorable cytogenetics 
among different cooperative groups (See table 3), there is agreement on abnormalities of 
chromosomes 5 and 7 (monosomies of 5 and/or 7 (−5/−7) and deletions of 5q and 7q) 
,chromosome 3 abnormalities (inv(3)/t(3;3) and 3q abnormalities except t(3;5) ), and 
complex karyotype. 
3.3.1 Chromosome 3 abnormalities 
AML with inv(3)/t(3;3) represents approximately 1% to 2% of AML. CR rate has been 
reported to be < 50% with long term OS < 10%. (Grimwade et al., 2010; Byrd et al., 2002; 
Slovak et al., 2000). Advanced age and high WBC counts at diagnosis seem to confer an even 
worse outcome (Weisser et al., 2007). 
As part of MDS-related cytogenetic abnormalities per 2008 WHO classification (Swerdlow et 
al., 2008), all 3q abnormalities have been associated with poor prognosis except for t(3;5). 
t(3;5) is a rare translocation associated with formation of the NPM1-MLF1 fusion gene. 
Clinically it occurs mainly occur in younger patients with a median age of 30 years and has 
a favorable outcome with CR rate exceeding 95%.(Grimwade et al., 2010)  
3.3.2 Chromosome 5, 7 abnormalities 
Aberrations of chromosomes 5 and 7 (-7/-5, 5q-, 7q-) are seen in 5% and 10% of 
cytogenetically abnormal AML respectively. There are usually associated with complex 
karyotype and rarely occur as a sole aberration. There are associated with MDS as well as t-
AML related to alkylating agents and radiation. Prognosis is poor especially when part of 
complex karyotype, see Figure 8. On exception to that if these abnormalities are associated 
with favorable cytogenetic changes (t(15;17), t(8;21 and inv(16)/t(16;16)). (Heim & Mitelman, 
2009) 
3.3.3 Complex karyotype 
The definition of complex karyotype differs between major cooperative groups while MRC 
defines it as the presence of a clone with at least five unrelated cytogenetic abnormalities , 
SWOG/ECOG, CALGB and AMLCG all go with three or more abnormalities. Although the 
outcome of patients with three or four abnormalities [other than t(8;21), inv(16)/t(16;16) or 
t(9;11)(p22;q23)] was better when compared to that of patients with five or more abnormal 
ties, both were grouped together due to the dismal prognosis in both (See figure 9).  
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Aberrations of chromosome band 11q23 occur in approximately 5% to 10% of adults with 
AML. In the current WHO classification, AML with these aberrations are regarded as a 
distinct entity. These aberrations occur in de novo as well as in therapy-related AML 
especially after treatment with topoisomerase II inhibitors. Aberrations of 11q23 commonly 
affect the MLL gene (also called HTRX, HRX, TRX1,and ALL-1). A special feature of the 
MLL translocations in AML is the large diversity of fusion partners. More than 50 different 
partner genes on various chromosomes have been described. The most common of those 
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Fig. 9. Survival curves according to the complexity of cytogenetics. a: Patients treated in 
CALGB 8461, tria l( Byrd et al., 2002) b: Patients treated in MRC AML trials (AML10, 12, and 
15) (Grimwade et al., 2010).  
While initially regarded of poor prognosis as a whole group, outcome of AML with 11q23 
band aberrations differs according to the fusion partner. While t(6;11)(q27;q23) and 
t(10;11)(p12;q23) are associated with a poor prognosis in a number of studies (Martineau et 
al., 1998; Grimwade et al., 2010; Blum et al., 2004), t(9;11)(p22;q23) is considered of 
intermediate prognosis. Different trials have shown CR rates of of 79-84% and 10-year 
survival of about 39%. (Grimwade et al., 2010; Byrd et al., 2002)  
4. Gene mutations 
As previously stated, AML is a heterogeneous disease with variable outcome in each 
subgroup. Recent advances in molecular technology have revolutionized our understanding 
of AML biology and prognosis. It has been of great help in defining biological and clinically 
discrete subgroups especially in the heterogeneous group of AML-NC. It also provides new 
insight on new possible therapeutic targets. The impact of newly recognized gene mutations 
on the understanding of AML biology is evident by adding provisionally new subtypes of 
AML in the new WHO classification of myeloid neoplasms (i.e. AML with mutated NPM1 
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and AML with mutated CEBPA) (Swerdlow et al., 2008). The prognostic significance of 
certain mutation is evident by the new genetic risk grouping proposed by European 
LeukemiaNet (ELN) which divide AML-NC to subgroups according to associated mutations 
and put them in different risk groups. (Dohner et al., 2010) 
4.1 FLT3 
FMS-like tyrosine kinase 3 (FLT3) gene encodes a member of the class III receptor tyrosine 
kinase family that is normally expressed on the surface of hematopoietic progenitor cells 
and plays an important role in the survival and differentiation of multipotent stem. First 
described by Nakao et al in 1996, mutations in FLT3 are among the most common genetic 
mutations in AML with prevalence of 30 - 40% (Nakao et al, 1996; Gregory et al., 2009).  
Mutations affect one of two functional domains of the receptor, the juxtamembrane domain 
(JMD) and the activation loop of the tyrosine kinase domain (TKD). The most common 
mutation in the JMD of the FLT3 gene is internal tandem duplications (FLT3-ITD) involving 
JMD with a prevalence of about 25% of adult AML patients. It is particularly more common 
in AML-NC and AML with t(15;17) where it is reported to in 28-38% and 20-35% 
respectively. Point mutations affecting TKD and JMD have been reported in about 5-10% 
and 2% of all AML patients respectively. (Marcucci et al., 2011; Thiede et al., 2002; Schnittger 
et al., 2002, Mrozek et al., 2007) Clinically, FLT3-ITD–positive patients present with 
increased WBC counts and are more often diagnosed 
with de novo than secondary AML. While CR rates are comparable to unmutated AML-CN, 
prognosis is poor due to high relapse risk. The adverse outcome seen is related to the size of 
ITD. The longer the duplication the worse the prognosis. (Gregory et al., 2009)  
In contrast to FLT3-ITD mutations, the prognostic significance of FLT3-TKD mutation is still 
controversial with conflicting conclusions from various studies (Mead et al., 2007; Whitman 
et al., 2008). In another report from Bacher et al., a neutral impact was seen when looking at 
all patients with TKD mutation. However in the presence of NPM1 or CEBPA mutation a 
favorable impact was observed and a negative impact was seen if a TKD mutation occurred 
in conjunction with MLL-PTD, t (15;17) or FLT3-ITD. (Schlenk et al. 2008, Bacher et al., 2008) 
In addition to being a prognostic marker, FLT3-ITD is a potential therapeutic target. Several 
small-molecule inhibitors of FLT3 tyrosine kinase activity in combination with 
chemotherapy as a frontline therapy for patients with FLT3 mutation are currently 
evaluated in phase III clinical trials (Marcucci et al., 2011) 
4.2 NPM1 
Nucleophosmin (NPM1) is nucleocytoplasmic shuttling protein mainly localized in the 
nucleolus that has multiple functions involved in cell proliferation, apoptosis, DNA repair 
and ribosome biogenesis. The NPM1 gene belongs to a new category that functions both as 
an oncogene and tumor-suppressor gene, depending on gene dosage, expression levels, 
interacting partners, and compartmentalization. First reported by Falini et al in 2005, NPM1 
mutations are very common as they are present in 50% to 60% of patients with AML-NC. 
(Falini et al, 2005; Gregory et al., 2009; Foran 2010) 
Clinically, NPM1 mutations are associated with specific features, including predominance of 
female sex, higher bone marrow blast percentages, LDH levels, WBC and platelet counts, 
and high CD33 but low or absent CD34 antigen expression. NPM1 mutations tend to be 
stable over the disease course, supporting their role as primary lesions in leukemogenesis 
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and accordingly is recognized as a provisional entity in the 2008 revision of the WHO 
classification of myeloid neoplasms and acute leukemia. (Swerdlow et al., 2008). 
Of notice, FLT3-ITD mutation is detected in approximately 40% of patients with NPM1 
mutations. Mutated NPM1 without concurrent FLT3-ITD has been associated consistently 
with achievement of CR and favorable outcome comparable to CBF AML. (Smith et al., 
2011). On the basis of this observation, AML with mutated NPM1 without FLT3-ITD has 
then recently been allocated to the genetic favorable-risk category of AML together with 
CBF AML in the new classification suggested by ELN. On the other hand, NPM1 
mutations did not impact the poor outcome of patients with FLT3-ITD mutation. 
(Marcucci et al., 2011; Foran 2010) 
4.3 CEBPA 
The transcription factor CCAAT enhancer-binding protein alpha (CEBPA) is a key molecule 
in the mediation of lineage specification and differentiation of multipotent myeloid 
progenitors into mature neutrophils. Mutations in CEBPA were first identified in AML in a 
report from Pabst et al in 2001 . Reports following indicate 5% to 10% of de novo AML have 
this mutation with higher prevalence in AML-NC (15-20%). (Pabst et al., 2001; Fröhling et 
al., 2004; Foran 2010) 
AML-NC patients carrying a CEBPA mutation are characterized by distinct clinical features 
such as higher peripheral blood blast counts, lower platelet counts, less lymphadenopathy, 
or extramedullary leukemia. As compared to NPM1 mutations, CEBPA mutations are less 
frequently associated with FLT3-ITD or TKD mutations. (Schlenk et al., 2008) 
In the absence of a FLT3-ITD, CEBPA mutation has a favorable prognosis in patients with 
AML-NC with approximately 60% long-term survival. Prognosis is better if the mutation is 
biallelic, where it is categorized in the favorable risk group. (Dufour et al., 2010; Foran 2010; 
Smith et al., 2011) 
4.4 KIT 
KIT is the receptor for stem cell factor (KIT ligand) and is expressed on less than 5% of 
marrow cells. KIT mutation is frequently noted in CBF leukemia with prevalence of 30-40% 
and 20-30% in inv(16)/t(16;16) and t(8;21) leukemia respectively. 
Clinically, Patients affected appear to have higher WBC counts and higher frequency of 
extramedullary disease such as paraspinal masses. (Foran 2010; Smith et al., 2011). Recent 
trials have reported significantly higher incidence of relapse and significantly lower survival 
in CBF leukemia harboring KIT mutation (Schnittger et al., 2006; Baschka et al., 2006). 
Clinical trials are currently underway evaluating KIT inhibitors in CBF leukemias. (Marcucci 
et al., 2011) 
5. Future perspectives 
Advances in molecular studies have changed our understanding of AML as a single disease. 
As discussed in previous section , certain gene mutations has fragmented previously known 
risk groups into smaller and more homogenous groups. Identification of new mutations and 
understanding their prognostic and predictive value is a major goal in AML research. In 
addition, gene and microRNA expression profiling is a very active area of research in AML 
with interesting recent observations. We hope that such advances will provide us with more 
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information that will help in systematic characterization of cancer genomes. We will review 
briefly few areas of active research showing promising results that need further efforts 
before it has its practical implications as prognostic and predictive tools. 
5.1 Gene mutations 
Further gene mutations have been identified in recent trials which are still waiting further 
clinical data to support their prognostic implications. 
5.1.1 IDH1/IDH2 mutations  
IDH1/IDH2 gene mutations, which were first reported in gliomas with good prognostic 
impact, have been recognized recently in AML with aggregate frequency of these two 
mutations of about 15% to 20% of all patients with AML and 25% to 30% of patients with 
AML-NC. There are conflicting data concerning the prognostic significance of IDH 
mutations in AML, with some studies suggesting that they are associated with a poorer 
outcome especially in NPM1 mutated AML, while others have found no evidence of that 
(Marcucci et al., 2010; Thol et al., 2010). Further studies with larger number of patients 
harboring this mutation are needed to further characterize the prognostic significance of this 
rare mutation. 
5.1.2 CBL mutation 
The Casitas B-cell lymphoma (CBL) gene on chromosome 11q23.3 contains several 
functional domains. One of these domains, the C-terminal domain, gives rise to the CBL 
protein which has ubiquitin ligase activity that targets a variety of tyrosine kinases for 
degradation by ubiquitination. Heterozygous CBL mutations have been recognized in 0.6% 
to 33% of AML patient (Sargin et al., 2007; Bacher et al., 2010; Ghassemifar et al., 2011). 
Interestingly, CBF AML patients represented a significant proportion of patients who have 
this mutation. (Abbas et al., 2008; Reindel et al., 2009). In one retrospective review including 
more than two hundred AML patients along with similar number of MDS and MDS/MPD 
diseases, the presence of CBL mutation was an independent adverse prognostic factor for 
OS. (Makishima et al., 2009)  
5.2 Gene expression profiling 
In addition to structural genetic aberrations, changes in expression of specific genes seem to 
impact prognosis of molecular subsets of patients with AML. Increased or decreased 
expression of specific genes (typically those involved in hematopoiesis, myeloid 
differentiation, or immune response) has been associated with response to therapy as well 
as survival.  
5.2.1 BAALC 
The brain and acute leukemia cytoplasmic (BAALC) gene is localized on chromosome band 
8q22.3. It has been postulated to function in the cytoskeleton network due to its cellular 
location. It is most commonly seen in AML with trisomy 8 and AML-NC. Several studies 
have demonstrated that high BAALC expression is a poor prognostic indicator in AML-NC 
for such factors as OS, DFS, and resistant disease. BAALC expression appears to be 
particularly useful as a prognostic marker in AML-NC patients lacking FLT3-ITD and 
CEBPA mutations. (Mrozek et al., 2007; Gregory et al., 2009) 
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differentiation, or immune response) has been associated with response to therapy as well 
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5.2.1 BAALC 
The brain and acute leukemia cytoplasmic (BAALC) gene is localized on chromosome band 
8q22.3. It has been postulated to function in the cytoskeleton network due to its cellular 
location. It is most commonly seen in AML with trisomy 8 and AML-NC. Several studies 
have demonstrated that high BAALC expression is a poor prognostic indicator in AML-NC 
for such factors as OS, DFS, and resistant disease. BAALC expression appears to be 
particularly useful as a prognostic marker in AML-NC patients lacking FLT3-ITD and 
CEBPA mutations. (Mrozek et al., 2007; Gregory et al., 2009) 
 




The meningioma 1 (MN1) gene encodes a protein that participates in a gene transcription 
regulator complex involving retinoid receptors. Recent studies have shown MN1 
overexpression is associated with poor prognosis in AML in terms of response to induction 
chemotherapy, relapse rate and therefore OS. Interestingly, one study has shown low MN1 
expression was correlated with better response therapy in AML. Together, both 
observations suggest that MN1 expression is not only a prognostic but also a predictive 
marker for response to treatment. (Foran 2010; Marcucci et al., 2011)  
5.2.3 ERG 
The ETS-related gene (ERG) is a member of the ETS family of transcription factors. High 
ERG expression is associated with the upregulation of many genes which are involved in 
cell proliferation, differentiation, and apoptosis. ERG overexpression mostly impacted 
outcome of low molecular risk AML-NC (mutated NPM1 without FLT3-ITD) and AML with 
low BAALC expression. (Gregory et al., 2009; Marcucci et al., 2011) 
5.3 MicroRNA expression 
MicroRNAs are noncoding RNAs of 19 to 25 nucleotides in length that regulate gene 
expression. They perform critical functions in cell development, differentiation, 
proliferation, and apoptosis. They have been shown to play a role in malignant 
transformation in solid malignancies. Recent studies in AML have shown that specific 
patterns of microRNA expression are closely associated with certain cytogenetics and 
molecular changes like FLT3-ITD. Results are reproduced and such patterns are considered 
like signatures. For example in two separate studies, upregulation of microRNAs expression 
from genes localized at chromosome band 14q32 has been found in APL with t(15;17) while 
the downregulation of certain mircoRNAs (miR-133a) was observed in patients with t(8;21). 
In AML-NC, specific microRNAs expression signature (miR-155) was associated with the 
presence of high risk features (lack of NPM1 mutation or the presence of FLT3-ITD), while 
upregulation of microRNAs (miR-181) was identified in CEBPA mutated AML. (Foran 2010; 
Marcucci et al., 2011) 
6. Conclusion 
AML is markedly heterogeneous disease with variable response to therapy and survival. 
While advances in AML therapy have been moving slowly over last few decades, there have 
been dramatic breakthroughs in the identification of reproducible prognostic variables in 
AML. In particular, advances in molecular biology as well as genomics technology have 
revolutionized our approach to AML and have added substantially to our understanding of 
biology and prognosis of this disease through identification of novel prognostic markers. 
This is particularly important in AML-NC which comprises a large heterogeneous group of 
patients. While such advances help separating AML patients into smaller homogenous 
groups, we hope to look for a day where individualized therapy for patients AML can be 
tailored to achieve the best outcome. Such breakthroughs facilitate risk-stratified approach 
to therapy in AML where more groups are separated into favorable or poor risk groups 
rather staying the large grey intermediate group. They also provide us with insight into 
potential therapeutic targets that can be assessed in clinical trials on which we largely 
depend to achieve breakthroughs.  
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1. Introduction  
Fatal sepsis during chemotherapy-induced neutropenia is the most severe complication of 
which physicians must be keenly aware. Common bacterial pathogens in neutropenic 
patients usually include gram-positive cocci such as coagulase-negative staphylococci, 
Staphylococcus aureus, Enterococcus species, and gram-negative rods such as Escherichia coli, 
Klebsiella species, Enterobacter species, and Pseudomonas aeruginosa (Wisplinghoff, et al 
2003). Thus, clinical practice guidelines for the use of antibiotics are likely to be aimed at 
targeting these pathogens including antibiotic-resistant strains (Freifeld, et al 2011). In the 
absence of effector cells for these pathogens, the rapid progression of invasive bacterial 
infections may occur; therefore, antibiotics are a life-saving measure during severe 
neutropenia. 
Bacillus cereus (B. cereus) is an aerobic gram-positive, spore-forming, and rod-shaped 
bacterium that is widely distributed in the environment. Although B. cereus is a common 
cause of food-poisoning, abdominal distress such as vomiting and diarrhea is usually mild 
and self-limiting unless the host is immunocompromised. Some patients that undergo 
prolonged hospitalization have Bacillus species as a part of the normal flora in their intestine 
(Drobniewski 1993). Therefore, identification of this microorganism in clinical cultures has 
usually been considered to be due to contamination. For example, 78 patients were found to 
have cultures positive for B. cereus in a single center in the United States; however, only 6% 
of them resulted in clinically significant infections (Weber, et al 1989). On the other hand, B. 
cereus is a growing concern as a cause of life-threatening infections in patients with 
hematologic malignancies, including septic shock, brain abscess, meningitis, colitis, 
respiratory infections, endocarditis, and infection-related coagulopathy and hemolysis. The 
risk factors for patients with unfavorable outcomes, however, have not been totally 
elucidated. In addition, B. cereus sepsis generally does not respond to any antibiotics in spite 
of their in vitro efficacy (Drobniewski 1993). Akiyama et al. reviewed 16 case reports of B. 
cereus sepsis in patients with leukemia, and consequently reported only 3 survivors 
(Akiyama, et al 1997). Therefore, physicians should identify specific risk factors of B. cereus 
sepsis during chemotherapy for leukemia patients and establish a proper strategy to 
overcome this life-threatening sepsis. 
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2. B. cereus sepsis in patients with hematologic malignancies 
In recent years, we encountered several cases of B. cereus sepsis including 4 fatal cases with 
acute leukemia in our hospital. These episodes prompted us to review all cases of B. cereus 
sepsis especially in hematologic malignancies. In the present study, we collected the data 
and the clinical features of these patients with B. cereus sepsis in a retrospective fashion, and 
identified risk factors for a fatal prognosis in these patients (Inoue, et al 2010). Based on these 
data, we also put forward a proposal for the rapid diagnosis of B. cereus sepsis and earlier 
therapeutic intervention for this infection. 
2.1 Patients and methods 
We reviewed the microbiology records of all patients who produced a positive blood culture 
for B. cereus from September 2002 to November 2009 in our hospital. We routinely took at 
least two sets of blood culture samples from all patients with hematologic malignancies who 
developed a high-grade fever of over 38℃. Each set consisted of two blood culture vials for 
both aerobic and anaerobic cultures. Identification of B. cereus was made on the basis of 
Gram-staining, colony morphology, and analysis with NGKG agar (Nissui, Tokyo, Japan). 
Antimicrobial disk susceptibility tests were performed using Sensi-Disc (Beckton 
Dickinson). 
We defined a case as sepsis when more than two blood culture sets were positive for B. 
cereus or only a single set was positive in the absence of other microorganisms in patients 
who had definite infectious lesions, such as brain or liver abscesses. Instead, febrile cases 
that did not satisfy the above criteria were defined as an unknown pathogen or 
contaminated culture. 
With regard to sepsis patients, we also reviewed their charts to obtain clinical information, 
including the underlying disease, insertion of a central venous (CV) catheter, nutrition 
route, neutrophil count, and prior chemotherapy or steroid treatment. Oral nutrition was 
defined only when patients were eating a regular diet without high-calorie parenteral 
nutrition support. We also documented clinical signs at febrile events, such as 
gastrointestinal (GI) and central nervous system (CNS) symptoms, antibiotic use, and the 
drug sensitivity of B. cereus. Then, we assessed the risk factors for a fatal prognosis; i.e., 
whether the underlying disease was acute leukemia, whether a CV catheter was inserted, 
whether the patient was receiving oral or parenteral nutrition, whether their neutrophil 
count was 0/mm3 or above 0/mm3, and whether characteristic clinical signs were present at 
the time of febrile events. We also reviewed the charts of patients without hematologic 
malignancies who had cultures positive for B. cereus in the same period. Furthermore, we 
assessed the above data in conjunction with those from previously reported patients with B. 
cereus sepsis, who had hematologic malignancies.  
Statistical tests included χ2 and Fisher’s exact tests. All calculations were made using the 
program JMP 8.0 (SAS Institute, Cary, NC, US). All P-values of <0.05 were considered 
significant. 
2.2 Results 
2.2.1 Characteristics of B. cereus sepsis patients 
A total of 68 febrile patients that produced positive blood cultures for B. cereus were 
identified from September 2002 to November 2009 in our institute. Twenty-three of these 
patients had hematologic malignancies, including 4 patients who died of fatal sepsis. 
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Although 11 of the 23 patients showed signs of infection such as a high-grade fever, we 
classified them with an unknown pathogen or contaminated culture, since other causes of 
fever could not be totally excluded. With respect to underlying diseases, 2 of 5 cases of non-
Hodgkin lymphoma (NHL), 3 of 5 cases of acute lymphoblastic leukemia (ALL), 5 of 6 cases 
of acute myeloid leukemia (AML), 1 of 4 cases of myelodysplastic syndrome (MDS), and 1 of 
3 cases of multiple myeloma (MM) were diagnosed with B. cereus sepsis. Thus, we 
determined as many as 12 (patients 1 to 12) of 23 patients with hematologic malignancies as 
having B. cereus sepsis; whereas, only 10 of 45 patients without hematologic malignancies 
were similarly diagnosed on the basis of the same criteria (P=0.012). All of these 10 patients 
recovered from B. cereus sepsis after treatment with appropriate antimicrobials including 
carbapenems, vancomycin, or fluoroquinolones. None of the 10 patients received 
chemotherapy. Their underlying diseases were as follows: chronic obstructive pulmonary 
disease, congestive heart failure, bronchial asthma, acute hepatitis, malnutrition, 
subarachnoid hemorrhage, ovarian cancer, gastric cancer, and cerebral infarction in 2 
patients. 
As shown in Table 1, we analyzed the profiles of the 12 patients with hematologic 
malignancies: 6 men and 6 women with a median age of 53.5 ranging from 20 to 85 years; 8 
patients with acute leukemia, 5 who were treated with a CV catheter and 12 who received 
oral nutrition; 5 patients with a neutrophil count of 0/mm3; all patients, except for patients 
5, 10, and 12, had undergone prior steroid treatment within 2 weeks; and 8 patients 
exhibited GI symptoms including nausea, vomiting, diarrhea, and abdominal pain, and 6 
patients displayed CNS symptoms ranging from disorientation to deep coma at the time of 
febrile episodes. Although CV catheters were removed in patients 2, 4, 6, and 12 as a part of 
the management for their febrile status, none of these catheters were found to be positive for 
B. cereus. In one patient (patient 6), postmortem cultures from CSF samples were performed, 
with positive results for B. cereus. Among 5 patients with CNS symptoms, lumbar puncture 
was only performed in patient 8, without B. cereus isolation. Lumbar puncture was not 
conducted for the remaining 4 patients because of their unstable conditions. No patient 
demonstrated other organisms as co-isolates in their initial blood cultures. 
Patients 1 and 2, who had ALL, and patients 6 and 12, who had AML, developed 
consciousness disturbance, which resulted in a deep coma and brain stem dysfunction 3 
days, 6 hours, 18 hours, and 8 hours after their febrile episode and they died 12 days, 7 days, 
20 hours, and 15 hours after their febrile event, respectively, despite intensive antimicrobial 
therapy and supportive care (Table 1). All 4 patients had received intensive chemotherapy 
for acute leukemia, and febrile events occurred on day 13 after re-induction chemotherapy 
in patient 1; on day 18 after induction therapy in patient 2; on day 14 after consolidation in 
patient 6; and day 13 after induction therapy in patient 12. On the other hand, patient 7, who 
had received high-dose etoposide for the collection of peripheral blood stem cells, similarly 
developed a deep coma but recovered without sequela 28 hours after the onset of 
consciousness disturbance. Patients 8, 9, 10, and 11 also received intensive chemotherapy 
prior to B. cereus sepsis, as shown in Table 1. Patient 4 received methylprednisolone 
treatment (20 mg/day) for chronic graft-versus-host disease when the sepsis developed. The 
characteristics of the remaining patients are also shown in Table 1. In addition to patients 1, 
2, 6, and 12, patient 8 died of underlying refractory AML 6 months after the onset of B. cereus 
brain abscesses despite successful treatment of the abscesses with long-term vancomycin 
administration, and patient 4 died of multiple organ failure caused by another bacterial 
infection 11 months later. No sequela or death occurred in the remaining patients, including 
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5, 10, and 12, had undergone prior steroid treatment within 2 weeks; and 8 patients 
exhibited GI symptoms including nausea, vomiting, diarrhea, and abdominal pain, and 6 
patients displayed CNS symptoms ranging from disorientation to deep coma at the time of 
febrile episodes. Although CV catheters were removed in patients 2, 4, 6, and 12 as a part of 
the management for their febrile status, none of these catheters were found to be positive for 
B. cereus. In one patient (patient 6), postmortem cultures from CSF samples were performed, 
with positive results for B. cereus. Among 5 patients with CNS symptoms, lumbar puncture 
was only performed in patient 8, without B. cereus isolation. Lumbar puncture was not 
conducted for the remaining 4 patients because of their unstable conditions. No patient 
demonstrated other organisms as co-isolates in their initial blood cultures. 
Patients 1 and 2, who had ALL, and patients 6 and 12, who had AML, developed 
consciousness disturbance, which resulted in a deep coma and brain stem dysfunction 3 
days, 6 hours, 18 hours, and 8 hours after their febrile episode and they died 12 days, 7 days, 
20 hours, and 15 hours after their febrile event, respectively, despite intensive antimicrobial 
therapy and supportive care (Table 1). All 4 patients had received intensive chemotherapy 
for acute leukemia, and febrile events occurred on day 13 after re-induction chemotherapy 
in patient 1; on day 18 after induction therapy in patient 2; on day 14 after consolidation in 
patient 6; and day 13 after induction therapy in patient 12. On the other hand, patient 7, who 
had received high-dose etoposide for the collection of peripheral blood stem cells, similarly 
developed a deep coma but recovered without sequela 28 hours after the onset of 
consciousness disturbance. Patients 8, 9, 10, and 11 also received intensive chemotherapy 
prior to B. cereus sepsis, as shown in Table 1. Patient 4 received methylprednisolone 
treatment (20 mg/day) for chronic graft-versus-host disease when the sepsis developed. The 
characteristics of the remaining patients are also shown in Table 1. In addition to patients 1, 
2, 6, and 12, patient 8 died of underlying refractory AML 6 months after the onset of B. cereus 
brain abscesses despite successful treatment of the abscesses with long-term vancomycin 
administration, and patient 4 died of multiple organ failure caused by another bacterial 
infection 11 months later. No sequela or death occurred in the remaining patients, including 
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patient 9, in whom the long-term administration of vancomycin was required for liver 
abscesses. Patients 9 and 10 successfully received allogeneic bone marrow transplantation 
(BMT) after recovering from severe B. cereus sepsis. 
2.2.2 Results of autopsies 
Of the 4 fatal cases, we performed autopsy in 3 patients. Autopsy of patient 2 demonstrated 
the presence of a small number of B. cereus in the subarachnoid space and venous 
thrombosis in the Vein of Galen and the superior sagittal sinus. In contrast, coagulation 
necrosis with bacterial infiltration in the liver and necrotizing leptomeningitis with 
subarachnoid hemorrhage (SAH) were observed in patient 6, and coagulation necrosis 
accompanied by B. cereus infiltration in the colon could be seen in patient 12. Histologic 
analyses of organs obtained in the autopsies of patients 2 and 6 are shown in Figure 1. Large 
venous thromboses in the vein of Gallen and superior sagittal sinus can be seen in patient 2 
(A and B, H.E. staining, ×40). On the other hand, in patient 6, numerous gram-positive rods 
are present in the subarachnoid space (D, Gram staining, ×400) and outside of the 
subarachnoid membrane (E, H.E. staining, ×100, in the circle), which may have caused the 
coagulation necrosis of the vessels in the subarachnoid membrane (arrows). The coagulation 
necrosis is also seen without the infiltration of inflammatory cells in the surface area of the 
cerebrum (arrowheads), which is distant from the B. cereus clusters. Extensive coagulation 
necrosis with bacterial infiltration stands out without an inflammatory response in the liver 
of patient 6 (C, H.E. staining, ×100). A number of gram-positive rods can be seen clustering 
in the circle. In patient 12, coagulation necrosis with bacterial infiltration could be similarly 
seen in the liver in addition to B. cereus infiltration in the colon, although we could not 
obtain pathological analysis in CNS. 
2.2.3 Risk factors for a fatal prognosis, which were identified in patients in our 
institution 
As shown in Table 1, all 4 fatal cases shared common factors, that is, acute leukemia, 
insertion of a CV catheter, an extremely low neutrophil count, and CNS symptoms at febrile 
episodes. We then statistically analyzed clinical parameters of 12 patients listed in Table 1, 
and identified the following risk factors for death due to B. cereus sepsis: CV catheter 
insertion (P=0.010), a neutrophil count of 0/mm3 (P=0.010), and CNS symptoms at the time 
of febrile events (P=0.010). While acute leukemia (P=0.141), GI symptoms (P=0.594), and 
prior steroid treatment within 2 weeks (P=0.764) did not show a close relationship with a 
fatal course of B. cereus sepsis. 
2.2.4 Antibiotic susceptibility 
The antibiotics employed in the present study included meropenem or doripenem for 8 
patients (patients 2, 6-12) and vancomycin for 7 patients (patients 2, 6, 8-12). All of the 
isolated B. cereus strains were susceptible to imipenem, vancomycin, levofloxacin, and 
gentamicin; whereas, no isolated B. cereus strains, except for that from patient 5, were 
sensitive to penicillins or cephalosporins in vitro. 
2.2.5 Risk factors for a fatal prognosis in previously reported patients and ours 
To our knowledge, 46 B. cereus sepsis patients with hematologic malignancies have been 
previously reported (Akiyama, et al 1997, Arnaout, et al 1999, Christenson, et al 1999, Colpin, 
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patient 9, in whom the long-term administration of vancomycin was required for liver 
abscesses. Patients 9 and 10 successfully received allogeneic bone marrow transplantation 
(BMT) after recovering from severe B. cereus sepsis. 
2.2.2 Results of autopsies 
Of the 4 fatal cases, we performed autopsy in 3 patients. Autopsy of patient 2 demonstrated 
the presence of a small number of B. cereus in the subarachnoid space and venous 
thrombosis in the Vein of Galen and the superior sagittal sinus. In contrast, coagulation 
necrosis with bacterial infiltration in the liver and necrotizing leptomeningitis with 
subarachnoid hemorrhage (SAH) were observed in patient 6, and coagulation necrosis 
accompanied by B. cereus infiltration in the colon could be seen in patient 12. Histologic 
analyses of organs obtained in the autopsies of patients 2 and 6 are shown in Figure 1. Large 
venous thromboses in the vein of Gallen and superior sagittal sinus can be seen in patient 2 
(A and B, H.E. staining, ×40). On the other hand, in patient 6, numerous gram-positive rods 
are present in the subarachnoid space (D, Gram staining, ×400) and outside of the 
subarachnoid membrane (E, H.E. staining, ×100, in the circle), which may have caused the 
coagulation necrosis of the vessels in the subarachnoid membrane (arrows). The coagulation 
necrosis is also seen without the infiltration of inflammatory cells in the surface area of the 
cerebrum (arrowheads), which is distant from the B. cereus clusters. Extensive coagulation 
necrosis with bacterial infiltration stands out without an inflammatory response in the liver 
of patient 6 (C, H.E. staining, ×100). A number of gram-positive rods can be seen clustering 
in the circle. In patient 12, coagulation necrosis with bacterial infiltration could be similarly 
seen in the liver in addition to B. cereus infiltration in the colon, although we could not 
obtain pathological analysis in CNS. 
2.2.3 Risk factors for a fatal prognosis, which were identified in patients in our 
institution 
As shown in Table 1, all 4 fatal cases shared common factors, that is, acute leukemia, 
insertion of a CV catheter, an extremely low neutrophil count, and CNS symptoms at febrile 
episodes. We then statistically analyzed clinical parameters of 12 patients listed in Table 1, 
and identified the following risk factors for death due to B. cereus sepsis: CV catheter 
insertion (P=0.010), a neutrophil count of 0/mm3 (P=0.010), and CNS symptoms at the time 
of febrile events (P=0.010). While acute leukemia (P=0.141), GI symptoms (P=0.594), and 
prior steroid treatment within 2 weeks (P=0.764) did not show a close relationship with a 
fatal course of B. cereus sepsis. 
2.2.4 Antibiotic susceptibility 
The antibiotics employed in the present study included meropenem or doripenem for 8 
patients (patients 2, 6-12) and vancomycin for 7 patients (patients 2, 6, 8-12). All of the 
isolated B. cereus strains were susceptible to imipenem, vancomycin, levofloxacin, and 
gentamicin; whereas, no isolated B. cereus strains, except for that from patient 5, were 
sensitive to penicillins or cephalosporins in vitro. 
2.2.5 Risk factors for a fatal prognosis in previously reported patients and ours 
To our knowledge, 46 B. cereus sepsis patients with hematologic malignancies have been 
previously reported (Akiyama, et al 1997, Arnaout, et al 1999, Christenson, et al 1999, Colpin, 
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al 1977, Marley, et al 1995, Motoi, et al 1997, Musa, et al 1999, Nishikawa, et al 2009, 
Ozkocaman, et al 2006, Sakai, et al 2001, Strittmatter, et al 1995, Tomiyama, et al 1989, Trager 
and Panwalker 1979, Yoshida, et al 1993). On analyses of the clinical parameters of these 
patients, as in shown in Table 2, patients with acute leukemia, a neutrophil count of 0/mm3 
or below the lower limit of each institute, or CNS symptoms at febrile episodes were 
identified as risk factors closely correlated with a fatal prognosis (P=0.044, 0.004, and 0.002, 
respectively). Patients younger than 15 years old had a tendency to show a more favorable 
prognosis in comparison with older patients. (P=0.063). Male, GI symptom, corticosteroid 
administration, CV catheter insertion, and antimicrobial therapy except for that with 
vancomycin did not have a significant impact on the prognosis. 
2.3 Discussion and proposal 
2.3.1 How do we efficiently select high-risk patients? 
Our report contains 12 adult B. cereus sepsis cases of hematologic malignancy, which is, to 
our knowledge, the largest cohort of B. cereus sepsis in adult patients from a single center. 
Because of the serious outcomes of these patients with hematologic malignancies, the 
detection of B. cereus from blood culture samples at febrile events from these patients should 
not be regarded as contamination. In our cohort, patients with a neutrophil count of 0/mm3, 
with CNS symptoms, or who had undergone CV catheter insertion definitely had a poor 
prognosis. However, we had difficulties in identifying further precise prognostic factors 
because of the small number of B. cereus infection cases in our institution. Therefore, we 
assessed the data in conjunction with those from our 12 patients and from 46 previously 
reported patients, giving a total of 42 patients with acute leukemia, although reporting bias 
may have existed because severe cases with peculiar clinical features tend to be selectively 
reported and some reports did not refer all factors which we consider to be important. 
Consequently, patients who had acute leukemia, a neutrophil count of 0/mm3 or a count 
below the lower limit of each institute, or CNS symptoms at febrile episodes were identified 
as being associated with a fatal prognosis. Interestingly, the relatively more favorable 
prognosis in younger patients implies the importance of appropriate evaluation in adult 
patients (Table 2). 
Regarding the neutrophil count, patients 7, 8, 10, and 11 fully recovered from B. cereus sepsis 
complicated with coma, in clear contrast to patients 1, 2, 6, and 12 who had a neutrophil 
count of 0/mm3 (Table 1), suggesting that both immediate therapeutic intervention and even 
a small number of neutrophils can effectively work against B. cereus sepsis. The poor 
outcomes in acute leukemia patients may have been an indirect consequence because of the 
greater immunosuppression following intensive chemotherapy, rather than due to the 
underlying disease. Regarding the relationship between B. cereus sepsis and the treatment 
process of acute leukemia in the combined clinical parameters, 35 patients developed sepsis 
during remission induction or reinduction therapy, 9 consolidation therapy, 4 post-
transplantation, and 1 maintenance therapy in a total of 49 acute leukemia patients whose 
clinical data were available (Akiyama, et al 1997, Arnaout, et al 1999, Christenson, et al 1999, 
Colpin, et al 1981, Cone, et al 2005, Coonrod, et al 1971, Dohmae, et al 2008, Feldman and 
Pearson 1974, Frankard, et al 2004, Funada, et al 1988, Garcia, et al 1984, Gaur, et al 2001, 
Ginsburg, et al 2003, Ihde and Armstrong 1973, Jenson, et al 1989, Katsuya, et al 2009, 
Kawatani, et al 2009, Kiyomizu, et al 2008, Kobayashi, et al 2005, Kuwabara, et al 2006, Le 
Scanff, et al 2006, Leff, et al 1977, Marley, et al 1995, Motoi, et al 1997, Musa, et al 1999, 
Nishikawa, et al 2009, Ozkocaman, et al 2006, Sakai, et al 2001, Strittmatter, et al 1995, 
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al 1977, Marley, et al 1995, Motoi, et al 1997, Musa, et al 1999, Nishikawa, et al 2009, 
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and Panwalker 1979, Yoshida, et al 1993). On analyses of the clinical parameters of these 
patients, as in shown in Table 2, patients with acute leukemia, a neutrophil count of 0/mm3 
or below the lower limit of each institute, or CNS symptoms at febrile episodes were 
identified as risk factors closely correlated with a fatal prognosis (P=0.044, 0.004, and 0.002, 
respectively). Patients younger than 15 years old had a tendency to show a more favorable 
prognosis in comparison with older patients. (P=0.063). Male, GI symptom, corticosteroid 
administration, CV catheter insertion, and antimicrobial therapy except for that with 
vancomycin did not have a significant impact on the prognosis. 
2.3 Discussion and proposal 
2.3.1 How do we efficiently select high-risk patients? 
Our report contains 12 adult B. cereus sepsis cases of hematologic malignancy, which is, to 
our knowledge, the largest cohort of B. cereus sepsis in adult patients from a single center. 
Because of the serious outcomes of these patients with hematologic malignancies, the 
detection of B. cereus from blood culture samples at febrile events from these patients should 
not be regarded as contamination. In our cohort, patients with a neutrophil count of 0/mm3, 
with CNS symptoms, or who had undergone CV catheter insertion definitely had a poor 
prognosis. However, we had difficulties in identifying further precise prognostic factors 
because of the small number of B. cereus infection cases in our institution. Therefore, we 
assessed the data in conjunction with those from our 12 patients and from 46 previously 
reported patients, giving a total of 42 patients with acute leukemia, although reporting bias 
may have existed because severe cases with peculiar clinical features tend to be selectively 
reported and some reports did not refer all factors which we consider to be important. 
Consequently, patients who had acute leukemia, a neutrophil count of 0/mm3 or a count 
below the lower limit of each institute, or CNS symptoms at febrile episodes were identified 
as being associated with a fatal prognosis. Interestingly, the relatively more favorable 
prognosis in younger patients implies the importance of appropriate evaluation in adult 
patients (Table 2). 
Regarding the neutrophil count, patients 7, 8, 10, and 11 fully recovered from B. cereus sepsis 
complicated with coma, in clear contrast to patients 1, 2, 6, and 12 who had a neutrophil 
count of 0/mm3 (Table 1), suggesting that both immediate therapeutic intervention and even 
a small number of neutrophils can effectively work against B. cereus sepsis. The poor 
outcomes in acute leukemia patients may have been an indirect consequence because of the 
greater immunosuppression following intensive chemotherapy, rather than due to the 
underlying disease. Regarding the relationship between B. cereus sepsis and the treatment 
process of acute leukemia in the combined clinical parameters, 35 patients developed sepsis 
during remission induction or reinduction therapy, 9 consolidation therapy, 4 post-
transplantation, and 1 maintenance therapy in a total of 49 acute leukemia patients whose 
clinical data were available (Akiyama, et al 1997, Arnaout, et al 1999, Christenson, et al 1999, 
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limited to ≧ 15 years old 7.000
1.497
Age, y 5.600 0.063
limited to ≧ 15 years old 3.056 0.122
Sex
0.451
GI symptom at febrile
episodes
2.692 0.069
limited to ≧ 15 years old 0.808 0.754
limited to ≧ 15 years old 3.250 0.149
CNS lesion or CNS
symptoms
limited to ≧ 15 years old
limited to ≧ 15 years old 11.571 0 .032
limited to ≧ 15 years old 2.099 0.367




These data include both previous reports and our 12 sepsis patients. P-values were calculated using χ2 
and Fisher’s exact tests. Odds ratios predict the possibility of death from Bacillus cereus sepsis. GI, 
gastrointestinal. CNS, central nervous system. CV, central vein. VCM, vancomycin. 
Table 2. Univariate analysis of prognostic factors of B. cereus sepsis 
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Tomiyama, et al 1989, Trager and Panwalker 1979, Yoshida, et al 1993). Therefore, patients 
under induction or reinduction therapy may be more likely to be susceptible to B. cereus 
sepsis. Also, previous studies have shown that variations in toxins and enzymes, which 
were produced by B. cereus, such as cereolysin, enterotoxin, emetic toxin, phospholipase C, 
and sphingomyelinase, between isolates of B. cereus were correlated with the reversibility of 
clinical courses (Turnbull, et al 1979, Turnbull and Kramer 1983). With respect to clinical 
symptoms related to B. cereus sepsis, patients with CNS disturbance mostly had a fatal 
outcome (P=0.005, in adult patients) (Table 2). Gaur et al. reported that patients with 
possible CNS involvement had a tendency to exhibit severe neutropenia at the onset of 
sepsis and to have an unfavorable outcome, although their study was conducted in a 
children’s hospital (Gaur, et al 2001). Given that most of the patients with a fatal prognosis 
had GI symptoms at the time of febrile episodes (Table 2), clinicians must be cautious of the 
early signs of CNS in addition to GI symptoms. Although GI symptoms were not 
significantly correlated with a fatal prognosis, we consider that the symptoms are very 
important in terms of early clues to the diagnosis of B. cereus sepsis. CV catheter insertion 
did not have a significant impact on the prognosis (P=0.149, in adult patients), although the 
result was opposite to that found in our cohort. 
2.3.2 We have a very limited time to avoid CNS damage in the face of B. cereus sepsis 
With respect to the results of autopsy, the findings observed in patient 2 have not been 
reported elsewhere, although coagulation necrosis with B. cereus infiltration of the liver and 
the GI tract may not be rare in B. cereus sepsis, as demonstrated in patients 6 and 12, 
respectively. In any case, the patients’ condition rapidly deteriorated in spite of intensive 
antibiotic coverage, including carbapenems and vancomycin, which were effective against 
B. cereus in vitro, although these agents (especially meropenem and vancomycin) are still 
recommended because of the inherent ability of B. cereus to produce β lactamases and the 
presence of the blood brain barrier (Hasbun, et al 1999, Zinner 1999). The failure of 
apparently adequate therapy may have been due to inadequate tissue concentrations of 
antibiotics. However, we emphasize that delays in therapeutic intervention must be avoided 
even if the CNS may have already been damaged by B. cereus before the administration of 
adequate antibiotics, as seen in our fatal cases. Patient 7 (Table 1), with a neutrophil count of 
near 0, had consciousness disturbance at the febrile event. We started to treat this patient 
very quickly based on information from Patient 2 and 6 with antibiotics effective for B. 
cereus, with the successful recovery from sepsis including CNS symptoms. This experience 
may be very important in terms of the necessity of very early therapeutic intervention. 
2.3.3 Proposal: Initial management of fever and neutropenia in AML patients in view 
of fatal B. cereus sepsis  
According to the Infectious Diseases Society of America (IDSA) guideline for neutropenic 
patients with cancer, ‘high-risk’ patients are considered to be those with anticipated 
sustaining (>7-day duration) and profound neutropenia (absolute neutrophil count (ANC) 
<100 cells/mm3) and/or significant medical co-morbid conditions, including hypotension, 
pneumonia, new-onset abdominal pain, or neurologic changes (Freifeld, et al 2011). It is 
generally assumed that all AML patients during intensive chemotherapy meet the high-risk 
criteria.  
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Tomiyama, et al 1989, Trager and Panwalker 1979, Yoshida, et al 1993). Therefore, patients 
under induction or reinduction therapy may be more likely to be susceptible to B. cereus 
sepsis. Also, previous studies have shown that variations in toxins and enzymes, which 
were produced by B. cereus, such as cereolysin, enterotoxin, emetic toxin, phospholipase C, 
and sphingomyelinase, between isolates of B. cereus were correlated with the reversibility of 
clinical courses (Turnbull, et al 1979, Turnbull and Kramer 1983). With respect to clinical 
symptoms related to B. cereus sepsis, patients with CNS disturbance mostly had a fatal 
outcome (P=0.005, in adult patients) (Table 2). Gaur et al. reported that patients with 
possible CNS involvement had a tendency to exhibit severe neutropenia at the onset of 
sepsis and to have an unfavorable outcome, although their study was conducted in a 
children’s hospital (Gaur, et al 2001). Given that most of the patients with a fatal prognosis 
had GI symptoms at the time of febrile episodes (Table 2), clinicians must be cautious of the 
early signs of CNS in addition to GI symptoms. Although GI symptoms were not 
significantly correlated with a fatal prognosis, we consider that the symptoms are very 
important in terms of early clues to the diagnosis of B. cereus sepsis. CV catheter insertion 
did not have a significant impact on the prognosis (P=0.149, in adult patients), although the 
result was opposite to that found in our cohort. 
2.3.2 We have a very limited time to avoid CNS damage in the face of B. cereus sepsis 
With respect to the results of autopsy, the findings observed in patient 2 have not been 
reported elsewhere, although coagulation necrosis with B. cereus infiltration of the liver and 
the GI tract may not be rare in B. cereus sepsis, as demonstrated in patients 6 and 12, 
respectively. In any case, the patients’ condition rapidly deteriorated in spite of intensive 
antibiotic coverage, including carbapenems and vancomycin, which were effective against 
B. cereus in vitro, although these agents (especially meropenem and vancomycin) are still 
recommended because of the inherent ability of B. cereus to produce β lactamases and the 
presence of the blood brain barrier (Hasbun, et al 1999, Zinner 1999). The failure of 
apparently adequate therapy may have been due to inadequate tissue concentrations of 
antibiotics. However, we emphasize that delays in therapeutic intervention must be avoided 
even if the CNS may have already been damaged by B. cereus before the administration of 
adequate antibiotics, as seen in our fatal cases. Patient 7 (Table 1), with a neutrophil count of 
near 0, had consciousness disturbance at the febrile event. We started to treat this patient 
very quickly based on information from Patient 2 and 6 with antibiotics effective for B. 
cereus, with the successful recovery from sepsis including CNS symptoms. This experience 
may be very important in terms of the necessity of very early therapeutic intervention. 
2.3.3 Proposal: Initial management of fever and neutropenia in AML patients in view 
of fatal B. cereus sepsis  
According to the Infectious Diseases Society of America (IDSA) guideline for neutropenic 
patients with cancer, ‘high-risk’ patients are considered to be those with anticipated 
sustaining (>7-day duration) and profound neutropenia (absolute neutrophil count (ANC) 
<100 cells/mm3) and/or significant medical co-morbid conditions, including hypotension, 
pneumonia, new-onset abdominal pain, or neurologic changes (Freifeld, et al 2011). It is 
generally assumed that all AML patients during intensive chemotherapy meet the high-risk 
criteria.  
 
Myeloid Leukemia – Clinical Diagnosis and Treatment 
 
290 
In the face of febrile AML patients, physicians should evaluate a complete blood count 
including a differential leukocyte count, although therapeutic intervention must be 
performed without delay in cases when the neutrophil count is expected to be 0/mm3 or 
below the lower limit of each institute. At least 2 sets of blood culture are recommended, 
with a set collected simultaneously from each lumen of an existing CV catheter and from a 
peripheral vein. Without a CV catheter, 2 sets of blood culture should be obtained from 
different peripheral sites. The number of blood cultures has been described as correlated 
with the detectability of circulating pathogens, that is, only a single blood culture may cause 
misevaluation regarding underlying pathogens (Lee, et al 2007).  
In the IDSA guideline, high-risk patients require initial antibiotic therapy that covers 
Pseudomonas aeruginosa and other serious gram-negative pathogens (Freifeld, et al 2011). 
Although the isolation of gram-positive organisms, such as coagulase-negative 
staphylococci, is more common than that of gram-negative pathogens, gram-negative 
bacteremias, especially those caused by Pseudomonas aeruginosa, are generally associated 
with greater mortality (Schimpff 1986). Thus, empirical monotherapy with an anti-
pseudomonal β-lactam agent, such as cefepime, carbapenem (meropenem or imipenem-
cilastatin), or piperacillin-tazobactam, is recommended and vancomycin should be 
considered only for clinically special indications, including suspected catheter-related 
infection, skin or soft tissue infection, pneumonia or hemodynamic instability (Freifeld, et al 
2011). Coagulase-negative staphylococci, the most commonly identified microorganisms in 
septic patients with neutropenia, are clinically weak pathogens that rarely cause rapid 
deterioration; therefore, for many physicians, there is no urgent need to treat such infections 
with vancomycin at the time of a febrile event.  
However, such a strategy as described above does not sufficiently satisfy appropriate 
treatment for fatal B. cereus sepsis, since B. cereus has an inherent ability to produce β 
lactamases (Hasbun, et al 1999, Zinner 1999). If neutropenic patients really suffer from B. 
cereus sepsis, it takes at least a few days to determine bacterial strains and, meanwhile, the 
patients’ condition rapidly deteriorates. Although physicians should avoid the unnecessary 
administration of broad-spectrum antibiotics to prevent widely distributing resistant 
bacteria, including methicillin-resistant Staphylococcus aureus (MRSA), vancomycin-resistant 
enterococcus (VRE), extended-spectrum β lactamase (ESBL)-producing gram-negative 
bacteria, and Klebsiella pneumonia carbapenemase (KPC), therapeutic delays for B. cereus 
sepsis would result in a fatal outcome.  
Therefore, as shown in Figure 2, at the first febrile event, we propose the prompt 
administration of both carbapenems and vancomycin for the following neutropenic AML 
patients with possible B. cereus sepsis, especially for patients with a neutrophil count of 
0/mm3 or below the lower limit of each institute, and CNS symptoms at febrile episodes. 
These 2 antibiotics are also desirable for febrile and neutropenic AML patients with CV 
catheter insertion or GI symptoms (Inoue, et al 2010). We consider that both agents are 
necessary as an initial management because of the presence of fulminant sepsis with B. 
cereus resistant to carbapenem (Kiyomizu, et al 2008). CV catheter removal is recommended 
if clinically possible. In patients with clinically and microbiologically documented infections 
other than B. cereus, appropriate agents should be started instead of carbapenems and 
vancomycin, and the duration of therapy depends on the species of pathogen and their 
infection site.  
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The IDSA guideline recommends fluoroquinolone prophylaxis for high-risk patients with 
expected durations of prolonged and marked neutropenia (ANC≦100/mm3 for >7 days) to 
reduce febrile events, documented infections, and infections involving the blood stream due 
to gram-positive or -negative bacteria (Bucaneve, et al 2005). Although fluoroquinolones, 
such as levofloxacin and ciprofloxacin, are usually efficacious against B. cereus in vitro and 
may prevent the rapid production of a large amount of bacterial toxins, there has been no 
report concerning the prophylactic efficacy of antibiotics against B. cereus sepsis (Bucaneve, 
et al 2005, Freifeld, et al 2011, Gafter-Gvili, et al 2005). The question of whether gut 
decontamination with oral fluoroquinolones can contribute to the reduction of B. cereus-
related mortality remains to be addressed.  
Fungal infections are encountered after the first week of prolonged neutropenia and 
empirical antibiotic therapy in the early phase of neutropenia, so that empirical antifungal 
therapy and investigation for invasive fungal infections should be considered for patients 
with persistent or recurrent fever after 2-4 days of antibiotics, including cases receiving 
prophylactic agents against Candida infections or invasive Aspergillus infection  (Freifeld, et 
al 2011). Also, physicians should recurrently monitor possible fungal infection using the β-
(1-3)-D glucan test, the galactomannan test, and high-resolution CT, leading to pre-emptive 
therapy if necessary. 
2.3.4 What kind of environmental precautions should be taken? 
It is reasonable to assume that B. cereus, which forms spores and is heat-resistant, in the 
environment or food passes through the GI tract or a CV catheter and enters into the 
circulation based on the results and information from our cases and previously reported 
patients (Banerjee, et al 1988, Terranova and Blake 1978). Especially, GI symptoms were 
present prior to the development of B. cereus sepsis in 8 cases, while no organism was 
grown from the tip of a CV catheter in any case (patients 2, 4, and 6) (Table 1). We 
regarded bananas, strawberries, and fried noodles as possibly causative foods in patients 
1, 2, and 6, respectively. In these patients, the impairment of mucosal barriers due to 
intensive chemotherapy may have been an important factor; therefore, clinicians should 
pay strict attention to the foods consumed by such patients and prepared luncheon meats 
should be avoided, although Gardner et al. reported that avoidance of raw fruits and 
vegetables did not prevent major infection that led to death among AML patients in a 
randomized trial where cooked and noncooked food diets were compared (Gardner, et al 
2008). 
In previous reports, the inadequate sterilization of respiratory circuits (Bryce, et al 1993) and 
bacterial contamination of hospital linen (Barrie, et al 1994, Dohmae, et al 2008) were also 
considered to be major sources of nosocomial infection. B. cereus sepsis in patients 2 and 3 
occurred in the same room and the same period (May, 2007). These facts prompted us to 
compare each B. cereus strain cultured from the blood samples of the 2 patients with B. cereus 
detected from hand towels, pajamas, a shared sink, and so on. However, each train proved 
distinct from the other strains detected, suggesting little possibility of nosocomial infection. 
Although B. cereus is widely distributed in the environment, the bacterial burden should be 
minimized because the threshold of the burden might determine the frequency of B. cereus 
sepsis. From this point of view, the regular surveillance of B. cereus strains in the 
environment may also be important. 
 




We encountered fatal B. cereus sepsis in patients with acute leukemia, in whom apparently 
appropriate antibiotics were not effective, while we also encountered reversible cases. This 
report has provided risk factors for a fatal prognosis in combination with previous data. It 
may be highly instructive for clinicians treating leukemia patients with several prognostic 
factors identified in this study for B. cereus sepsis with special relevance to patients with 
acute leukemia, and we strongly recommend the immediate initiation of treatment with 
carbapenems and vancomycin in such situations. Similar studies with a larger cohort are 
necessary to establish successful therapeutic interventions. 
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